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 Abbreviations 
AcOH acetic acid 
An anisyl  
aq.  aqueous 
Ar undefined aryl substituent 
ATR attenuated total reflection 
Bn benzyl 
Boc tert-butyloxycarbonyl 
Bu butyl 
ca. circa 
calc. calculated 
CCDC Cambridge Crystallographic Data Center 
CDER Center for Drug Evaluation and Research 
d doublet (NMR) 
DABCO 1,4-diazabicyclo[2.2.2]octan 
DABSO 1,4-diazabicyclo[2.2.2]octan-bis(sulfur dioxide) 
dba dibenzylideneacetone 
DBU 1,8-diazabicyclo[5.4.0]undec-7-en 
DCM dichloromethane 
DDQ 2,3-dichloro-5,6-dicyano-1,4-benzoquinone 
DMF N,N-dimethylformamide 
DMSO dimethylsulfoxide 
d.r. diastereomeric ratio 
E-X electrophile 
EI electron ionization (MS) 
e.g. for example 
equiv equivalents 
ESI electrospray ionization (MS) 
Et ethyl 
etc. et cetera 
FDA U.S. Food and Drug Administration 
FG functional group 
GC gas chromatography 
Het undefined heteroaryl substituent 
Hex hexyl 
HRMS high resolution mass spectroscopy 
i iso 
IR infrared 
J coupling constant (NMR) 
m multiplet (NMR) 
 M mol·L−1 
Me methyl 
Met metal 
M.p. melting point 
MS mass spectrometry 
MTBE methyl-tert-butylether 
NMP 1-methylpyrrolidin-2-one 
NMR nuclear magnetic resonance 
o ortho 
Ph phenyl 
Piv pivaloyl 
PMDTA bis(2-dimethylaminoethyl)methylamin 
ppm parts per million 
Pr propyl 
q quartet (NMR) 
R undefined organic substituent 
s sec 
s singulet (NMR) 
sat. saturated 
SPhos 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl 
t tert 
t triplett (NMR) 
TFA trifluoroacetic acid 
THF tetrahydrofuran  
Tf trifluoromethanesulfonate 
TLC thin layer chromatography 
TMEDA N,N,N′,N′-tetramethylethylenediamine 
TMP 2,2,6,6-tetramethylpiperidyl 
TMS trimethylsilyl 
Tol tolyl 
TP typical procedure 
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A. INTRODUCTION    3 
1 Overview 
In the year 2018, the United States Food and Drug Administration’s Center for Drug Evaluation and 
Research (FDA, CDER) has approved as many as 59 novel drugs.1 This is a record in the FDAs 
approvals since 1993, with the previous number lying at 53 drugs in the year 1996. Out of the estimated 
most potential blockbuster approvals for 2018, eight out of nine small molecule drugs contain a nitrogen 
heterocycle, showing the incredible value of heteroaromatic scaffolds in modern pharmaceutical 
chemistry. Baricitinib (Incyte/Eli Lilly, rheumatoid arthritis), apalutamide (Johnson & Johnson, 
prostate cancer), bictegravir (Gilead Sciences, HIV), and tezacaftor (Vertex Pharmaceuticals, cystic 
fibrosis) belong to the most promising aprovals of the year 2018 and contain numerous N-heterocycles 
such as a pyridine, an indole or a pyrazole (Figure 1).1 
 
Figure 1: Selected potential blockbuster drugs approved by the FDA in 2018.1 
However, not only these well established ring structures are represented, but also less investigated 
heterocycles, such as a 7H-pyrrolo[2,3-d]pyrimidine (baracitinib) or a pyrido[1,2-a]pyrazine 
(bictegravir) structure can be detected. This indicates that research in the field of nitrogen containing 
heterocycles is yet of utmost importance, and, that especially less common stuctures can lead to 
breakthroughs in modern medicinal chemistry.2 A research field which allows the preparation and 
functionalization of various (hetero)aromatic scaffolds is organometallic chemistry. By being able to 
create a carbon-metal bond via various methods such as oxidative insertion, halogen/metal exchange, 
directed metalation or transmetalation, a plethora of functionalizations, including the formation of C-C 
and C-N bonds, have been made possible.3 Therefore, it is evident, that making use of organometallic 
chemistry to conduct research towards the functionalization of challenging N-heterocycles and to 
develop novel organometallic transformations is of high interest. 
                                                     
1
 A. Mullard, Nat. Rev. Drug Discovery 2019, 18, 85–89. 
2
 a) W. R. Pitt, D. M. Parry, B. G. Perry, C. R. Groom, J. Med. Chem. 2009, 52, 2952–2963; b) E. Vitaku, D. T. 
Smith, J. T. Njardarson, J. Med. Chem. 2014, 57, 10257–10274. 
3
 a) W. F. Bailey, J. J. Patricia, J. Organomet. Chem. 1988, 352, 1–46; b) D. Seyferth, Organometallics 2006, 25, 
2–24. c) Handbook of Functionalized Organometallics Vol. 1 and 2 (Ed.: P. Knochel), Wiley-VCH, Weinheim, 
2005. 
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2 Amination of Arenes and Heteroarenes 
2.1 Transition-Metal-Catalyzed Amination 
Transition-metal-catalyzed amination reactions have been pioneered by Ullman,4 Migita,5 Buchwald,6 
and Hartwig7. In 1901, Ullman reported the first copper mediated ipso-substitution of an aryl halide.4 
However, it was not until 1983, when Migita performed the first palladium-catalyzed amination 
reactions between aryl bromides and tin amides.5 The first tin-free catalysis was developed 
independently by Buchwald and Hartwig in 1995, followed by several optimizations and reaction scope 
expansions by e.g. varying the reaction conditions, the palladium catalyst or the phosphine ligand.6,7 
This eventually made the Buchwald-Hartwig amination reaction one of the most versatile reactions for 
the construction of the C-N bond. However, transition-metal-catalysts are expensive and often toxic.8 
Therefore, the development of transition-metal-free alternatives for the formation of the carbon nitrogen 
bond is highly desirable. 
2.2 Transition-Metal-Free Amination 
Not only have transition-metal-catalyzed reactions made huge progress in the last decades, but also 
have there been several developments towards alternative, transition-metal-free coupling reactions.9 
Especially, the amination of N-heterocycles, including pyridines, has gained interest over the years. The 
main approach is the use of nucleophilic aromatic substitution reactions (SNAr) between amines or 
amides and activated 2-functionalized pyridines, such as 2-halo, or 2-cyanopyridines.10 Also, 2-pyridyl 
trifluoromethanesulfonates, dihydrothiazolopyridinium salts, or pyridine-N-oxides have been employed 
                                                     
4
 a) F. Ullmann, J. Bielecki, Ber. Dtsch. Chem. Ges. 1901, 34, 2174−2185; b) J. Lindley, Tetrahedron 1984, 40, 
1433–1456. 
5
 K. Masanori, K. Masayuki, M. Toshihiko, Chem. Lett. 1983, 12, 927–928. 
6
 a) A. S. Guram, R. A. Rennels, S. L. Buchwald, Angew. Chem. Int. Ed. 1995, 34, 1348–1350; b) J. P. Wolfe, S. 
Wagaw, J.-F. Marcoux, S. L. Buchwald, Acc. Chem. Res. 1998, 31, 805–818; c) B. H. Yang, S. L. Buchwald, J. 
Organomet. Chem. 1999, 576, 125–146; d) S. L. Buchwald, A. Muci, Top. Curr. Chem. 2002, 219, 133–209. 
7
 a) J. Louie, J. F. Hartwig, Tetrahedron Lett. 1995, 36, 3609–3612; b) J. F. Hartwig, Angew. Chem. Int. Ed. 1998, 
37, 2046–2067; c) J. F. Hartwig, Acc. Chem. Res. 1998, 31, 852–860; d) J. Hartwig, Pure Appl. Chem. 1999, 71, 
1417–1423. 
8
 K. S. Egorova, V. P. Ananikov, Angew. Chem. Int. Ed. 2016, 55, 12150–12162. 
9
 a) T. Hatakeyama, Y. Yoshimoto, S. K. Ghorai, M. Nakamura, Org. Lett. 2010, 12, 1516–1519; b) Q. Xiao, L. 
Tian, R. Tan, Y. Xia, D. Qiu, Y. Zhang, J. Wang, Org. Lett. 2012, 14, 4230–4233; c) C.-L. Sun, Z.-J. Shi, Chem. 
Rev. 2014, 114, 9219–9280; d) V. Tona, A. de la Torre, M. Padmanaban, S. Ruider, L. González, N. Maulide, J. 
Am. Chem. Soc. 2016, 138, 8348–8351; e) J. J. Farndon, X. Ma, J. F. Bower, J. Am. Chem. Soc. 2017, 139, 14005–
14008. 
10
 a) L. Pasumansky, A. R. Hernández, S. Gamsey, C. T. Goralski, B. Singaram, Tetrahedron Lett. 2004, 45, 
6417–6420; b) J. M. Penney, Tetrahedron Lett. 2004, 45, 2667–2669; c) S. Narayan, T. Seelhammer, R. E. 
Gawley, Tetrahedron Lett. 2004, 45, 757–759; d) B. C. Hamper, E. Tesfu, Synlett 2007, 2257–2261; e) J. L. 
Bolliger, C. M. Frech, Tetrahedron 2009, 65, 1180–1187; f) J. G. Kim, E. H. Yang, W. S. Youn, J. W. Choi, D.-
C. Ha, J. D. Ha, Tetrahedron Lett. 2010, 51, 3886–3889; g) K. Walsh, H. F. Sneddon, C. J. Moody, ChemSusChem 
2013, 6, 1455–1460. 
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as substrates.11 A recent approach towards the amination of pyridines and other diazines is the reaction 
of heterocyclic phosphonium salts with sodium azide, leading to iminophosphoranes, which can be 
further functionalized, in good to excellent yields (Scheme 1).12 
 
Scheme 1: Selected example for for the metal-free amination of heterocylic phosphonium salts using 
sodium azide. 
3 Generation of Polyfunctional Organomagnesium, -Zinc, and -Lithium 
Reagents and their Use in Organic Synthesis 
 
With the discovery of diethylzinc in 1848 and the Grignard reagent in 1901, the era of organometallic 
chemistry began.13 Since then, a large variety of carbon-metal bond forming reactions were discovered 
and employed in carbon-carbon and carbon-heteroatom bond formation. The first major method to 
generate an organometallic species is the oxidative insertion of a metal into a carbon halogen bond 
(Scheme 2a).13 The second major pathway is the halogen/metal exchange reaction, in which a 
thermodynamically less stable metal species reacts with an alkyl or aryl halide to form the more stable 
organometallic (Scheme 2b).14 The third method is the directed metalation, in which a base abstracts 
(“metalates”) a proton, giving rise to the desired metal species (Scheme 2c).15 The final pathway is the 
transmetalation reaction in which an existing metal species reacts with a metal salt, forming a more 
covalent and thus stable carbon metal bond (Scheme 2d).3b  
                                                     
11
 a) S. Cacchi, A. Carangio, G. Fabrizi, L. Moro, P. Pace, Synlett 1997, 12, 1400–1402; b) J. Yin, B. Xiang, M. 
A. Huffman, C. E. Raab, I. W. Davies, J. Org. Chem. 2007, 72, 4554–4557; c) B. Poola, W. Choung, M. H. Nantz, 
Tetrahedron 2008, 64, 10798–10801. 
12
 a) K. Murakami, S. Yamada, T. Kaneda, K. Itami, Chem. Rev. 2017, 117, 9302–9332; b) C. Patel, M. Mohnike, 
M. C. Hilton, A. McNally, Org. Lett. 2018, 20, 2607–2610. 
13
 a) E. Frankland, J. Chem. Soc. 1848, 2, 263; b) V. Grignard, Compt. Rend. Acad. Sci. 1900, 130, 1322; c) V. 
Grignard, Ann. Chim 1901, 24, 433–490. 
14
 a) G. Wittig, U. Pockels, H. Droge, Chem. Ber. 1938, 71, 1903–1912; b) H. Gilman, W. Langham, A. L. Jacoby, 
J. Am. Chem. Soc. 1939, 61, 106–109; c) W. F. Bailey, J. J. Patricia, J. Organomet. Chem. 1988, 352, 1–46; d) D. 
Seyferth, Organometallics 2006, 25, 2–24. 
15
 a) B. Haag, M. Mosrin, H. Ila, V. Malakhov, P. Knochel, Angew. Chem. Int. Ed. 2011, 50, 9794–9824; b) T. 
Klatt, J. T. Markiewicz, C. Sämann, P. Knochel, J. Org. Chem. 2014, 79, 4253–4269; c) M. Balkenhohl, P. 
Knochel, SynOpen 2018, 2, 78–95. 
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Scheme 2: The four pathways for the generation of polyfunctional organomagnesium, -zinc, and  
-lithium reagents. 
3.1 Oxidative Insertion 
The oldest method for generating organometallic reagents is the oxidative insertion, pioneered by 
Frankland and Grignard.13 A limiting factor for this transformation was the reactivity of the zerovalent 
metal. In the past centuries, chemists have developed several methods to improve the oxidative insertion 
reaction by activating the metal species.16 Amongst others, grinding the metal, addition of activating 
substances such as iodine or dibromotetrachloroethane, the use of polar solvents or the addition of 
inorganic salts have all in all led to an improvement of the oxidative insertion reaction.16 Major 
improvements have been made by Rieke, who prepared activated metals via reduction of metal salts 
with e.g. lithium or potassium.17 With these activated metals it is possible to perform the oxidative 
insertion reaction in the presence of functional groups such as esters or nitriles, since the insertion step 
proceeds even at low temperatures. Bromoarene 1, for example, reacts with Rieke magnesium (Mg*) 
to form the desired magnesium species 2, which is quenched with benzaldehyde to yield the expected 
alcohol 3 in 76% yield (Scheme 3).18 
 
                                                     
16
 R. D. Rieke, Acc. Chem. Res. 1977, 10, 301–306. 
17
 a) R. D. Rieke, Science 1989, 246, 1260–1264; b) L. Zhu, R. M. Wehmeyer, R. D. Rieke, J. Org. Chem. 1991, 
56, 1445–1453; c) R. D. Rieke, M. V. Hanson, Tetrahedron 1997, 53, 1925–1956. 
18
 J.-s. Lee, R. Velarde-Ortiz, A. Guijarro, R. D. Rieke, J. Org. Chem. 2000, 65, 5428–5430. 
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Scheme 3: Oxidative insertion of Rieke magnesium to an aryl bromide at low temperature. 
Also, sonification of reaction mixtures facilitates the synthesis of organozinc reagents.19 The addition 
of an inorganic salt such as LiCl leads to improved results in the formation of sensitive organometallic 
reagents, allowing the preparation of a wide variety of sensitive organomagnesium and zinc species.20 
The magnesium insertion to 3-bromopyridine (4) in the presence of lithium chloride proceeds smoothly, 
producing the magnesium species 5 which undergoes a copper mediated acylation reaction with acetyl 
chloride, giving ketone 6 in 90% yield.20 Zinc insertion to 4-iodobenzonitrile (7) followed by quenching 
with tetramethylthiuram disulfide gives the dithiocarbamate 8 in 89% yield.20 Interestingly, in the case 
of the di-iodo substituted arene 9, the halogen which is positioned ortho to a directing group is favored 
regarding site selectivity for the insertion reaction. This phenomenon is known as the directed ortho-
insertion (DoI).20 The zinc species 10 prepared via directed ortho-insertion readily reacts with  
3-iodocyclohexenone in the presence of CuCN·2LiCl (20 mol%) to give the substitution product 11 in 
73% yield (Scheme 4).20 Interstingly, the role of LiCl has also been investigated using fluorescence 
microscopy.21 
 
Scheme 4: Preparation of various sensitive (hetero)arylzinc and -magnesium reagents via oxidative 
insertion.  
                                                     
19
 a) T. Kentaro, Chem. Lett. 1993, 22, 469–472; b) T. Kentaro, S. Yasuaki, S. Ken, Chem. Lett. 1994, 23, 2055–
2058. 
20
 a) R. Ikegami, A. Koresawa, T. Shibata, K. Takagi, J. Org. Chem. 2003, 68, 2195–2199; b) S. Huo, Org. Lett. 
2003, 5, 423–425; c) A. Krasovskiy, V. Malakhov, A. Gavryushin, P. Knochel, Angew. Chem. Int. Ed. 2006, 45, 
6040–6044; d) N. Boudet, S. Sase, P. Sinha, C.-Y. Liu, A. Krasovskiy, P. Knochel, J. Am. Chem. Soc. 2007, 129, 
12358–12359; e) F. M. Piller, P. Appukkuttan, A. Gavryushin, M. Helm, P. Knochel, Angew. Chem. Int. Ed. 2008, 
47, 6802–6806; f) T. D. Blümke, T. Klatt, K. Koszinowski, P. Knochel, Angew. Chem. Int. Ed. 2012, 51, 9926–
9930. 
21
 a) C. Feng, D. W. Cunningham, Q. T. Easter, S. A. Blum, J. Am. Chem. Soc. 2016, 138, 11156–11159; b) C. 
Feng, Q. T. Easter, S. A. Blum, Organometallics 2017, 36, 2389–2396. 
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3.2 Halogen/Metal Exchange 
The halogen/metal exchange, first discovered by Gilman and Wittig,14 is a versatile reaction in the 
synthesis of organometallic reagents.22 The driving force of the halogen/metal exchange reaction is the 
formation of a thermodynamically more stable metal species in comparison to the exchange reagent 
itself, with the stability of the organometallic species decreasing from C(sp) > C(sp2vinyl) > C(sp2aryl) > 
C(sp3primary) > C(sp3secondary) > C(sp3tertiary).23 With the development of the turbo-Grignard iPrMgCl·LiCl 
in 2004, a wide range of functionalized magnesium organometallics were preparable due to the higher 
kinetic activity in comparison to the salt free predecessor iPrMgCl.24 Almost simultaneously to the 
improved halogen/magensium exchange reagent, a Li(acac) catalyzed iodine/zinc exchange was 
reported.25 Li(acac) leads to the formation of catalytic amounts of a more reactive zincate species, which 
reacts with various aryl iodides bearing sensitive functional groups such as ketones or aldehydes. For 
example, the iodothiophene 12 reacts with iPr2Zn (0.55 equiv) in the presence of Li(acac) (10 mol%) 
leading to the diarylzinc species 13, which is subsequently submitted to a palladium catalyzed Negishi 
cross-coupling,26 producing the arylated thiophene 14 in 52% yield. Using iPrMgCl·LiCl, not only 
(hetero)aryl, but also alkenyl halides undergo halogen/metal exchange reactions. The alkenyl 
magnesium species 15 formed by reaction of an alkenyl halide 16 with iPrMgCl·LiCl readily reacts 
with ethanal, providing alcohol 17 in 82% yield and excellent diastereoselectivity (E/Z = 99:1).27 
Furthermore, the turbo Grignard undergoes facile sulfoxide/magnesium exchange reactions. Thus, 
treatment of the sulfoxide 18 with iPrMgCl·LiCl (1.1 equiv) at –50 °C for 5 min results in the formation 
of the desired magnesium species 19, which is quenched with a halogenated benzaldehyde, producing 
the alcohol 20 in 88% yield.28 The preparation of organometallic reagents via oxidative insertion is 
challenging in the presence of nitro groups, since they are prone to undergo single electron transfer 
processes during the reaction.29 However, when a nitro-substituted iodoanisole 21 is treated with the 
milder exchange reagent PhMgCl, a halogen/metal exchange proceeds rapidly at –40 °C, and the metal 
species can be quenched with benzaldehyde, leading to arene 22 in 72% yield (Scheme 5).29 
                                                     
22
 a) W. F. Bailey, E. R. Punzalan, J. Org. Chem. 1990, 55, 5404–5406; b) E. Negishi, D. R. Swanson, C. J. 
Rousset, J. Org. Chem. 1990, 55, 5406–5409; c) C. E. Tucker, T. N. Majid, P. Knochel, J. Am. Chem. Soc. 1992, 
114, 3983–3985; For reviews, see: d) D. Tilly, F. Chevallier, F. Mongin, P. C. Gros, Chem. Rev. 2014, 114, 1207-
1257; e) R. Li-Yuan Bao, R. Zhao, L. Shi, Chem. Commun. 2015, 51, 6884–6900; f) D. S. Ziegler, B. Wei, P. 
Knochel, Chem. Eur. J. 2019, 25, 2695–2703. 
23
 D. Hauk, S. Lang, A. Murso, Org. Process Res. Dev. 2006, 10, 733–738. 
24
 A. Krasovskiy, P. Knochel, Angew. Chem. Int. Ed. 2004, 43, 3333–3336. 
25
 F. F. Kneisel, M. Dochnahl, P. Knochel, Angew. Chem. Int. Ed. 2004, 43, 1017–1021. 
26
 a) A. O. King, N. Okukado, E.-i. Negishi, J. Chem. Soc., Chem. Commun. 1977, 683; b) D. Haas, J. M. 
Hammann, R. Greiner, P. Knochel, ACS Catal. 2016, 6, 1540. 
27
 H. Ren, A. Krasovskiy, P. Knochel, Org. Lett. 2004, 6, 4215–4217. 
28
 C. B. Rauhut, L. Melzig, P. Knochel, Org. Lett. 2008, 10, 3891–3894. 
29
 I. Sapountzis, P. Knochel, Angew. Chem. 2002, 114, 1680–1681. 
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Scheme 5: Various halogen/metal exchange reactions using iPr2Zn, iPrMgCl·LiCl, and PhMgCl. 
Recently, a new class of exchange reagents has been developed, allowing not only a rapid 
bromine/magnesium, but also a chlorine/magnesium exchange, using lithium alkoxide complexed 
dialkylmagnesium reagents.30 Additionally, these reagents are soluble in unpolar hydrocarbons and 
therefore enable the generation of highly reactive magnesium reagents in toluene. Electron rich  
3-bromo-N,N-dimethylaniline (23) is converted into the corresponding magnesium species 24 using 
sBuMgOR·LiOR (R = 2-ethylhexyl, 1.2 equiv) in the presence of TMEDA at room temperature within 
 
Scheme 6: The halogen/magnesium exchange on aryl bromides and chlorides in toluene. 
                                                     
30
 D. S. Ziegler, K. Karaghiosoff, P. Knochel, Angew. Chem. Int. Ed. 2018, 57, 6701–6704. 
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3 h. This metal species 24 reacts with dicyclopropylketone to give 25 in 80% yield. Also the azaindole 
26 is converted under similar conditions to the corresponding magnesium species 27, which, upon 
quenching with 2-benzofurancarboxaldehyde, gives alcohol 28 in 70% yield. Finally, the 
dialkylmagnesium reagent sBu2Mg·2LiOR (R = 2-ethylhexyl, 0.6 equiv) reacts with an electron rich 
aryl chloride 29 bearing a methoxy group in ortho position, to afford, after quenching with allyl bromide 
in the presence of CuI (10 mol%), the functionalized naphthalene 30 in 75% yield (Scheme 6). 
3.3 Directed Metalation 
A possibility to generate a metal species without requiring a carbon-halogen bond (as in chapters 3.1 
and 3.2) is the directed metalation.15c In this case, a base deprotonates (“metalates”) a substrate, thus 
forming a carbon-metal bond. Initially discovered by Gilman31 and Wittig32, the directed metalation 
was pioneered by Snieckus,33 Hauser,34 Eaton35 and Mulzer.36 Lithium bases were employed as 
metalating reagents, which however only tolerate few functional groups and often led to degradation of 
the lithiated reagents. The use of metal amides firstly allowed the functionalization of sensitive arenes 
and heteroarenes. These early amide bases however tended to form aggregates and often reacted 
sluggishly, thus requiring a large excess of metalating reagent. A huge improvement was made when 
the metal amides of type TMPMgCl (TMP = 2,2,6,6-tetramethylpiperidyl) were mixed with one 
equivalent of lithium chloride, leading to TMPMgCl·LiCl (31).37 Similarly as in the case of 
iPrMgCl·LiCl, the lithium chloride breaks up the aggregates and therefore provides a kinetically highly 
reactive base.24 Furthermore, the use of lithium magnesiate or zincate bases pioneered by Mulvey, 
Mongin, Uchiyama, and Kondo has considerably broadened the scope of metalations for the 
functionalizations of (hetero)arenes.38 In the case of TMP-Mg or -Zn metalations, magnesiated or 
zincated heterocycles are produced, which are compatible with a range of functional groups at moderate 
to low temperatures. In the case of the zincation of azines, ambient temperatures or elevated 
temperatures (up to 120 °C) can be used, offering considerable potential for industrial applications.39 
                                                     
31
 H. Gilman, R. L. Bebb, J. Am. Chem. Soc. 1939, 61, 109–112. 
32
 G. Wittig, G. Fuhrmann, Ber. Dtsch. Chem. Ges. 1940, 73, 1197–1218. 
33
 V. Snieckus, Chem. Rev. 1990, 90, 879–933.  
34
 a) C. R. Hauser, H. G. Walker, J. Am. Chem. Soc. 1947, 69, 295–297; b) F. C. Frostick, C. R. Hauser, J. Am. 
Chem. Soc. 1949, 71, 1350–1352. 
35
 P. E. Eaton, C. H. Lee, Y. Xiong, J. Am. Chem. Soc. 1989, 111, 8016–8018. 
36
 a) W. Schlecker, A. Huth, E. Ottow, J. Mulzer, J. Org. Chem. 1995, 60, 8414–8416; b) W. Schlecker, A. Huth, 
E. Ottow, J. Mulzer, Liebigs Ann. 1995, 1441–1446; c) W. Schlecker, A. Huth, E. Ottow, J. Mulzer, Synthesis 
1995, 1225–1227. 
37
 A. Krasovskiy, V. Krasovskaya, P. Knochel, Angew. Chem. Int. Ed. 2006, 45, 2958–2961 
38
 a) R. E. Mulvey, Organometallics 2006, 25, 1060–1075; b) R. E. Mulvey, F. Mongin, M. Uchiyama, Y. Kondo, 
Angew. Chem. Int. Ed. 2007, 46, 3802–3824; c) R. E. Mulvey, Acc. Chem. Res. 2009, 42, 743–755; d) P. J. 
Harford, A. J. Peel, F. Chevallier, R. Takita, F. Mongin, M. Uchiyama, A. E. H. Wheatley, Dalton Trans. 2014, 
43, 14181–14203; e) S. D. Robertson, M. Uzelac, R. E. Mulvey, Chem. Rev. 2019, DOI: 
10.1021/acs.chemrev.9b00047 
39
 S. Wunderlich, P. Knochel, Org. Lett. 2008, 10, 4705. 
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3.3.1 Magnesiation Using TMPMgCl·LiCl 
Usually, magnesium amides of type R2NMgX or (R2N)2Mg are aggregated and relatively slow 
deprotonation reagents, partially because of their moderate solubility.34,35 Mulzer pioneered the use of 
TMPMgCl for the magnesiation of an azine.36 A more THF soluble and more active base was obtained 
by using TMPMgCl with LiCl (1 equiv). Thus, the mixing of TMP-H with i-PrMgCl·LiCl in THF 
(25 °C, 24 h) provides a ca. 1.4 M soluble base TMPMgCl·LiCl (31).15,40 This base magnesiates a range 
of functionalized pyridines and quinolines under mild conditions. Since magnesium reagents are 
produced, there is no need for low temperatures as it is often the case with corresponding lithiations.41 
Thus, the magnesiation of 2-bromoquinoline (32) with TMPMgCl·LiCl (31) at –20 °C for 2 h provides 
the ortho-magnesiated product 33 (Scheme 7). After bromolysis, the dibromoquinoline 34 is obtained 
in 65% yield.42 Pyridines bearing less sensitive functional groups like 3,5-dibromopyridine (35) or 2,6-
dichloropyridine (36) are magnesiated at convenient temperatures (–25 °C or 25 °C) regioselectively 
providing the pyridylmagnesium derivatives 37 and 38. Quenching with various electrophiles such as 
DMF or 4-methoxybenzaldehyde affords the polyfunctional pyridines 39 and 40 in 65–92% yield. The 
latter reaction can be readily scaled up to a 100 mmol-scale with no yield loss.43 Aminopyridines are  
 
Scheme 7: Regioselective magnesiation of halogenoazines using TMPMgCl·LiCl. 
                                                     
40
 P. García-Álvarez, D. V. Graham, E. Hevia, A. R. Kennedy, J. Klett, R. E. Mulvey, C. T. O'Hara, S. 
Weatherstone, Angew. Chem. Int. Ed. 2008, 47, 8079–8081. 
41
 a) G. W. Gribble, M. G. Saulnier, Tetrahedron Lett. 1980, 21, 4137–4140; b) J. Verbeek, L. Brandsma, J. Org. 
Chem. 1984, 49, 3857–3859; c) J. Verbeek, A. V. E. George, R. L. P. de Jong, L. Brandsma, J. Chem. Soc., Chem. 
Commun. 1984, 257–258; d) A. I. Subota, O. O. Grygorenko, Y. B. Valter, M. A. Tairov, O. S. Artamonov, D. 
M. Volochnyuk, S. V. Ryabukhin, Synlett 2015, 26, 408–411. 
42
 N. Boudet, J. R. Lachs, P. Knochel, Org. Lett. 2007, 9, 5525–5528. 
43
 S. H. Wunderlich, C. J. Rohbogner, A. Unsinn, P. Knochel, Org. Process Res. Dev. 2010, 14, 339–345. 
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converted to the corresponding trifluoroacetamides such as 41. Deprotonation of the amide function 
with MeMgCl and ring-magnesiation with TMPMgCl·LiCl (31) furnishes the Grignard reagent 42, 
which, after a transmetalation with ZnCl2 and Negishi cross-coupling,26 affords the 4-arylated pyridine 
43 in 80% yield (Scheme 7).44 
3.3.2 Magnesiation Using TMP2Mg·2LiCl 
Although TMPMgCl·LiCl (31) is a very powerful magnesiation reagent, in the case of substrates 
bearing weakly acidic or sterically hindered protons, the magnesiation is advantageously performed 
using TMP2Mg·2LiCl (44).45 Often, the presence of sensitive functional groups, such as a carbethoxy 
group, requires low magnesiation temperatures, since higher temperatures lead to considerable side 
reactions. TMP2Mg·2LiCl (44), which is prepared in quantitative yield by treating TMPLi with 31, can 
be stored at 25 °C for several hours. A degradation after several days is however observed. This base 
readily magnesiates 4-carbethoxypyridine (45) at –40 °C for 12 h leading to 46, furnishing, after 
iodolysis, the iodopyridine 47 in 66% yield (Scheme 8).45 The phosphordiamidate substituted pyridine 
48 was magnesiated with 44, yielding the magnesium reagent 49 (–50 °C, 1 h). After transmetalation 
with ZnCl2 and Negishi cross-coupling using PhI, 5% Pd(dba)2 and 10% P(o-furyl)3 as catalyst,46 the 
arylated quinoline 50 is obtained in 81% yield. Interestingly, the quinoline 50 can now be magnesiated 
with TMPMgCl·LiCl (31) at 25 °C within 1 h. The presence of the phenyl group at position 2 avoids 
nucleophilic additions to the quinoline ring and allows higher metalation temperatures (0 °C instead of 
–50 °C). Quenching with NC-CO2Et produces the 2,3,4-trisubstituted quinoline 51 which is further 
converted to talnetant (52), an NK3 receptor antagonist, in 86% yield (Scheme 8).47 
 
Scheme 8: Azine functionalization using TMP2Mg·2LiCl (44).  
                                                     
44
 G. Monzón, I. Tirotta, Y. Nishii, P. Knochel, Angew. Chem. Int. Ed. 2012, 51, 10624–10627. 
45
 G. C. Clososki, C. J. Rohbogner, P. Knochel, Angew. Chem. Int. Ed. 2007, 46, 7681–7684. 
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 V. Farina, B. Krishnan, J. Am. Chem. Soc. 1991, 113, 9585–9595. 
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3.3.3 BF3·OEt2-Promoted Metalation 
A typical mono-substituted pyridine, 3-fluoropyridine (53), can be metalated in two complementary 
positions (position C2 or position C4) with TMPMgCl·LiCl (31), either in the absence or in the presence 
of the strong Lewis acid BF3·OEt2. Preliminary experiments showed, that BF3·OEt2 does not react in 
an irreversible manner with TMPMgCl·LiCl (31) at tempeartures below –30 °C. Also, the 3-fluoro 
substituent considerably acidifies the adjacent positions C2 and C4 of 53. The position of the metalation 
is determined by the nature of the complexation with the TMP-base.48 Thus, by adding TMPMgCl·LiCl 
(31) to 53 a complexation of 31 to the heterocyclic N-atom takes place, leading to a complex of type 
54, which favors a metalation at position C2. On the other hand, in the presence of BF3·OEt2, this strong 
Lewis acid forms a complex with the N-atom of the pyridine ring and the base 31 may, if at all, only 
complex the fluorine substituent. This favors a metalation at position C4 (see 55). Thus, the presence 
or absence of BF3·OEt2 allows the arylation of 3-fluoropyridine (53) either in position C2 or C4 leading 
to the expected products 56 and 57 (Scheme 9).48 The exact nature of the organometallic species 
obtained after the metalation of 53 in the presence of BF3·OEt2 has been examined by 13C-NMR-
spectroscopy.48,49 
 
Scheme 9: Regioselective metalation of 3-fluoropyridine 53 in the presence or absence of BF3·OEt2. 
This regioselectivity switch is observed for a range of pyridines. An unexpected regioselectivity is 
observed in the case of 2-phenylpyridine (58). Thus, the treatment of 58 with TMPMgCl·LiCl (31) at 
55 °C provides the magnesiated pyridine 59. After iodolysis, the pyridine 60 is obtained in 85% yield. 
Alternatively, the treatment of 58 with BF3·OEt2, followed by TMPMgCl·LiCl (31), furnishes, after 
iodolysis, the 2,6-disubstituted pyridine 61 in 83% yield (Scheme 10).48 
                                                     
48
 M. Jaric, B. A. Haag, A. Unsinn, K. Karaghiosoff, P. Knochel, Angew. Chem. Int. Ed. 2010, 49, 5451–5455. 
49
 S. M. Manolikakes, M. Jaric, K. Karaghiosoff, P. Knochel, Chem. Commun. 2013, 49, 2124–2126. 
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Scheme 10: Regioselective metalation of 2-phenylpyridine (58) with or without BF3·OEt2. 
3.3.4 Zincation of Pyridines and Related Azines Using TMPZnCl·LiCl and 
TMP2Zn·2LiCl·2MgCl2 
The availability of kinetically active zinc amides further extends the scope of directed metalations of 
functionalized azines. Two complementary zinc bases TMPZnCl·LiCl (62) and 
TMP2Zn·2LiCl·2MgCl2 (63) are obtained from TMPLi and ZnCl2 or TMPMgCl·LiCl (31) and ZnCl2 
(Scheme 11).50,51 Since the carbon-zinc bond is much more covalent than the carbon-magnesium bond, 
electrophilic functional groups are much better tolerated in such zinc organometallics and the directed 
zincation of various functionalized pyridines is readily achieved. Furthermore, organozinc 
organometallics do not undergo electron-transfer reactions. Therefore, the electron-deficient nitro group 
is well tolerated in the zincation of nitro-substituted pyridines such as 64. In this case, the zincation 
proceeds at –40 °C within 1.5 h, leading to the bis-pyridylzinc 65. After a copper-catalyzed allylation 
with 3-bromocyclohexene, the trisubstituted pyridine 66 is obtained in 80% yield (Scheme 11).51 
Alternatively, the milder zinc base TMPZnCl·LiCl (62) is able to zincate 64 at 25 °C within 5 h and 
does not require low temperature metalations50,51 leading to the acylated pyridine 67 in 77% yield on 
50 mmol scale (Scheme 11).52 
 
Scheme 11: Zincation of nitro-substituted pyridine 64 using TMPZnCl·LiCl (62) or 
TMP2Zn·2LiCl·2MgCl2 (63). 
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3.4 Transmetalation 
When a magnesium or lithium organometallic species is treated with an inorganic salt such as ZnCl2, 
the more stable carbon-metal bond forms. This so called transmetalation process was found to be useful 
in the preparation of sensitive reagents and also allows the metalation of certain scaffolds with new 
selectivities.53 Additionally, the transmetalation process is used for e.g. allylation, acylation or cross-
coupling reactions, in which the reactive organometallic is required to be either a copper or a zinc 
species.15 Thus, in the presence of a zinc salt and lithium chloride, magnesium inserts to the carbon 
bromine bond of ethyl 4-bromobenzoate, and is then rapidly transmetalated to the more stable zinc 
species, which, after copper-mediated acylation with pivaloyl chloride, leads to the ketone 68 in 85% 
yield (Scheme 12). 
 
Scheme 12: A magnesium insertion followed by an in situ transmetalation to zinc. 
When arene 69 is treated with TMPMgCl·LiCl (31) the most acidic proton is deprotonated. After 
quenching of this metal species with iodine, arene 70 is obtained in 46% yield. However, performing 
the metalation with TMPLi in the presence of ZnCl2·2LiCl, the least sterically hindered site, adjacent 
to the more powerful ester directing group, is deprotonated and rapidly transmetalated to zinc. Due to 
the transmetalation process, unwanted side reactions, such as attack of the sensitive functional groups, 
are avoided, and the iodinated arene 71 is obtained in 54% yield (Scheme 13). 
 
Scheme 13: Metalation of arene 69 using either TMPMgCl·LiCl or TMPLi in the presence of 
ZnCl2·2LiCl.  
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4 Objectives 
Since the development of transition-metal-free amination reactions is highly desirable, the amination of 
several N-heterocycles using magnesium amides was to be tested. First, pyridine-2-sulfonyl chloride 
and the corresponding sulfonamide were investigated,54 followed by the related sulfonic acids. Also, 
substituted 2-pyridones and related N-heterocycles were to be treated with magnesium amides 
(Scheme 14). 
 
Scheme 14: Transition-metal-free amination reactions of pyridine-2-sulfonyl chlorides, sulfonic acids, 
and substituted 2-pyridones. 
For pyridine-2-sulfonamides and substituted 2-pyridones, a directed ortho-metalation/amination 
sequence was envisioned, which would allow the facile preparation of 2,3-difunctionalized pyridines 
(Scheme 15). 
 
Scheme 15: Directed ortho-metalation and subsequent amination of pyridine-2-sulfonamides and 
substituted 2-pyridones using magnesium amides. 
Another task was the metalation and functionalization of the heterocycles 1,5-naphthyridine,55 
pyrazolo[1,5-a]pyridine, and pyridazine using TMP-bases. The regioselectivity of the metalation was 
to be investigated and adjusted by choice of an appropriate Lewis acid. Especially in the case of 
pyridazine, it was envisioned, that the use of a bidentate boron Lewis acid might enable a directed 
metalation in the meta position (Scheme 16). 
                                                     
54
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Scheme 16: Regioselective metalation and functionalization of 1,5-naphthyridine,  
pyrazolo[1,5-a]pyridine, and pyridazine using TMP-bases and boron Lewis acids. 
A final objective was the development of a halogen/zinc exchange reaction using lithium alkoxide 
complexed dialkyl zinc reagents.56 It was anticipated, that these reagents are suitable for the preparation 
of organometallic species in toluene (see chapter 3.2). Since zinc organometallics are very mild, 
sensitive functional groups such as ketones, aldehydes or nitro-groups should be tolerated by these 
novel exchange reagents (Scheme 17). 
 
Scheme 17: The halogen/zinc exchange reaction using lithium alcoxide complexed dialkylzinc 
reagents. 
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1 Transition-Metal-Free Amination of Pyridine-2-Sulfonyl Chloride and 
Related N-Heterocycles Using Magnesium Amides 
1.1 Introduction 
Aminopyridines and related aminated N-heterocycles are important targets for the pharmaceutical 
industry.57 The amination of 2-halopyridines has been extensively studied using either Pd-, Ni-, Cu-, 
Co-, or Cr-catalysis, or a transition-metal-free substitution with various amines or lithium 
amides.6,7,10,11,12,58 Most of the transition-metal-free aminations proceed at high temperatures, require 
long reaction times or highly basic lithium amides. Also, 2-halo, 2-cyano or 2-
trifluoromethylsulfonylpyridines were often used as substrates. Additionally, pyridine sulfonamides 
have attracted attention due to their medical significance and as building blocks for the preparation of 
more complex pyridine derivatives.59 
Herein, we describe a new amination procedure of chlorosulfonyl substituted N-heterocycles of type 72 
or related sulfonamides of type 73 with magnesium amides of type 74 leading to the aminated pyridine 
derivatives of type 75 (Scheme 18). So far, only ortho-lithiation of (hetero)aryl sulfonamides and 
subsequent Suzuki-Miyaura cross-coupling or reaction with selected electrophiles has been reported.60 
Thus, to extend the utility of the amination method, the ortho-magnesiation33,61 of sulfonamides of type 
73 with TMPMgCl·LiCl15,37 (TMP = 2,2,6,6-tetramethylpiperidyl) was investigated.62 
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241, 1033–1040; c) S. Cacchi, A. Carangio, G. Fabrizi, L. Moro, P. Pace, Synlett 1997, 12, 1400–1402; d) L. B. 
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Liu, Y. Dong, H. Liu, Chem. Eur. J. 2017, 23, 2481–2511; i) Y. Park, Y. Kim, S. Chang, Chem. Rev. 2017, 117, 
9247–9301; j) Y. H. Chen, S. Graßl, P. Knochel, Angew. Chem. Int. Ed. 2018, 57, 1108–1111 
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Wang, Curr. Top. Med. Chem. 2011, 11, 1464–1475. 
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 a) C. Schneider, E. Broda, V. Snieckus, Org. Lett. 2011, 13, 3588–3591; b) F. Marsais, A. Cronnier, F. Trécourt, 
G. Quéquiner, J. Org. Chem. 1987, 52, 1133–1136; c) B. I. Alo, O. B. Familoni, F. Marsais, G. Quéguiner, J. 
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 The compounds 75a,c,d,f, 77a–e, 79a–d, 81a–f, 83b were prepared by C. François and P. Quinio and will be 
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Scheme 18: Synthesis of 2-aminopyridines using magnesium amides (74). 
1.2 Amination of Pyridine-2-sufonyl Chloride and the Directed ortho-Metalation of Pyridine-2-
sulfonamides. 
Thus, pyridine-2-sulfonyl chloride (72) was treated with Et2NMgCl·LiCl (2.4 equiv) in THF at 0 °C 
and stirred for 2 h at 25 °C, leading to the 2-aminated pyridine 75a in 84% yield. This amination was 
extended to various magnesium amides affording the corresponding 2-aminopyridines 75b–f under 
similar conditions in 73–88% yield (Scheme 19). 
 
Scheme 19: Synthesis of 2-aminopyridines 75a–f starting from pyridine-2-sulfonyl chloride (72) 
using magnesium amides (74). 
The pyridine sulfonamide 73a was prepared from pyridine-2-sulfonyl chloride (72) and piperidine 
(3 equiv) in 81% yield. Subsequent reaction of 73a with TMPMgCl·LiCl at 0 °C for 2 h lead to the 
corresponding 3-magnesiated sulfonamide of type 76 (Table 1). Quenching of this metalated species 
with various electrophiles such as (BrCl2C)2, I2 or TMSCl furnished the expected products 77a–c in 64–
81% yield (entries 1–3). Arylation of the magnesium species of type 76 was achieved by transmetalation 
with ZnCl2 and Negishi cross-coupling26 with iodobenzene in the presence of 3 mol% Pd(OAc)2 and 
6 mol% SPhos63 which gave the sulfonamide 77d in 82% yield (entry 4). Transmetalation of the 
Grignard reagent of type 76 to the corresponding copper derivative using CuCN·2LiCl64 and subsequent 
reaction with allyl bromide (–20 °C to 25 °C, 1 h) afforded the allylated sulfonamide 77e in 90% yield 
(entry 5). Similarly, the pyridine sulfonamide 73b, prepared from pyridine-2-sulfonyl chloride (72) and 
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the acyclic amine N-butylmethylamine in 86% yield, was magnesiated and subsequently quenched with 
several electrophiles leading to the 3-substituted sulfonamides 78a–e in 73–92% yield (entries 6–10). 
Table 1: ortho-Functionalization of sulfonamides 73a and 73b using TMPMgCl·LiCl. 
 
1.3 Amination of ortho-Functionalized Pyridine- and Quinoline-Sulfonamides and 
Quinolinesulfonyl Chlorides 
The substituted sulfonamides of type 77 and 78 were smoothly aminated with two different magnesium 
amides leading to the corresponding aminopyridines 79a–h under standard conditions in up to 97% 
yield (Scheme 20).65 A one-pot procedure involving first the magnesiation of 73a or 73b with 
TMPMgCl·LiCl, then a reaction with an electrophile (such as (BrCl2C)2, TMSCl or PhI) and subsequent 
amination with a magnesium amide gave the 2,3-disubstituted aminopyridines 79g–i in 48–70% yield 
(Scheme 20). 
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 Amination of 78e led to double-bond isomerization instead of clean formation of the desired aminated 
compound of type 79. 
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Scheme 20: Desulfonylation of sulfonamides of type 77 and 78 to give aminopyridines 79a–i. 
Additionally, the amination procedure was performed with commercially available 8-quinolinesulfonyl 
chloride (80). Interestingly, the magnesium amide of type 74 prepared from pyrrolidine (5 equiv) using 
iPrMgCl·LiCl (5 equiv) reacted with 80 to afford the aminated quinoline 81a in 99% yield. Extension 
to further cyclic amides led to the corresponding amination products 81b–f in 36–98% yield 
(Scheme 21). 
 
Scheme 21: Synthesis of 8-aminoquinolines 81a–f starting from 8-quinolinesulfonyl chloride (80). 
Furthermore, the ortho-metalation of the quinoline scaffold was investigated. Thus, the quinoline 
sulfonamides 82a–b were readily magnesiated using TMPMgCl·LiCl and reacted with iodine. 
Subsequent reactions with the piperidine magnesium amide of type 74 afforded the 2,3- and 7,8-
functionalized quinolines 83a–b in 52–59% yield over two steps (Scheme 22). 
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Scheme 22: ortho-Functionalization and desulfonylation of quinoline sulfonamides 82a and 82b. 
1.4 Mechanistic Investigations and Intramolecular Cyclization Reactions 
Also, the mechanism of this amination was briefly examined. Two mechanistic pathways can be 
postulated. The first mechanism involves an addition of the magnesium amide of type 74 to the pyridine 
core leading to the intermediate 84, which, after elimination of R2NSO2MgCl, afforded the aminated 
pyridine 75 (SNAr; pathway A; Scheme 23). Alternatively, a second mechanism may involve the 
addition of R2NMgCl·LiCl (74) to the sulfonamide group providing intermediate 85, which may 
undergo an intramolecular transfer of the amino moiety leading to intermediate 84 and finally to the 
aminopyridine 75 (pathway B, Scheme 23). Evidence for this second pathway was found when a 
pyridine-2-sulfonamide PySO2NR12 reacted with the magnesium amide R22NMgCl·LiCl which led to 
mixtures of PyNR12 and PyNR22. 
 
Scheme 23: Plausible mechanisms for the amination of pyridines using magnesium amides. 
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When for example sulfonamide 73a reacted with the pyrrolidine magnesium amide of type 74 
(1.5 equiv) the ratio between amines 75c and 75d was 20:1 (Scheme 23).66 Notice, that the treatment of 
1-naphthalenesulfonyl chloride with an excess of magnesium amide R2NMgCl·LiCl only led to the 
formation of the corresponding sulfonamide, and no amination product was detected, showing the 
importance of the heterocyclic nitrogen atom present in intermediate 85 for this amination. 
Finally, the amination method was extended to cyclization reactions. Thus, pyridine sulfonamide 73a 
was magnesiated with TMPMgCl·LiCl and then transmetalated with CuCN·2LiCl. Subsequent reaction 
with 2-methoxyallyl bromide67 followed by acidic enol ether cleavage gave the corresponding ketone 
in 94% yield. Subsequent reductive amination using benzylamine, sodium triacetoxyborohydride and 
acetic acid68 afforded the desired pyridine sulfonamide in 73% yield. Deprotonation with phenyllithium 
(1.2 equiv) led to a lithium amide that underwent a smooth cyclization, which, after aromatization using 
DDQ (1.05 equiv), gave the azaindole 86 in 47% yield over two steps (Scheme 24). Also, sulfonamide 
87 reacted with the Boc-protected iodoaniline 88 under Suzuki-Miyaura cross-coupling conditions.60a,69 
Subsequent deprotection using TFA gave the desired pyridine sulfonamide in 49% yield over two steps. 
Reaction with phenyllithium led to the aza-carbazole 89 in 84% yield (Scheme 24). 
 
Scheme 24: Synthesis of heterocycles via cyclization reactions using phenyllithium. 
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2 Amination of 2-Pyridinesulfonic and 8-Quinolinesulfonic Acids with 
Magnesium Amides 
2.1 Introduction 
Aminated N-heterocycles and especially aminopyridines and -quinolines are important targets for the 
pharmaceutical industry.57 Chloropyramine (90), for example, is an antihistaminic and the pyridine 91 
is a CXCR3 Inhibitor.70 The aminoquinoline primaquine (92) is commonly prescribed for the treatment 
of malaria,71 and crenolanib (93) is currently being evaluated as a drug against various types of tumors 
(Figure 2).72 
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Figure 2: Various pharmaceutically active aminopyridines and -quinolines. 
Thus, the development of C-N bond forming reactions is of high importance. So far, transition-metal-
catalyzed methods using Ni-, Pd-, Cr-, Co-, or Cu-salts have been used for the formation of the C-N 
bond (Figure 3a).6,7,58 However, transition-metals are expensive and often toxic.8 Therefore, the 
development of transition-metal-free amination methods is highly desirable. So far, 2-halo, 2-mercapto 
and 2-cyanopyridines, and 2-pyridyl trifluoromethanesulfonate or pyridine N-oxides were found to be 
suitable substrates for this transformation (Figure 3b).10,11,12 However, many of these methods require 
high temperatures or highly basic lithium amides. Transition-metal-free aminations of 2-
pyridinesulfonyl chloride and related heterocycles using magnesium amides of type R2NMgCl·LiCl are 
described in chapter 1. 2-Pyridinesulfonyl chloride, though, is a sensitive reagent which decomposes at 
25 °C within several hours.73 Albeit being commercially available, quinoline-8-sulfonyl chloride also 
decomposes at ambient temperature within three to five months. 2-Pyridine- or 8-quinolinesulfonic 
acids (94 and 95) are commercially available and stable reagents, which are formed upon decomposition 
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of the corresponding sulfonyl chloride. Herein, we report the amination of 2-pyridine- and 8-
quinolinesulfonic acids using magnesium amides of type R2NMgCl·LiCl, leading to aminopyridines of 
type 96 and 97 and aminoquinolines of type 98 (Figure 3c). 
 
Figure 3: Various conditions for amination reactions, including the transition-metal-free amination of 
2-pyridinesulfonic acids using magnesium amides. 
2.2 Amination of 2-Pyridinesulfonic Acid with Magnesium Amides 
Thus, pyrrolidine (3.0 equiv) was dissolved in THF and treated with iPrMgCl·LiCl (3.0 equiv) at 0 °C. 
The resulting magnesium amide R2NMgCl·LiCl was then added to a suspension of 2-pyridinesulfonic 
acid (94) in THF at 0 °C and stirred at 25 °C for 12 h. After workup, the aminopyridine 96a was isolated 
in 91% yield (Scheme 25). Using less equivalents of magnesium amide led to a decrease in yield. Other 
cyclic amides derived from piperidine, azepane, morpholine, N-methylpiperazine, or 4-
methylpiperidine gave aminopyridines 96b–f in 90–97% yield. Additionally, the upscaling of the 
reaction was evaluated by preparing the aminopyridine 96b on a 50 mmol scale in 90% yield. 
Symmetrical amides prepared from diethyl-, dibutyl-, or diallylamine yielded pyridines 96g–i in 76–
88% yield. The unsymmetrical amine N-butylmethylamine was also suitable for the amination reaction, 
leading to the aminopyridine 96j in 98% yield. Other amines bearing e.g. a cyclobutane ring or a 
TBDMS-protected alcohol, produced the aminopyridines 96k–o in 59–94% yield. Amines containing 
a heterocycle such as a pyridine or a thiophene gave the corresponding pyridines 96p–q in 65–91% 
yield (Scheme 25). 
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Scheme 25: Amination of 2-pyridinesulfonic acid (94) using magnesium amides of type 
R2NMgCl·LiCl leading to aminopyridines 96a–q. 
As an extension, several amines important in medicinal chemistry were employed in this amination 
protocol. Thus, lorcaserin hydrochloride hemihydrate was treated with an excess of iPrMgCl·LiCl in 
order to neutralize the hemihydrate and the HCl salt, which resulted in the formation of the respective 
magnesium amide. This amide readily reacted with 2-pyridinesulfonic acid (94), to give aminopyridine 
97a in 73% yield (Scheme 26). Also, the HCl salts of the amines nortriptyline and desipramine were 
neutralized and deprotonated using iPrMgCl·LiCl. The resulting amides were employed in the 
amination reaction, leading to pyridines 97b–c in 84–90% yield. The antidepressant amoxapine gave 
the polycyclic heterocycle 97d in 52% yield (Scheme 26). 
 
Scheme 26: Amination of 2-pyridinesulfonic acid (94) using magnesium amides leading to 
aminopyridines 97a–d.  
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2.3 Amination of Quinoline-8-sulfonic Acid with Magnesium Amides 
Interestingly, 8-quinolinesulfonic acid (95) was also a suitable reagent for the amination reaction. Thus, 
when the amides (5.0 equiv) derived from several amines, including 4-methylpiperidine or N-
methylpiperazine, were employed in the amination reaction, 8-aminoquinolines 98a–f were obtained in 
61–96% yield. The upscaling of this method was demonstrated upon the synthesis of aminoquinoline 
98b on a multi-gram scale in 66% yield (Scheme 27). 
 
Scheme 27: Amination of 8-quinolinesulfonic acid (95) using magnesium amides, leading to 
aminoquinolines 98a–f. 
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3 Amination of Phosphorodiamidate-Substituted Pyridines and Related N-
Heterocycles with Magnesium Amides 
3.1 Introduction 
Aminated N-heterocycles play a major role in modern pharmaceutical chemistry.57 Especially 
aminopyridines and -quinolines have shown to be of high importance. For example, tripelennamine and 
chlorothen are antihistamines, flupirtine is a non-opioid analgesic and chloroquine is used for the 
treatment of malaria (Figure 4).74  
 
Figure 4: Biologically active aminopyridines tripelennamine, chlorothen, flupirtine, and chloroquine. 
A range of heteroaryl amines have been prepared via nucleophilic aminations using transition metal 
catalysts of Pd, Ni, Cu, Co, and Cr.6,7,58 The development of transition-metal-free amination methods is 
highly desirable.8 So far, 2-halo-, 2-mercapto-, and 2-cyanopyridines, and 2-pyridyl 
trifluoromethanesulfonates or pyridine N-oxides were employed as electrophilic substrates for 
transition-metal-free amination reactions.10,11,12 However, most of these methods require high 
temperatures or highly basic lithium amides. In chapter 1, it was demonstrated, that pyridine-2-sulfonyl 
chloride, which was prepared from 2-mercaptopyridine, readily undergoes an amination when being 
treated with a magnesium amide of type R2NMgCl·LiCl. However, pyridine-2-sulfonyl chloride is 
instable at room temperature,73 and 2-mercaptopyridine has to be prepared from a halopyridine, making 
this procedure lengthy and inefficient. 
On another hand, hydroxypyridines (pyridones) or hydroxyquinolines (quinolones) are readily available 
scaffolds, which are building blocks for the synthesis of several pharmaceuticals and natural products.75 
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They are readily converted to the corresponding phosphorodiamidates of type 99, which are prone to 
undergo directed ortho-metalation (DoM), allowing the synthesis of 2,3-difunctionalized N-
heterocycles.47 Herein, we report, that the treatment of such phosphorodiamidate substituted pyridines 
with R2NMgCl·LiCl leads to the desired aminated heterocycles in the absence of any transition-metal 
catalyst. 
3.2 Amination of Phosphorodiamidate-Substituted Pyridines, Quinolines, and Quinoxalines 
Thus, 2-pyridone was treated with (Me2N)2P(O)Cl (1.2 equiv) in THF to give the phosphorodiamidate 
99a in 91% yield (Scheme 28). Other N-heterocyclic phosphorodiamidates were obtained using the 
same or a slightly modified procedure to give the substituted N-heterocycles 99b–i in 56–94% yield.47 
Next, piperidine (1.4 equiv) was dissolved in THF, cooled to 0 °C, and treated with iPrMgCl·LiCl (1.4 
equiv) to give the corresponding magnesium amide R2NMgCl·LiCl within 30 min. This amide was 
added to a solution of 99a in THF at 0 °C and stirred at 25 °C for 8 h. After workup, the desired aminated 
pyridine 100a was isolated in 88% yield (Scheme 28). Other cyclic amines, such as pyrrolidine, 
morpholine, N-methyl piperazine, or 4-phenylpiperidine were also converted into the corresponding 
amide derivatives using iPrMgCl·LiCl and employed in the amination reaction, leading to aminated 
pyridines 100b–e in 68–86% yield. Also, the more challenging TBDMS-protected 3-hydroxypiperidine 
and indoline were suitable substrates for the amination protocol, leading to aminopyridines 100f–g in 
52-54% yield. 
 
Scheme 28: Synthesis of pyridine-2-phosphorodiamidates of type 99 followed by the amination of 99 
using magnesium amides R2NMgCl·LiCl, leading to aminopyridines of type 100. 
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Acyclic amines were converted into the corresponding amides, which, after amination, resulted in the 
formation of the pyridines 100h–k in 64–78% yield. When N'-benzyl-N,N-dimethylethylenediamine 
was used as substrate, the antihistaminic tripelennamine 100l was obtained in 74% yield. Additionally, 
prefunctionalized pyridones were transformed into the corresponding phosphorodiamidates, leading, 
after amination, to pyridines 100m–p in 66–74% yield (Scheme 28). 
Amination at the C4-position of the pyridine ring is often difficult to achieve, mainly due to instability 
of the corresponding starting material. Thus, 4-bromopyridine is only stable when being stored as the 
corresponding HCl salt76 and pyridine-4-sulfonyl chloride decomposes rapidly and is difficult to 
isolate.73 However, 4-pyridone is a commercially available solid, which can be stored at 25 °C over 
months. Thus, after conversion of 4-pyridone to the corresponding phosphorodiamidate 99d, several 
amines, including a mixed nitrogen sulfur heterocycle and azepane, were applied to the amination 
protocol, yielding the 4-aminopyridines 101a–d in 69–98% yield (Scheme 29). The aminopyridines  
101e–f were isolated in 43–70% yield, by the reaction of the magnesium amides derived from the 
antidepressants nortriptyline and fluoxetine with 99d (Scheme 29). 
 
Scheme 29: Synthesis of 4-aminopyridines 101a–f using magnesium amides R2NMgCl·LiCl. 
Apart from the pyridine scaffold, also hydroxyquinolines and 2-hydroxyquinoxaline were aminated. 
Thus, 2-, 4-, and 8-hydroxyquinoline and 2-hydroxyquinoxaline were converted into the corresponding 
phosphorodiamidates 99e–i and submitted to the standard amination protocol. The substituted 2- and 4-
hydroxyquinolines were aminated using various amines including amoxapine, leading to quinolines 
102a–h in 57–90% yield (Scheme 30a). Interestingly, the phosphorodiamidate derived from  
8-hydroxyquinoline or 5-chloro-8-hydroxyquinoline also underwent amination, yielding  
8-aminoquinolines 102i–l in 52–68% yield (Scheme 30b). Finally, the electron-rich quinoxaline 
derivative 99i was treated with various magnesium amides, including the amides derived from 
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desipramine or the sterically demanding 1-methyl-3-phenyl-piperazine, and the quinoxalines 103a–f 
were isolated in 54–89% yield (Scheme 30c). 
 
Scheme 30: Synthesis of 2-, 4- and 8-aminoquinolines 102a–l and 2-aminoquinoxalines 103a–f using 
magnesium amides R2NMgCl·LiCl. 
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3.3 Directed ortho-Metalation and Amination of Various Phosphorodiamidate-Substituted N-
Heterocycles 
Since the phosphorodiamidate functional group is a strong directed metalation group (DMG),33,61 it was 
possible to combine the amination with an ortho-functionalization. Thus, several phosphorodiamidate 
substituted N-heterocycles (99a,d,f,i) were treated with TMPMgCl·LiCl (TMP = 2,2,6,6-
tetramethylpiperidyl)15,37 or TMP2Mg·2LiCl15,45 in THF at 0 °C for 1 h. The formed magnesium species 
of type 104 was then either quenched with electrophiles (E-X) such as I2 or (BrCl2C)2 or underwent Cu-
catalyzed acylation reactions or Pd-catalyzed Negishi26 cross-couplings after transmetalation to Zn.77 
The resulting functionalized heterocycles of type 105 were then aminated, leading to difunctionalized 
pyridines 106a–d, quinoline 107, and to quinoxalines 108a–c in 35–66% yield over two steps 
(Scheme 31). 
 
Scheme 31: Directed ortho-Metalation and Functionalization of Various Phosphorodiamidates, 
Followed by Amination with R2NMgCl·LiCl. 
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 Transmetalation to the corresponding zinc organometallic was performed using a 1 M ZnCl2 solution in THF. 
For more details see the Experimental Part C. 
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4 Zn-, Mg-, and Li-TMP Bases for the Successive Regioselective 
Metalations of the 1,5-Naphthyridine Scaffold 
4.1 Introduction 
Heterocyclic structures are ubiquitous in pharmaceutical and agrochemical research, and the discovery 
of new medicinal targets requires the functionalization of always less common heterocycles.2,78 
Naphthyridines certainly belong to the heterocycles of the future79 and their functionalization via 
metalation is still in its infancy.80 Especially 1,5-naphthyridines have been identified as suitable 
candidates for antimalarial,81 antibacterial,82 anti-Alzheimer,83 antiparasitic,84 or anticancer85 drugs. 
Also, their applicability for OLED materials has been demonstrated.86 Recently, it has reported, that 
various metallic TMP bases (TMP = 2,2,6,6-tetramethylpiperidyl) are powerful metalating reagents, 
and, that Lewis acids such as BF3·OEt2 may enhance their metalation power and/or improve 
regioselective metalations.15,48,49,87 
Herein, we report a convenient regioselective metalation and functionalization of the 1,5-naphthyridine 
scaffold (109) and show, that, by using a combination of Zn-, Mg-, and Li-TMP bases with or without 
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80
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BF3·OEt2, it is possible to regioselectively metalate the 1,5-naphthyridine scaffold providing mono-, 
di-, tri-, or tetra- substituted naphthyridines of type 110–114 (Scheme 32).55,88 
 
Scheme 32: Regioselective functionalization of the 1,5-naphthyridine scaffold (109) using Zn-, Mg-, 
and Li-TMP bases. 
4.2 Metalation and Functionalization of 1,5-Naphthyridine in Positions C2, C4 and C8. 
Thus, it was found that the precomplexation89of 109 with the magnesium amide TMP2Mg·2LiCl (44; 
1.1 equiv)45 at –78 °C in THF induces a magnesiation at position C4 within 5 min leading to the 
magnesiated heterocycle 115, which, after quenching with several electrophiles (E1-X), leads to 4-
substituted 1,5-naphthyridines of type 110 (Table 2). When the magnesium species 115 was treated 
with iodine and 1,2-dibromotetrachloroethane, the 4-halo-1,5-naphthyridines 110a–b were isolated in 
49–62% yield (entries 1–2). Transmetalation of 115 with ZnCl2 and subsequent acylation with pivaloyl 
chloride in the presence of 2 mol% Pd(PPh3)4 gave the 4-acyl-1,5-naphthyridine 110c in 63% yield 
(entry 3). Transmetalation of 115 to the corresponding copper derivative using CuCN·2LiCl64 and 
reaction with 3-bromocyclohexene or ethyl 2-(bromomethyl)acrylate90 provided the allylated 1,5-
naphthyridines 110d–e in 53–60% yield (entries 4–5). Arylation of the magnesium species 115 was 
performed by transmetalation with ZnCl2 and Negishi cross-coupling26 with electron rich, neutral, and 
poor aryl iodides in the presence of either 3 mol% Pd(dba)2 and 6 mol% tfp (tri(2-furyl)phosphine)46 or 
5 mol% Pd(PPh3)4 leading to 1,5-naphthyridines 110f–h in 48–75% yield (entries 6–8). 
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Table 2: Metalation and functionalization of 1,5-naphthyridine (109) in the C4 position using 
TMP2Mg·2LiCl (44). 
 
entry electrophile product yield[a] 
  
 
 
1 I2    110a: X = I; 62% 
2 (BrCCl2)2    110b: X = Br; 49% 
3 tBuCOCl    110c: X = COtBu; 63%[b] 
   
4 
 
 
   110d: 60%[c] 
5 
 
 
   110e: 53%[c] 
 
 
 
 
 
6     X = H    110f:  X = H; 63%[d] 
7     X = OMe    110g: X = OMe; 75%[d] 
8     X = CN    110h: X = CN; 48%[e] 
  
 
[a] Isolated yield. [b] 2 mol% Pd(PPh3)4 after transmetalation with a 1 M ZnCl2 solution was used [c] A 1 M 
CuCN·2LiCl solution was used for transmetalation. [d] 3 mol% Pd(OAc)2 and 6 mol% SPhos after 
transmetalation with a 1 M ZnCl2 solution was used. [e] 5 mol% Pd(PPh3)4 after transmetalation with a 1 M 
ZnCl2 solution was used. 
 
The presence of a substituent E1 in the naphthyridine 110 at position C4 prevents further complexation 
of a metallic amide at N5 and favors the precomplexation of TMPMgCl·LiCl (31)15,37 or TMPZnCl·LiCl 
(62)15,50 at N1. This favors a directed magnesiation (or zincation) at C8, providing, after quenching with 
several electrophiles (E2-X), the regioselectively defined 4,8-substituted 1,5-naphthyridines of type 111. 
Alternatively, the naphthyridine 110 can be treated with BF3·OEt2 which has two consequences: (1) 
BF3 hampers a metalation at position C8, since no efficient complexation of the magnesium base (31) 
is possible; (2) the BF3-complexation dramatically enhances the acidity at C2. This results in a 
regioselective magnesiation at C2 using TMPMgCl·LiCl (31). After quenching with an electrophile 
(E2-X), 2,4-disubstituted 1,5-naphthyridines of type 112 are obtained (Scheme 33). Thus, the 
naphthyridine 110b was metalated with TMPMgCl·LiCl (31, 1.2 equiv, –40 °C, 1 h) to give the 
magnesiated species 116. Reaction of 116 after transmetalation to zinc with 1-chloro-4-iodobenzene 
under standard Negishi cross-coupling conditions26 resulted in the formation of the biaryl 111a in 59% 
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Scheme 33: Metalation and functionalization of 4-substituted 1,5-naphthyridines (110) using 
TMPMgCl·LiCl (31) or TMPZnCl·LiCl (62). 
 
Table 3: Metalation and functionalization of 1,5-naphthyridines of type 110 in the C8- and C2-position 
using TMPMgCl·LiCl (31) or TMPZnCl·LiCl (62). 
entry substrate electrophile product, yield[a] 
 
 
 
 
1 110b  111a: 59%[b][c] 
 
 
(BrCCl2)2 
 
2 110g: p-An = p-C6H4OMe 111b: 60%[b] 
3 110g 
 
 
   
111c: 60%[b][d] 
4 
 
 
 
 
110c 
 
111d: 71%[e] 
 
 
 
 
5 110c     X = p-CF3 111e: X = p-CF3; 98%[c][e] 
6 110c     X = m-COiPr 111f: X = m-COiPr; 97%[c][e] 
7 110c 
 
 
   
111g: 80%[d][e] 
 
entry substrate electrophile product, yield[a] 
 
 
 
 
8 110a I2      112a: X = I; 74%[f] 
9 110a (BrCCl2)2      112b: X = Br; 72%[f] 
10 110a PhCOCl  112c: X = COPh; 53%[d][f]
11 
 
 
 
 
110g 
 
            112d: 70%[d][f] 
12 110g p-Tol-I 
 
                              p-Tol = p-C6H4Me         112e: 56%[c][f] 
 
 
 
 
13 110f I2      112f: X = I; 58%[f] 
14 110f (BrCCl2)2      112g: X = Br; 89%[f] 
15 110f MeSSO2Me      112h: X = SMe; 52%[f]
16 110f 
 
 
   
112i: 59%[d][f] 
17 110f 
 
 
   
112j: 63%[d][f] 
[a] Isolated yield. [b] TMPMgCl·LiCl (1.3 equiv, –40 °C, 1 h) was used. 
[c] 4 mol% Pd(dba)2 and 8 mol% tfp after transmetalation with a 1 M
ZnCl2 solution was used. [d] A 1 M CuCN·2LiCl solution was used for 
transmetalation. [e] TMPZnCl·LiCl (1.5 equiv, 25 °C, 1 h) was used. 
[f] BF3·OEt2 (1.1 equiv, 0 °C, 10 min) and TMPMgCl·LiCl (1.2 equiv, 
–40 °C, 1 h) were used. 
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yield (Table 3, entry 1). Magnesiation of naphthyridine 110g and quenching with 1,2-
dibromotetrachloroethane gave the 8-bromo-naphthyridine 111b in 60% yield (entry 2). Allylation of 
the magnesium species 116 with 3-bromocyclohexene after transmetalation to copper afforded 
naphthyridine 111c in 60% yield (entry 3). Zincation of naphthyridine 110c with TMPZnCl·LiCl15,50 
(62, 1.5 equiv, 25 °C, 1 h) led to the formation of the heteroarylzinc halide 117, which was iodolyzed 
to give the 4,8-disubstituted naphthyridine 111d in 71% yield (entry 4). Cross-coupling of 117 with 1-
iodo-4-trifluoromethylbenzene or 1-(3-iodophenyl)-2-methylpropan-1-one yielded naphthyridines 
111e–f in 97–98% yield (entries 5–6). Allylation of 117 with allyl bromide gave naphthyridine 111g in 
80% yield (entry 7). A regioselectivity switch was possible as mentioned above by adding BF3·OEt2 
followed by TMPMgCl·LiCl (31).15,37 Both reagents are compatible with each other at temperatures 
below –40 °C.48 Thus, the 1,5-naphthyridines 110a,g and 110f were treated with BF3·OEt2 (1.1 equiv, 
0 °C, 10 min) followed by TMPMgCl·LiCl (31, 1.2 equiv, –40 °C, 1 h) providing the corresponding 
magnesium species 118 (Scheme 33). Subsequent acylation or halogenation provided 2,4-substituted 
1,5-naphthyridines 112a–c in 53–74% yield (entries 8–10). Applying a similar metalation protocol on 
the naphthyridine 110g furnished after acylation or cross-coupling the expected naphthyridines 112d-e 
in 56-70% yield (entries 11-12). Finally, 4-phenyl-1,5-naphthyridine (110f) was submitted to the 
standard metalation protocol and subsequent reaction with various electrophiles including S-methyl 
methanethiosulfonate gave naphthyridines 112f–j in 52–89% yield (entries 13–17). 
4.3 Metalation of Functionalized 1,5-Naphthyridines in Positions C7 and C8 
A third functionalization of 2,4-disubstituted 1,5-naphthyridines of type 112 was not possible using 
TMPMgCl·LiCl (31) or TMP2Mg·2LiCl (44), presumably due to a too weak precomplexation of these 
sterically hindered Mg-bases and a too low kinetic basicity. However, the stronger lithium amide 
TMPLi (119)91 readily complexes N1 and lithiates the closest C-H bond at C8. Thus, the treatment of 
112g with TMPLi (1.2 equiv, –78 °C, 30 min) afforded the 8-lithionaphthyridine of type 120 which was 
trapped by several electrophiles including methyl iodide and benzaldehyde providing 2,4,8-
trifunctionalized naphthyridines 113a–f in 70–99% yield. Addition of TMPLi to 112h followed by 1,2-
dibromotetrachloroethane gave the bromonaphthyridine 113g in 47% yield (Scheme 34). 
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Scheme 34: Metalation and functionalization of 2,4-functionalized 1,5-naphthyridines (112) in the C8 
position using TMPLi (119). 
A fourth functionalization was achieved using a lithium-mediated “halogen dance” rearrangement.92 
Thus, the reaction of the trifunctionalized naphthyridine 113a with TMPLi (1.2 equiv, –78 °C, 90 sec) 
followed by quenching with water gave the corresponding regioisomer 114a in 78% yield (Scheme 35). 
The formation of 114a was explained by a lithiation at position C7 leading to the lithium intermediate 
121 followed by a very fast “halogen dance” providing the more stable C8-lithiated naphthyridine (122). 
Reaction of 122 with various electrophiles (E-X) gave the 2,4,7,8-tetrasubstituted 1,5-naphthyridines 
114b–e in 62–74% yield. This iodine migration was also proven by an X-ray structure of 114b 
(Scheme 35).93 
 
Scheme 35: Performance of the “halogen dance” rearrangement leading to 2,4,7,8-tetrafunctionalized 
1,5-naphthyridines 114a–e. 
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4.4 Preparation of Precursors for OLED Materials and an Antibacterial Drug Candidate 
To demonstrate the utility of these naphthyridine functionalizations, a precursor for OLED materials 
12386c as well as a precursor for an antibacterial drug candidate 12482a were prepared. Thus, 1,5-
naphthyridine (109) was treated with TMPMgCl·LiCl (31, 3 equiv, –40 to –20 °C, 4 h) affording the 
4,8-dimagnesiated naphthyridine 125,94 which was subsequently quenched with 1,2-
dibromotetrachloroethane to give the desired dibrominated naphthyridine 123 in 53% yield on gram 
scale. Additionally, the reaction of 1,5-naphthyridine (109) with TMP2Mg·2LiCl (44, 0.6 equiv) and 
subsequent transmetalation with ZnCl2 followed by Negishi cross-coupling[16] with 1-iodo-4-tert-
butylbenzene yielded the substituted naphthyridine 126 in 88% yield. Subsequent directed lithiation 
using TMPLi (119) and quenching with methyl trifluoromethanesulfonate gave the naphthyridine 124 
in 53% yield (Scheme 36). 
 
Scheme 36: Synthesis of key step naphthyridines 123 and 124 for the synthesis of OLED materials 
and an antibacterial reagent 127. 
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 After iodolysis and GC-analysis (at 4 h, –20 °C) the ratio between the di-iodo and mono-iodo naphthyridine 
was 6:1. 
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5 Regioselective Metalation and Functionalization of the 
Pyrazolo[1,5-a]pyridine Scaffold Using Mg- and Zn-TMP Bases 
5.1 Introduction 
N-heterocycles are important scaffolds in pharmaceutical and agrochemical research.2,78 Whereas 
common N-heterocycles, such as pyridines, quinolines, or pyrimidines have been studied thoroughly, 
the functionalization of less conventional heterocycles is still in its infancy and the metalation of such 
unusual scaffolds is mainly unexplored. For example, pyrazolo[1,5-a]pyridines (128–132) have 
recently attracted much attention due to their multiple biologic activities and pharmaceutical 
applications.95 Pyrazolo[1,5-a]pyridine 129 is a dopamine D3 antagonist,95e 130 is a PI3 kinase 
inhibitor,95i and 131 and 132 act as EP1- and diuretic adenosine A1 antagonists, making them suitable 
candidates for the treatment of schizophrenia, cancer, or Parkinson’s disease (Figure 5).95b,c,k  
 
Figure 5: Biologically active derivatives of the pyrazolo[1,5-a]pyridine scaffold. 
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The direct functionalization of the pyrazolo[1,5-a]pyridine scaffold is not well studied,95h,96 and 
especially the regioselective functionalization of the C2 position is difficult to achieve.97 Recently, a 
range of TMP-Mg and TMP-Zn bases (TMP = 2,2,6,6-tetramethylpiperidyl) have been developed, 
which have proven to be very active metalating reagents, tolerating various functional groups, as well 
as sensitive heterocyclic structures.15,37,50 Furthermore, these Mg- and Zn-bases are compatible at low 
temperatures with strong Lewis acids, such as BF3·OEt2 or MgCl2.48,49,87 This combination (frustrated 
Lewis pair)98 greatly enhances the functionalization scope of such bases and allows to achieve new 
metalation patterns.48,49,87 Herein, the straightforward functionalization of the pyrazolo[1,5-a]pyridine 
scaffold 128 using a combination of Mg- or Zn-TMP bases and BF3·OEt2 is reported. 
5.2 Metalation and Functionalization of Pyrazolo[1,5-a]pyridine in the Presence or Absence of 
the Lewis Acid BF3·OEt2 
Thus, pyrazolo[1,5-a]pyridine (128) was treated with TMPMgCl·LiCl (1.2 equiv) for 15 min at  
–78 °C99 in THF, which results in the coordination of the TMP-base to the nitrogen atom N1, inducing 
a magnesiation in the C7-position. This led to the magnesium species of type 133, which, after 
quenching with iodine or dibromotetrachloroethane, gave the halogenated pyrazolo[1,5-a]pyridines 
134a–b in 69–93% yield (Table 4, entries 1–2). Reaction of the magnesium intermediate 133 with S-
methyl methanethiosulfonate gave the thiolated pyrazolo[1,5-a]pyridine 134c in 46% yield (entry 3). 
After transmetalation of 133 to the corresponding copper species using a CuCN·2LiCl64 solution in 
THF, quenching with 3-bromocyclohexene or ethyl 2-(bromomethyl)acrylate90 gave the allylated 
products 134d–e in 73–86% yield (entries 4–5). Such heterocyclic copper derivatives also reacted with 
several acid chlorides such as 2-chloro-, 2-iodo-, or 4-chlorobenzoyl chloride to give the acylated 
pyrazolo[1,5-a]pyridines 134f–h in 53–70% yield (entries 6–8). Reaction of 133 with DABSO 
(DABSO = DABCO-bis(sulfur dioxide)),100 followed by sulfuryl chloride and piperidine, gave the 
sulfonamide 134i in 55% yield (entry 9). After transmetalation of the magnesium species 133 to zinc 
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 A temperature of –78°C has to be used, since temperatures higher than –60 °C led to decomposition of the 
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 H. Woolven, C. González-Rodríguez, I. Marco, A. L. Thompson, M. C. Willis, Org. Lett. 2011, 13, 4876–
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using ZnCl2, a Negishi cross-coupling26 catalyzed by Pd(dba)2 (3 mol%, dba = dibenzylideneacetone) 
and tfp (6 mol%, tfp = tri-2-furylphosphine)46 with 4-iodotoluene was performed, leading to the arylated 
pyrazolo[1,5-a]pyridine 134j in 69% yield (entry 10). Reaction of this zinc species with other aryl 
iodides such as ethyl 3- or 4-iodobenzoate gave unsatisfactory results (yields below 20%). However, 
when the metalation was performed with TMPZnCl·LiCl (1.2 equiv) at 0 °C for 15 min, followed by 
standard Negishi cross-coupling conditions, the desired cross-coupling products 134k–l were obtained 
in 74–97% yield (entries 11–12). Apparently, the absence of magnesium salts had a significant influence 
on the reaction outcome of the corresponding cross-coupling reactions. 
Table 4: Metalation and functionalization of the pyrazolo[1,5-a]pyridine scaffold (128) using 
TMPMgCl·LiCl and TMPZnCl·LiCl. 
 
When pyrazolo[1,5-a]pyridine (128) was treated with BF3·OEt2 prior to the addition of the TMP-base, 
a switch of the metalation regioselectivity was observed. Presumably, BF3 coordinates to the nitrogen 
atom N1, which results in (1) blocking the coordination site for TMPMgCl·LiCl and (2) an enhancement 
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of the acidity at the C2 position. This leads to a regioselective magnesiation at C2 using 
TMPMgCl·LiCl. Thus, BF3·OEt2 was added to 128 at 0 °C for 10 min, followed by TMPMgCl·LiCl 
(1.2 equiv) at –78 °C, leading to the tentative magnesium species 135 after 10 min (Scheme 37). 
Reaction of 135 with iodine or dibromotetrachloroethane led to the C2 halogenated pyrazolo[1,5-
a]pyridines 136a–b in 55–92% yield. Palladium-catalyzed Negishi cross-couplings of 135 after 
transmetalation with ZnCl2 and reaction with ethyl 4-iodobenzoate or iodobenzene gave the arylated N-
heterocycles 136c–d in 67–68% yield. Copper-catalyzed acylation reactions with various acid 
chlorides, including 3-fluorobenzoyl chloride and 2-thiophenecarbonyl chloride, gave the acylated 
pyrazolo[1,5-a]pyridines 136e–h in 43–60% yield. Reaction of 135 with Tietze’s reagent101 yielded the 
aminomethylated N-heterocycle 136i in 51% yield (Scheme 37). 
 
Scheme 37: Metalation and functionalization of pyrazolo[1,5-a]pyridine (128) in the C2 position 
using BF3·OEt2 and TMPMgCl·LiCl. 
5.3 Metalation of Prefunctionalized Pyrazolo[1,5-a]pyridines 
Pyrazolo[1,5-a]pyridines were also functionalized in the C7 position using TMPMgCl·LiCl in the 
presence of a previously introduced substituent in position C2. Thus, several C2 functionalized 
pyrazolo[1,5-a]pyridines were treated with TMPMgCl·LiCl (1.2 equiv), leading to the magnesium 
species of type 137 (Scheme 38). Halogenation of 137 gave the expected products 138a–d in 49–77% 
yield. Interestingly, the metalation of 2-phenylpyrazolo[1,5-a]pyridine required 2.5 equivalents of the 
TMP-base to achieve full conversion. Palladium-catalyzed Negishi cross-couplings with various aryl 
halides or copper-mediated allylation reactions with allyl bromide or 3-bromocyclohexene gave the 
difunctionalized N-heterocycles 138e–i in 56–99% yield. Thiolation was achieved by quenching 137 
with S-methyl methanethiosulfonate or S-phenyl benzenethiosulfonate, producing the thioethers  
138j–k in 52–64% yield (Scheme 38). 
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Scheme 38: Metalation and functionalization of various substituted pyrazolo[1,5-a]pyridines using 
TMPMgCl·LiCl. 
Pyrazolo[1,5-a]pyridines bearing an ester functionality in the C3 position also underwent a metalation 
using TMPMgCl·LiCl, allowing facile functionalization of the C7 position. Thus, magnesiation of 139 
with TMPMgCl·LiCl (1.2 equiv) led to the metalated species 140. The reaction of 140 with several 
electrophiles, including N-formylmorpholine and cyclopropane carbonyl chloride gave the 3,7-
bisfunctionalized pyrazolo[1,5-a]pyridines 141a–i in 39–83% yield (Scheme 39). 
 
Scheme 39: Metalation and functionalization of pyrazolo[1,5-a]pyridine 139 bearing an ester 
functionality in position C3. 
Additionally, ethyl or NHBoc substituted pyrazolo[1,5-a]pyridines at the C5-position bearing an ester 
at C3 (142 and 143) did not influence the metalation selectivity, leading to 3,5,7-trifunctionalized 
pyrazolo[1,5-a]pyridines of type 144 and 145 (Scheme 40). In the case of 143, 2.0 equivalents of 
TMPMgCl·LiCl were required for a complete magnesiation due to a carbamate functionality 
deprotonation. Reaction of the corresponding magnesium species with several electrophiles, including 
2-bromoquinoline and 3-iodopyridine gave the trifunctionalized pyrazolo[1,5-a]pyridines 144a–d and 
145a–d in 46–98% yield (Scheme 40). 
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Scheme 40: Metalation and functionalization of substituted pyrazolo[1,5-a]pyridines bearing a 
substituent in position C3 and C5. 
5.4 Sulfoxide Directed ortho-Metalation and Amination Using a Magnesium Amide 
Sulfoxides have shown to be excellent directed metalation groups (DMGs) and are also prone to 
undergo sulfoxide/magnesium exchange reactions, making them versatile intermediates in heteroarene 
functionalization.102 Thus, pyrazolo[1,5a]pyridine (128) was magnesiated under standard conditions 
and then quenched with S-phenyl benzenethiosulfonate. The resulting thioether was then oxidized using 
mCPBA (1.1 equiv) to give the sulfoxide 146 in 77% yield over two steps (Scheme 41). Subsequent 
directed ortho-metalation33,61 using TMPMgCl·LiCl (1.1 equiv) at –30 °C for 15 min, followed by 
Negishi cross-coupling with iodobenzene gave the ortho-arylated pyrazolo[1,5-a]pyridine 147 in 89% 
yield. Surprisingly, a sulfoxide/magnesium exchange was not possible using iPrMgCl·LiCl.103 
However, a new transition-metal-free amination of a heteroaryl sulfoxide was achieved. Thus, 147 was 
treated with 1.2 equiv of piperidyl magnesium amide 148 at –78 °C and, after 40 min reaction time, the 
6,7-difunctionalized pyrazolo[1,5-a]pyridine 149 was isolated in 55% yield (Scheme 41). 
 
Scheme 41: Directed ortho-metalation of a sulfoxide-substituted pyrazolo[1,5-a]pyridine using 
TMPMgCl·LiCl, followed by a transition-metal-free amination reaction. 
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6 Lewis Acid Directed Regioselective Metalations of Pyridazine 
6.1 Introduction 
N-Heterocycles are invaluable scaffolds in pharmaceutical and material research.2,78 Whereas the 
functionalization of pyridines is well established, other diazines such as pyrimidines and pyrazines are 
much less investigated and the regioselective functionalization of the pyridazine scaffold (150) is still 
in its infancy.50,104 Pyridazines are especially important N-heterocycles since they are present in various 
pharmaceuticals and agrochemicals.105 Also, they play the role of bioisosteres of pyridines and may 
therefore be important in drug design.106 Although a metalation of pyridazine (150) using TMPLi (TMP 
= 2,2,6,6-tetramethylpiperidyl) in the presence of ZnCl2·TMEDA (TMEDA = tetramethylethylene-
diamine) has been reported by Mongin, the ortho-regioselectivity was only 83%.104b Earlier metalations 
were found to proceed in moderate yields (16–32%).104a Kondo has shown, that a meta-functionalization 
of 150 could be achieved using an excess of a bulky Schwesinger base.107 Previously, it has been 
reported that magnesium and zinc organometallics are compatible with strong Lewis acids including 
BF3·OEt2.48,49,87 These frustrated Lewis pairs98 proved to be exceptional reagents for the regioselective 
metalation of various N-heterocycles.87 So far, directed ortho-metalations (DoM) of N-heterocycles 
have been the privileged method for performing regioselective metalations.33,61 Meta-metalations of 
arenes have been achieved using mixed alkali-metal-mediated metalations in which the second metal 
sodium plays a pivotal role in the stability of the formed organometallic species.108 Remote lithiations 
are also feasible on sterically hindered silylated arenes.109 That Lewis acids strongly acidify the protons 
of pyridazine (150) was demonstrated by calculations,110 showing that the ease of deprotonation may 
increase by mono-complexation (see 151) and further by a bis-complexation as shown in 152 
(Scheme 42). These calculations led us to examine the metalation of 150 using mono- or bidentate Lewis 
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acids. Herein, we wish to report, that the appropriate choice of a Lewis acid considerably facilitates a 
metalation and, combined with steric effects, allows the regioselective metalation of the pyridazine 
scaffold (150) either in position C3 or in position C4 (Scheme 42). 
. . . . .. . . .. . . . . .. . . . . .
 
Scheme 42: Calculated pKa values of pyridazine (150), the pyridazine-BF3 adduct (151), and a 
bidentate Lewis acid-pyridazine adduct (152) and the directed ortho- and meta-metalation of 
pyridazine (150) using TMPZnCl·LiCl. 
6.2 Directed ortho- and meta-Metalation and Functionalization of Pyridazine Using BF3·OEt2 
Thus, the metalation of pyridazine (150) with TMPMgCl·LiCl (31)15,37 in THF in the absence or 
presence of BF3·OEt2 was examined. In both cases, the yield was low and a good regioselectivity for 
this metalation could only be achieved in the presence of the Lewis acid (Table 5, entries 1–2). Higher 
yields were obtained, using the more covalent metal amide TMPZnCl·LiCl (62, entries 3–6).15,50 A low 
regioselectivity of the zincation was observed in the absence of BF3·OEt2 (entry 3). However, in the 
presence of BF3·OEt2 (1.1 equiv), a room temperature metalation of 150 proceeds within 2 h reaction 
time (entry 4). A crude NMR-determination showed a 96:4 ratio between 3-iodopyridazine (153) and 
4-iodopyridazine (154). By using 1.5 equiv of TMPZnCl·LiCl (62) and extending the reaction time to 
6 h a maximum conversion and excellent regioselectivity (153:154 = 97:3) was obtained, leading, after 
iodolysis, to pure 3-iodopyridazine (153) in 57% isolated yield. 
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Table 5: Optimization of the reaction conditions for the directed ortho-metalation of pyridazine (150). 
 
entry TMP base BF3·OEt2 Time [h] yield[a] ratio (153:154)[b] 
1 TMPMgCl·LiCl (31)[c] (1.05 equiv) - 0.25 12% 32:68 
2 TMPMgCl·LiCl (31)[c] (1.05 equiv) 1.1 equiv 0.25 1% 96:4 
3 TMPZnCl·LiCl (62) (1.10 equiv) - 2 45% 60:40 
4 TMPZnCl·LiCl (62) (1.30 equiv) 1.1 equiv 2 45% 96:4 
5 TMPZnCl·LiCl (62) (1.30 equiv) 1.1 equiv 6 64% n.d. 
6 TMPZnCl·LiCl (62) (1.50 equiv) 1.1 equiv 6 72% (57%)[d] 97:3 
[a] NMR yield using trimethoxybenzene as standard. [b] Determined by NMR analysis. [c] The reaction was run at –78 °C. 
[d] Isolated yield of 154. 
 
Further functionalizations were performed and an arylation using palladium-catalyzed Negishi cross-
couplings26 with various electron-rich and -poor aryl iodides, provided the 3-arylated pyridazines  
153a–f in 53–72% yield (Scheme 43). 
 
Scheme 43: BF3·OEt2 mediated ortho-zincation and arylation of pyridazine (150). 
In order to expand the scope of such metalations, 3-phenylpyridazine (153a, prepared according to 
Scheme 43) was treated with various metalation conditions (Table 6). The very strong and kinetically 
active base TMPLi (119, 0.95 equiv) led to an almost completely regioselective lithiation at position 
C6 (155:156 ratio = 96:4), providing, after iodolysis and isolation, the pure iodopyridazine 155 in 72% 
yield (Table 6, entry 1). 
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Table 6: Optimization of the reaction conditions for the directed ortho- and meta- metalation of 3-
phenylpyridazine (153a). 
 
entry TMP base (equiv) BF3·OEt2 time yield ratio (155:156)[a] 
1 TMPLi (119) (0.95 equiv) - 5 min 72%[b] 96:4 
2 TMPMgCl·LiCl (31) (1.1 equiv) 1.1 equiv 20 min 65%[c] 44:56 
3 TMPMgCl·LiCl (31) (2.0 equiv) 1.1 equiv 20 min 82%[c] (58%)[b] 27:73 
4 TMPMgCl·LiCl (31) (3.0 equiv) 1.1 equiv 20 min 45%[c] 26:74 
[a] Determined by NMR analysis. [b] Isolated yield of the main regioisomer. [c] NMR yield using trimethoxybenzene as standard. 
 
These conditions were used for further reactions of the metal species with D2O, (Cl3C)2, MeSSO2Me, 
PhSSO2Ph, and N-formylmorpholine, as well as allylic bromides, to give various 2,6-disubstituted 
pyridazines 155a–g in 44–79% yield (Scheme 44). 
 
Scheme 44: Directed ortho- metalation of 3-phenylpyridazine (153a) using TMPLi (119). 
Alternatively, using TMPMgCl·LiCl (31, 1.1 equiv) in the presence of BF3·OEt2 (1.1 equiv) led to an 
unselective deprotonation. In this case, after iodolysis, a 44:56 ratio between the iodides 155 and 156 
was obtained (Table 6, entry 2). Interestingly, increasing the amount of 31 (2.0 equiv) led to an 
improved regioselectivity of 27:73 (Table 6, entry 3). This result may be explained by assuming that 
1.0 equiv of 31 is used up to activate the heterocycle in addition to BF3·OEt2, also playing the role of a 
Lewis acid, whereas the second equivalent acts as deprotonating agent. Further increase of the amount 
of 31 did not improve this regioselectivity (entry 4). This enhanced selectivity proved to be sufficient 
for preparative applications. Thus, the treatment of various 2-arylpyridazines (153a,c,e) with 
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TMPMgCl·LiCl (31) in the presence of BF3·OEt2 led, after iodolysis or thiolation, to the regiomerically 
pure products 156 and 156a in 38–58% yield. Interestingly, replacing the 2-phenyl substituent of 153a 
with a para-anisyl or para-chlorophenyl substituent, led, with the same base system, to an almost 
perfectly regioselective metalation (regioisomeric ratio = 98:2 (156b) and 99:1 (156c)). After iodolysis, 
the pyridazines 156b and 156c were obtained in 50% yield (Scheme 45). To confirm the regioselectivity 
of the reaction, a crystal structure ob 156c was obtained.111 
 
Scheme 45: Directed meta-metalation of 3-arylpyridazines 153a,c,e using BF3·OEt2 and 
TMPMgCl·LiCl (31). 
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6.3 Directed meta-Metalation of Pyridazine Using a Bidentate Lewis Acid 
These results led us to examine further possibilities for a Lewis acid directed meta-metalation. After 
several experiments, we chose the bidentate diboroanthracene 157, first reported by Kaufmann.112 Thus, 
mixing equimolar amounts of 157 and 150 at 0 °C led to a yellow solution, indicating the formation of 
a 1:1 complex. The structure of this complex 158 was confirmed by NMR studies.113 Treatment of 158 
with TMPZnCl·LiCl (62) at 0 °C led to the formation of the zincated pyridazine 159, which, after 
iodolysis, exclusively gave 4-iodopyridazine 154 in 40% yield (Table 7, entry 1). 
Table 7: Optimization of the reaction conditions for the Lewis acid directed meta-metalation of 
pyridazine (150). 
 
entry equiv temperature yield[a] ratio (meta:ortho)[b] 
1 1.3 0 °C 40%[c] 99:1 
2 1.3 –78 °C 52% 99:1 
3 1.7 –78 °C 86% (63%)[c] 99:1 
4 2.0 –78 °C 69% 99:1 
[a] NMR yield using trimethoxybenzene as standard. [b] Determined by NMR analysis. [c] Isolated yield. 
Lowering the temperature to –78 °C resulted in an increase in yield to 52% (entry 2). An additional 
screening of equivalents showed, that with 1.7 equiv of 62, the optimal reaction conditions were 
achieved, leading to 154 in 63% isolated yield (Table 7, entries 3–4, Scheme 46). According to the 
calculations,114 H1 is the most acidic proton (pKa(H1)=23.2). However, due to steric effects combined 
with a high acidity (pKa(H2)=25.8), exclusively H2 is deprotonated. 
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Scheme 46: Directed meta-metalation and functionalization of pyridazine using the bidentate Lewis 
acid 157 and TMPZnCl·LiCl (62). 
6.4 Preparation of the Herbicide Credazine 
Finally, to prove the synthetic utility of these regioselective metalations, the herbicide credazine (160)115 
was prepared. Thus, 3-iodopyridazine (150) was dissolved in toluene and mixed with o-cresol (1.2 
equiv), Pd(OAc)2 (2 mol%), tBuXPhos (3 mol%) and potassium phosphate (2.0 equiv). After stirring at 
100 °C for 14 h, credazine (153) was obtained in 93% yield (Scheme 47).  
 
Scheme 47: Synthesis of the herbicide credazine (160) starting from 3-iodopyridazine (153). 
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7 Preparation of Polyfunctional Arylzinc Organometallics in Toluene via 
Halogen/Zinc Exchange Reactions 
7.1 Introduction 
Organozinc reagents are key intermediates in organic synthesis since they tolerate most functional 
groups and readily participate in transition-metal-catalyzed C-C bond forming reactions.116 Especially, 
aryl and heteroaryl zinc halides have been widely used organometallics for preparing complex organic 
molecules.117 Organozinc compounds are generated by directed insertion of zinc powder to organic 
halides17,20c-d,118 or by directed metalation using TMP-zinc bases (TMP = 2,2,6,6-
tetramethylpiperidyl).15,50 A halogen/zinc exchange is possible using mixed metal reagents of type 
R3ZnLi or R4ZnLi2, leading to lithium organozincates.119 Also, a Li(acac)-catalyzed I/Zn-exchange 
performed on aryl and heteroaryl iodides using pyrophoric and light sensitive iPr2Zn in NMP has been 
reported.25 Unfortunately, the corresponding less expensive aryl or heteroaryl bromides do not react 
under these conditions. For preparing related organomagnesium species, the exchange reagent 
iPrMgCl·LiCl (turbo-Grignard) has been extensively used, since it allows high rates for the Br/Mg-
exchange reaction.24 This exchange can be further accelerated by replacing LiCl by a stronger donor, 
namely a lithium alkoxide (ROLi; R = 2-ethylhexyl).30 Furthermore, this exchange could be performed 
in the industrially friendly solvent toluene. Herein, we report a new I/Zn and firstly, a Br/Zn exchange 
using a bimetallic exchange reagent of type sBu2Zn·2LiOR (161), which allows the generation of a 
wide range of polyfunctional aryl- and heteroarylzinc reagents.56,120 
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 The compounds 166a–c,h,i,k–p,r and 169a,b,e–k,r were prepared by A. Desaintjean under the guidance of 
M. Balkenhohl and D.S. Ziegler and will be shown for the sake of completeness. See: A. Desaintjean, Dissertation, 
LMU München. The analytical data can be found in the corresponding publication. 
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7.2 The I/Zn Exchange of Aryl and Heteroaryl Iodides and Bromides 
Thus, we have prepared several zinc alkoxides ROZnEt·ROH of type 162 by treating various alcohols 
(ROH, 163) with Et2Zn (25 °C, 4 h) in toluene.121 These zinc alkoxides (162) further reacted with sBuLi 
(2.0 equiv, in cyclohexane) to produce the bimetallic reagent tentatively represented as sBu2Zn·2LiOR 
(161). Removal of the solvents and further redissolution in toluene provided a light yellow solution of 
161 (c = 0.8–1.2 M in toluene; Scheme 48) which can be stored at 25 °C over months without significant 
loss of reactivity. 
 
Scheme 48: Preparation of bimetallic exchange reagents of type 161. 
To our delight, the complex sBu2Zn·2LiOR (R = 2-octyl; 161a) reacted with 3-iodoanisole (164a) in 
toluene122 within 30 min at 25 °C, providing bis-anisylzinc (165a) in 23% yield, as determined by GC-
analysis of reaction aliquots (Table 8, entry 1). The use of alcohols bearing N-coordination sites further 
improved the I/Zn exchange.123 Thus, the complex 161b (R = -CH2CH2N(Et)2) led to the diarylzinc 
165a in 95% GC-yield (entry 2). 
Table 8: Optimization of the reaction conditions for the I/Zn exchange using dialkylzinc reagents of 
type 161. 
 
entry sBu2Zn·2LiOR (161) time [min] yield[a] 
1 
 
30 23% 
2 
 
30 95% 
3 
 
30 99% 
4 161c 1 99% 
[a] Yield of 165a determined by GC analysis of reaction aliquots quenched with water. 
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 a) R. L. Geerts, J. C. Huffman, K. G. Caulton, Inorg. Chem. 1986, 25, 1803–1805; b) S. C. Goel, M. Y. Chiang, 
W. E. Buhro, Inorg. Chem. 1990, 29, 4646–4652; c) K. Merz, S. Block, R. Schoenen, M. Driess, Dalton Trans. 
2003, 3365–3369. 
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 A solvent screening showed, that the halogen/zinc exchange can not only be performed in hydrocarbons such 
as toluene or hexane, but also in other industrially friendly ethereal solvents such as 2-methyl-THF or MTBE. 
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 D. Sälinger, R. Brückner, Chem. Eur. J. 2009, 15, 6688–6703. 
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An improvement was achieved by using an alcohol bearing a second N-coordination site. The new 
reagent 161c (R = -CH2CH2N(CH3)CH2CH2N(CH3)2) led to the formation of 165a in 99% GC-yield 
(entry 3). In fact, after 1 min reaction time, the I/Zn exchange was already complete (entry 4).Thus, 3-
iodoanisole (164a) reacted with sBu2Zn·2LiOR (161c) in toluene at 25 °C for 10 min, to produce the 
bis-anisylzinc reagent 165a. Reaction of 165a with allyl bromide in the presence of CuI (20 mol%) 
gave the allylated arene 166a in 67% yield (Scheme 49). Transmetalation of 165a to copper using CuI 
(0.6 equiv) followed by addition of 4-chlorobenzoyl chloride, gave the acylated anisole 166b in 86% 
yield. When the zinc species 165a was mixed with ethyl 4-iodobenzoate, Pd(OAc)2 (3 mol%), and 
SPhos (6 mol%),63a,124 a palladium-catalyzed Negishi cross-coupling26 took place, leading to the biaryl 
166c in 76% yield. 4-Iodobenzotrifluoride underwent a smooth I/Zn exchange using 161c, leading to 
the corresponding diarylzinc reagent 165b. 
 
Scheme 49: Reaction of various aryl iodides with sBu2Zn·2LiOR (161c), followed by electrophilic 
functionalizations.  
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 R. A. Altman, S. L. Buchwald, Nat. Protoc. 2007, 2, 3115. 
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Reaction of 165b with ethyl 2-(bromomethyl)acrylate or a palladium-catalyzed cross-coupling with 4-
iodothioanisole gave functionalized arenes 166d–e in 48–67% yield (Scheme 49). TBS- or TIPS-
protected iodophenols were treated with 161c and the resulting zinc organometallic was allylated or 
acylated, providing 166f–g in 61–83% yield. The zinc reagent obtained from sterically demanding 2-
iodo-1,3-dimethylbenzene was quenched with ethyl 2-(bromomethyl)acrylate and 4-fluorobenzoyl 
chloride to give the 2-substituted m-xylenes 166h–i in 67–80% yield. Various electron-poor aryl iodides 
bearing ester or nitrile groups readily reacted with 161c and quenching of the zinc reagent of type 165 
with various electrophiles gave products 166j–p in 59–98% yield. Exchange on an aryl iodide bearing 
a triazine moiety, followed by allylation, gave 166q in 72% yield. Next, the diaryl zinc species 
generated from 4-iodobenzophenone was allylated, providing ketone 166r in 83% yield. Finally, the 
I/Zn exchange could also be extended to nitro-substituted aryl iodides. In this case, Tol2Zn·2LiOR (167) 
gave the best result.125 Hence, the mild exchange reagent Tol2Zn·2LiOR (167, R = -
CH2CH2N(CH3)CH2CH2N(CH3)2; Tol = p-tolyl) was prepared by mixing the akoxide 162c with 
tolyllithium (2.0 equiv).126 
 
Scheme 50: Reaction of various heteroaryl iodides with sBu2Zn·2LiOR (161c), followed by 
electrophilic functionalizations.  
                                                     
125
 When 2,4-dinitroiodobenzene was treated with 1c, decomposition of the starting material was observed. 
126
 Tolyllithium was prepared by a direct lithium insertion to 4-chlorotoluene, see: C. G. Screttas, B. R. Steele, M. 
Micha-Screttas, G. A. Heropoulos, Org. Lett. 2012, 14, 5680–5683. 
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Treatment of 2,4-dinitroiodobenzene or 3-iodo-4-nitrobenzonitrile with 167 (0.6 equiv) at –15 °C for 
15 min, followed by a copper-mediated allylation reaction, afforded nitroarenes 166s–t in 71–79% 
yield. For converting an iodo-benzaldehyde to the corresponding zinc species, a short screening showed, 
that the best exchange reagent was tBu2Zn·2LiOR (168). Thus, the alkoxide 162c was treated with 
tBuLi (2.0 equiv) and the resulting less nucleophilic reagent tBu2Zn·2LiOR (168, R = -
CH2CH2N(CH3)CH2CH2N(CH3)2) was obtained as a 1 M solution in toluene. Reaction of 5-iodo-
veratraldehyde with 168 (0.8 equiv, 0 °C, 10 min) afforded a diarylzinc organometallic of type 165, 
which, after allylation, provided the vanillin derivative 166u in 48% yield (Scheme 49). 
Various aryl- and heteroaryl iodides reacted smoothly with 161c, to give a range of functionalized bis-
arylzinc organometallics. Thus, bis-thienylzinc either reacted with 3-bromocyclohexene or 2-
bromobenzoyl chloride to provide 169a–b in 61–71% yield (Scheme 50). Benzyl-protected 3-
iodopyrazole reacted with 161c to give, after allylation, 169c in 80% yield. Also, various iodopyridines, 
-pyrimidines and -quinoline were converted into the corresponding zinc reagents using 161c and 
quenched with several acid chlorides and allyl bromides, producing 169d–l in 72–96% yield. The 
organometallic obtained from an iodoquinoline underwent a copper-mediated 1,4-addition to methyl 
vinyl ketone in the presence of TMSCl. Subsequent enol ether cleavage using TBAF (1.1 equiv, 25 °C, 
1 h) gave ketone 169m in 56% yield over two steps. Reaction of more complex iodinated N-heterocycles 
namely pyrazolone, uracil or 5,6-dihydropyridone gave the expected bis-zinc reagents of type 165, 
which, after allylation or acylation provided 169n–q in 74–85% yield.127 4-Iodofuraldehyde was treated 
with tBu2·2LiOR (168) and the resulting zinc reagent reacted with 3-bromocyclohexene in the presence 
of CuI to give the furfural derivative 169r in 66% yield (Scheme 50). 
The excellent reactivity of these bimetallic exchange reagents led us to examine the Br/Zn exchange 
reaction. Thus, treatment of 4-bromobenzonitrile with 161c (0.8 equiv) at 25 °C for 5 h in toluene (1 M), 
provided the desired bis-arylzinc of type 165, which, after quenching with iodine, gave 4-
iodobenzonitrile (170a) in 77% yield (Scheme 51). Reaction of the same zinc reagent with 4-
iodoanisole under palladium-catalysis gave the desired biaryl 170b in 64% yield.128 Allylation, 
acylation and cross-coupling of the zinc reagents obtained from 2-bromobenzonitrile and 2-
bromobenzotrifluoride gave 170c–e in 63–67% yield. Various bromoarenes bearing e.g. an ester 
functional group underwent a smooth Br/Zn exchange, which, after allylation or cross-coupling, 
produced the arenes 170f–i in 60–79% yield. Additionally, bromopyridines and a bromoquinoline were 
treated with 161c. Allylation of the resulting zinc reagents gave the functionalized heteroarenes 170j–l 
in 61–70% yield. Finally, 2-bromobenzothiazole was mixed with 161c and the obtained metal species 
reacted with iodine to give 170m in 75% yield (Scheme 51). 
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 Due to poor solubility of the aryl iodides, the reactions leading to 169g,j,k,n–q were performed in THF. 
128
 Prior to the addition of the catalyst system and aryl iodide, TMSCl (0.8 equiv, 0 °C, 10 min) was added in 
order to quench the excess of alkoxide. 
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Scheme 51: Reaction of various aryl bromides with sBu2Zn·2LiOR (161c), followed by electrophilic 
functionalizations. 
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8 Summary 
In this thesis, several challenges in the field of organometallic chemistry were addressed. First, 
alternative methodologies for the transition-metal-free amination of pyridines and related N-
heterocycles, such as quinolines or quinoxalines were developed. Not only pyridine sulfonyl chlorides, 
but also sulfonic acids underwent a facile amination reaction using magnesium amides. Also, 
phosphorodiamidate-substituted N-heterocycles were readily aminated with magnesium amides, 
presenting a synthetic approach which does not require the use of 2-halo or 2-mercaptopyridines. Then, 
the regioselective metalation and functionalization of various complex N-heterocycles was investigated 
using Li-, Mg-, and Zn-TMP bases in the presence or absence of a Lewis acid, such as BF3·OEt2. First, 
the 1,5-naphthyridine scaffold was functionalized in up to four positions and a novel “halogen-dance” 
was disclosed. Pyrazolo[1,5-a]pyridines were metalated in up to three different positions with the help 
of the Lewis acid BF3·OEt2 or a previously introduced sulfoxide moiety. This sulfoxide was also 
aminated using a magnesium amide. Also, pyridazine underwent highly regioselective metalations, and 
the choice of the Lewis acid allowed either the functionalization in the ortho or the meta position. 
Finally, a lithium alkoxide complexed dialkylzinc reagent was developed for a solvent independent 
halogen/zinc exchange. These reagents of type R2Zn·2LiOR allowed not only the exchange of aryl 
iodides in solvents such as THF or toluene, but also the first bromine/zinc exchange using dialkylzinc 
reagents. Additionally, highly sensitive functional groups such as ketones, aldehydes or nitro groups 
were tolerated by these new reagents. 
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8.1 Transition-Metal-Free Amination of Pyridine-2-sulfonyl Chloride and Related N-
Heterocycles Using Magnesium Amides 
The transition-metal-free amination of pyridine-2-sulfonyl chloride and quinoline-8-sulfonyl chloride 
was described. Pyridine- and quinoline-sulfonamides, derived from the corresponding sulfonyl 
chlorides were also suitable candidates for this amination method. Since sulfonamides are good directed 
metalation groups (DMGs), an efficient ortho-metalation and functionalization was possible, which, 
after subsequent amination reaction, allowed the preparation of 2,3-difunctionalized pyridines and 
quinolines. Also, an aza-indole and an aza-carbazole were prepared via intramolecular cyclization 
reactions using phenyllithium (Scheme 52). 
 
Scheme 52: Preparation of 2,3-difunctionalized pyridines, an aza-indole, and an aza-carbazole. 
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8.2 Amination of 2-Pyridinesulfonic and 8-Quinolinesulfonic Acids with Magnesium Amides 
The amination of 2-pyridine- and 8-quinolinesulfonic acid was reported. Several amines, including 
pharmaceutically active substrates, were applicable to the reaction protocol, affording the respective 2-
aminopyridines and 8-aminoquinolines. Also, this amination was readily scaled-up to a 50 mmol scale 
(Scheme 53). 
 
Scheme 53: Amination of pyridine-2- and quinoline-8-sulfonic acids using magnesium amides. 
8.3 Amination of Phosphorodiamidate-Substituted Pyridines and Related N-Heterocycles with 
Magnesium Amides 
The amination of pyridones was performed by reaction of phosphorodiamidate-substituted pyridines 
with magnesium amides. Since pyridones are readily accessible reagents, it was not only possible to 
perform amination reactions with functionalized pyridines, but also the amination of the quinoxaline 
scaffold was achieved (Scheme 54). Similarly as in chapter 1, a directed ortho-metalation/amination 
sequence was performed. 
 
Scheme 54: Amination of phosphorodiamidate-substituted pyridines, quinolines and quinoxalines 
using magnesium amides. 
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8.4 Zn-, Mg-, and Li-TMP Bases for the Successive Regioselective Metalations of the 1,5-
Naphthyridine Scaffold 
The 1,5-naphthyridine scaffold was regioselectively metalated in up to three positions using Zn-, Mg- 
and Li-TMP bases in the presence or absence of the Lewis acid BF3·OEt2, producing a range of 
functionalized 1,5-naphtyridines. A fourth substituent was introduced by a novel “halogen-dance” 
rearrangement, induced by a lithiation using TMPLi (Scheme 55). Additionally the synthesis of two 
key 1,5-naphthyridines, required for the synthesis of OLED materials and an anti-bacterial agent, was 
disclosed. 
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Scheme 55: Metalation and functionalization of the 1,5-naphthyridine skeleton using TMP-bases. 
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8.5 Regioselective Metalation and Functionalization of the Pyrazolo[1,5-a]pyridine Scaffold 
Using Mg- and Zn-TMP Bases 
The regioselective metalation of the Pyrazolo[1,5-a]pyridine scaffold was investigated using Zn- and 
Mg-TMP bases. A switch in the selectivity of the metalation was observed, when the Lewis acid 
BF3·OEt2 was mixed with the N-heterocycle, prior to addition of the TMP-base, allowing the efficient 
functionalization of the C2-position. Pyrazolo[1,5-a]pyridines bearing various substituents, such as an 
ester or a carbamate, also underwent an efficient metalation and functionalization. Finally, the 
amination of a pyrazolo[1,5-a]pyridine sulfoxide was performed using a magnesium amide 
(Scheme 56). 
 
Scheme 56: Metalation and functionalization of pyrazolo[1,5-a]pyridine using TMP-bases and the 
amination of a pyrazolo[1,5-a]pyridine sulfoxide using a magnesium amide. 
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8.6 Lewis Acid Directed Regioselective Metalations of Pyridazine 
A highly regioselective Lewis acid directed ortho- and meta-metalation and functionalization of 
pyridazine was developed. The choice of the Lewis acid is key for the success and the regioselectivity 
of the reaction, allowing the first Lewis acid directed meta-metalation using a TMP-base. This 
unprecedented reactivity opens up new perspectives for the metalation of heterocycles using metal 
amide bases (Scheme 57). 
 
Scheme 57: The directed ortho- and meta-metalation of pyridazine using TMPZnCl·LiCl and the 
appropriate Lewis acid. 
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8.7 Preparation of Polyfunctional Arylzinc Organometallics in Toluene via Halogen/Zinc 
Exchange Reactions 
New bimetallic reagents of type R2Zn·2LiOR for the I/Zn and Br/Zn exchange reaction have been 
developed. Due to the nature of the carbon zinc bond, several highly sensitive functional groups 
including triazines, ketones, aldehydes or nitro groups could be tolerated. Thus, quenching of the 
formed diarylzinc species with various electrophiles allowed the preparation of a plethora of 
functionalized arenes and heteroarenes. Additionally, the exchange could be performed in hydrocarbons 
such as toluene or hexane, and in ethereal solvents including THF, 2-methyl-THF or MTBE 
(Scheme 58). 
 
Scheme 58: The halogen/zinc exchange using dialkylzinc reagents complexed with lithium alkoxides 
of type R2Zn·2LiOR. 
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1 General Considerations 
 
All reactions were carried out under argon or nitrogen atmosphere in glassware dried with a heat gun 
(650 °C) under high vacuum (<1 mbar). Syringes which were used to transfer anhydrous solvents or 
reagents were purged thrice with argon or nitrogen prior to use. Indicated yields are isolated yields of 
compounds estimated to be >95% pure as determined by 1H-NMR (25 °C) and capillary GC. Unless 
otherwise indicated, all reagents were obtained from commercial sources. Optical rotation values were 
recorded on a PerkinElmer 241 or Anton Paar MCP 200 polarimeter. The specific rotation is calculated 
as follows: 
??
? =
??? · 100
? · ?  
Thereby, the wavelength λ is reported in nm and the measuring temperature φ in °C.  
α represents the recorded optical rotation, c the concentration of the analyte in 10 mg/mL and d the 
length of the cuvette in dm. Thus, the specific rotation is given in 10−1·deg·cm2·g−1. Usage of the sodium 
D line (λ = 589 nm) is indicated by D instead of the wavelength in nm. The respective concentration as 
well as the solvent is reported at the relevant section of the experimental section. 
1.1 Solvents 
 
Solvents were dried according to standard procedures by distillation over drying agents and stored under 
argon. 
 
CH2Cl2 was predried over CaCl2 and distilled from CaH2. 
Et2O was predried over CaH2 and dried with the solvent purification system SPS-400-2 from 
INNOVATIVE TECHNOLOGIES INC. 
DMF was distilled from CaH2 and stored over molecular sieves (3 Å). 
MeCN was distilled from CaH2 and stored over molecular sieves (3 Å). 
THF was continuously refluxed and freshly distilled from sodium benzophenone ketyl under nitrogen. 
Solvents for column chromatography were distilled on a rotary evaporator prior to use. 
  
C. EXPERIMENTAL PART    71 
 
1.2 Reagents 
 
TMPLi: Tetramethylpiperidine (1.48 g, 10.5 mmol) was dissolved in THF (10 mL) and cooled to –
40 °C. Then, nBuLi (4.14 mL, 10.0 mmol) was added dropwise and the reaction stirred at 0 °C for 
30 min. 
TMPMgCl·LiCl: A dry and argon-flushed 250-mL Schlenk flask, equipped with a magnetic stirring 
bar and a septum, was charged with freshly titrated iPrMgCl·LiCl (100 mL, 1.2 M in THF, 120 mmol). 
TMPH (17.8 g, 126 mmol, 1.05 equiv) was added dropwise at 25 °C. The reaction mixture was stirred 
at 25 °C until gas evolution ceased (ca. 24 h).37 
TMP2Mg·2LiCl: In an argon-flushed Schlenk flask equipped with a magnetic stirring bar, TMPH 
(4.24 g, 30 mmol) was dissolved in THF (30 mL). This solution was cooled to –40 °C and nBuLi (2.4 M 
in Hexane, 12.5 mL, 30 mmol) was added dropwise. After the addition was complete, the reaction 
mixture was warmed to 0 °C and stirred at this temperature for 30 min. Freshly titrated TMPMgCl·LiCl 
(1.0 M in THF, 30 mL, 30 mmol) was then added dropwise to the reaction mixture. The reaction mixture 
was stirred at 0 °C for 30 min, warmed to 25 °C, and stirred for 1 h. The solvents were then removed 
under vacuum affording a yellowish solid. Freshly distilled THF was then slowly added under vigorous 
stirring until the salts were completely dissolved.45 
TMPZnCl·LiCl: A dry and argon flushed 250 mL Schlenk-flask, equipped with a magnetic stirrer and 
a septum, was charged with TMPH (8.48 g, 60 mmol) and dissolved in THF (60 mL). This solution was 
cooled to –40 °C and nBuLi (2.4 M in hexane, 25 mL, 60 mmol) was added dropwise. After the addition 
was complete, the reaction mixture was allowed to warm slowly to –10 °C for 1 h. ZnCl2 (1.0 M in THF, 
66 mL, 66 mmol) was added dropwise and the resulting solution stirred for 30 min at –10 °C and then 
for 30 min at 25 °C. The solvents were then removed under vacuum affording a yellowish solid. Freshly 
distilled THF was then slowly added under vigorous stirring until the salts were completely dissolved.50 
iPrMgCl·LiCl: Magnesium turnings (2.67 g, 110 mmol) and anhydrous LiCl (4.66 g, 100 mmol) were 
placed in an argon-flushed flask and THF (50 mL) was added. A solution of iPrCl (9.13 mL, 100 mmol) 
in THF (50 mL) was slowly added at 25 °C. The reaction starts within a few minutes. After addition, 
the reaction mixture was stirred for 12 h at 25 °C. The grey solution of iPrMgCl·LiCl was cannulated 
to another flask under argon and removed in this way from excess of magnesium. A yield of ca. 95–
98% of iPrMgCl·LiCl is obtained.24 
nBuLi solution was purchased from Albemarle (Hoechst, Germany). 
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sBuLi solution in cyclohexane was purchased from Albemarle or Sigma Aldrich. 
tBuLi solution in pentane was purchased from Albemarle or Sigma Aldrich. 
Et2Zn: Either a Commerially available Et2Zn (purchased from Sigma Aldrich, 15 wt.% (= 1.11 M) in 
toluene) was used or Et2Zn (100 mmol) was dissolved in dry toluene (100 mL) and titrated against I2 
in a 0.5 M LiCl solution at 0 °C. Both Et2Zn reagents were suitable for the performed reactions. 
0.5 M LiCl solution: LiCl (5 mmol) was dried in vacuo using a heatgun (400 °C) for 10 minutes. After 
cooling to room tempetature, dry THF (10 mL) was added and the mixture stirred until the salt was 
dissolved completely. 
CuCN·2LiCl: A CuCN·2LiCl solution (1.00 m) was prepared by drying CuCN (80.0 mmol, 7.17 g) 
and LiCl (160 mmol, 6.77 g) in a Schlenk-flask under vacuum at 140 °C for 12 h. After cooling, dry 
THF (80 mL) was added and stirring continued until the salts were dissolved.64 
ZnCl2: A ZnCl2 solution (1.00 m) was prepared by drying ZnCl2 (200 mmol, 27.3 g) in a Schlenk-flask 
under vacuum at 140 °C for 5 h. After cooling, dry THF (200 mL) was added and stirring continued 
until the salt was dissolved. 
BF3·OEt2 was distilled prior to use and stored under argon at 5 °C. 
Pyridazine was distilled from CaH2 prior to use and stored under argon at 5 °C. 
2-((2-(Dimethylamino)ethyl)(methyl)amino)ethane-1-ol: The alcohol was distilled in vacuo from 
CaH2 (29 mbar, 95 °C) and stored under argon in a Schlenk flask. 
 
1.3 Chromatography 
 
Flash column chromatography was performed using silica gel 60 (0.040–0.063 mm) from MERCK. 
Thin layer chromatography was performed using SiO2 pre-coated aluminum plates (Merck 60, F-
254). The chromatograms were examined under 254 nm UV irradiation, by incubating the plates in an 
iodine chamber and/or by staining the TLC plate with a KMnO4 solution followed by heating with a 
heat gun. 
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KMnO4 solution: KMnO4 (3.0 g), 5 drops of conc. H2SO4 in water (300 mL). 
HPLC was performed on an Agilent Technologies 1200 Series using a Chromolit® SemiPrep RP-18e 
100–10 mm column. The HPLC was run with a gradient of acetonitrile/water. 
 
1.4 Content Determination of Organometallic Reagents 
 
iPrMgCl·LiCl was titrated with I2 in THF.129  
Organolithium (nBuLi, tBuLi, TolLi) reagents were titrated with menthol and 1,10-phenanthroline as 
indicator in THF.130 
TMPMgCl·LiCl was titrated with benzoic acid and 4-(phenylazo)diphenylamine as indicator in THF.37 
TMP2Mg·2LiCl was titrated with benzoic acid and 4-(phenylazo)diphenylamine as indicator in THF.45 
TMPZnCl·LiCl was titrated with benzoic acid and 4-(phenylazo)diphenylamine as indicator in THF.50 
TMPLi was titrated with N-benzylbenzamide in THF.131 
sBuLi was titrated against N-benzylbenzamide in THF.131 
 
1.5 Analytical Data 
 
1H-NMR and 13C-NMR spectra were recorded on VARIAN Mercury 200, BRUKER ARX 300, 
VARIAN VXR 400 S and BRUKER AMX 600 instruments. Chemical shifts are reported as values in 
ppm relative to tetramethylsilane. CDCl3 peaks were set to 7.26 ppm in 1H NMR and 77.16 ppm in 13C 
NMR experiments. The following abbreviations were used to characterize signal multiplicities: s 
                                                     
129
 P. Knochel, A. Krasovskiy, Synthesis 2006, 890–891. 
130
 a) H.-S. Lin, L. A. Paquette, Synth. Commun. 1994, 24, 2503–2506; b) S. C. Watson, J. F. Eastham, J. 
Organomet. Chem. 1967, 9, 165–168. 
131
 A. F. Burchat, J. M. Chong, N. Nielsen, J. Organomet. Chem. 1997, 542, 281–283. 
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(singlet), d (doublet), dd (doublet of doublets),t (triplet),q (quartet), hept (heptett) as well as m 
(multiplet). 
Mass spectroscopy: High resolution (HRMS) and low resolution (MS) spectra were recorded on a 
FINNIGAN MAT 95Q instrument. Electron impact ionization (EI) was conducted with an ionization 
energy of 70 eV. For coupled gas chromatography/mass spectrometry, a HEWLETT-PACKARD HP 
6890/MSD 5973 GC/MS system was used. Molecular fragments are reported starting at a relative 
intensity of 10–20%. 
Infrared spectra (IR) were recorded from 4500 cm-1 to 650 cm-1 on a PERKIN ELMER Spectrum BX-
59343 instrument. For detection a SMITHS DETECTION DuraSamplIR II Diamond ATR sensor was 
used. The main absorption peaks are reported in cm-1. 
Melting points (m.p.) were determined on a BÜCHI B-540 melting point apparatus and are 
uncorrected. 
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2 Transition-Metal-Free Amination of Pyridine-2-sulfonyl Chloride and 
Related N-Heterocycles Using Magnesium Amides 
2.1 Typical Procedures 
 
Typical Procedure 1: Amination of pyridine-2-sulfonyl chloride (72) and 8-quinolinesulfonyl chloride 
(80) 
 
iPrMgCl·LiCl (2.4–5 equiv) was added to a solution of amine (2.4–5 equiv) in THF (5 mL/mmol of 
sulfonyl chloride) at 0 °C. The solution was stirred for 15 min at 0 °C and then 15 min at 25 °C before 
being added to a suspension/solution of freshly prepared sulfonyl chloride  
(1 equiv) in THF (5 mL/mmol of sulfonyl chloride) at 0 °C. The reaction mixture was then stirred at 
25 °C until completion. The reaction mixture was quenched with water and extracted with ethyl acetate. 
The organic phase was then dried over Na2SO4 and concentrated in vacuo. If the crude product needed 
purification, it was purified by flash chromatography on silica gel using the appropriate eluent. 
 
Typical Procedure 2: ortho-Functionalization of heteroaryl sulfonamides 73a–b and 82a–b using 
TMPMgCl·LiCl 
 
To a solution of the sulfonamide (1 equiv) in THF (5 mL/mmol of the sulfonamide) a solution of 
TMPMgCl·LiCl (1.2 equiv) was added at 0 °C. After completion of the metalation (2 h, 0 °C) which 
was checked via GC aliquots (hydrolysis and iodolysis), a solution of the electrophile (1.2–1.5 equiv) 
in THF (5 mL/mmol of sulfonamide) was added and the reaction mixture was allowed to warm slowly 
to 25 °C. The reaction mixture was stirred at 25 °C until completion, then quenched with water and 
extracted with ethyl acetate. The organic phase was dried over Na2SO4 and concentrated in vacuo. The 
crude product was then purified by flash chromatography on silica gel using the appropriate eluent. 
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Typical Procedure 3: Desulfonylation of ortho-substituted heteroaryl sulfonamides 77a–e, 78a–d, A, 
B. 
 
To a solution of sulfonamide in THF (5 mL/mmol of sulfonamide) was added a solution of the 
corresponding magnesium amide of type 74 at 0 °C. The reaction was then stirred at 25 °C until 
completion. The reaction mixture was quenched with water and extracted with ethyl acetate. The 
organic phase was dried over Na2SO4 and concentrated in vacuo. If the crude product needed 
purification, it was purified by flash chromatography on silica gel using the appropriate eluent. 
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2.2 Preparation of Compounds 72 to 89 
 
Synthesis of pyridine-2-sulfonyl chloride (72) 
 
 
 
Adapted from a literature procedure,132 2-mercaptopyridine (1.11 g, 10.0 mmol) was dissolved in conc. 
sulfuric acid (28 mL) and cooled to –10°C in a dry ice / acetone bath. Then, NaOCl 13% (42 mL, 
30 mmol) was added dropwise without letting the temperature rise above 0 °C. After completion of the 
addition, the reaction mixture was stirred for 30 min at 0°C. The reaction mixture was extracted with 
DCM (3 x 150 mL), washed with an aq. 10% Na2SO3 solution (200 mL) until decoloration and dried 
over Na2SO4. After filtration, the solvent was removed in vacuo yielding compound 72 (1.26 g, 
7.09 mmol, 71%) as a colorless oil. The crude product 72 was used without purification in the next step. 
 
The spectra matched those of the literature.132 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.81 ‒ 8.79 (m, 1H), 8.11 ‒ 8.05 (m, 2H), 7.72 ‒ 7.68 (m, 1H). 
  
                                                     
132
 M. K. Nielsen, C. R. Ugaz, W. Li, A. G. Doyle, J. Am. Chem. Soc. 2015, 137, 9571–9574. 
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Synthesis of 2-(piperidin-1-ylsulfonyl)pyridine (73a) 
 
 
 
Piperidine (0.29 mL, 3.00 mmol) was added to a solution of sulfonyl chloride 72 (177 mg, 1.00 mmol) 
in DCM (3 mL) at 0 °C. After stirring at 25 °C for 12 h, the reaction mixture was quenched with water, 
extracted with DCM (3 x 10 mL) and dried over Na2SO4. After filtration, the solvent was removed in 
vacuo. The crude product was purified via column chromatography (isohexane:ethyl acetate = 6:4) to 
give 73a (184 mg, 813 µmol, 81%) as a colorless oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.73 ‒ 8.67 (m, 1H), 7.95 - 7.86 (m, 2H), 7.47 (ddd, J = 6.8, 
4.7, 1.9 Hz, 1H), 3.26 (t, 4H), 1.67 - 1.58 (m, 4H), 1.52 - 1.44 (m, 2H). 
 
The spectra matched those of the literature.60b 
 
Synthesis of N-butyl-N-methylpyridine-2-sulfonamide (73b) 
 
 
 
N-Butylmethylamine (0.33 mL, 3.00 mmol) was added to a solution of sulfonyl chloride 72 (165 mg, 
0.93 mmol) in DCM (3 mL) at 0 °C. After stirring at 25 °C for 12 h, the reaction mixture was quenched 
with water, extracted with DCM (3 x 10 mL) and dried over Na2SO4. After filtration, the solvent was 
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removed in vacuo. The crude product was purified via column chromatography (isohexane:ethyl acetate 
= 7:3) to give 73b (182 mg, 797 µmol, 86%) as a colorless oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.68 (ddd, J = 4.8, 1.7, 1.0 Hz, 1H), 7.96 - 7.84 (m, 2H), 7.46 
(ddd, J = 7.3, 4.7, 1.6 Hz, 1H), 3.21 (t, J = 7.3 Hz, 2H), 2.90 (s, 3H), 1.57 - 1.46 (m, 2H), 1.39 - 1.27 
(m, 2H), 0.90 (t, J = 7.4 Hz, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 157.3, 150.0, 137.9, 126.5, 122.8, 50.7, 35.4, 30.0, 19.8, 13.8. 
IR (Diamond-ATR, neat): ? / cm-1 = 3053, 2959, 2933, 2873, 1577, 1426, 1333, 1170, 1115, 927, 757. 
MS (EI, 70 eV): m/z (%) = 185 (100), 121 (39), 79 (71). 
HRMS (EI) for C10H17O2N2S (229.0966): 229.0988 (M++H). 
 
Synthesis of 2-(N-butylmethylamine)pyridine (75b) 
 
 
 
The aminopyridine 75b was prepared via TP1 using pyridine-2-sulfonyl chloride (177 mg, 1.00 mmol), 
iPrMgCl·LiCl (1.87 mL, 2.40 mmol) and N-butylmethylamine (0.28 mL, 2.40 mmol). After stirring at 
25 °C for 2 h, the reaction mixture was quenched with water (15 mL), extracted with ethyl acetate (3 x 
20 mL) and dried over Na2SO4. After filtration, the solvents were removed in vacuo. The crude product 
was purified via column chromatography (isohexane:ethyl acetate = 9:1) to give 75b (144 mg, 
876 µmol, 88%) as an orange oil. 
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1H-NMR (400 MHz, CDCl3): δ / ppm = 8.14 (ddd, J = 5.0, 2.0, 0.9 Hz, 1H), 7.39 (ddd, J = 8.8, 7.1, 
2.0 Hz, 1H), 6.51 ‒ 6.41 (m, 2H), 3.51 ‒ 3.43 (m, 2H), 3.02 (s, 3H), 1.61 ‒ 1.50 (m, 2H), 1.40 ‒ 1.27 
(m, 2H), 0.93 (t, J = 7.3 Hz, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 158.6, 148.0, 137.1, 111.1, 105.7, 50.0, 36.3, 29.4, 20.4., 
14.1. 
IR (Diamond-ATR, neat): ? / cm-1 = 2970, 3950, 2880, 2860, 1590, 1550, 1500, 1460, 765, 730. 
MS (EI, 70 eV): m/z (%) = 164 (18), 121 (100), 106 (13), 78 (19). 
HRMS (EI) for C10H16N2 (164.1313): 164.1307 (M+). 
 
Synthesis of N1,N1,N2-trimethyl-N2-(pyridin-2-yl)ethane-1,2-diamine (75e) 
 
 
 
The aminopyridine 75e was prepared via TP1 using pyridine-2-sulfonyl chloride (177 mg, 1.00 mmol), 
iPrMgCl·LiCl (1.87 mL, 2.40 mmol) and N,N,N’-trimethyl-ethylenediamine (0.31 mL, 2.40 mmol). 
After stirring at 25 °C for 2 h, the reaction mixture was quenched with water (15 mL), extracted with 
ethyl acetate (3 x 20 mL) and dried over Na2SO4. After filtration, the solvents were removed in vacuo. 
The crude product was purified via column chromatography (DCM:MeOH = 7.5:2.5) to give 75e 
(130 mg, 725 µmol, 74%) as an orange oil. 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.12 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 7.39 (ddd, J = 8.6, 7.1, 
2.0 Hz, 1H), 6.50 ‒ 6.44 (m, 2H), 3.66 ‒ 3.61 (m, 2H), 3.03 (s, 3H), 2.50 ‒ 2.45 (m, 2H), 2.27 (s, 6H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 158.6, 148.1, 137.1, 111.5, 105.6, 56.6, 48.4, 45.9, 36.6. 
IR (Diamond-ATR, neat): ? / cm-1 = 2970, 3950, 2880, 2860, 1590, 1550, 1500, 1460, 765, 730. 
MS (EI, 70 eV): m/z (%) = 179 (6), 121 (75), 109 (14), 108 (13), 77 (21), 71 (25), 58 (100). 
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HRMS (EI) for C10H17N3 (179.1422): 179.1418 (M+). 
 
Synthesis of 3-bromo-N-butyl-N-methylpyridine-2-sulfonamide (78a) 
 
 
 
The pyridine sulfonamide 78a was prepared via TP2 using 73b (205 mg, 898 µmol), TMPMgCl·LiCl 
(1.19 mL, 1.08 mmol) and 1,2-dibromotetrachloroethane (351 mg, 1.08 mmol). The reaction was 
complete after 12 h. After work-up, the crude product was purified via column chromatography 
(isohexane:ethyl acetate = 8:2) to give 78a (202 mg, 658 µmol, 73%) as a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.48 (dd, J = 4.6, 1.4 Hz, 1H), 8.07 (dd, J = 8.0, 1.4 Hz, 1H), 
7.30 (dd, J = 8.1, 4.6 Hz, 1H), 3.40 (t, J = 7.3 Hz, 2H), 3.09 (s, 3H), 1.67 - 1.59 (m, 2H), 1.44 - 1.34 
(m, 2H), 0.94 (t, J = 7.4 Hz, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 156.8, 146.5, 143.7, 126.9, 118.4, 51.7, 36.4, 30.4, 19.8, 13.9. 
IR (Diamond-ATR, neat): ? / cm-1 = 2958, 2934, 2872, 1558, 1460, 1433, 1395, 1338, 1213, 1163, 
1137, 1019, 771. 
MS (EI, 70 eV): m/z (%) = 263 (33), 199 (10), 158 (36), 86 (100). 
HRMS (EI) for C7H8BrO2N2S (262.9490): 262.9329 (M+-C3H7). 
M.p. (°C): 69 – 70. 
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Synthesis of N-butyl-3-iodo-N-methylpyridine-2-sulfonamide (78b) 
 
 
 
The pyridine sulfonamide 78b was prepared via TP2 using 73b (272 mg, 1.19 mmol), TMPMgCl·LiCl 
(1.57 mL, 1.43 mmol) and iodine (453 mg, 1.79 mmol). The reaction was complete after 12 h. After 
work-up, the crude product was purified via column chromatography (isohexane:ethyl acetate = 8:2) to 
give 78b (251 mg, 865 µmol, 73%) as an off-white solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.49 (dd, J = 4.6, 1.5 Hz, 1H), 8.35 (dd, J = 7.9, 1.5 Hz, 1H), 
7.12 (dd, J = 8.0, 4.6 Hz, 1H), 3.38 (t, J = 7.2 Hz, 2H), 3.07 (s, 3H), 1.67 - 1.56 (m, 2H), 1.44 - 1.32 
(m, 2H), 0.93 (t, J = 7.3 Hz, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 159.6, 150.5, 147.0, 126.6, 89.1, 51.7, 36.4, 30.3, 19.8, 13.8. 
IR (Diamond-ATR, neat): ? / cm-1 = 2958, 2933, 2872, 1553, 1460, 1388, 1333, 1165, 1131, 766. 
MS (EI, 70 eV): m/z (%) = 310 (73), 247 (34), 219 (40), 205 (53), 204 (83), 86 (100), 43 (90). 
HRMS (EI) for C7H8IO2N2S (310.9351): 310.9349 (M+-C3H7). 
M.p. (°C): 71 – 73. 
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Synthesis of N-butyl-N-methyl-3-(trimethylsilyl)pyridine-2-sulfonamide (78c) 
 
 
 
The pyridine sulfonamide 78c was prepared via TP2 using 73b (228 mg, 1.00 mmol), TMPMgCl·LiCl 
(1.32 mL, 1.20 mmol) and trimethylsilyl chloride (0.16 mL, 1.3 mmol). The reaction was complete after 
12 h. After work-up, the crude product was purified via column chromatography (isohexane:ethyl 
acetate = 8.5:1.5) to give 78c (251 mg, 835 µmol, 84%) as a colorless oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.54 (dd, J = 4.6, 1.8 Hz, 1H), 8.05 (dd, J = 7.7, 1.8 Hz, 1H), 
7.37 (dd, J = 7.6, 4.6 Hz, 1H), 3.30 (t, J = 7.2 Hz, 2H), 2.99 (s, 3H), 1.61 - 1.52 (m, 2H), 1.43 - 1.32 
(m, 2H), 0.93 (t, J = 7.3 Hz, 3H), 0.43 (s, 9H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 163.2, 148.7, 145.2, 135.3, 125.2, 51.4, 36.2, 30.3, 19.9, 13.9, 
0.6. 
IR (Diamond-ATR, neat): ? / cm-1 = 2958, 2935, 2874, 1564, 1548, 1371, 1330, 1168, 1125, 844, 775. 
MS (EI, 70 eV): m/z (%) = 286 (15), 285 (79), 257 (19), 193 (19), 165 (45), 152 (31), 151 (74), 150 
(100), 136 (25), 86 (66). 
HRMS (EI) for C13H23O2N2SSi (299.1250): 299.1242 (M+-H). 
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Synthesis of N-butyl-N-methyl-3-phenylpyridine-2-sulfonamide (78d) 
 
 
 
The pyridine sulfonamide 78d was prepared via TP2 using 73b (228 mg, 1.00 mmol) and 
TMPMgCl·LiCl (1.32 mL, 1.20 mmol). After the metalation was complete, a 1.0 M ZnCl2 solution in 
THF (1.20 mL, 1.20 mmol) was added at 0 °C and the reaction was stirred at this temperature for 
30 min. Then, iodobenzene (0.11 mL, 1.00 mmol), SPhos (16.0 mg, 40.0 µmol) and Pd(OAc)2 
(4.50 mg, 20.0 µmol) were added and the reaction stirred at 25 °C for 12 h. After work-up, the crude 
product was purified via column chromatography (isohexane:ethyl acetate = 8.5:1.5) to give 78d 
(259 mg, 851 µmol, 85%) as a light yellow solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.55 (dd, J = 4.7, 1.7 Hz, 1H), 7.75 (dd, J = 7.8, 1.7 Hz, 1H), 
7.54 - 7.38 (m, 6H), 3.31 (t, J = 7.2 Hz, 2H), 3.00 (s, 3H), 1.61 - 1.50 (m, 2H), 1.40 - 1.27 (m, 2H), 0.90 
(t, J = 7.4 Hz, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 156.5, 147.0, 141.0, 137.8, 137.0, 129.5, 128.5, 128.2, 125.7, 
51.5, 36.2, 30.4, 19.8, 13.9. 
IR (Diamond-ATR, neat): ? / cm-1 = 2958, 2934, 2872, 1444, 1334, 1161, 722. 
MS (EI, 70 eV): m/z (%) = 261 (14), 197 (27), 156 (17), 155 (98), 154 (100), 127 (40), 86 (69). 
HRMS (EI) for C16H20N2O2S (305.1323): 305.1279 (M++H). 
M.p. (°C): 100 – 102. 
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Synthesis of 3-allyl-N-butyl-N-methylpyridine-2-sulfonamide (78e) 
 
 
 
The pyridine sulfonamide 78e was prepared via TP2 using 73b (228 mg, 1.00 mmol) and 
TMPMgCl·LiCl (1.65 mL, 1.50 mmol). After the metalation was complete, a 1.0 M CuCN·2LiCl 
solution in THF (1.50 mL, 1.50 mmol) was added at –20°C and the reaction stirred at this temperature 
for 30 min. Then, allyl bromide (0.13 mL, 1.50 mmol) was added and the reaction was stirred at 25 °C 
for 12 h. After work-up, the crude product was purified via column chromatography (isohexane:ethyl 
acetate = 8.5:1.5) to give 78e (246 mg, 917 µmol, 92%) as a colorless oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.38 (dd, J = 4.6, 1.6 Hz, 1H), 7.75 - 7.69 (m, 1H), 7.36 (dd, 
J = 7.8, 4.6 Hz, 1H), 6.08 - 5.93 (m, 1H), 5.22 - 5.11 (m, 2H), 3.84 (d, J = 6.8 Hz, 2H), 3.40 (t, J = 7.3 
Hz, 2H), 3.07 (s, 3H), 1.67 - 1.55 (m, 2H), 1.46 - 1.33 (m, 2H), 0.94 (t, J = 7.4 Hz, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 156.9, 145.9, 140.0, 135.5, 135.4, 126.1, 117.8, 51.7, 36.4, 
35.5, 30.4, 19.9, 13.9. 
IR (Diamond-ATR, neat): ? / cm-1 = 2959, 2934, 2873, 1640, 1563, 1450, 1416, 1333, 1160, 723. 
MS (EI, 70 eV): m/z (%) = 225 (18), 161 (9), 133 (18), 118 (100), 86 (47). 
HRMS (EI) for C13H20N2O2S (268.1245): 268.1235 (M+). 
  
C. EXPERIMENTAL PART    86 
 
Synthesis of 3-bromo-N-butyl-N-methylpyridine-2-amine (79e) 
 
 
 
The aminopyridine 79e was prepared via TP3 using 78a (76.8 mg, 0.25 mmol), N-butylmethylamine 
(60.0 µL, 0.50 mmol) and iPrMgCl·LiCl (0.30 mL, 0.50 mmol). The reaction was complete after 2 h at 
25 °C. After work-up, compound 79e (47.0 mg, 193 µmol, 77%) was isolated as a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.18 (dd, J = 4.7, 1.6 Hz, 1H), 7.74 (dd, J = 7.7, 1.7 Hz, 1H), 
6.67 (dd, J = 7.7, 4.7 Hz, 1H), 3.33 - 3.26 (m, 2H), 2.94 (s, 3H), 1.68 - 1.58 (m, 2H), 1. - 1.27 (m, 2H), 
0.92 (t, J = 7.4 Hz, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 160.3, 146.1, 142.5, 117.3, 111.5, 53.8, 39.1, 30.0, 20.3, 14.1. 
IR (Diamond-ATR, neat): ? / cm-1 = 2957, 2930, 2861, 1577, 1477, 1434, 1407, 1011, 780. 
MS (EI, 70 eV): m/z (%) = 198 (16), 99 (15), 85 (55), 71 (73), 57 (100). 
HRMS (ESI) for C10H16BrN2 (243.0497): 243.0493 (M++H). 
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Synthesis of N-butyl-3-iodo-N-methylpyridine-2-amine (79f) 
 
 
 
The aminopyridine 79f was prepared via TP3 using 78b (88.0 mg, 248 µmol), N-butylmethylamine 
(59.0 µL, 497 µmol) and iPrMgCl·LiCl (0.30 mL, 497 µmol). The reaction was complete after 2 h at 
25 °C. After work-up, compound 79f (70.0 mg, 241 µmol, 97%) was isolated as a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.22 (dd, J = 4.7, 1.7 Hz, 1H), 8.02 (dd, J = 7.6, 1.7 Hz, 1H), 
6.55 (dd, J = 7.6, 4.7 Hz, 1H), 3.25 - 3.18 (m, 2H), 2.88 (s, 3H), 1.65 - 1.56 (m, 2H), 1.38 - 1.27 (m, 
2H), 0.91 (t, J = 7.4 Hz, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 163.3, 149.2, 146.9, 118.3, 87.1, 54.6, 40.0, 29.9, 20.4, 14.1. 
IR (Diamond-ATR, neat): ? / cm-1 = 2958, 2930, 2861, 1570, 1466, 1438, 1400, 1000, 723. 
MS (EI, 70 eV): m/z (%) = 290 (14), 248 (10), 247 (100), 119 (14), 86 (16), 78 (12), 57 (11). 
HRMS (EI) for C10H15IN2 (290.0280): 290.0293 (M+). 
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Synthesis of N-butyl-N-methyl-3-(trimethylsilyl)pyridine-2-amine (79g) 
 
 
 
The aminopyridine 79g was prepared via TP3 using 78c (179 mg, 596 µmol), N-butylmethylamine 
(0.14 mL, 1.19 mmol) and iPrMgCl·LiCl (0.72 mL, 1.19 mmol). The reaction was complete after 2 h 
at 25 °C. After work-up, the crude product was purified via column chromatography (isohexane:ethyl 
acetate = 10:0.5) to give 79g (105 mg, 359 µmol, 59%) as a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.31 (dd, J = 4.8, 2.1 Hz, 1H), 7.73 (dd, J = 7.2, 2.1 Hz, 1H), 
6.89 (dd, J = 7.2, 4.8 Hz, 1H), 3.12 - 3.05 (m, 2H), 2.73 (s, 3H), 1.55 - 1.45 (m, 2H), 1.34 - 1.23 (m, 
2H), 0.89 (t, J = 7.4 Hz, 3H), 0.30 (s, 9H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 169.4, 148.7, 145.2, 127.9, 118.2, 55.4, 42.4, 30.0, 20.8, 14.2, 
0.1. 
IR (Diamond-ATR, neat): ? / cm-1 = 2956, 2932, 2863, 1560, 1427, 1392, 1247, 837, 732. 
MS (EI, 70 eV): m/z (%) = 193 (11), 97 (22), 85 (38), 71 (52), 43 (100). 
HRMS (ESI) for C13H25N2Si (237.1787): 237.1783 (M++H). 
 
One-pot procedure: 
 
The aminopyridine 79g was prepared via TP2 using 73b (228 mg, 1.00 mmol), TMPMgCl·LiCl 
(0.96 mL, 1.20 mmol) and trimethylsilyl chloride (0.16 mL, 1.30 mmol). The reaction was stirred at 
25 °C for 12 h. Then the reaction mixture was cooled to 0 °C and the magnesium amide prepared from 
N-butylmethylamine (0.36 mL, 3.00 mmol) and iPrMgCl·LiCl (1.91 mL, 3.00 mmol) was added 
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dropwise. The reaction was complete after 4 h. After work-up, the crude product was purified via 
column chromatography (isohexane:ethyl acetate = 10:0.8) to give 79g (163 mg, 542 µmol, 54%) as a 
yellow oil. 
 
Synthesis of N-butyl-N-methyl-3-phenylpyridine-2-amine (79h) 
 
 
 
The aminopyridine 79h was prepared via TP3 using 78d (80.0 mg, 263 µmol), N-butylmethylamine 
(57.0 µL, 479 µmol) and iPrMgCl·LiCl (0.29 mL, 479 µmol). The reaction was complete after 2 h at 
25 °C. After work-up, compound 79h (61 mg, 254 µmol, 97%) was isolated as a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.19 (dd, J = 4.9, 1.9 Hz, 1H), 7.48 - 7.43 (m, 2H), 7.43 - 7.36 
(m, 3H), 7.32 - 7.27 (m, 1H), 6.79 (dd, J = 7.3, 4.8 Hz, 1H), 3.07 - 3.01 (m, 2H), 2.71 (s, 3H), 1.44 - 
1.34 (m, 2H), 1.15 - 1.04 (m, 2H), 0.78 (t, J = 7.4 Hz, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 160.1, 146.2, 141.2, 139.8, 128.7, 128.2, 126.9, 125.9, 115.1, 
52.7, 38.9, 29.5, 20.3, 14.0. 
IR (Diamond-ATR, neat): ? / cm-1 = 3055, 2958, 2930, 2861, 1584, 1559, 1481, 1446, 1400. 
MS (EI, 70 eV): m/z (%) = 240 (23), 239 (22), 198 (14), 197 (100), 183 (15), 127 (13). 
HRMS (EI) for C16H20N2 (240.1626): 240.1622 (M+). 
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One-pot procedure: 
The aminopyridine 79h was prepared via TP2 using 73b (228 mg, 1.00 mmol) and TMPMgCl·LiCl 
(0.96 mL, 1.20 mmol). After the metalation was complete, a 1.0 M ZnCl2 solution in THF (1.20 mL, 
1.20 mmol) was added at 0 °C and the reaction mixture stirred at this temperature for 30 min. Then, 
iodobenzene (0.11 mL, 1.00 mmol), SPhos (16.0 mg, 40.0 µmol) and Pd(OAc)2 (4.50 mg, 20.0 µmol) 
were added and the reaction stirred at 25 °C for 12 h. Then, the reaction mixture was cooled to 0 °C and 
the magnesium amide prepared from N-butylmethylamine (0.48 mL, 4.00 mmol) and iPrMgCl·LiCl 
(2.54 mL, 4.00 mmol) was added dropwise. The reaction was complete after 3 h. After work-up, the 
crude product was purified via column chromatography (isohexane:ethyl acetate = 10:1) to give 79h 
(167 mg, 695 µmol, 70%) as a yellow oil. 
 
Synthesis of 3-bromo-2-(piperidin-1-yl)pyridine (79i) 
One-pot procedure: 
 
 
 
The aminopyridine 79i was prepared via TP2 using 73a (134 mg, 0.59 mmol), TMPMgCl·LiCl 
(0.69 mL, 0.71 mmol) and 1,2-dibromotetrachloroethane (230 mg, 0.71 mmol). The reaction was 
stirred at 25 °C for 12 h. Then the reaction mixture was cooled to 0 °C and the magnesium amide 
prepared from piperidine (0.18 mL, 1.77 mmol) and iPrMgCl·LiCl (1.50 mL, 1.77 mmol) was added 
dropwise. The reaction was complete after 3 h. After work-up, the crude product was purified via 
column chromatography (isohexane:ethyl acetate = 9:1) to give 79i (68 mg, 222 µmol, 48%) as a yellow 
oil. 
 
1H NMR (300 MHz, CDCl3): δ / ppm = 8.21 (dd, J = 4.8, 1.8 Hz, 1H), 7.75 (dd, J = 7.5, 1.8 Hz, 1H), 
6.72 (dd, J = 7.5, 4.8 Hz, 1H), 3.27 - 3.23 (m, 4H), 1.76 - 1.69 (m, 4H), 1.66 - 1.59 (m, 2H). 
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13C NMR (75 MHz, CDCl3): δ / ppm = 160.8, 146.5, 142.2, 118.1, 113.4, 51.1, 26.1, 24.6. 
IR (Diamond-ATR, neat): υ / cm-1 = 2931, 1574, 1437, 1428, 1373, 1239, 1105, 1008, 932, 780. 
MS (EI, 70 eV): m/z (%) = 242 (78), 213/211 (100), 161 (75), 84 (54). 
HRMS (ESI) for C10H1479BrN2 (241.0340): 241.0335 (M++H).  
 
Synthesis of 2-(Piperidin-1-ylsulfonyl)quinoline (82a) 
 
 
 
Adapted from a literature procedure,133 nBuMgCl (0.89 mL, 0.80 mmol) was dissolved in THF (2 mL) 
and cooled to 0 °C. Then, nBuLi (0.65 mL, 1.60 mmol) was added dropwise and the mixture stirred at 
this temperature for 15 min. Then a solution of 2-bromoquinoline (416 mg, 2.00 mmol) in THF (4 mL) 
was added at –10 °C and the reaction mixture stirred at this temperature for 2 h. Then, SO2Cl2 (0.24 mL, 
3.00 mmol) in hexane (2 mL) was added at –10 °C and the reaction mixture stirred for 10 min. 
Piperidine (1.00 mL, 10.0 mmol) was added and the reaction mixture stirred at 0 °C for 30 min. The 
reaction was quenched with water (20 mL), extracted with ethyl acetate (3 x 50 mL) and dried over 
Na2SO4. After filtration, the solvents were evaporated in vacuo. The crude product was purified via 
column chromatography (isohexane:ethyl acetate = 8.5:1.5) to give 82a (325 mg, 1.18 mmol, 59%) as 
a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.36 (d, J = 8.7 Hz, 1H), 8.21 (d, J = 8.6 Hz, 1H), 7.97 (d, J = 
8.5 Hz, 1H), 7.91 (dd, J = 8.1, 1.4 Hz, 1H), 7.82 (ddd, J = 8.5, 6.9, 1.5 Hz, 1H), 7.68 (ddd, J = 8.2, 6.9, 
1.3 Hz, 1H), 3.45 - 3.36 (m, 4H), 1.71 - 1.60 (m, 4H), 1.56 - 1.46 (m, 2H). 
                                                     
133
 T. Emura, H. Yoshino, K. Tachibana, T. Shiraishi, A. Honma, A. Mizutani, T. Muraoka, Synlett 2011, 1117–
1120. 
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13C-NMR (101 MHz, CDCl3): δ / ppm = 156.8, 147.3, 138.4, 130.9, 130.4, 128.9, 128.8, 127.9, 119.0, 
47.8, 25.6, 23.9. 
IR (Diamond-ATR, neat): ? / cm-1 = 2939, 2854, 1582, 1497, 1334, 1323, 1174, 719, 637. 
MS (EI, 70 eV): m/z (%) = 156 (27), 130 (16), 129 (82), 128 (40), 101 (14), 84 (100). 
HRMS (EI) for C14H15N2O2S (275.0854): 275.0870 (M+-H). 
M.p. (°C): 144–145. 
 
Synthesis of 3-iodo-2-(piperidin-1-yl)quinoline (83a) 
Synthesis of 3-iodo-2-(piperidin-1-ylsulfonyl)quinoline (A) 
 
 
 
The quinoline sulfonamide A was prepared via TP2 using 82a (88.0 mg, 318 µmol), TMPMgCl·LiCl 
(0.38 mL, 414 µmol) and iodine (121 mg, 477 µmol). The reaction was complete after 12 h. After work-
up, the crude product was purified via column chromatography (isohexane:ethyl acetate = 7:3) to give 
A (85 mg) as a yellow oil. The compound contained 5% impurities which could not be removed via 
column chromatography. It was used as is in the next step (synthesis of compound 83a). 
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Synthesis of 3-iodo-2-(piperidin-1-yl)quinoline (83a) 
 
 
 
The aminoquinoline 83a was prepared via TP3 using A (85 mg, 234 µmol), piperidine (50.0 µL, 
468 µmol) and iPrMgCl·LiCl (0.30 mL, 468 µmol). The reaction was complete after 2 h. After work-
up, the crude product was purified via column chromatography (isohexane:ethyl acetate = 9:1) to give 
83a (63.0 mg, 186 µmol, 59% over two steps) as an orange oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.54 (s, 1H), 7.83 (d, J = 8.5 Hz, 1H), 7.64 - 7.54 (m, 2H), 
7.35 (ddd, J = 8.1, 6.8, 1.2 Hz, 1H), 3.38 - 3.29 (m, 4H), 1.84 - 1.75 (m, 4H), 1.71 - 1.62 (m, 2H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 160.8, 148.8, 146.6, 129.9, 127.8, 126.8, 126.3, 124.8, 88.5, 
52.1, 25.9, 24.5. 
IR (Diamond-ATR, neat): ? / cm-1 = 3054, 2932, 1612, 1582, 1448, 1408, 1371, 1233, 752. 
MS (EI, 70 eV): m/z (%) = 338 (100), 309 (83), 295 (38), 255 (62), 211 (70), 129 (44), 128 (90), 84 
(43). 
HRMS (EI) for C14H15IN2 (338.0280): 338.0279 (M+). 
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Synthesis of compound 86 
 
Synthesis of 1-(2-(piperidin-1-ylsulfonyl)pyridin-3-yl)propan-2-one (B) 
 
 
 
The pyridine sulfonamide B was prepared via TP2 using 73a (2.02 g, 8.94 mmol) and TMPMgCl·LiCl 
(11.2 mL, 13.4 mmol). After the metalation was complete, a 1.0 M CuCN·2LiCl solution in THF 
(13.4 mL, 13.4 mmol) was added at –20°C and the reaction stirred at this temperature for 30 min. Then, 
2-methoxyallyl bromide67 (2.70 g, 17.9 mmol) was added dropwise and the reaction stirred at 25 °C for 
12 h. Then, according to a literature procedure9 a 1 M aq. oxalic acid solution (18 mL) was added and 
the reaction stirred for 30 minutes at 25 °C. After work-up, the crude product was purified via column 
chromatography (isohexane:ethyl acetate = 6:4) to give B (2.38 g, 8.44 mmol, 94%) as a colorless oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.49 (dd, J = 4.7, 1.7 Hz, 1H), 7.61 (dd, J = 7.8, 1.7 Hz, 1H), 
7.40 (dd, J = 7.8, 4.6 Hz, 1H), 4.14 (s, 2H), 3.50 - 3.42 (m, 4H), 2.32 (s, 3H), 1.69 - 1.55 (m, 6H). 
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13C-NMR (101 MHz, CDCl3): δ / ppm = 204.5, 157.2, 147.2, 142.0, 130.0, 126.0, 48.1, 46.3, 30.3, 
26.0, 24.0. 
IR (Diamond-ATR, neat): ? / cm-1 =2942, 2858, 2256, 1724, 1563, 1331, 1321, 1164, 726. 
MS (EI, 70 eV): m/z (%) = 162 (20), 134 (53), 93 (28), 84 (100), 83 (15), 43 (17). 
HRMS (EI) for C16H19N2 (283.1116): 283.1100 (M++1H ). 
 
Synthesis of N-benzyl-1-(2-(piperidin-1-ylsulfonyl)pyridin-3-yl)propan-2-amine (C) 
 
 
 
Adapted from a literature procedure,68 compound B (1.41 g, 5.00 mmol) was dissolved in THF (25 mL) 
and benzylamine (0.66 mL, 6.00 mmol), NaBH(OAc)3 (1.48 g, 7.00 mmol) and glacial acetic acid 
(0.29 mL, 5.00 mmol) were added subsequently. The reaction mixture was then stirred for 36 h at 25 °C. 
The reaction mixture was quenched with 2 M aq. NaOH (10 mL), extracted with ethyl acetate (3 x 
50 mL) and dried over Na2SO4. After filtration, the crude product was purified via column 
chromatography (DCM:methanol:triethylamine = 95:5:1) to give C (1.30 g, 3.63 mmol, 73%) as a 
colorless oil. 
1H-NMR (599 MHz, CDCl3): δ / ppm = 8.48 (dd, J = 4.6, 1.7 Hz, 1H), 7.77 (dd, J = 7.8, 1.7 Hz, 1H), 
7.39 (dd, J = 7.8, 4.6 Hz, 1H), 7.35 - 7.24 (m, 5H), 3.93 (d, J = 13.2 Hz, 1H), 3.80 (d, J = 13.2 Hz, 1H), 
3.59 - 3.52 (m, 4H), 3.32 (dd, J = 13.6, 6.9 Hz, 1H), 3.21 (sept, J = 6.4 Hz, 1H), 3.05 (dd, J = 13.6, 6.3 
Hz, 1H), 1.76 - 1.70 (m, 4H), 1.70 - 1.63 (m, 2H), 1.21 (d, J = 6.3 Hz, 3H). 
13C-NMR (151 MHz, CDCl3): δ / ppm = 157.6, 146.1, 141.4, 140.8, 135.4, 128.4, 128.2, 126.9, 125.6, 
53.6, 51.4, 48.2, 39.4, 26.1, 24.2, 20.5. 
IR (Diamond-ATR, neat): ? / cm-1 = 3027, 2940, 2858, 1560, 1450, 1331, 1319, 1165, 724. 
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MS (EI, 70 eV): m/z (%) = 134 (74), 93 (9), 91 (100). 
HRMS (EI) for C19H24O2N3S (258.1595): 258.1565 (M+-CH3). 
 
Synthesis of 1-benzyl-2-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine (D) 
 
 
 
Compound C (996 mg, 2.78 mmol) was dissolved in THF (15 mL) and cooled to –78 °C. Then, phenyl 
lithium (1.50 mL, 3.34 mmol) was added dropwise and the reaction mixture slowly warmed to 25 °C 
over 12 h. After hydrolysis (5 mL), the reaction mixture was extracted with ethyl acetate (3 x 50 mL) 
and dried over Na2SO4. After filtration, the solvents were removed in vacuo and the crude product 
purified via column chromatography (isohexane:ethyl acetate = 9:1) to give D (571 mg, 2.55 mmol, 
92%) as a colorless oil: 
. 
1H-NMR (800 MHz, CDCl3): δ / ppm = 7.90 - 7.88 (m, 1H), 7.32 - 7.27 (m, 4H), 7.24 - 7.22 (m, 1H), 
7.15 (dq, J = 6.9, 1.4 Hz, 1H), 6.43 (dd, J = 7.0, 5.3 Hz, 1H), 4.92 (d, J = 15.6 Hz, 1H), 4.36 (d, J = 
15.6 Hz, 1H), 3.76 - 3.71 (m, 1H), 3.11 (ddt, 1H), 2.56 (ddt, J = 16.2, 7.9, 1.3 Hz, 1H), 1.23 (d, J = 6.2 
Hz, 3H). 
13C-NMR (201 MHz, CDCl3): δ / ppm = 162.9, 146.0, 138.5, 130.8, 128.5, 128.1, 127.1, 122.2, 112.3, 
55.7, 46.4, 34.8, 20.0. 
IR (Diamond-ATR, neat): ? / cm-1 = 3061, 3031, 2966, 2936, 2846, 2360, 1610, 1579, 1494, 1486, 
1444, 1358, 769, 699. 
MS (EI, 70 eV): m/z (%) = 224 (58), 223 (13), 209 (51), 147 (10), 92 (14), 91 (100), 65 (15). 
HRMS (EI) for C15H16N2 (224.1313): 224.1310 (M+). 
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Synthesis of 1-benzyl-2-methyl-1H-pyrrolo[2,3-b]pyridine (86) 
 
 
 
Compound D (22 mg, 100 µmol) was dissolved in THF (2 mL) and DDQ (25 mg, 110 µmol) was added 
at 25 °C. The reaction mixture was then stirred for two days at the same temperature. Full conversion 
was observed via GC-MS. The reaction mixture was then diluted with water (2 mL), extracted with 
dichloromethane (3 x 10 mL) and dried over Na2SO4. After filtration, the crude product was purified 
via column chromatography (isohexane: ethyl acetate = 9:1) to give 86 (13 mg, 59 µmol, 59%) as a 
colorless solid. 
 
1H-NMR (599 MHz, CDCl3): δ / ppm = 8.25 (dd, J = 4.8, 1.6 Hz, 1H), 7.82 (dd, J = 7.7, 1.6 Hz, 1H), 
7.27 - 7.23 (m, 2H), 7.23 - 7.19 (m, 1H), 7.06 - 7.02 (m, 3H), 6.25 (q, J = 1.1 Hz, 1H), 5.53 (s, 2H), 
2.35 (d, J = 1.2 Hz, 3H). 
13C-NMR (151 MHz, CDCl3): δ / ppm = 148.8, 141.9, 138.2, 137.7, 128.8, 127.3, 127.3, 126.6, 120.7, 
116.0, 98.5, 44.9, 13.3. 
IR (Diamond-ATR, neat): ? / cm-1 = 3057, 3027, 2923, 2854, 1592, 1549, 1434, 1311, 730. 
MS (EI, 70 eV): m/z (%) = 223 (17), 222 (100), 221 (78), 207 (45), 91 (79), 57 (22), 43 (57). 
HRMS (EI) for C15H14N2 (222.1157): 222.1153 (M+). 
M.p. (°C): 111-112. 
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Synthesis of compounds 87–89 
 
Synthesis of N,N-diethylpyridine-2-sulfonamide (E) 
 
 
 
Diethylamine (11.6 mL, 112 mmol) was added to a solution of sulfonyl chloride 72 (6.62 g, 37.3 mmol) 
in DCM (50 mL) at 0 °C. After stirring at 25 °C for 12 h, the reaction mixture was quenched with water, 
extracted with DCM (3 x 100 mL) and dried over Na2SO4. After filtration, the solvent was removed in 
vacuo. The crude product was purified via column chromatography (isohexane:ethyl acetate = 6:4) to 
give E (6.74 g, 31.5 mmol, 84%) as an orange oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.67 (ddd, J = 4.7, 1.7, 0.9 Hz, 1H), 7.95 (dt, J = 7.9, 1.1 Hz, 
1H), 7.87 (td, J = 7.7, 1.7 Hz, 1H), 7.45 (ddd, J = 7.6, 4.7, 1.2 Hz, 1H), 3.40 (q, J = 7.2 Hz, 4H), 1.14 
(t, J = 7.2 Hz, 6H). 
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The spectra matched those of the literature.60b 
 
Synthesis of N,N-diethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-2-sulfonamide 
(87) 
 
 
 
According to a literature procedure60a diisopropylamine (4.92 mL, 35.0 mmol) was dissolved in THF 
(35 mL) and cooled to 0 °C. Then, nBuLi (14.8 mL, 38.5 mmol) was added dropwise and the reaction 
stirred for 30 min at the same temperature. In a separate flask, F (2.14 g, 10.0 mmol) was dissolved in 
THF (50 mL) and cooled to –78 °C. The freshly prepared solution of LDA was added dropwise and the 
reaction stirred for 60 min at the same temperature. Then, iPrOBpin was added dropwise and the 
mixture stirred for five minutes. Then, the cold bath was removed and the reaction stirred at 25 °C for 
12 h. The reaction was quenched with a sat. NH4Cl solution (50 mL) extracted with ethyl acetate (3 x 
100 mL) and dried over Na2SO4. After filtration, the solvent was removed in vacuo. The crude product 
was purified via column chromatography (isohexane:ethyl acetate = 6:4) to give 16 (3.28 g, 9,64 mmol, 
96%) as a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.65 (dd, J = 4.7, 1.8 Hz, 1H), 7.86 (dd, J = 7.6, 1.8 Hz, 1H), 
7.39 (dd, J = 7.6, 4.7 Hz, 1H), 3.41 (q, J = 7.1 Hz, 4H), 1.41 (s, 12H), 1.14 (t, J = 7.1 Hz, 6H). 
 
The spectra matched those of the literature60a 
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Synthesis of 2-iodo-N-methylaniline (F) 
 
 
 
Adapted from a literature procedure,134 2-iodoaniline (8.67 g, 40.0 mmol) was dissolved in THF 
(50 mL) and cooled to –78 °C. Then, MeLi (47.1 mL, 40.0 mmol) was added dropwise over 30 min. 
After stirring at the same temperature for 30 min, methyl iodide (3.25 mL, 52.0 mmol) was added 
dropwise over 5 min and the reaction mixture stirred for 1 h. After warming to 25 °C and stirring for 
1 h, the reaction mixture was quenched with sat. NH4Cl solution (50 mL), extracted with ethyl acetate 
(3 x 100 mL) and dried over Na2SO4. After filtration, the solvents were removed in vacuo and the crude 
product purified via column chromatography (isohexane:ethyl acetate = 10:0.3) to give F (6.00 g, 
25.8 mmol, 65%) as an orange oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 7.67 (dd, J = 7.8, 1.5 Hz, 1H), 7.25 (ddd, J = 8.5, 7.2, 1.5 Hz, 
1H), 6.57 (dd, J = 8.1, 1.4 Hz, 1H), 6.46 (td, J = 7.5, 1.5 Hz, 1H), 4.21 (s, 1H), 2.89 (s, 3H). 
 
The spectra matched those of the literature.134  
  
                                                     
134
 B. Yao, Q. Wang, J. Zhu, Angew. Chem. Int. Ed. 2012, 51, 12311–12315. 
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Synthesis of 2-iodo-N-boc-N-methylaniline (88) 
 
 
 
Hexamethyldisilazane (5.93 mL, 28.3 mmol) was dissolved in THF (20 mL) and cooled to 0 °C. Then, 
nBuLi (10.9 mL, 27.0 mmol) was added dropwise and the reaction stirred for 30 min at the same 
temperature. In a separate flask, F (6.00 g, 25.8 mmol) was dissolved in THF (50 mL) and cooled to  
–78 °C. The freshly prepared solution of LiHMDS was added dropwise and the reaction stirred for 
30 min. Then, Boc2O (16.6 mL, 77.4 mmol) was added dropwise and the reaction stirred for 10 min. 
Then the cold bath was removed and the reaction stirred at 25 °C for 12 h. The reaction was quenched 
with sat. NH4Cl (25 mL) and water (25 mL), extracted with ethyl acetate (3 x 100 mL) and dried over 
Na2SO4. After filtration, the crude product was purified via column chromatography (isohexane:ethyl 
acetate = 10:0.5) to give 88 (7.87 g, 23.6 mmol, 92%) as a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 7.85 (dd, J = 7.9, 1.4 Hz, 1H), 7.34 (td, J = 7.6, 1.4 Hz, 1H), 
7.20 (dd, J = 7.8, 1.6 Hz, 1H), 6.97 (td, J = 7.7, 1.7 Hz, 1H), 3.13 (s, 3H), 1.54 (s, 3H), 1.35 (s, 9H). 
 
The spectra matched those of the literature.135  
  
                                                     
135
 Y. Yasui, H. Kamisaki, T. Ishida, Y. Takemoto, Tetrahedron 2010, 66, 1980–1989. 
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Synthesis of tert-butyl (2-(2-(N,N-diethylsulfamoyl)pyridin-3-yl)phenyl)(methyl) 
carbamate (G) 
 
 
 
Adapted from a literature procedure,60a 87 (340 mg, 1.00 mmol) was dissolved in degassed dioxane 
(10 mL). Then Pd(PPh3)2Cl2·CH2Cl2 (65 mg, 80 µmol). K2CO3 (552 mg, 4.00 mmol), and 88 (334 mg, 
1.00°mmol) were added at 25 °C and the reaction stirred for 14 h. The reaction mixture was then 
quenched with water (15 mL), extracted with ethyl acetate (3 x 50 mL) and dried over Na2SO4. After 
filtration, the solvent was removed in vacuo. The crude product was purified via column 
chromatography (isohexane:ethyl acetate = 85:15) to give G (244 mg, 582 µmol, 58%) as a light yellow 
oil. 
1H-NMR (400 MHz, (CD3)2CO): δ / ppm = 8.64 (b, 1H), 7.81 (b, 1H), 7.63 (b, 1H), 7.51 - 7.38 (m, 
2H), 7.38 - 7.25 (m, 2H), 3.60 - 3.32 (m, 4H), 3.00 - 2.68 (s, 3H), 1.39 (s, 9H), 1.17 (s, 6H). 
13C-NMR (101 MHz, (CD3)2CO): δ / ppm = 157.4, 155.6, 155.3, 148.6, 142.6, 142.2, 141.8, 136.6, 
135.7, 134.9, 132.1, 129.9, 129.3, 129.0, 127.1, 127.1, 126.3, 80.1, 45.2, 37.4, 36.5, 28.4, 15.7. 
IR (Diamond-ATR, neat): ? / cm-1 = 2978, 2435, 1694, 1497, 1456, 1439, 1363, 1330, 1153, 1124, 
754. 
MS (EI, 70 eV): m/z (%) = 184 (13), 183 (100), 182 (12), 181 (19), 72 (11), 57 (18). 
HRMS (EI) for C21H29N3O4S (419.1879): 419.1869 (M+). 
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Synthesis of N,N-diethyl-3-(2-(methylamino)phenyl)pyridine-2-sulfonamide (H) 
 
 
 
The pyridine sulfonamide G (210 mg, 657 µmol) was dissolved in dichloromethane (4 mL). Then 
trifluoroacetic acid (1.5 mL, 1.95 mmol) was added dropwise at 25 °C and the reaction mixture stirred 
for 20 min. After removal of the solvents in vacuo the crude product was dissolved in water (10 mL) 
and dichloromethane (10 mL). After phase separation, the aqueous phase was extracted with 
dichloromethane (2 x 10 mL). The organic phases were combined and dried over Na2SO4. After 
filtration, the solvent was removed in vacuo. The crude product was purified via column 
chromatography (isohexane:ethyl acetate = 7:3) to give H (136 mg, 426 µmol, 85%) as an off-white 
solid. 
 
1H-NMR (599 MHz, CDCl3): δ / ppm = 8.60 (dd, J = 4.7, 1.8 Hz, 1H), 7.72 (dd, J = 7.6, 1.7 Hz, 1H), 
7.49 (dd, J = 7.7, 4.7 Hz, 1H), 7.32 (ddd, J = 8.2, 7.4, 1.6 Hz, 1H), 7.03 (dd, J = 7.4, 1.6 Hz, 1H), 6.80 
(td, J = 7.4, 1.2 Hz, 1H), 6.75 (dd, J = 8.3, 1.1 Hz, 1H), 3.33 (q, J = 7.2 Hz, 4H), 2.79 (s, 3H), 1.17 (t, 
J = 7.2 Hz, 6H). 
13C-NMR (151 MHz, CDCl3): δ / ppm = 157.8, 147.7, 146.9, 142.4, 134.5, 130.4, 130.0, 126.3, 122.9, 
116.9, 110.7, 44.0, 31.1, 15.4. 
IR (Diamond-ATR, neat): ? / cm-1 = 3047, 2976, 2936, 2815, 1605, 1581, 1512, 1330, 1159, 1022, 
705. 
MS (EI, 70 eV): m/z (%) = 184 (13), 183 (100), 182 (12), 181 (19), 71 (11), 57 (18). 
HRMS (EI) for C16H21N3O2S (319.1354): 319.1359 (M+). 
M.p. (°C): 87–88. 
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Synthesis of 9-methyl-9H-pyrido[2,3-b]indole (89) 
 
 
 
The pyridine sulfonamide H (71 mg, 222 µmol) was dissolved in THF (3 mL) and cooled to –78 °C. 
Then, phenyl lithium (0.13 mL, 266 µmol) was added dropwise and the reaction mixture slowly 
warmed to 25 °C over 12 h. After hydrolysis (5 mL), the reaction mixture was extracted with ethyl 
acetate (3 x 10 mL) and dried over Na2SO4. After filtration, the solvents were removed in vacuo and 
the crude product purified via column chromatography (isohexane:ethyl acetate = 8:2) to give 89 
(34 mg, 187 µmol, 84%) as a colorless oil. 
 
1H-NMR (599 MHz, CDCl3): δ / ppm = 8.51 (dd, J = 4.9, 1.7 Hz, 1H), 8.32 (dd, J = 7.6, 1.6 Hz, 1H), 
8.08 (dt, J = 7.8, 1.0 Hz, 1H), 7.55 (ddd, J = 8.3, 7.1, 1.1 Hz, 1H), 7.47 (dt, J = 8.3, 0.9 Hz, 1H), 7.29 
(ddd, J = 8.0, 7.2, 1.1 Hz, 1H), 7.17 (dd, J = 7.6, 4.8 Hz, 1H), 3.98 (s, 3H). 
13C-NMR (151 MHz, CDCl3): δ / ppm = 151.9, 146.1, 140.4, 128.2, 126.9, 121.1, 120.5, 119.9, 116.1, 
115.0, 109.2, 27.8. 
IR (Diamond-ATR, neat): ? / cm-1 = 3051, 2929, 1627, 1589, 1571, 1472, 1403, 1243, 772. 
MS (EI, 70 eV): m/z (%) = 182 (100), 127 (12), 91 (11). 
HRMS (EI) for C12H10N2 (182.0844): 182.0842 (M+). 
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2.3 Mechanistic Insights 
1 Investigation of the Sulfonamide Substitution Mechanism 
Pyridine-2-sulfonamides of type PySO2NR12 reacted with magnesium amides of type R22NMgCl·LiCl 
which led to mixtures of PyNR12 and PyNR22 (Scheme 59). 
 
Scheme 59: Reaction of a pyridine sulfonamide PySO2NR12 with a magnesium amide R22NMgCl·LiCl. 
 
Typical procedure for the above described mechanistic experiments and results 
 
iPrMgCl·LiCl (1.5 – 3.0 equiv) was added to a solution of amine (1.5 – 3.0 equiv) in THF (5 mL/mmol 
of sulfonamide) at 0 °C. The solution was stirred for 15 min at 0 °C and then 15 min at 25 °C before 
being added to a solution of sulfonamide (1.0 equiv) in THF (5 mL/mmol of sulfonamide) at 0 °C. The 
reaction mixture was then stirred at 0 °C for 15 min and 105 min at 25 °C. GC aliquots (hydrolysis) 
were taken at this point. After another 60 min the reaction mixture was quenched with water and 
extracted with ethyl acetate. The organic phase was then dried over Na2SO4 and concentrated in vacuo. 
The minimum amount of magnesium amide equivalents used was set to 1.5 equiv, to assure complete 
conversion in 2 h reaction time. 
 
Competition experiments (1) to (4) were performed according to the typical procedure. 
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Experiment (1) 
 
 
 
Sulfonamide 73a (751 mg, 3.32 mmol) was dissolved in THF (10 mL). For each run, 3 mL of 
sulfonamide solution was used and diluted with additional THF (2 mL). This resulted in 996 µmol 
sulfonamide per reaction in 5 mL THF. The pyrrolidine magnesium amide was prepared according to 
the typical procedure. The exact amounts can be found in Table 9. 
Table 9: Amount of reagents used for mechanistic experiment (1) 
Entry Amide base eq. iPrMgCl·LiCl (1.66 m) Pyrrolidine THF 
1 1.5 0.90 mL, 1.49 mmol 0.12 mL 3.75 mL 
2 2.0 1.20 mL, 1.99 mmol 0.16 mL 5.00 mL 
3 3.0 1.80 mL, 2.99 mmol 0.25 mL 7.50 mL 
 
GC Analysis led to the results in Table 10. 
Table 10: Results from mechanistic experiment (1). 
Entry Amide base eq. Ratio (75d / 75c)  
1 1.5 1:20 
2 2.0 1:34 
3 3.0 1:50 
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Experiment (2) 
 
Sulfonamide I (760 mg, 3.58 mmol) was dissolved in THF (10 mL). For each run, 3 mL of sulfonamide 
solution was used and diluted with additional THF (2 mL). This resulted in 1.07 mmol sulfonamide per 
reaction in 5 mL THF. The piperidine magnesium amide was prepared according to the typical 
procedure. The exact amounts can be found in Table 11. 
Table 11: Amount of reagents used for mechanistic experiment (2). 
Entry Amide base eq. iPrMgCl·LiCl (1.66 m) Piperidine THF 
1 1.5 0.97 mL, 1.61 mmol 0.16 mL 3.75 mL 
2 2.0 1.29 mL, 2.15 mmol 0.21 mL 5.00 mL 
3 3.0 1.94 mL, 3.22 mmol 0.32 mL 7.50 mL 
 
GC Analysis lead to the results in Table 12. 
Table 12: Results from mechanistic experiment (2). 
Entry Amide base eq. Ratio (75d / 75c)  
1 1.5 15:1 
2 2.0 34:1 
3 3.0 56:1 
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Experiment (3) 
 
For the first two experiments (Table 13, entries 1–2) sulfonamide 73b (916 mg, 4.01 mmol) was 
dissolved in THF (10 mL). For each run, 3 mL of sulfonamide solution was used and diluted with 
additional THF (2 mL). This resulted in 1.20 mmol sulfonamide per reaction in 5 mL THF. For the third 
experiment (Table 13, entry 3) 113 mg (495 µmol) sulfonamide was used. The pyrrolidine magnesium 
amide was prepared according to the typical procedure. The exact amounts can be found in Table 13. 
 
Table 13: Amount of reagents used for mechanistic experiment (3). 
Entry Amide base eq. iPrMgCl·LiCl (1.66 m) pyrrolidine THF 
1 1.5 1.09 mL, 1.80 mmol 0.15 mL 4.50 mL 
2 2.0 1.45 mL, 2.40 mmol 0.20 mL 6.00 mL 
3 3.0 895 µL, 1.48 mmol 122 µL 3.70 mL 
 
GC Analysis lead to the results in Table 14. 
Table 14: Results from mechanistic experiment (3). 
Entry Amide base eq. Ratio (75b / 75c)  
1 1.5 1:36 
2 2.0 1:60 
3 3.0 1:216 
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Experiment (4) 
 
Sulfonamide I (862 mg, 4.06 mmol) was dissolved in THF (10 mL). For each run, 3 mL of sulfonamide 
solution was used and diluted with additional THF (3 mL). This resulted in 1.22 mmol sulfonamide per 
reaction in 6 mL THF. The N-butylmethylamine magnesium amide was prepared according the typical 
procedure. The exact amounts can be found in Table 15. 
Table 15: Amount of reagents used for mechanistic experiment (4). 
Entry Amide base eq. iPrMgCl·LiCl (1.66 M) N-Butylmethylamine THF 
1 1.5 1.16 mL, 1.83 mmol 0.22 mL 4.50 mL 
2 2.0 1.55 mL, 2.44 mmol 0.29 mL 6.00 mL 
3 3.0 2.33 mL, 3.65 mmol 0.433 mL 9.60 mL 
 
GC Analysis lead to the results in Table 16. 
Table 16: Results from mechanistic experiment (4). 
Entry Amide base eq. Ratio (75b / 75c)  
1 1.5 7.5:1 
2 2.0 8.7:1 
3 3.0 18.4:1 
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Synthesis of 2-(Pyrrolidin-1-ylsulfonyl)pyridine (I) 
 
 
 
Pyrrolidine (0.95 mL, 11.6 mmol) was added to a solution of sulfonyl chloride 1 (686 mg, 3.86 mmol) 
in DCM (10 mL) at 0 °C. After stirring at 25 °C for 12 h, the reaction mixture was quenched with water, 
extracted with DCM (3 x 20 mL) and dried over Na2SO4. After filtration, the solvent was removed in 
vacuo. The crude product was purified via column chromatography (isohexane:ethyl acetate = 7:3) to 
give I (793 mg, 3.74 mmol, 97%) as a colorless oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.71 - 8.66 (m, 1H), 7.99 - 7.93 (m, 1H), 7.89 (td, J = 7.7, 1.8 
Hz, 1H), 7.48 (ddd, J = 7.5, 4.7, 1.3 Hz, 1H), 3.53 - 3.42 (m, 4H), 1.87 - 1.79 (m, 4H). 
 
The spectra matched those of the literature.60b 
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3 Amination of 2-Pyridinesulfonic Acid and 8-Quinolinesulfonic Acid with 
Magnesium Amides 
3.1 Typical Procedure 
Amination of 2-pyridinesulfonic- and 8-quinolinesulfonic acids (94 or 95) using magnesium 
amides of type R2NMgCl·LiCl (TP4) 
 
iPrMgCl·LiCl (3.0–5.0 mmol) was added to a solution of the amine (3.0–5.0 mmol) in THF 
(5 mL/mmol of sulfonic acid) at 0 °C. The solution was stirred for 15 min at 0 °C and 15 min at 25 °C 
before being added to a suspension of the sulfonic acid (1 mmol) in THF (5 mL/mmol sulfonic acid) at 
0 °C. The reaction mixture was stirred at 25 °C until completion. The reaction mixture was quenched 
with water (20 mL) and extracted with ethyl acetate (3 x 30 mL). The organic phase was dried over 
Na2SO4 and concentrated in vacuo. If the crude product needed purification, it was purified by flash 
chromatography on silica gel using the appropriate eluent. 
3.2 Preparation of Compounds 96 to 98 
 
Synthesis of 2-(pyrrolidin-1-yl)pyridine (96a) 
 
 
 
The aminopyridine 7a was prepared via TP4 using 2-pyridinesulfonic acid (159 mg, 1.00 mmol), 
iPrMgCl·LiCl (1.92 mL, 3.00 mmol) and pyrrolidine (0.25 mL, 3.00 mmol). After stirring at 25 °C for 
12 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) 
and dried over Na2SO4. After filtration, the solvents were removed in vacuo to give 96a (135 mg, 
0.91 mmol, 91%) as a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.15 (ddd, J = 5.0, 1.9, 0.9 Hz, 1H), 7.42 (ddd, J = 8.5, 7.1, 
2.0 Hz, 1H), 6.50 (ddd, J = 7.1, 5.0, 0.9 Hz, 1H), 6.35 (dt, J = 8.6, 1.0 Hz, 1H), 3.50 - 3.39 (m, 4H), 
2.04 - 1.97 (m, 4H). 
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13C-NMR (101 MHz, CDCl3) δ (ppm): 157.5, 148.3, 137.0, 111.2, 106.6, 46.8, 25.7. 
 
The spectra matched those of the literature.10a 
 
Synthesis of 2-(piperidin-1-yl)pyridine (96b) 
 
 
 
The aminopyridine 96b was prepared via TP4 using 2-pyridinesulfonic acid (159 mg, 1.00 mmol), 
iPrMgCl·LiCl (1.92 mL, 3.00 mmol) and piperidine (0.30 mL, 3.00 mmol). After stirring at 25 °C for 
12 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) 
and dried over Na2SO4. After filtration, the solvents were removed in vacuo to give 96b (154 mg, 
0.95 mmol, 95%) as a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.17 (ddd, J = 4.9, 2.1, 0.9 Hz, 1H), 7.43 (ddd, J = 8.9, 7.1, 
2.0 Hz, 1H), 6.64 (dd, J = 8.6, 1.0 Hz, 1H), 6.55 (ddd, J = 7.1, 4.9, 0.9 Hz, 1H), 3.58 - 3.47 (m, 4H), 
1.65 (td, J = 3.5, 1.7 Hz, 6H). 
13C-NMR (101 MHz, CDCl3) δ (ppm): 159.9, 148.1, 137.4, 112.5, 107.2, 46.5, 25.7, 24.9. 
 
The spectra matched those of the literature.10a  
 
Reaction on 50 mmol scale: 
 
The aminopyridine 96b was prepared via TP4 using 2-pyridinesulfonic acid (7.96 g, 50.0 mmol), 
iPrMgCl·LiCl (95.9 mL, 150 mmol) and piperidine (14.9 mL, 150 mmol). After stirring at 25 °C for 
12 h, the reaction mixture was quenched with water (200 mL), extracted with ethyl acetate (3 x 200 mL) 
and dried over Na2SO4. After filtration, the solvents were removed in vacuo to give 96b (7.29 g, 
44.9 mmol, 90%) as a yellow oil. 
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Synthesis of 1-(pyridin-2-yl)azepane (96c) 
 
 
 
The aminopyridine 96c was prepared via TP4 using 2-pyridinesulfonic acid (159 mg, 1.00 mmol), 
iPrMgCl·LiCl (1.92 mL, 3.00 mmol) and azepane (0.34 mL, 3.00 mmol). After stirring at 25 °C for 
12 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) 
and dried over Na2SO4. After filtration, the solvents were removed in vacuo to give 96c (164 mg, 
0.93 mmol, 93%) as a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.17 - 8.10 (m, 1H), 7.40 (ddd, J = 8.4, 7.2, 2.0 Hz, 1H), 6.51 
- 6.44 (m, 2H), 3.65 - 3.58 (m, 4H), 1.81 - 1.75 (m, 4H), 1.55 (dt, J = 5.8, 2.7 Hz, 4H). 
13C-NMR (101 MHz, CDCl3) δ (ppm): 158.4, 148.2, 137.2, 111.0, 105.5, 47.6, 28.0, 27.4. 
 
The spectra matched those of the literature.10a  
 
Synthesis of 4-(pyridin-2-yl)morpholine (96d) 
 
N N
O
 
 
The aminopyridine 96d was prepared via TP4 using 2-pyridinesulfonic acid (159 mg, 1.00 mmol), 
iPrMgCl·LiCl (1.92 mL, 3.00 mmol) and morpholine (0.27 mL, 3.00 mmol). After stirring at 25 °C for 
12 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) 
and dried over Na2SO4. After filtration, the solvents were removed in vacuo to give 96d (148 mg, 
0.90 mmol, 90%) as a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.21 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 7.50 (ddd, J = 8.6, 7.2, 
2.0 Hz, 1H), 6.70 - 6.60 (m, 2H), 3.88 - 3.80 (m, 4H), 3.54 - 3.46 (m, 4H). 
13C-NMR (101 MHz, CDCl3) δ (ppm): 159.7, 148.1, 137.7, 114.0, 107.1, 66.9, 45.8. 
 
The spectra matched those of the literature.10a  
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Synthesis of 1-methyl-4-(pyridin-2-yl)piperazine (96e) 
 
 
 
The aminopyridine 96e was prepared via TP4 using 2-pyridinesulfonic acid (159 mg, 1.00 mmol), 
iPrMgCl·LiCl (1.92 mL, 3.00 mmol) and 1-methylpiperazine (0.34 mL, 3.00 mmol). After stirring at 
25 °C for 12 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 
x 30 mL) and dried over Na2SO4. After filtration, the solvents were removed in vacuo to give 96e 
(171 mg, 0.97 mmol, 97%) as a light brown oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.19 (ddd, J = 5.0, 2.0, 0.9 Hz, 1H), 7.47 (ddd, J = 8.9, 7.1, 
2.0 Hz, 1H), 6.68 - 6.58 (m, 2H), 3.59 - 3.53 (m, 4H), 2.55 - 2.50 (m, 4H), 2.35 (s, 3H). 
13C-NMR (101 MHz, CDCl3) δ (ppm): 159.7, 148.1, 137.6, 113.4, 107.2, 55.1, 46.4, 45.3. 
 
The spectra matched those of the literature.58b  
 
Synthesis of 2-(4-methylpiperidin-1-yl)pyridine (96f) 
 
 
 
The aminopyridine 96f was prepared via TP4 using 2-pyridinesulfonic acid (159 mg, 1.00 mmol), 
iPrMgCl·LiCl (1.92 mL, 3.00 mmol) and 4-methylpiperidine (0.36 mL, 3.00 mmol). After stirring at 
25 °C for 12 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 
x 30 mL) and dried over Na2SO4. After filtration, the solvents were removed in vacuo to give 96f 
(170 mg, 0.96 mmol, 96%) as a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 7.43 (ddd, J = 8.9, 7.1, 2.0 Hz, 
1H), 6.64 (dt, J = 8.6, 0.9 Hz, 1H), 6.54 (ddd, J = 7.1, 4.9, 0.9 Hz, 1H), 4.29 - 4.20 (m, 2H), 2.87 - 2.74 
(m, 2H), 1.77 - 1.67 (m, 2H), 1.67 - 1.54 (m, 1H), 1.30 - 1.16 (m, 2H), 0.96 (d, J = 6.6 Hz, 3H). 
13C-NMR (101 MHz, CDCl3) δ (ppm): 159.8, 148.1, 137.4, 112.5, 107.3, 45.8, 33.9, 31.3, 22.1. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 2950, 2922, 1593, 1483, 1464, 1438, 1314, 1237, 972, 
770. 
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MS (EI, 70 eV): m/z = 176 (80), 161, (51), 133 (100), 119, (43), 107 (31), 106 (33). 
HRMS (EI) for C11H16N2 (176.1313): 176.1307 (M+). 
 
Synthesis of N,N-diethylpyridin-2-amine (96g) 
 
 
 
The aminopyridine 96g was prepared via TP4 using 2-pyridinesulfonic acid (159 mg, 1.00 mmol), 
iPrMgCl·LiCl (1.92 mL, 3.00 mmol) and diethylamine (0.31 mL, 3.00 mmol). After stirring at 25 °C 
for 12 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 
30 mL) and dried over Na2SO4. After filtration, the solvents were removed in vacuo to give 96g 
(114 mg, 0.76 mmol, 76%) as a brown oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.14 (ddd, J = 5.0, 2.0, 0.9 Hz, 1H), 7.40 (ddd, J = 9.0, 7.1, 
2.0 Hz, 1H), 6.52 - 6.42 (m, 2H), 3.51 (q, J = 7.1 Hz, 4H), 1.18 (t, J = 7.1 Hz, 6H). 
13C-NMR (101 MHz, CDCl3) δ (ppm): 157.6, 148.2, 137.2, 110.9, 105.6, 42.5, 13.1. 
 
The spectra matched those of the literature.10a 
 
Synthesis of N,N-dibutylpyridin-2-amine (96h) 
 
 
 
The aminopyridine 96h was prepared via TP4 using 2-pyridinesulfonic acid (159 mg, 1.00 mmol), 
iPrMgCl·LiCl (1.77 mL, 3.00 mmol) and dibutylamine (0.51 mL, 3.00 mmol). After stirring at 25 °C 
for 12 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 
30 mL) and dried over Na2SO4. After filtration, the solvents were removed in vacuo to give 96h 
(157 mg, 0.76 mmol, 76%) as a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.12 (ddd, J = 5.0, 2.0, 0.9 Hz, 1H), 7.37 (ddd, J = 8.9, 7.0, 
2.0 Hz, 1H), 6.48 - 6.39 (m, 2H), 3.46 - 3.39 (m, 4H), 1.63 - 1.53 (m, 4H), 1.35 (dq, J = 14.7, 7.4 Hz, 
4H), 0.95 (t, J = 7.3 Hz, 6H). 
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13C-NMR (101 MHz, CDCl3) δ (ppm): 158.1, 148.2, 137.0, 110.8, 105.6, 48.5, 30.0, 20.5, 14.2. 
 
The spectra matched those of the literature.136 
 
Synthesis of N,N-diallylpyridin-2-amine (96i) 
 
 
 
The aminopyridine 96i was prepared via TP4 using 2-pyridinesulfonic acid (159 mg, 1.00 mmol), 
iPrMgCl·LiCl (1.92 mL, 3.00 mmol) and diallylamine (0.37 mL, 3.00 mmol). After stirring at 25 °C 
for 12 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 
30 mL) and dried over Na2SO4. After filtration, the solvents were removed in vacuo to give 96i (153 mg, 
0.88 mmol, 88%) as a light brown oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.15 (ddd, J = 5.0, 2.0, 0.9 Hz, 1H), 7.40 (ddd, J = 8.9, 7.1, 
2.0 Hz, 1H), 6.53 (ddd, J = 7.1, 5.0, 0.9 Hz, 1H), 6.47 (dt, J = 8.7, 0.9 Hz, 1H), 5.93 - 5.80 (m, 2H), 
5.16 (dq, J = 7.2, 1.7 Hz, 2H), 5.13 (t, J = 1.6 Hz, 2H), 4.11 (dt, J = 5.1, 1.7 Hz, 4H). 
13C-NMR (101 MHz, CDCl3) δ (ppm): 158.2, 148.1, 137.3, 134.2, 116.2, 111.9, 106.2, 50.2. 
 
The spectra matched those of the literature.137 
 
Synthesis of N-butyl-N-methylpyridin-2-amine (96j) 
 
 
 
The aminopyridine 96j was prepared via TP4 using 2-pyridinesulfonic acid (159 mg, 1.00 mmol), 
iPrMgCl·LiCl (1.92 mL, 3.00 mmol) and N-methylbutylamine (0.36 mL, 3.00 mmol). After stirring at 
25 °C for 12 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 
                                                     
136
 M.-T. Chen, D. A. Vicic, M. L. Turner, O. Navarro, Organometallics 2011, 30, 5052–5056. 
137
 O. Navarro, N. Marion, J. Mei, S. P. Nolan, Chem. Eur. J. 2006, 12, 5142–5148. 
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x 30 mL) and dried over Na2SO4. After filtration, the solvents were removed in vacuo to give 96j 
(161 mg, 0.98 mmol, 98%) as a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.15 (ddd, J = 5.0, 2.1, 0.9 Hz, 1H), 7.41 (ddd, J = 8.8, 7.0, 
2.0 Hz, 1H), 6.52 - 6.44 (m, 2H), 3.53 - 3.45 (m, 2H), 3.04 (s, 3H), 1.63 - 1.52 (m, 2H), 1.35 (dq, J = 
14.7, 7.4 Hz, 2H), 0.94 (t, J = 7.3 Hz, 3H). 
13C-NMR (101 MHz, CDCl3) δ (ppm): 158.8, 148.1, 137.1, 111.1, 105.8, 50.1, 36.4, 29.5, 20.4, 14.2. 
 
The spectra matched those of the literature.11c  
 
Synthesis of 2-(pyridin-2-yl)-1,2,3,4-tetrahydroisoquinoline (96k) 
 
 
 
The aminopyridine 96k was prepared via TP4 using 2-pyridinesulfonic acid (159 mg, 1.00 mmol), 
iPrMgCl·LiCl (1.92 mL, 3.00 mmol) and 1,2,3,4-tetrahydroisoquinoline (0.38 mL, 3.00 mmol). After 
stirring at 25 °C for 12 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl 
acetate (3 x 30 mL) and dried over Na2SO4. After filtration, the solvents were removed in vacuo and 
the crude product purified via column chromatography (isohexane:ethyl acetate = 9:1) to give 96k 
(175 mg, 0.83 mmol, 83%) as a light yellow solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.22 (ddd, J = 5.0, 2.0, 0.9 Hz, 1H), 7.50 (ddd, J = 8.9, 7.1, 
2.0 Hz, 1H), 7.24 - 7.15 (m, 4H), 6.68 (dt, J = 8.7, 1.0 Hz, 1H), 6.60 (ddd, J = 7.1, 5.0, 0.9 Hz, 1H), 
4.71 (s, 2H), 3.85 (t, J = 5.9 Hz, 2H), 2.98 (t, J = 5.8 Hz, 2H). 
13C-NMR (101 MHz, CDCl3) δ (ppm): 158.8, 148.1, 137.6, 135.5, 134.5, 128.5, 126.7, 126.5, 126.3, 
112.6, 106.8, 47.3, 42.7, 29.2. 
The spectra matched those of the literature.58b   
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Synthesis of 1-phenyl-4-(pyridin-2-yl)piperazine (96l) 
 
 
 
The aminopyridine 96l was prepared via TP4 using 2-pyridinesulfonic acid (159 mg, 1.00 mmol), 
iPrMgCl·LiCl (1.92 mL, 3.00 mmol) and 1-phenylpiperazine (0.46 mL, 3.00 mmol). After stirring at 
25 °C for 12 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 
x 30 mL) and dried over Na2SO4. After filtration, the solvents were removed in vacuo and the crude 
product purified via column chromatography (isohexane:ethyl acetate = 8:2) to give 96l (193 mg, 
0.81 mmol, 81%) as a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.22 (ddd, J = 5.0, 2.0, 0.9 Hz, 1H), 7.51 (ddd, J = 8.8, 7.0, 
2.0 Hz, 1H), 7.33 - 7.27 (m, 2H), 7.02 - 6.97 (m, 2H), 6.89 (tt, J = 7.3, 1.1 Hz, 1H), 6.71 (d, J = 8.6 Hz, 
1H), 6.69 - 6.63 (m, 1H), 3.75 - 3.67 (m, 4H), 3.35 - 3.26 (m, 4H). 
13C-NMR (101 MHz, CDCl3) δ (ppm): 159.6, 151.4, 148.1, 137.7, 129.3, 120.2, 116.5, 113.7, 107.4, 
49.3, 45.5. 
 
The spectra matched those of the literature.58d 
 
Synthesis of N-benzyl-N-methylpyridin-2-amine (96m) 
 
 
 
The aminopyridine 96m was prepared via TP4 using 2-pyridinesulfonic acid (159 mg, 1.00 mmol), 
iPrMgCl·LiCl (1.92 mL, 3.00 mmol) and N-benzylmethylamine (0.39 mL, 3.00 mmol). After stirring 
at 25 °C for 12 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl acetate 
(3 x 30 mL) and dried over Na2SO4. After filtration, the solvents were removed in vacuo and the crude 
product purified via column chromatography (isohexane:ethyl acetate:triethylamine = 10:0.5:0.1) to 
give 96m (170 mg, 0.86 mmol, 86%) as a colorless oil. 
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1H-NMR (400 MHz, CDCl3): δ / ppm = 8.19 (ddd, J = 5.0, 2.0, 0.9 Hz, 1H), 7.43 (ddd, J = 8.9, 7.1, 
2.0 Hz, 1H), 7.34 - 7.28 (m, 2H), 7.26 - 7.19 (m, 3H), 6.56 (ddd, J = 7.1, 4.9, 0.9 Hz, 1H), 6.51 (dt, J = 
8.6, 0.9 Hz, 1H), 4.81 (s, 2H), 3.07 (s, 3H). 
13C-NMR (101 MHz, CDCl3) δ (ppm): 159.1, 148.1, 138.9, 137.4, 128.7, 127.2, 127.0, 112.0, 105.8, 
53.4, 36.3. 
 
The spectra matched those of the literature.58b  
 
Synthesis of 2-(piperidin-1-yl)pyridine (96n) 
 
 
 
The aminopyridine 96n was prepared via TP4 using 2-pyridinesulfonic acid (54 mg, 0.34 mmol), 
iPrMgCl·LiCl (1.09 mL, 1.71 mmol) and N-benzyl-1-cyclobutylmethanamine (300 mg, 1.71 mmol). 
After stirring at 25 °C for 12 h, the reaction mixture was quenched with water (20 mL), extracted with 
ethyl acetate (3 x 30 mL) and dried over Na2SO4. After filtration, the solvents were removed in vacuo 
and the crude product purified via column chromatography (isohexane:ethyl acetate:triethylamine = 
10:0.2:0.1) to give 96n (50 mg, 0.20 mmol, 59%) as a colorless oil. 
 
1H-NMR (599 MHz, CDCl3): δ / ppm = 8.16 (ddd, J = 5.0, 2.0, 0.9 Hz, 1H), 7.37 (ddd, J = 8.9, 7.0, 
2.0 Hz, 1H), 7.32 - 7.27 (m, 2H), 7.24 - 7.18 (m, 3H), 6.52 (ddd, J = 7.0, 5.0, 0.9 Hz, 1H), 6.42 (dt, J = 
8.7, 0.9 Hz, 1H), 4.77 (s, 2H), 3.60 (d, J = 7.1 Hz, 2H), 2.76 - 2.66 (m, 1H), 2.06 - 1.98 (m, 2H), 1.90 - 
1.71 (m, 4H). 
13C-NMR (101 MHz, CDCl3) δ (ppm): 158.7, 148.1, 139.2, 137.2, 128.6, 126.9, 126.8, 111.7, 106.1, 
53.9, 52.0, 34.7, 27.1, 18.7. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 2972, 2934, 1594, 1559, 1488, 1452, 1436, 1366, 768, 729, 696. 
MS (EI, 70 eV): m/z = 252 (27), 197 (34), 183 (62), 133 (33), 91 (100), 78 (17), 43 (64). 
HRMS (EI) for C17H20N2 (252.1626): 252.1622 (M+). 
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Synthesis of 2-(3-(tert-butyldimethylsilyl)piperidin-1-yl)pyridine (96o) 
 
 
 
The aminopyridine 96o was prepared via TP4 using 2-pyridinesulfonic acid (159 mg, 1.00 mmol), 
iPrMgCl·LiCl (1.92 mL, 3.00 mmol) and 3-((tert-butyldimethylsilyl)oxy)piperidine (650 mg, 
3.00 mmol). After stirring at 25 °C for 12 h, the reaction mixture was quenched with water (20 mL), 
extracted with ethyl acetate (3 x 30 mL) and dried over Na2SO4. After filtration, the solvents were 
removed in vacuo and the crude product purified via column chromatography (isohexane:ethyl acetate 
= 9:1) to give 96o (274 mg, 0.94 mmol, 94%) as a colorless oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.16 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 7.43 (ddd, J = 8.9, 7.1, 
2.0 Hz, 1H), 6.63 (dt, J = 8.7, 1.0 Hz, 1H), 6.55 (ddd, J = 7.1, 4.9, 0.9 Hz, 1H), 4.16 - 4.04 (m, 2H), 
3.70 (tt, J = 8.8, 4.2 Hz, 1H), 2.95 - 2.77 (m, 2H), 2.02 - 1.94 (m, 1H), 1.84 - 1.76 (m, 1H), 1.61 - 1.44 
(m, 2H), 0.89 (s, 9H), 0.09 (d, J = 2.7 Hz, 6H). 
13C-NMR (101 MHz, CDCl3) δ (ppm): 159.5, 148.2, 137.5, 112.6, 107.1, 67.7, 53.1, 45.4, 34.6, 26.0, 
23.2, 18.3, -4.5. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 2930, 2857, 1596, 1484, 1438, 1242, 1097, 975, 859, 836, 771. 
MS (EI, 70 eV): m/z = 236 (20), 235 (100), 161 (22), 160 (15), 159 (16), 121 (20). 
HRMS (EI) for C16H28ON2Si (292.1971): 292.1964 (M+). 
 
Synthesis of 5-(pyridin-2-yl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine (96p) 
 
 
 
The aminopyridine 96p was prepared via TP4 using 2-pyridinesulfonic acid (168 mg, 1.06 mmol), 
iPrMgCl·LiCl (2.01 mL, 3.18 mmol) and 4,5,6,7-tetrahydrothieno[3,2-c]pyridine (441 mg, 
3.18 mmol). After stirring at 25 °C for 12 h, the reaction mixture was quenched with water (20 mL), 
extracted with ethyl acetate (3 x 30 mL) and dried over Na2SO4. After filtration, the solvents were 
removed in vacuo and the crude product purified via column chromatography (isohexane:ethyl acetate 
= 9:1) to give 96p (208 mg, 0.96 mmol, 91%) as a light yellow solid. 
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1H-NMR (400 MHz, CDCl3): δ / ppm = 8.21 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 7.50 (ddd, J = 8.9, 7.1, 
2.0 Hz, 1H), 7.15 - 7.10 (m, 1H), 6.86 (d, J = 5.1 Hz, 1H), 6.70 (dt, J = 8.6, 0.9 Hz, 1H), 6.61 (ddd, J = 
7.1, 4.9, 0.9 Hz, 1H), 4.60 (t, J = 1.7 Hz, 2H), 3.99 (t, J = 5.6 Hz, 2H), 3.00 - 2.94 (m, 2H). 
13C-NMR (101 MHz, CDCl3) δ (ppm): 159.1, 148.1, 137.6, 134.0, 133.1, 125.3, 123.0, 113.0, 107.1, 
45.9, 43.0, 25.1. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3098, 3066, 3004, 2904, 2841, 1589, 1560, 1478, 1434, 1308, 
1237, 986, 979, 769. 
MS (EI, 70 eV): m/z = 216 (100), 215 (15), 199 (19), 187 (16), 121 (10), 110 (70), 79 (38), 78 (18). 
HRMS (EI) for C12H12N2S (216.0721): 216.0715 (M+). 
M.p. (°C): 149-150. 
 
Synthesis of 1,4-di(pyridin-2-yl)piperazine (96q) 
 
 
 
The aminopyridine 96q was prepared via TP4 using 2-pyridinesulfonic acid (80 mg, 0.50 mmol), 
iPrMgCl·LiCl (0.95 mL, 1.50 mmol) and 1-(2-pyridyl)piperazine (0.23 mL, 1.50 mmol). After stirring 
at 25 °C for 12 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl acetate 
(3 x 30 mL) and dried over Na2SO4. After filtration, the solvents were removed in vacuo and the crude 
product purified via column chromatography (isohexane:ethyl acetate:triethylamine = 5:5:0.1) to give 
96q (78 mg, 0.326 mmol, 65%) as a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.21 (ddd, J = 4.9, 2.0, 0.9 Hz, 2H), 7.49 (ddd, J = 8.6, 7.1, 
2.0 Hz, 2H), 6.68 (dt, J = 8.6, 0.9 Hz, 2H), 6.64 (ddd, J = 7.1, 4.9, 0.9 Hz, 2H), 3.68 (s, 8H). 
13C-NMR (101 MHz, CDCl3) δ (ppm): 159.5, 148.1, 137.6, 113.6, 107.3, 45.0. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3098, 3067, 2888, 2848, 1592, 1559, 1482, 1467, 1438, 1382, 
1309, 1238, 1162, 977, 954, 769, 728. 
MS (EI, 70 eV): m/z = 240 (15), 146 (33), 133 (73), 120 (17), 107 (100), 83 (28), 79 (57), 57 (50), 43 
(42). 
HRMS (EI) for C14H16N4 (240.1375): 240.1361 (M+). 
M.p. (°C): 133–135. 
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Synthesis of (R)-8-chloro-1-methyl-3-(pyridin-2-yl)-2,3,4,5-tetrahydro-1H-benzo[d] 
azepine (97a) 
 
 
 
The aminopyridine 97a was prepared via TP4 using 2-pyridinesulfonic acid (80 mg, 0.50 mmol), 
iPrMgCl·LiCl (2.40 mL, 3.75 mmol) and lorcaserine hydrochloride hemihydrate (362 mg, 1.50 mmol). 
After stirring at 25 °C for 12 h, the reaction mixture was quenched with water (20 mL), extracted with 
ethyl acetate (3 x 30 mL) and dried over Na2SO4. After filtration, the solvents were removed in vacuo 
and the crude product purified via column chromatography (isohexane:ethyl acetate:triethylamine = 
9:1:0.1) to give 97a (100 mg, 0.367 mmol, 73%) as a colorless oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.17 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 7.44 (ddd, J = 8.9, 7.1, 
2.0 Hz, 1H), 7.15 (d, J = 2.1 Hz, 1H), 7.10 - 7.01 (m, 2H), 6.59 (dt, J = 8.7, 0.9 Hz, 1H), 6.53 (ddd, J = 
7.1, 4.9, 0.8 Hz, 1H), 4.00 - 3.88 (m, 2H), 3.69 - 3.59 (m, 2H), 3.24 (pd, J = 7.4, 3.2 Hz, 1H), 3.10 (ddd, 
J = 15.1, 9.2, 2.9 Hz, 1H), 2.95 (ddd, J = 15.1, 6.8, 2.8 Hz, 1H), 1.32 (d, J = 7.2 Hz, 3H). 
13C-NMR (101 MHz, CDCl3) δ (ppm): 158.5, 148.2, 146.8, 138.3, 137.5, 132.2, 131.6, 127.9, 126.0, 
112.0, 106.2, 52.0, 47.3, 40.3, 35.3, 18.9. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3093, 3004, 2962, 2926, 2848, 1592, 1558, 1478, 1439, 1429, 
1240, 1228, 949, 814, 765, 728. 
MS (EI, 70 eV): m/z = 272 (18), 257 (9), 119 (12), 115 (16), 107 (100), 78 (11). 
HRMS (EI) for C16H17ClN2 (272.1080): 272.1075 (M+). 
Optical rotation: ????= 15.5 (c 1.10, CH2Cl2). 
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Synthesis of N-(3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)propyl)-N-
methylpyridin-2-amine (97b) 
 
 
 
The aminopyridine 97b was prepared via TP4 using 2-pyridinesulfonic acid (80 mg, 0.50 mmol), 
iPrMgCl·LiCl (1.92 mL, 3.00 mmol) and nortriptyline hydrochloride (450 mg, 1.50 mmol). After 
stirring at 25 °C for 12 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl 
acetate (3 x 30 mL) and dried over Na2SO4. After filtration, the solvents were removed in vacuo to give 
97b (143 mg, 0.42 mmol, 84%) as a colorless oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.19 (ddd, J = 5.0, 2.0, 0.9 Hz, 1H), 7.39 (ddd, J = 8.9, 7.1, 
2.0 Hz, 1H), 7.33 - 7.26 (m, 1H), 7.28 - 7.19 (m, 2H), 7.23 - 7.13 (m, 4H), 7.11 - 7.04 (m, 1H), 6.54 
(ddd, J = 7.1, 5.0, 0.9 Hz, 1H), 6.34 (dt, J = 8.6, 0.9 Hz, 1H), 5.96 (t, J = 7.7 Hz, 1H), 3.68 - 3.59 (m, 
2H), 3.47 - 3.27 (m, 2H), 3.08 - 2.95 (m, 4H), 2.80 (s, 1H), 2.47 (q, J = 7.5 Hz, 2H). 
13C-NMR (101 MHz, CDCl3) δ (ppm): 158.5, 148.0, 144.6, 141.2, 140.0, 139.5, 137.1, 137.1, 130.1, 
128.6, 128.4, 128.3, 128.1, 127.5, 127.2, 126.1, 125.9, 111.4, 105.7, 50.0, 36.5, 33.9, 32.1, 27.4. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 2918, 1596, 1558, 1498, 1422, 1321, 767, 756. 
MS (EI, 70 eV): m/z = 340 (2), 202 (4), 122 (8), 121 (100), 94 (7), 78 (6). 
HRMS (EI) for C24H24N2 (340.1939): 340.1941 (M+). 
 
Synthesis of N-(3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl)-N-methylpyridin-2-amine 
(97c) 
 
 
 
The aminopyridine 97c was prepared via TP4 using 2-pyridinesulfonic acid (80 mg, 0.50 mmol), 
iPrMgCl·LiCl (1.92 mL, 3.00 mmol) and desipramine hydrochloride (454 mg, 1.50 mmol). After 
stirring at 25 °C for 12 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl 
acetate (3 x 30 mL) and dried over Na2SO4. After filtration, the solvents were removed in vacuo and 
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the crude product purified via column chromatography (isohexane:ethyl acetate:triethylamine = 9:1:0.1) 
to give 97c (154 mg, 0.45 mmol, 90%) as a colorless oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.12 (ddd, J = 5.0, 2.0, 0.9 Hz, 1H), 7.30 (ddd, J = 8.9, 7.1, 
2.0 Hz, 1H), 7.19 - 7.12 (m, 4H), 7.12 - 7.07 (m, 2H), 6.99 - 6.91 (m, 2H), 6.48 (ddd, J = 7.1, 5.0, 0.9 
Hz, 1H), 6.23 (dt, J = 8.7, 1.0 Hz, 1H), 3.82 (t, J = 6.6 Hz, 2H), 3.59 - 3.51 (m, 2H), 3.23 (s, 4H), 2.96 
(s, 3H), 1.94 - 1.83 (m, 2H). 
13C-NMR (101 MHz, CDCl3) δ (ppm): 158.6, 148.2, 148.0, 137.1, 134.3, 130.0, 126.5, 122.6, 120.0, 
111.3, 105.6, 48.2, 48.1, 36.4, 32.3, 25.4. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3011, 2917, 2842, 1594, 1495, 1485, 1421, 1319, 1289, 1244, 
1226, 1110, 981, 910, 766, 749. 
MS (EI, 70 eV): m/z = 343 (42), 235 (65), 234 (42), 208 (48), 195 (36), 194 (44), 193 (59), 149 (39), 
135 (36), 122 (100), 121 (38), 93 (75), 78 (32). 
HRMS (EI) for C23H25N3 (343.2048): 343.2045 (M+). 
 
Synthesis of 2-chloro-11-(4-(pyridin-2-yl)piperazin-1-yl)dibenzo[b,f][1,4]oxazepine (97d) 
 
 
 
The aminopyridine 97d was prepared via a slightly modified TP4 using 2-pyridinesulfonic acid (13 mg, 
79.6 µmol), iPrMgCl·LiCl (0.15 mL, 1.50 mmol) and amoxapine (75 mL, 239 µmol). After stirring at 
25 °C for 12 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 
x 30 mL) and dried over Na2SO4. After filtration, the solvents were removed in vacuo and the crude 
product purified via column chromatography (isohexane:ethyl acetate:triethylamine = 8:2:0.1) to give 
97d (16 mg, 41 µmol, 52%) as a light yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = δ 8.22 (ddd, J = 5.0, 2.0, 0.8 Hz, 1H), 7.54 (ddd, J = 8.9, 7.1, 
2.0 Hz, 1H), 7.41 (dd, J = 8.6, 2.6 Hz, 1H), 7.37 (d, J = 2.6 Hz, 1H), 7.23 - 7.16 (m, 2H), 7.13 - 7.07 
(m, 2H), 7.04 - 6.98 (m, 1H), 6.75 - 6.66 (m, 2H), 3.67 (s, 8H). 
13C-NMR (101 MHz, CDCl3) δ (ppm): δ 159.5, 159.1, 152.0, 147.6, 140.1, 138.1, 132.8, 130.5, 129.2, 
127.3, 126.0, 125.1, 124.9, 122.9, 120.3, 114.0, 107.8, 47.3, 45.5. 
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IR (Diamond-ATR, neat): ?̃ / cm-1 = 3065, 3002, 2923, 2849, 1588, 1558, 1478, 1471, 1436, 1236, 
1020, 980, 772, 733. 
MS (EI, 70 eV): m/z = 390 (27), 271 (27), 257 (48), 193 (36), 146 (100), 145 (46), 133 (85), 119 (25), 
57 (25). 
HRMS (EI) for C22H19ClN4O (390.1247): 390.1249 (M+). 
 
Synthesis of 8-(pyrrolidin-1-yl)quinoline (98a) 
 
 
 
The aminopyridine 98a was prepared via TP4 using 8-quinolinesulfonic acid (209 mg, 1.00 mmol), 
iPrMgCl·LiCl (3.20 mL, 5.00 mmol) and pyrrolidine (0.41 mL, 5.00 mmol). After stirring at 25 °C for 
12 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) 
and dried over Na2SO4. After filtration, the solvents were removed in vacuo to give 98a (167 mg, 
0.84 mmol, 84%) as a light-brown oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.76 (dd, J = 4.1, 1.8 Hz, 1H), 8.04 (dd, J = 8.3, 1.8 Hz, 1H), 
7.37 (t, J = 7.9 Hz, 1H), 7.31 (dd, J = 8.3, 4.1 Hz, 1H), 7.17 (d, J = 8.0 Hz, 1H), 6.84 (d, J = 7.8 Hz, 
1H), 3.78 - 3.69 (m, 4H), 2.08 - 1.99 (m, 4H). 
13C-NMR (101 MHz, CDCl3) δ (ppm): 147.6, 146.2, 141.6, 135.9, 130.0, 127.1, 120.8, 116.7, 111.0, 
52.1, 25.6. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 2965, 2870, 1562, 1504, 1471, 1460, 1426, 1393, 1354, 1328, 
1108, 814, 787, 742. 
MS (EI, 70 eV): m/z = 198 (49), 197 (26), 170 (17), 169 (48), 156 (53), 155 (32), 129 (100), 128 (17). 
HRMS (EI) for C13H14N2 (198.1157): 198.1151 (M+). 
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Synthesis of 8-(piperidin-1-yl)quinoline (98b) 
 
 
 
The aminopyridine 98b was prepared via TP4 using 8-quinolinesulfonic acid (209 mg, 1.00 mmol), 
iPrMgCl·LiCl (3.20 mL, 5.00 mmol) and piperidine (0.50 mL, 5.00 mmol). After stirring at 25 °C for 
12 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) 
and dried over Na2SO4. After filtration, the solvents were removed in vacuo to give 98b (198 mg, 
0.93 mmol, 93%) as a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.89 (dd, J = 4.1, 1.8 Hz, 1H), 8.09 (dd, J = 8.2, 1.8 Hz, 1H), 
7.46 - 7.37 (m, 2H), 7.35 (dd, J = 8.2, 4.2 Hz, 1H), 7.15 (dd, J = 7.2, 1.8 Hz, 1H), 3.35 - 3.29 (m, 4H), 
1.91 (p, J = 5.6 Hz, 4H), 1.70 - 1.63 (m, 2H). 
13C-NMR (101 MHz, CDCl3) δ (ppm): 151.0, 148.3, 143.1, 136.5, 129.8, 126.8, 121.3, 120.8, 116.2, 
53.9, 26.4, 24.8. 
 
The spectra matched those of 81b. 
 
Reaction on 20 mmol scale: 
 
The aminopyridine 98b was prepared via TP4 using 8-quinolinesulfonic acid (3.98 g, 20.0 mmol), 
iPrMgCl·LiCl (94.0 mL, 100.0 mmol) and piperidine (9.90 mL, 100.0 mmol). After stirring at 25 °C 
for 12 h, the reaction mixture was quenched with water (100 mL), extracted with ethyl acetate (3 x 
100 mL) and dried over Na2SO4. After filtration, the solvents were removed in vacuo to give 98b 
(2.82 g, 13.3 mmol, 66%) as a yellow oil. 
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Synthesis of 8-(4-methylpiperidin-1-yl)quinoline (98c) 
 
 
 
The aminopyridine 98c was prepared via TP4 using 8-quinolinesulfonic acid (209 mg, 1.00 mmol), 
iPrMgCl·LiCl (3.20 mL, 5.00 mmol) and 4-methylpiperidine (0.60 mL, 5.00 mmol). After stirring at 
25 °C for 12 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 
x 30 mL) and dried over Na2SO4. After filtration, the solvents were removed in vacuo to give 98c 
(138 mg, 0.61 mmol, 61%) as a light-yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.89 (dd, J = 4.1, 1.8 Hz, 1H), 8.09 (dd, J = 8.3, 1.8 Hz, 1H), 
7.45 - 7.37 (m, 2H), 7.35 (dd, J = 8.2, 4.2 Hz, 1H), 7.15 (dd, J = 7.2, 1.8 Hz, 1H), 3.96 - 3.87 (m, 2H), 
2.74 (td, J = 11.5, 2.7 Hz, 2H), 1.79 (dp, J = 7.7, 3.0, 2.6 Hz, 2H), 1.70 (qd, J = 12.4, 11.8, 3.7 Hz, 2H), 
1.60 (dddd, J = 10.9, 8.5, 6.3, 3.4 Hz, 1H), 1.04 (d, J = 6.3 Hz, 3H). 
13C-NMR (101 MHz, CDCl3) δ (ppm): 150.7, 148.3, 143.1, 136.5, 129.7, 126.8, 121.2, 120.8, 116.2, 
53.2, 34.6, 31.2, 22.2. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 2947, 2923, 2360, 1566, 1450, 1469, 1455, 1389, 1368, 1238, 
1104, 825, 792. 
MS (EI, 70 eV): m/z = 226 (47), 183 (51), 169 (57), 157 (31), 156 (35), 155 (43), 143 (59), 129 (100). 
HRMS (EI) for C15H18N2 (226.1470): 226.1462 (M+). 
 
Synthesis of 4-(quinolin-8-yl)morpholine (98d) 
 
 
 
The aminopyridine 98d was prepared via TP4 using 8-quinolinesulfonic acid (209 mg, 1.00 mmol), 
iPrMgCl·LiCl (3.20 mL, 5.00 mmol) and morpholine (0.44 mL, 5.00 mmol). After stirring at 25 °C for 
12 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) 
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and dried over Na2SO4. After filtration, the solvents were removed in vacuo to give 98d (205 mg, 
0.957 mmol, 96%) as an orange oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.88 (dd, J = 4.2, 1.8 Hz, 1H), 8.12 (dd, J = 8.3, 1.8 Hz, 1H), 
7.47 - 7.44 (m, 2H), 7.38 (dd, J = 8.2, 4.1 Hz, 1H), 7.14 (dd, J = 5.0, 3.9 Hz, 1H), 4.08 - 4.02 (m, 4H), 
3.47 - 3.38 (m, 4H). 
13C-NMR (101 MHz, CDCl3) δ (ppm): 149.4, 148.4, 142.8, 136.7, 129.8, 126.8, 122.0, 121.1, 115.9, 
67.4, 52.7. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 2972, 2933, 1594, 1489, 1437, 768, 729, 696. 
MS (EI, 70 eV): m/z = 214 (16), 196 (27), 195 (27), 183 (25), 169 (29), 168 (44), 156 (20), 155 (35), 
129 (100). 
HRMS (EI) for C13H14ON2 (214.1106): 214.1099 (M+). 
 
Synthesis of 8-(4-methylpiperazin-1-yl)quinoline (98e) 
 
 
 
The aminopyridine 98e was prepared via TP4 using 8-quinolinesulfonic acid (209 mg, 1.00 mmol), 
iPrMgCl·LiCl (3.20 mL, 5.00 mmol) and 1-methylpiperazine (0.56 mL, 5.00 mmol). After stirring at 
25 °C for 12 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 
x 30 mL) and dried over Na2SO4. After filtration, the solvents were removed in vacuo to give 98b 
(196 mg, 0.86 mmol, 86%) as a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.88 (dd, J = 4.2, 1.8 Hz, 1H), 8.10 (dd, J = 8.2, 1.8 Hz, 1H), 
7.47 - 7.39 (m, 2H), 7.36 (dd, J = 8.2, 4.2 Hz, 1H), 7.15 (dd, J = 6.3, 2.7 Hz, 1H), 3.46 (s, 4H), 2.79 (t, 
J = 5.0 Hz, 4H), 2.42 (s, 3H). 
13C-NMR (101 MHz, CDCl3) δ (ppm): 149.6, 148.3, 142.9, 136.6, 129.7, 126.8, 121.7, 120.9, 116.1, 
55.4, 52.2, 46.3. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 2936, 2795, 1567, 1500, 1470, 1448, 1389, 1373, 1308, 1289, 
1246, 1150, 1109, 1029, 1011, 825, 793. 
MS (EI, 70 eV): m/z = 227 (38), 183 (25), 170 (17), 169 (14), 157 (100), 155 (15), 144 (20), 129 (34), 
128 (11). 
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HRMS (EI) for C14H17N3 (227.1422): 227.1416 (M+). 
 
Synthesis of 5-(quinolin-8-yl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine (98f) 
 
 
 
The aminopyridine 98f was prepared via TP4 using 8-quinolinesulfonic acid (209 mg, 1.00 mmol), 
iPrMgCl·LiCl (3.20 mL, 5.00 mmol) and 4,5,6,7-tetrahydrothieno[3,2-c]pyridine (681 mg, 
5.00 mmol). After stirring at 25 °C for 12 h, the reaction mixture was quenched with water (20 mL), 
extracted with ethyl acetate (3 x 30 mL) and dried over Na2SO4. After filtration, the solvents were 
removed in vacuo to give 98f (246 mg, 0.92 mmol, 92%) as a light brown oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.91 (dd, J = 4.2, 1.8 Hz, 1H), 8.11 (dd, J = 8.3, 1.8 Hz, 1H), 
7.45 - 7.41 (m, 2H), 7.38 (dd, J = 8.3, 4.1 Hz, 1H), 7.19 (dd, J = 6.1, 2.8 Hz, 1H), 7.14 (dd, J = 5.1, 0.8 
Hz, 1H), 6.85 (d, J = 5.1 Hz, 1H), 4.56 - 4.51 (m, 2H), 3.90 (t, J = 5.6 Hz, 2H), 3.06 (td, J = 5.7, 2.8 
Hz, 2H). 
13C-NMR (101 MHz, CDCl3) δ (ppm): 148.9, 148.4, 143.1, 136.5, 134.1, 133.8, 129.7, 126.7, 125.2, 
122.7, 121.6, 121.0, 116.9, 51.6, 50.8, 25.4. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3034, 3007, 2917, 2812, 2774, 2708, 2213, 1660, 1567, 1498, 
1470, 1388, 1325, 1225, 1103, 1045, 907. 
MS (EI, 70 eV): m/z = 267 (17), 266 (100), 265 (23), 248 (24), 233 (11), 155 (48), 144 (75), 129 (92), 
102 (15). 
HRMS (EI) for C16H14N2S (266.0878): 266.0874 (M+). 
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4 Amination of Phosphorodiamidate-Substituted Pyridines and Related 
N-Heterocycles with Magnesium Amides 
4.1 Typical Procedures 
 
Typical Procedure 5: Synthesis of phosphorodiamidates 99a–i starting from the corresponding 
pyridones, quinolones, and 2-hydroxy-quinoxaline. 
 
According to a literature procedure,47 the hydroxy-substituted heterocycles (20.0 mmol) were dissolved 
in THF (20 mL) and 4-dimethylaminopyridine (DMAP, 244 mg, 2.00 mmol) was added to the 
solution/suspension. Then, Cl-P(O)(NMe2)2 (3.9 mL, 24.0 mmol) and triethylamine (3.33 mL, 
24.0 mmol) were added and the reaction stirred at 25 °C for 12 h. The reaction mixture was quenched 
with brine (20 mL), extracted with ethyl acetate (3 x 50 mL). The organic phase was then dried over 
Na2SO4 and concentrated in vacuo. If the crude product needed purification, it was purified by flash 
chromatography on silica gel using the appropriate eluent. 
 
Typical Procedure 6: Amination of phosphorodiamidate substituted heterocycles (99a–i) using 
magnesium amides of type R2NMgCl·LiCl 
 
iPrMgCl·LiCl (1.4–3.0 equiv) was added to a solution of amine (1.4–3.0 equiv) in THF (5 mL/mmol 
of phosphorodiamidate substituted heterocycle) at 0 °C. The solution was stirred for 15 min at 0 °C and 
then 15 min at 25 °C before being added to a suspension/solution of the freshly prepared substrates 
99a–i (1 equiv) in THF (5 mL/mmol substrates 99a–i) at 0 °C. The reaction mixture was then stirred at 
25 °C until completion. The reaction mixture was quenched with water (20 mL) and extracted with 
ethyl acetate (3 x 30 mL). The organic phase was then dried over Na2SO4 and concentrated in vacuo. If 
the crude product needed purification, it was purified by flash chromatography on silica gel using the 
appropriate eluent. 
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Typical Procedure 7: Directed ortho-metalation and functionalization of substituted N-heterocycles of 
type 99 using TMPMgCl·LiCl. 
To a solution of substituted N-heterocycle of type 99 in THF (5 mL/mmol substituted N-heterocycle) 
was added dropwise a solution of TMPMgCl·LiCl (1.5 equiv) at 0 °C. After full metalation (1 h, 
checked via TLC analysis of iodolyzed reaction aliquots), a solution of the corresponding electrophile 
in THF (2 mL/mmol substituted N-heterocycle) was added dropwise and the reaction slowly warmed 
to 25 °C and stirred until completion. The reaction mixture was quenched with an aq. sat. NH4Cl 
solution (20 mL/mmol substituted N-heterocycle) and extracted with ethyl acetate (3 x 50 mL/mmol 
substituted N-heterocycle). The organic phase was then dried over Na2SO4, filtered and concentrated in 
vacuo. If the crude product needed purification, it was purified via flash chromatography on silica gel 
using the appropriate eluent. 
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4.2 Preparation of Compounds 99 to 108 
 
Synthesis of pyridin-2-yl N,N,N’,N’-tetramethyldiamidophosphate (99a) 
 
 
 
Phosphorodiamidate 99a was prepared via TP5 using 2-hydroxypyridine (1.90 g, 20.0 mmol), bis(N,N-
dimethylamino)phosphoryl chloride (3.90 mL, 24.0 mmol), DMAP (244 mg, 2.00 mmol) and 
triethylamine (3.34 mL, 24 mmol). After workup, the crude product was isolated without further 
purification to give pyridin-2-yl N,N,N',N'-tetramethyldiamidophosphate 99a (4.18 g, 18.2 mmol, 91%) 
as a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.26 (dd, J = 5.0, 2.0 Hz, 1H), 7.67 (ddd, J = 8.5, 7.3, 2.0 Hz, 
1H), 7.13 - 7.08 (m, 1H), 7.06 (dd, J = 7.2, 4.9 Hz, 1H), 2.73 (d, J = 10.3 Hz, 12H). 
 
The spectra matched those of the literature.47  
 
Synthesis of 5-methylpyridin-2-yl N,N,N’,N’-tetramethyldiamidophosphate (99b) 
 
 
 
Phosphorodiamidate 99b was prepared via TP5 using 5-methylpyridin-2-ol (1.09 g, 10.0 mmol), 
bis(N,N-dimethylamino)phosphoryl chloride (1.95 mL, 12.0 mmol), DMAP (122 mg, 1.00 mmol) and 
triethylamine (1.67 mL, 12 mmol). After workup, the crude product was isolated without further 
purification to give 5-methylpyridin-2-yl N,N,N',N'-tetramethyldiamidophosphate 99b (1.36 g, 
5.59 mmol, 56%) as an orange oil. 
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1H-NMR (400 MHz, CDCl3): δ / ppm = 8.10 - 8.05 (m, 1H), 7.51 - 7.45 (m, 1H), 7.03 (d, J = 8.3 Hz, 
1H), 2.73 (d, J = 10.3 Hz, 12H), 2.27 (s, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 156.5, 156.4, 148.0, 140.4, 129.6, 113.5, 113.5, 36.9, 36.8, 
17.7. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3421, 2962, 2900, 1560, 1580, 1478, 1378, 1304, 1242, 1204, 
988, 914, 764. 
MS (EI, 70 eV): 200 (21), 199 (50), 156 (86), 111 (24), 109 (100), 107 (67), 92 (42), 65 (24), 44 (65), 
42 (27). 
HRMS (EI) for C8H12N2O2P (199.0636): 199.0630 (M+-(NMe2)) 
 
Synthesis of 5-chloropyridin-2-yl N,N,N’,N’-tetramethyldiamidophosphate (99c) 
 
 
 
Phosphorodiamidate 99c was prepared via TP5 using 5-chloropyridin-2-ol (1.30 g, 10.0 mmol), 
bis(N,N-dimethylamino)phosphoryl chloride (1.95 mL, 12.0 mmol), DMAP (122 mg, 1.00 mmol) and 
triethylamine (1.67 mL, 12 mmol). After workup, the crude product was isolated without further 
purification to give 5-chloropyridin-2-yl N,N,N',N'-tetramethyldiamidophosphate 99c (2.24 g, 
8.50 mmol, 85%) as a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.22 - 8.20 (m, 1H), 7.66 - 7.62 (m, 1H), 7.09 (dt, J = 8.7, 0.8 
Hz, 1H), 2.73 (d, J = 10.4 Hz, 12H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 156.8, 156.8, 146.8, 139.4, 127.8, 127.8, 115.1, 115.0, 36.8, 
36.8. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3457, 2931, 2812, 1678, 1579, 1461, 1371, 1305, 1253, 1218, 
1113, 992, 914, 786, 760. 
MS (EI, 70 eV): 219 (30), 176 (40), 129 (38), 127 (39), 112 (38), 44 (69), 43 (100). 
HRMS (EI) for C9H15ClN3O2P (263.0590): 263.0582 (M+) 
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Synthesis of pyridin-4-yl N,N,N’,N’-tetramethyldiamidophosphate (99d) 
 
 
 
Phosphorodiamidate 99d was prepared via TP5 using 4-hydroxypyridine (951 mg, 10.0 mmol), 
bis(N,N-dimethylamino)phosphoryl chloride (1.95 mL, 12.0 mmol), DMAP (122 mg, 1.00 mmol) and 
triethylamine (1.67 mL, 12 mmol). After workup, the crude product was isolated without further 
purification to give pyridin-4-yl N,N,N',N'-tetramethyldiamidophosphate 99d (2.05 g, 8.94 mmol, 89%) 
as a red oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.51 - 8.47 (m, 2H), 7.16 - 7.13 (m, 2H), 2.70 (d, J = 10.2 Hz, 
12H). 
 
The spectra matched those of the literature.47  
 
Synthesis of quinolin-4-yl N,N,N’,N’-tetramethyldiamidophosphate (99e) 
 
 
 
Phosphorodiamidate 99e was prepared via TP5 using 4-hydroxyquinoline (1.45 g, 10.0 mmol), 
bis(N,N-dimethylamino)phosphoryl chloride (1.95 mL, 12.0 mmol), DMAP (122 mg, 1.00 mmol) and 
triethylamine (1.67 mL, 12 mmol). After workup, the crude product was isolated without further 
purification to give quinolin-4-yl N,N,N',N'-tetramethyldiamidophosphate 99e (2.37 g, 8.49 mmol, 
85%) as a yellow oil. 
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1H-NMR (400 MHz, CDCl3): δ / ppm = 8.79 (dd, J = 5.1, 1.6 Hz, 1H), 8.09 (dddd, J = 17.5, 8.5, 1.9, 
1.0 Hz, 2H), 7.71 (ddt, J = 8.5, 6.9, 1.6 Hz, 1H), 7.54 (ddt, J = 8.3, 6.9, 1.4 Hz, 1H), 7.49 (dt, J = 5.1, 
1.3 Hz, 1H), 2.77 (dd, J = 10.2, 1.7 Hz, 12H). 
 
The spectra matched those of the literature.47  
 
Synthesis of quinolin-2-yl N,N,N’,N’-tetramethyldiamidophosphate (99f) 
 
 
 
Phosphorodiamidate 99f was prepared similarly to TP5 using 2-hydroxyquinoline (1.45 g, 10.0 mmol), 
bis(N,N-dimethylamino)phosphoryl chloride (1.95 mL, 12.0 mmol), DMAP (122 mg, 1.00 mmol) and 
triethylamine (1.67 mL, 12 mmol). After stirring at 50 °C for 48 h, the reaction mixture was quenched 
with water (20 mL) and extracted with ethyl acetate (3 x 50 mL) and dried over Na2SO4. After filtration, 
the solvents were removed in vacuo and the crude product purified via column chromatography 
(isohexane:ethyl acetate = 2:8) to give 99f (2.54 g, 9.09 mmol, 91%) as a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.14 (d, J = 8.7 Hz, 1H), 7.93 (d, J = 8.4 Hz, 1H), 7.78 (d, J = 
8.1 Hz, 1H), 7.64-7.69 (m, 1H), 7.45-7.49 (m, 1H), 7.28 (d, J = 8.8 Hz, 1H), 2.80 (d, J = 10.4 Hz, 12H). 
 
The spectra matched those of the literature.47 
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Synthesis of 5-chloroquinolin-8-yl N,N,N’,N’-tetramethyldiamidophosphate (99g) 
 
 
 
Phosphorodiamidate 99g was prepared via TP5 using 5-chloroquinolin-8-ol (1.80 g, 10.0 mmol), 
bis(N,N-dimethylamino)phosphoryl chloride (1.95 mL, 12.0 mmol), DMAP (122 mg, 1.00 mmol) and 
triethylamine (1.67 mL, 12 mmol). After workup, the crude product was isolated without further 
purification to give 5-chloroquinolin-8-yl N,N,N',N'-tetramethyldiamidophosphate 99g (2.95 g, 
9.40 mmol, 94%) as a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.93 (dd, J = 4.2, 1.7 Hz, 1H), 8.49 (dd, J = 8.6, 1.7 Hz, 1H), 
7.60 (dd, J = 8.3, 1.6 Hz, 1H), 7.52 (d, J = 8.4 Hz, 1H), 7.49 (dd, J = 8.6, 4.1 Hz, 1H), 2.78 (d, J = 10.2 
Hz, 12H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 150.5, 146.7, 146.7, 142.0, 142.0, 132.9, 127.3, 
126.4, 126.4, 126.3, 126.3, 122.2, 119.3, 119.2, 36.8, 36.8. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3457, 2926, 2811, 1589, 1495, 1464, 1383, 1357, 
1296, 1216, 1066, 985, 852, 757, 672. 
MS (EI, 70 eV): 271 (33), 269 (100), 206 (24), 179 (52), 177 (22), 150 (23), 44 
(50), 42 (20). 
HRMS (EI) for C13H17O2N3ClP (313.0747): 313.0744. 
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Synthesis of quinolin-8-yl N,N,N’,N’-tetramethyldiamidophosphate (99h) 
 
 
 
Phosphorodiamidate 99h was prepared via TP5 using 8-hydroxyquinoline (1.80 g, 10.0 mmol), 
bis(N,N-dimethylamino)phosphoryl chloride (1.95 mL, 12.0 mmol), DMAP (122 mg, 1.00 mmol) and 
triethylamine (1.67 mL, 12 mmol). After workup, the crude product was isolated without further 
purification to give quinolin-8-yl N,N,N',N'-tetramethyldiamidophosphate 99h (2.43 g, 8.70 mmol, 
87%) as a yellow solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.92 (dd, J = 4.2, 1.7 Hz, 1H), 8.13 (dd, J = 8.3, 1.7 Hz, 1H), 
7.68 (dt, J = 7.6, 1.5 Hz, 1H), 7.58 (dt, J = 8.3, 1.2 Hz, 1H), 7.48 (d, J = 7.9 Hz, 1H), 7.40 (dd, J = 8.3, 
4.1 Hz, 1H), 2.82 (d, J = 10.2 Hz, 12H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 150.0, 149.9, 136.3, 129.7, 126.8, 123.7, 121.6, 119.6, 119.5, 
118.0, 37.0, 36.9. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3392, 2929, 2853, 2809, 1632, 1595, 1570, 1499, 1470, 1311, 
1201, 1171, 1091, 993, 914, 823, 762. 
MS (EI, 70 eV): 235 (100), 192 (36), 172 (19), 157 (29), 145 (43), 143 (27). 
HRMS (EI) for C11H12N2O2P (235.0636): 235.0629 (M+-(NMe2)) 
M.p. (°C): 67–69. 
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Synthesis of quinoxalin-2-yl N,N,N’,N’-tetramethyldiamidophosphate (99i) 
 
 
 
Phosphorodiamidate 99i was prepared via TP5 using 2-hydroxyquinoxaline (1.46 g, 10.0 mmol), 
bis(N,N-dimethylamino)phosphoryl chloride (1.95 mL, 12.0 mmol), DMAP (122 mg, 1.00 mmol) and 
triethylamine (1.67 mL, 12 mmol). After workup, the crude product was isolated without further 
purification to give quinoxalin-2-yl N,N,N',N'-tetramethyldiamidophosphate 99i (2.57 g, 9.17 mmol, 
92%) as a red oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.69 (d, J = 0.7 Hz, 1H), 8.08 - 8.04 (m, 1H), 7.94 - 7.89 (m, 
1H), 7.73 - 7.64 (m, 2H), 2.82 (d, J = 10.5 Hz, 12H). 
 
The spectra matched those of the literature.47  
 
Synthesis of 2-(piperidin-1-yl)pyridine (100a) 
 
 
 
The aminopyridine 100a was prepared via TP6 using 99a (112 mg, 0.49 mmol), iPrMgCl·LiCl 
(0.44 mL, 0.70 mmol) and piperidine (0.07 mL, 0.70 mmol). After stirring at 25 °C for 8 h, the reaction 
mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) and dried over 
Na2SO4. After filtration, the solvents were removed in vacuo and the crude product purified via column 
chromatography (isohexane:ethyl acetate = 9:1) to give 100a (70 mg, 0.43 mmol, 88%) as a colorless 
oil. 
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1H-NMR (400 MHz, CDCl3) δ (ppm): 8.16 (dd, J = 5.0, 2.0 Hz, 1H), 7.46 - 7.39 (m, 1H), 6.63 (d, J = 
8.6 Hz, 1H), 6.54 (dd, J = 7.1, 4.9 Hz, 1H), 3.56 - 3.43 (m, 4H), 1.63 (d, J = 3.1 Hz, 6H). 
13C-NMR (100 MHz, CDCl3) δ (ppm): 159.8, 148.0, 137.4, 112.5, 107.2, 46.4, 25.6, 24.8. 
 
The spectra matched those of the literature.10a 
 
Reaction on 1 mmol scale: 
 
The aminopyridine 100a was prepared via TP6 using 99a (229 mg, 1.00 mmol), iPrMgCl·LiCl 
(0.88 mL, 1.40 mmol) and piperidine (0.14 mL, 1.40 mmol). After stirring at 25 °C for 8 h, the reaction 
mixture was quenched with water (40 mL), extracted with ethyl acetate (3 x 50 mL) and dried over 
Na2SO4. After filtration, the solvents were removed in vacuo and the crude product purified via column 
chromatography (isohexane:ethyl acetate = 9:1) to give 100a (129 mg, 0.795 mmol, 80%) as a colorless 
oil. 
 
Synthesis of 2-(pyrrolidin-1-yl)pyridine (100b) 
 
 
 
The aminopyridine 100b was prepared via TP6 using 99a (115 mg, 0.50 mmol), iPrMgCl·LiCl 
(0.46 mL, 0.70 mmol) and pyrrolidine (0.055 mL, 0.70 mmol). After stirring at 25 °C for 8 h, the 
reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) and dried 
over Na2SO4. After filtration, the solvents were removed in vacuo and the crude product purified via 
column chromatography (isohexane:ethyl acetate = 8:2) to give 100b (55 mg, 0.37 mmol, 74%) as an 
orange oil. 
 
C. EXPERIMENTAL PART    140 
 
1H-NMR (400 MHz, CDCl3) δ (ppm): 8.14 (ddd, J = 5.1, 2.0, 0.9 Hz, 1H), 7.41 (ddd, J = 8.8, 7.1, 2.0 
Hz, 1H), 6.49 (ddd, J = 7.1, 5.1, 1.0 Hz, 1H), 6.38 - 6.29 (m, 1H), 3.48 - 3.40 (m, 4H), 2.02 - 1.95 (m, 
4H). 
13C-NMR (100 MHz, CDCl3) δ (ppm): 157.4, 148.3, 137.0, 111.1, 106.6, 46.7, 25.7. 
 
The spectra matched those of the literature.10a  
 
Synthesis of 4-(pyridin-2-yl)morpholine (100c) 
 
N N
O
 
 
The aminopyridine 100c was prepared via TP6 using 99a (115 mg, 0.50 mmol), iPrMgCl·LiCl 
(0.46 mL, 0.70 mmol) and morpholine (0.065 mL, 0.70 mmol). After stirring at 25 °C for 8 h, the 
reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) and dried 
over Na2SO4. After filtration, the solvents were removed in vacuo and the crude product purified via 
column chromatography (isohexane:ethyl acetate = 8:2) to give 100c (65 mg, 0.40 mmol, 80%) as an 
orange oil. 
 
1H-NMR (400 MHz, CDCl3) δ (ppm): 8.19 (ddd, J = 4.9, 2.0, 0.9 Hz, 1H), 7.48 (m, 1H), 6.68 - 6.59 
(m, 2H), 3.83 - 3.78 (m, 4H), 3.50 - 3.45 (m, 4H). 
13C-NMR (100 MHz, CDCl3) δ (ppm): 159.7, 148.1, 137.6, 113.9, 107.0, 66.9, 45.7. 
 
The spectra matched those of the literature.10a  
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Synthesis of 1-methyl-4-(pyridin-2-yl)piperazine (100d) 
 
 
 
The aminopyridine 100d was prepared via TP6 using 99a (115 mg, 0.50 mmol), iPrMgCl·LiCl 
(0.46 mL, 0.70 mmol) and 4-methylpiperazine (70 mg, 0.70 mmol). After stirring at 25 °C for 8 h, the 
reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) and dried 
over Na2SO4. After filtration, the solvents were removed in vacuo and the crude product purified via 
column chromatography (dichloromethane:methanol = 9:1) to give 100d (76 mg, 0.43 mmol, 86%) as 
a colorless oil. 
 
1H-NMR (400 MHz, CDCl3) δ (ppm): 8.20-8.18 (m, 1H), 7.50-7.45 (m, 1H), 6.68 - 6.58 (m, 2H), 3.64 
- 3.54 (t, J = 5.0 Hz, 4H), 2.61 - 2.52 (t, J = 5.0 Hz, 4H), 2.37 (s, 3H). 
13C-NMR (100 MHz, CDCl3) δ (ppm): 159.6, 148.1, 137.6, 113.6, 107.3, 55.0, 46.2, 45.2. 
 
The spectra matched those of the literature.58b 
 
Synthesis of 2-(4-phenylpiperidin-1-yl)pyridine (100e) 
 
 
 
The aminopyridine 100e was prepared via TP6 using 99a (115 mg, 0.50 mmol), iPrMgCl·LiCl 
(0.46 mL, 0.70 mmol) and 4-phenylpiperidine (113 mg, 0.70 mmol). After stirring at 25 °C for 8 h, the 
reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) and dried 
over Na2SO4. After filtration, the solvents were removed in vacuo and the crude product purified via 
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column chromatography (isohexane:ethyl acetate = 9:1) to give 100e (82 mg, 0.34 mmol, 68%) as a 
colorless oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.24 - 8.22 (m, 1H), 7.51 - 7.47 (m, 1H), 7.35 - 7.31 (m, 2H), 
7.27 - 7.21 (m, 3H), 6.74 - 6.71 (m, 1H), 6.63 - 6.60 (m, 1H), 4.49 - 4.44 (m, 2H), 2.94 (td, J = 12.8, 
2.7 Hz, 2H), 2.77 (tt, J = 12.2, 3.7 Hz, 1H), 2.00 - 1.94 (m, 2H), 1.85-1.75 (m, 2H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 159.6, 148.1, 146.1, 137.6, 128.6, 126.9, 126.4, 112.9, 107.4, 
46.3, 43.0, 33.1. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 1593, 1482, 1437, 1224, 699. 
MS (EI, 70 eV): m/z = 238 (28), 223 (48), 182 (19), 169 (51), 133 (100), 119 (44), 107 (20). 
HRMS (EI) for C16H18N2 (238.1470): 238.1464 (M+) 
 
Synthesis of 2-(3-((tert-butyldimethylsilyl)oxy)piperidin-1-yl)pyridine (100f) 
 
 
 
The aminopyridine 100f was prepared via TP6 using 99a (115 mg, 0.50 mmol), iPrMgCl·LiCl 
(0.46 mL, 0.70 mmol) and 3-((tert-butyldimethylsilyl)oxy)piperidine (149 mg, 0.70 mmol). After 
stirring at 25 °C for 8 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl 
acetate (3 x 30 mL) and dried over Na2SO4. After filtration, the solvents were removed in vacuo and 
the crude product purified via column chromatography (isohexane:ethyl acetate = 99:1) to give 100f 
(79 mg, 0.27 mmol, 54%) as a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.17 - 8.15 (m, 1H), 7.46 - 7.41 (m, 1H), 6.64 - 6.62 (m, 1H), 
6.57 - 6.53 (m, 1H), 4.15 - 4.06 (m, 2H), 3.74 - 3.67 (m, 1H), 2.92 - 2.86 (m, 1H), 2.81 (dd, J = 12.5, 
9.2 Hz, 1H), 1.99 - 1.95 (m, 1H), 1.83 - 77 (m, 1H), 1.57 - 1.44 (m, 2H), 0.89 (s, 9H), 0.09 (d, J = 2.7 
Hz, 6H). 
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13C-NMR (101 MHz, CDCl3): δ / ppm = 159.5, 148.2, 137.5, 112.6, 107.1, 67.7, 53.1, 45.3, 34.6, 26.0, 
23.2, 18.3, -4.50. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 2926, 2856, 1595, 1492, 1437, 1241, 1096, 858, 835, 771. 
MS (EI, 70 eV): m/z = 235 (100), 161 (33), 121 (19), 75 (19). 
HRMS (EI) for C16H28N2OSi (292.1971): 292.1972 (M+) 
 
Synthesis of 1-(pyridin-2-yl)indoline (100g) 
 
 
 
The aminopyridine 100g was prepared via TP6 using 99a (115 mg, 0.50 mmol), iPrMgCl·LiCl 
(0.46 mL, 0.70 mmol) and indoline (0.08 mL, 0.70 mmol). After stirring at 25 °C for 8 h, the reaction 
mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) and dried over 
Na2SO4. After filtration, the solvents were removed in vacuo and the crude product purified via column 
chromatography (isohexane:ethyl acetate = 10:0.5) to give 100g (51 mg, 0.26 mmol, 52%) as an orange 
solid. 
 
1H-NMR (400 MHz, CDCl3) δ (ppm): 8.35 (ddd, J = 5.0, 2.0, 0.9 Hz, 1H), 8.17 - 8.12 (m, 1H), 7.60 
(ddd, J = 8.5, 7.2, 2.0 Hz, 1H), 7.22 - 7.15 (m, 2H), 6.88 (td, J = 7.4, 1.1 Hz, 1H), 6.85 - 6.75 (m, 2H), 
4.07 (t, J = 8.6 Hz, 2H), 3.26 - 3.17 (m, 2H). 
13C-NMR (101 MHz, CDCl3) δ (ppm): 155.3, 147.7, 144.9, 137.7, 131.6, 127.4, 124.8, 120.8, 114.5, 
113.4, 109.0, 49.7, 27.9. 
 
The spectra matched those of the literature.138  
  
                                                     
138
 N. Chatani, T. Asaumi, S. Yorimitsu, T. Ikeda, F. Kakiuchi, S. Murai, J. Am. Chem. Soc. 2001, 123, 10935–
10941. 
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Synthesis of N-benzyl-N-ethylpyridin-2-amine (100h) 
 
 
 
The aminopyridine 100h was prepared via TP6 using 99a (115 mg, 0.50 mmol), iPrMgCl·LiCl 
(0.46 mL, 0.70 mmol) and N-ethyl-N-benzylamine (0.11 mL, 0.70 mmol). After stirring at 25 °C for 
8 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) 
and dried over Na2SO4. After filtration, the solvents were removed in vacuo and the crude product 
purified via column chromatography (isohexane:ethyl acetate = 95:5) to give 100h (77 mg, 0.36 mmol, 
72%) as a colorless oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.21 - 8.18 (m, 1H), 7.41 - 7.36 (m, 1H), 7.34 - 7.21 (m, 5H), 
6.55 - 6.51 (m, 1H), 6.46 - 6.44 (m, 1H). 4.75 (s, 2H), 3.59 (q, J = 7.0 Hz, 2H), 1.19 (t, J = 7.1 Hz, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 158.2, 148.2, 139.2, 137.3, 128.6, 127.0, 126.9, 111.7, 105.9, 
51.0, 42.8, 12.4. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 1593, 1489, 1432, 1360, 767, 727, 695. 
MS (EI, 70 eV): m/z = 212 (15), 183 (90), 121 (100), 91 (37). 
HRMS (EI) for C15H17N2 (212.1313): 212.1304 (M+). 
 
Synthesis of N,N,N’-trimethyl-N’-(pyridin-2-yl)ethane-1,2-diamine (100i) 
 
 
 
The aminopyridine 100i was prepared via TP6 using 99a (115 mg, 0.50 mmol), iPrMgCl·LiCl 
(0.46 mL, 0.70 mmol) and N,N,N'-trimethylethylenediamine (0.093 mL, 0.70 mmol). After stirring at 
25 °C for 8 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 
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30 mL) and dried over Na2SO4. After filtration, the solvents were removed in vacuo and the crude 
product purified via column chromatography (dichloromethane:methanol = 8:2) to give 100i (57 mg, 
0.32 mmol, 64%) as a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.13 (ddd, J = 5.0, 2.0, 0.9 Hz, 1H), 7.40 (ddd, J = 8.8, 7.1, 
2.0 Hz, 1H), 6.52 - 6.44 (m, 2H), 3.72 - 3.60 (m, 2H), 3.04 (s, 3H), 2.55 - 2.48 (m, 2H), 2.30 (s, 6H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 158.6, 148.1, 137.2, 111.5, 105.7, 56.4, 48.3, 45.8, 36.7. 
 
The spectra matched those of 75e. 
 
Synthesis of N-butyl-N-methylpyridin-2-amine (100j) 
 
 
 
The aminopyridine 100j was prepared via TP6 using 99a (115 mg, 0.50 mmol), iPrMgCl·LiCl 
(0.46 mL, 0.70 mmol) and N-methylbutane-1-amine (0.09 mL, 0.70 mmol). After stirring at 25 °C for 
8 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) 
and dried over Na2SO4. After filtration, the solvents were removed in vacuo and the crude product 
purified via column chromatography (isohexane:ethyl acetate = 9:1) to give 100j (57 mg, 0.35 mmol, 
70%) as a colorless oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.14 (ddd, J = 5.0, 2.0, 0.9 Hz, 1H), 7.41 (ddd, J = 8.6, 7.1, 
2.0 Hz, 1H), 6.52 - 6.44 (m, 2H), 3.53 - 3.45 (m, 2H), 3.04 (s, 3H), 1.62 - 1.52 (m, 2H), 1.41 - 1.29 (m, 
2H), 0.94 (t, J = 7.3 Hz, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 158.7, 148.1, 137.1, 111.1, 105.8, 50.1, 36.4, 29.5, 20.4, 14.2. 
 
The spectra matched those of 75b.  
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Synthesis of N,N-diallylpyridin-2-amine (100k) 
 
 
 
The aminopyridine 100k was prepared via TP6 using 99a (115 mg, 0.50 mmol), iPrMgCl·LiCl 
(0.46 mL, 0.70 mmol) and diallylamine (0.084 mL, 0.70 mmol). After stirring at 25 °C for 8 h, the 
reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) and dried 
over Na2SO4. After filtration, the solvents were removed in vacuo and the crude product purified via 
column chromatography (isohexane:ethyl acetate = 9:1) to give 100k (68 mg, 0.39 mmol, 78%) as a 
colorless oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.15 (ddd, J = 5.0, 2.0, 0.9 Hz, 1H), 7.40 (ddd, J = 8.8, 7.1, 
2.0 Hz, 1H), 6.53 (ddd, J = 7.0, 5.0, 0.9 Hz, 1H), 6.47 (dt, J = 8.6, 1.0 Hz, 1H), 5.93 - 5.79 (m, 2H), 
5.21 - 5.09 (m, 4H), 4.11 (dt, J = 5.1, 1.7 Hz, 4H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 158.1, 148.0, 137.3, 134.1, 116.1, 111.9, 106.2, 50.2. 
 
The spectra matched those of the literature.137 
  
C. EXPERIMENTAL PART    147 
 
Synthesis of N-benzyl-N’,N’-dimethyl-N-(pyridin-2-yl)ethane-1,2-diamine (Tripelen-namine) 
(100l) 
 
 
 
The aminopyridine 100l was prepared via TP6 using 99a (115 mg, 0.50 mmol), iPrMgCl·LiCl 
(0.46 mL, 0.70 mmol) and N-benzyl-N’,N’-dimethylethane-1,2-diamine (0.14 mL, 0.70 mmol). After 
stirring at 25 °C for 8 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl 
acetate (3 x 30 mL) and dried over Na2SO4. After filtration, the solvents were removed in vacuo and 
the crude product purified via column chromatography (dichloromethane:methanol = 9:1) to give 100l 
(94 mg, 0.37 mmol, 74%) as a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.17 (ddd, J = 5.0, 2.0, 0.9 Hz, 1H), 7.38 (ddd, J = 8.9, 7.1, 
2.0 Hz, 1H), 7.33 - 7.27 (m, 2H), 7.25 - 7.21 (m, 3H), 6.54 (ddd, J = 7.1, 5.0, 0.9 Hz, 1H), 6.46 (dt, J = 
8.5, 0.9 Hz, 1H), 4.78 (s, 2H), 3.71 - 3.63 (m, 2H), 2.57 - 2.48 (m, 2H), 2.27 (s, 6H).p 
13C-NMR (101 MHz, CDCl3): δ / ppm = 158.3, 148.2, 139.0, 137.3, 128.6, 127.0, 127.0, 111.9, 105.8, 
56.9, 52.0, 46.7, 45.9. 
 
The spectra matched those of the literature.139 
  
                                                     
139
 M. H. S. Hamid, C. L. Allen, G. W. Lamb, A. C. Maxwell, H. C. Maytum, A. J. Watson, J. M. Williams, J. 
Am. Chem. Soc. 2009, 131, 1766–1774. 
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Synthesis of 5-methyl-2-(piperidin-1-yl)pyridine (100m) 
 
 
 
The aminopyridine 100m was prepared via TP6 using 99b (122 mg, 0.50 mmol), iPrMgCl·LiCl 
(0.46 mL, 0.70 mmol) and piperidine (0.07 mL, 0.70 mmol). After stirring at 25 °C for 8 h, the reaction 
mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) and dried over 
Na2SO4. After filtration, the solvents were removed in vacuo and the crude product purified via column 
chromatography (isohexane:ethyl acetate = 95:5) to give 100m (58 mg, 0.33 mmol, 66%) as a colorless 
oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.00 (dt, J = 2.5, 0.8 Hz, 1H), 7.29 (dd, J = 8.7, 2.5 Hz, 1H), 
6.60 (d, J = 8.7 Hz, 1H), 3.47 (dd, J = 5.5, 3.4 Hz, 4H), 2.18 (s, 3H), 1.70 - 1.56 (m, 6H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 158.1, 147.1, 138.8, 121.6, 107.5, 47.1, 25.6, 24.8, 17.4. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 2931, 2851, 1609, 1494, 1394, 1247, 1130, 1025, 932, 808. 
MS (EI, 70 eV): m/z = 176 (83), 147 (100), 133 (55), 120 (66), 93 (46). 
HRMS (EI) for C11H16N2 (176.1313): 176.1311 (M+). 
 
Synthesis of N-benzyl-N-ethyl-5-methylpyridin-2-amine (100n) 
 
 
 
The aminopyridine 100n was prepared via TP6 using 99b (122 mg, 0.50 mmol), iPrMgCl·LiCl 
(0.46 mL, 0.70 mmol) and N-benzyl-N-ethylamine (0.105 mL, 0.70 mmol). After stirring at 25 °C for 
8 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) 
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and dried over Na2SO4. After filtration, the solvents were removed in vacuo and the crude product 
purified via column chromatography (isohexane:ethyl acetate = 99:1) to give 100n (80 mg, 0.353 mmol, 
71%) as a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.01 - 8.00 (m, 1H), 7.32 - 7.27 (m, 2H), 7.25 - 7.21 (m, 4H), 
6.39 (dd, J = 8.6, 0.8 Hz, 1H), 4.72 (s, 2H), 3.57 (q, J = 7.0 Hz, 2H), 2.17 (s, 3H), 1.17 (t, J = 7.0 Hz, 
3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 156.6, 147.8, 139.5, 138.4, 128.6, 127.0, 126.8, 120.3, 105.6, 
51.2, 43.0, 17.4, 12.5. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 1608, 1497, 1451, 1407, 1358, 804, 730, 704. 
MS (EI, 70 eV): m/z = 226 (16), 197 (98), 135 (100), 92 (23). 
HRMS (EI) for C15H18N2 (226.1470): 226.1459 (M+). 
 
Synthesis of 5-chloro-2-(pyrrolidin-1-yl)pyridine (100o) 
 
 
 
The aminopyridine 100o was prepared via TP6 using 99c (131 mg, 0.50 mmol), iPrMgCl·LiCl 
(0.46 mL, 0.70 mmol) and pyrrolidine (0.055 mL, 0.70 mmol). After stirring at 25 °C for 8 h, the 
reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) and dried 
over Na2SO4. After filtration, the solvents were removed in vacuo and the crude product purified via 
column chromatography (isohexane:ethyl acetate = 99:1) to give 100o (70 mg, 0.358 mmol, 71%) as a 
colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.07 (d, J = 2.3 Hz, 1H), 7.36 (dd, J = 9.0, 2.6 Hz, 1H), 6.28 
(d, J = 9.0 Hz, 1H), 3.46 - 3.35 (m, 4H), 2.04 - 1.98 (m, 4H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 155.8, 146.6, 136.8, 118.2, 107.2, 47.0, 25.7. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 2973, 1599, 1518, 1461, 1417, 1238, 1162, 1107, 991, 947, 808.  
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MS (EI, 70 eV): m/z = 182 (57), 181 (25), 155 (37), 154 (36), 153 (100), 141 (20), 112 (24), 70 (34). 
HRMS (EI) for C9H11ClN2 (182.0611): 182.0602 (M+). 
M.p. (°C): 82-83. 
 
Synthesis of N-benzyl-5-chloro-N-(cyclobutylmethyl)pyridin-2-amine (100p) 
 
 
 
The aminopyridine 100p was prepared via TP6 using 99c (131 mg, 0.50 mmol), iPrMgCl·LiCl 
(0.46 mL, 0.70 mmol) and N-benzyl-N-cyclobutylmethanamine (122 mg, 0.70 mmol). After stirring at 
25 °C for 8 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 
30 mL) and dried over Na2SO4. After filtration, the solvents were removed in vacuo and the crude 
product purified via column chromatography (isohexane:ethyl acetate = 95:5) to give 100p (106 mg, 
0.37 mmol, 74%) as a colorless oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.14 (dd, J = 2.7, 0.7 Hz, 1H), 7.35 (tt, J = 7.5, 1.5 Hz, 3H), 
7.31 - 7.27 (m, 1H), 7.24 - 7.19 (m, 2H), 6.39 (dd, J = 9.1, 0.7 Hz, 1H), 4.78 (s, 2H), 3.63 (d, J = 7.1 
Hz, 2H), 2.81 - 2.67 (m, 1H), 2.13 - 2.01 (m, 2H), 2.00 - 1.73 (m, 4H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 156.9, 146.3, 138.6, 136.8, 128.6, 127.0, 126.7, 118.6, 106.7, 
54.2, 52.3, 34.6, 27.0, 18.7. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 2931, 2860, 1590, 1490, 1407, 1364, 804, 729, 696. 
MS (EI, 70 eV): m/z = 286 (7), 244 (18), 231 (18), 217 (30), 167 (33), 112 (14), 91 (100). 
HRMS (EI) for C17H19ClN2 (286.1237): 286.1237 (M+).  
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Synthesis of 4-(pyridin-4-yl)morpholine (101a) 
 
 
 
The aminopyridine 101a was prepared via TP6 using 99d (115 mg, 0.50 mmol), iPrMgCl·LiCl 
(0.46 mL, 0.70 mmol) and morpholine (0.065 mL, 0.70 mmol). After stirring at 25 °C for 8 h, the 
reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) and dried 
over Na2SO4. After filtration, the solvents were removed in vacuo and the crude product purified via 
column chromatography (ethyl acetate) to give 101a (81 mg, 0.49 mmol, 98%) as a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.29 (d, J = 6.7 Hz, 2H), 6.71 - 6.58 (m, 2H), 3.87 - 3.77 (m, 
4H), 3.33 - 3.21 (m, 4H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 155.3, 150.3, 108.3, 66.5, 46.2. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 1597, 1247, 1123, 934, 668. 
MS (EI, 70 eV): m/z = 164 (100), 133 (17), 106 (92), 78 (35). 
HRMS (EI) for C9H12N2O (164.0945): 164.0950 (M+). 
M.p. (°C): 101–103. 
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Synthesis of 5-(pyridin-4-yl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine (101b) 
 
 
 
The aminopyridine 101b was prepared via TP6 using 99d (115 mg, 0.50 mmol), iPrMgCl·LiCl 
(0.46 mL, 0.70 mmol) and 4,5,6,7-tetrahydrothieno[3,2-c]pyridine (0.085 mL, 0.70 mmol). After 
stirring at 25 °C for 8 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl 
acetate (3 x 30 mL) and dried over Na2SO4. After filtration, the solvents were removed in vacuo and 
the crude product purified via column chromatography (dichloromethane:methanol = 95:5) to give 101b 
(75 mg, 0.347 mmol, 69%) as a yellow solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.30 - 8.27 (m, 2H), 7.15 (d, J = 5.1 Hz.1H), 6.84 (d, J = 5.1 
Hz, 1H), 6.72 - 6.71 (m, 2H), 4.42 (s, 2H), 3.73 (t, J = 5.7 Hz, 2H), 2.98 (t, J = 5.6 Hz, 2H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 154.4, 150.3, 133.5, 132.2, 125.1, 123.6, 108.2, 46.7, 44.2, 
24.9. 
IR (Diamond-ATR, neat): ?̃ / cm–1 = 2912, 2844, 1658, 1642, 1591, 1537, 1591, 1508, 1404, 1332, 
1236, 1166, 986, 924, 831, 802, 716. 
MS (EI, 70 eV): m/z = 216 (21), 135 (12), 110 (100), 84 (10). 
HRMS (EI) for C12H12N2S (216.0721): 216.0716 (M+). 
M.p. (°C): 90–92.  
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Synthesis of 1-(pyridin-4-yl)azepane (101c) 
 
 
 
The aminopyridine 101c was prepared via TP6 using 99d (115 mg, 0.50 mmol), iPrMgCl·LiCl 
(0.46 mL, 0.70 mmol) and azepane (0.08 mL, 0.70 mmol). After stirring at 25 °C for 8 h, the reaction 
mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) and dried over 
Na2SO4. After filtration, the solvents were removed in vacuo and the crude product purified via column 
chromatography (ethyl acetate) to give 101c (62 mg, 0.352 mmol, 70%) as a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.22 - 8.16 (m, 2H), 6.49 - 6.47 (m, 2H), 3.49 - 3.41 (m, 4H), 
1.80-1.75 (m, 4H), 1.56-1.53 (m, 4H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 153.3, 150.0, 106.3, 48.7, 27.2, 27.0. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 2926, 1598, 1515, 1409, 1370, 1228, 1003, 988, 905, 802. 
MS (EI, 70 eV): m/z = 176 (88), 147 (100), 133 (54), 121 (37), 78 (28). 
HRMS (EI) for C11H16N2 (176.1313): 176.1307 (M+). 
 
Synthesis of N-butyl-N-methylpyridin-4-amine (101d) 
 
 
 
The aminopyridine 101c was prepared via TP6 using 99d (115 mg, 0.50 mmol), iPrMgCl·LiCl 
(0.46 mL, 0.70 mmol) and N-methylbutane-1-amine (0.095 mL, 0.70 mmol). After stirring at 25 °C for 
8 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) 
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and dried over Na2SO4. After filtration, the solvents were removed in vacuo and the crude product 
purified via column chromatography (dichloromethane:methanol = 9:1) to give 101d (62 mg, 
0.38 mmol, 75%) as a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.21 - 8.10 (m, 2H), 6.51 - 6.41 (m, 2H), 3.36 - 3.28 (m, 2H), 
2.96 (s, 3H), 1.63 - 1.49 (m, 2H), 1.33 (dq, J = 14.6, 7.3 Hz, 2H), 0.94 (t, J = 7.3 Hz, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 153.8, 148.8, 106.5, 51.5, 37.7, 28.9, 20.3, 14.0. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 2955, 2927, 2872, 1644, 1593, 1515, 1463, 1390, 
1225, 1208, 985, 929, 800. 
MS (EI, 70 eV): m/z = 164 (11), 121 (100), 94 (13). 
HRMS (EI) for C10H16N2 (164.1313): 164.1306 (M+). 
 
Synthesis of 4-(nortriptyline-N-yl)pyridine (101e) 
 
 
 
The aminopyridine 101e was prepared via TP6 using 99d (115 mg, 0.50 mmol), iPrMgCl·LiCl 
(0.92 mL, 1.40 mmol) and nortriptyline hydrochloride (210 mg, 0.70 mmol). After stirring at 25 °C for 
8 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) 
and dried over Na2SO4. After filtration, the solvents were removed in vacuo and the crude product 
purified via column chromatography (ethyl acetate) to give 101e (73 mg, 0.214 mmol, 43%) as a yellow 
oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.12 - 8.09 (m, 2H), 7.25 - 7.22 (m, 3H), 7.16 - 7.12 (m, 3H), 
7.08 - 7.03 (m, 2H), 6.27 - 6.24 (m, 2H), 5.87 (t, J = 7.7 Hz, 1H), 3.37 - 3.27 (m, 4H), 3.00 - 2.96 (m, 
1H), 2.90 (s, 3H), 2.79 - 2.72 (m, 1H), 2.46 - 2.34 (m, 2H). 
C. EXPERIMENTAL PART    155 
 
13C-NMR (101 MHz, CDCl3): δ / ppm = 153.2, 149.8, 145.8, 140.8, 139.8, 139.6, 137.2, 130.3, 128.5, 
128.2, 128.1, 127.9, 127.4, 127.0, 126.2, 126.1, 106.5, 51.2, 37.7, 33.9, 32.1, 26.7. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 2914, 1597, 1517, 1391, 1229, 987, 804, 777, 756. 
MS (EI, 70 eV): m/z = 340 (2), 122 (9), 121 (100). 
HRMS (EI) for C24H24N2 (340.1939): 340.1935 (M+). 
 
Synthesis of 4-(fluoxetin-N-yl)pyridine (101f) 
 
 
 
The aminopyridine 101f was prepared via TP6 using 99d (115 mg, 0.50 mmol), iPrMgCl·LiCl 
(0.92 mL, 1.40 mmol) and fluoxetine hydrochloride (243 mg, 0.70 mmol). After stirring at 25 °C for 
8 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) 
and dried over Na2SO4. After filtration, the solvents were removed in vacuo and the crude product 
purified via column chromatography (ethyl acetate) to give 101f (137 mg, 0.355 mmol, 70%) as a 
yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.17 - 8.16 (m, 2H), 7.46 - 7.44 (m, 2H), 7.37 - 7.27 (m, 5H), 
6.91 - 6.89 (m, 2H), 6.46 - 6.44 (m, 2H), 5.17 (dd, J = 8.3, 4.4 Hz, 1H), 3.65 - 3.53 (m, 2H), 2.95 (s, 
3H), 2.26 - 2.12 (m, 2H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 160.3, 153.4, 150.0, 140.4, 129.1, 128.3, 127.0, 125.7, 123.5, 
123.2, 123.1, 115.8, 106.7, 48.0, 37.8, 36.0. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 2917, 1598, 1539, 1517, 1326, 1248, 1110, 1067, 988, 836, 805, 
701. 
MS (EI, 70 eV): m/z = 387 (3), 122 (10), 121 (100). 
HRMS (EI) for C22H21N2F3O (386.1606): 386.1599 (M+).  
C. EXPERIMENTAL PART    156 
 
Synthesis of N-benzyl-N-ethylquinolin-4-amine (102a) 
 
 
 
The aminopyridine 102a was prepared via TP6 using 99e (115 mg, 0.50 mmol), iPrMgCl·LiCl 
(0.46 mL, 0.70 mmol) and N-benzyl-N-ethylamine (0.105 mL, 0.70 mmol). After stirring at 25 °C for 
8 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) 
and dried over Na2SO4. After filtration, the solvents were removed in vacuo and the crude product 
purified via column chromatography (ethyl acetate) to give 102a (118 mg, 0.45 mmol, 90%) as a yellow 
oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.67 (d, J = 5.1 Hz, 1H), 8.15 (ddd, J = 8.5, 1.5, 0.6 Hz, 1H), 
8.05 (ddd, J = 8.4, 1.4, 0.6 Hz, 1H), 7.65 (ddd, J = 8.4, 6.8, 1.4 Hz, 1H), 7.45 (ddd, J = 8.3, 6.8, 1.3 Hz, 
1H), 7.35 - 7.31 (m, 5H), 6.83 (d, J = 5.1 Hz, 1H), 4.52 (s, 2H), 3.35 (q, J = 7.1 Hz, 2H), 1.18 (t, J = 
7.1 Hz, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 155.7, 150.5, 137.9, 130.1, 129.1, 128.7, 128.5, 128.3, 127.9, 
127.4, 125.2, 124.0, 110.7, 56.8, 46.8, 12.0. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 1599, 1505, 1424, 1398, 1297, 768, 737. 
MS (EI, 70 eV): m/z = 262 (41), 247 (84), 91 (100). 
HRMS (EI) for C18H18N2 (262.1470): 262.1468 (M+). 
  
C. EXPERIMENTAL PART    157 
 
Synthesis of N-butyl-N-methylquinolin-4-amine (102b) 
 
 
 
The aminopyridine 102b was prepared via TP6 using 99e (115 mg, 0.50 mmol), iPrMgCl·LiCl 
(0.46 mL, 0.70 mmol) and N-methylbutane-1-amine (0.095 mL, 0.70 mmol). After stirring at 25 °C for 
8 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) 
and dried over Na2SO4. After filtration, the solvents were removed in vacuo and the crude product 
purified via column chromatography (ethyl acetate) to give 102b (64 mg, 0.30 mmol, 60%) as a yellow 
oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.65 (d, J = 5.1 Hz, 1H), 8.06 - 7.99 (m, 2H), 7.62 (ddd, J = 
8.3, 6.8, 1.5 Hz, 1H), 7.44 (ddd, J = 8.3, 6.8, 1.3 Hz, 1H), 6.78 (d, J = 5.1 Hz, 1H), 3.30 - 3.23 (m, 2H), 
2.98 (s, 3H), 1.77 - 1.65 (m, 2H), 1.34 (h, J = 7.4 Hz, 2H), 0.93 (t, J = 7.4 Hz, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 157.7, 150.5, 149.9, 129.9, 128.9, 124.7, 124.4, 123.6, 108.4, 
56.0, 40.8, 29.7, 20.3, 14.1. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3364, 2955, 2928, 2860, 1573, 1508, 1395, 1300, 1044, 925, 766. 
MS (EI, 70 eV): m/z = 214 (20), 171 (100), 170 (21), 85 (17), 71 (25), 57 (39), 55 (16), 41 (16). 
HRMS (EI) for C14H18N2 (214.1470): 214.1469 (M+). 
  
C. EXPERIMENTAL PART    158 
 
Synthesis of 4-(piperidin-1-yl)quinoline (102c) 
 
 
 
The aminopyridine 102c was prepared via TP6 using 99e (140 mg, 0.50 mmol), iPrMgCl·LiCl 
(0.46 mL, 0.70 mmol) and piperidine (0.07 mL, 0.70 mmol). After stirring at 25 °C for 8 h, the reaction 
mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) and dried over 
Na2SO4. After filtration, the solvents were removed in vacuo and the crude product purified via column 
chromatography (ethyl acetate) to give 102c (65 mg, 0.306 mmol, 61%) as a yellow solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.70 (d, J = 5.0 Hz, 1H), 8.07 - 7.97 (m, 2H), 7.64 (ddd, J = 
8.4, 6.8, 1.5 Hz, 1H), 7.46 (ddd, J = 8.3, 6.8, 1.3 Hz, 1H), 6.81 (d, J = 5.0 Hz, 1H), 3.23 - 3.15 (m, 4H), 
1.90 - 1.80 (m, 4H), 1.74 - 1.65 (m, 2H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 158.2, 150.9, 149.6, 130.0, 129.0, 125.1, 124.1, 123.9, 108.7, 
53.8, 26.2, 24.6. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 2933, 2851, 2810, 1738, 1577, 1567, 1505, 1423, 1395, 1295, 
1243, 1221, 1115, 1101, 1007, 920, 829, 766. 
MS (EI, 70 eV): m/z = 212 (45), 211 (100), 155 (22), 128 (11). 
HRMS (EI) for C14H15N2 (211.1241): 211.1228 (M+-H). 
M.p. (°C): 83–86. 
  
C. EXPERIMENTAL PART    159 
 
Synthesis of 4-(azepan-1-yl)quinoline (102d) 
 
 
 
The aminopyridine 102d was prepared via TP6 using 99e (140 mg, 0.50 mmol), iPrMgCl·LiCl 
(0.46 mL, 0.70 mmol) and azepane (0.07 mL, 0.70 mmol). After stirring at 25 °C for 8 h, the reaction 
mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) and dried over 
Na2SO4. After filtration, the solvents were removed in vacuo and the crude product purified via column 
chromatography (ethyl acetate) to give 102d (87 mg, 0.384 mmol, 75%) as a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.60 (d, J = 5.3 Hz, 1H), 8.06 (dd, J = 8.6, 1.4 Hz, 1H), 8.00 
(dd, J = 8.5, 1.3 Hz, 1H), 7.63 - 7.58 (m, 1H), 7.42-7.38 (m, 1H), 6.77 (d, J = 5.3 Hz, 1H), 3.54 - 3.51 
(m, 4H), 1.95 - 1.90 (m, 4H), 1.78 - 1.75 (m, 4H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 157.9, 150.4, 150.2, 129.9, 128.8, 124.9, 124.1, 123.3, 107.3, 
54.5, 28.7, 27.8. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 2924, 1567, 1507, 1429, 1397, 1300, 902, 763. 
MS (EI, 70 eV): m/z = 226 (100), 197 (73), 183 (63), 169 (64), 155 (45). 
HRMS (EI) for C15H18N2 (226.1470): 226.1464 (M+). 
  
C. EXPERIMENTAL PART    160 
 
Synthesis of 2-(pyrrolidin-1-yl)quinoline (102e) 
 
 
 
The aminopyridine 102e was prepared via TP6 using 99f (140 mg, 0.50 mmol), iPrMgCl·LiCl 
(0.46 mL, 0.70 mmol) and pyrrolidine (0.07 mL, 0.70 mmol). After stirring at 25 °C for 8 h, the reaction 
mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) and dried over 
Na2SO4. After filtration, the solvents were removed in vacuo and the crude product purified via column 
chromatography (pentane:ethyl acetate = 8:2) to give 102e (78 mg, 0.393 mmol, 78%) as a colorless 
solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 7.82 (d, J = 9.0 Hz, 1H), 7.73 (dd, J = 8.5, 3.1 Hz, 1H), 7.58 
(d, J = 7.9 Hz, 1H), 7.52 (t, J = 7.7 Hz, 1H), 7.17 (t, J = 7.4 Hz, 1H), 6.71-6.68 (m, 1H), 3.61 (s, 4H), 
2.03 (s, 4H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 155.9, 148.7, 137.0, 129.4, 127.5, 126.2, 122.7, 121.3, 110.3, 
46.9, 25.6. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 1607, 1513, 1482, 1430, 1402, 810. 
MS (EI, 70 eV): m/z = 198 (50), 169 (100), 129 (30), 71 (22), 57 (33), 43 (84). 
HRMS (EI) for C13H24N2 (198.1157): 198.1153 (M+). 
M.p. (°C): 89–90. 
  
C. EXPERIMENTAL PART    161 
 
Synthesis of N,N-diallylquinolin-2-amine (102f) 
 
 
 
The aminopyridine 102f was prepared via TP6 using 99f (140 mg, 0.50 mmol), iPrMgCl·LiCl 
(0.46 mL, 0.70 mmol) and diallylamine (0.085 mL, 0.70 mmol). After stirring at 25 °C for 8 h, the 
reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) and dried 
over Na2SO4. After filtration, the solvents were removed in vacuo and the crude product purified via 
column chromatography (pentane:ethyl acetate = 99:1) to give 102f (100 mg, 0.446 mmol, 89%) as a 
yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 7.84 (dd, J = 9.1, 0.8 Hz, 1H), 7.71 - 7.68 (m, 1H), 7.58 (dd, 
J = 7.9, 1.5 Hz, 1H), 7.54-7.50 (m, 1H), 7.21-7.17 (m, 1H), 6.81 (d, J = 9.1 Hz, 1H), 5.98-5.89 (m, 2H), 
5.24 - 5.16 (m, 4H), 4.28-4.26 (m, 4H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 156.6, 148.2, 137.3, 134.3, 129.5, 127.3, 122.9, 121.9, 116.5, 
109.6, 50.1. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 1618, 1606, 1507, 1487, 1432, 1398, 1236, 809, 754. 
MS (EI, 70 eV): m/z = 209 (11), 183 (100), 169 (37), 128 (47). 
HRMS (EI) for C15H15N2 (223.1235): 223.1227 (M+-H). 
  
C. EXPERIMENTAL PART    162 
 
Synthesis of 2-(4-(pyrimidin-2-yl)piperidin-1-yl)quinoline (102g) 
 
 
 
The aminopyridine 102g was prepared via TP6 using 99f (140 mg, 0.50 mmol), iPrMgCl·LiCl 
(0.46 mL, 0.70 mmol) and 4-(pyrimidin-2-yl)piperidine (0.11 mL, 0.70 mmol). After stirring at 25 °C 
for 8 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) 
and dried over Na2SO4. After filtration, the solvents were removed in vacuo and the crude product 
purified via column chromatography (pentane:ethyl acetate = 8:2) to give 102g (126 mg, 0.434 mmol, 
86%) as a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.35 (d, J = 4.7 Hz, 2H), 7.92 (dd, J = 9.2, 0.8 Hz, 1H), 7.75 
- 7.72 (m, 1H), 7.62 (dd, J = 8.0, 1.5 Hz, 1H), 7.57 - 7.53 (m, 1H), 7.26 - 7.22 (m, 1H), 7.03 (d, J = 9.1 
Hz, 1H), 6.53 (t, J = 4.7 Hz, 1H), 4.01 - 3.98 (m, 4H), 3.86 - 3.84 (m, 4H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 161.9, 157.9, 157.6, 148.0, 137.7, 129.7, 127.4, 126.8, 123.3, 
122.7, 110.3, 109.8, 45.1, 43.7. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 1618, 1605, 1585, 1548, 1505, 1430, 1232, 981. 
MS (EI, 70 eV): m/z = 291 (24), 183 (21), 169 (25), 157 (100), 147 (29), 128 (35), 80 (16). 
HRMS (EI) for C18H19N4 (291.1610): 291.1453 (M+-H). 
M.p. (°C): 147–149. 
  
C. EXPERIMENTAL PART    163 
 
Synthesis of 2-(amoxapin-N-yl)quinoline (102h) 
 
 
 
The aminopyridine 102h was prepared via TP6 using 99f (140 mg, 0.50 mmol), iPrMgCl·LiCl 
(0.46 mL, 0.70 mmol) and amoxapine (220 mg, 0.70 mmol). After stirring at 25 °C for 8 h, the reaction 
mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) and dried over 
Na2SO4. After filtration, the solvents were removed in vacuo and the crude product purified via column 
chromatography (pentane:ethyl acetate = 9:1) to give 102h (172 mg, 0.39 mmol, 78%) as a yellow solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 7.94 (dd, J = 9.2, 0.7 Hz, 1H), 7.74 (dd, J = 8.5, 1.1 Hz, 1H), 
7.63 (dd, J = 8.0, 1.5 Hz, 1H), 7.58 - 7.54 (m, 1H), 7.43 - 7.40 (m, 2H), 7.28 - 7.24 (m, 1H), 7.22 - 7.18 
(m, 2H), 7.13-7.09 (m, 2H), 7.05 - 6.99 (m, 2H), 3.88 (s, 4H), 3.69 (s, 4H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 159.5, 159.2, 157.6, 152.0, 147.8, 140.2, 137.8, 132.8, 130.5, 
129.8, 129.2, 127.4, 127.2, 126.9, 126.0, 125.1, 124.9, 123.5, 122.9, 122.9, 120.3, 109.9, 47.5, 45.3. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 1600, 1586, 1557, 1505, 1450, 1429, 1394, 1229, 906, 726, 727. 
MS (EI, 70 eV): m/z = 440 (17), 271 (31), 257 (25), 228 (21), 196 (86), 183 (100), 169 (69), 157 (49), 
128 (76). 
HRMS (EI) for C26H21ClN4O (440.1404): 440.1384 (M+). 
M.p. (°C): 104–106. 
  
C. EXPERIMENTAL PART    164 
 
Synthesis of 5-chloro-8-(4-phenylpiperidin-1-yl)quinoline (102i) 
 
 
 
The aminopyridine 102i was prepared via TP6 using 99g (156 mg, 0.50 mmol), iPrMgCl·LiCl 
(0.99 mL, 1.50 mmol) and 4-phenylpiperidine (242 mg, 1.50 mmol). After stirring at 25 °C for 8 h, the 
reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) and dried 
over Na2SO4. After filtration, the solvents were removed in vacuo and the crude product purified via 
column chromatography (pentane:ethyl acetate = 99:1) to give 102i (109 mg, 0.338 mmol, 68%) as a 
yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.96 (dd, J = 4.1, 1.7 Hz, 1H), 8.55 (dd, J = 8.5, 1.7 Hz, 1H), 
7.53 (d, J = 8.3 Hz, 1H), 7.49 (dd, J = 8.5, 4.1 Hz, 1H), 7.35 (d, J = 4.3 Hz, 4H), 7.25 - 7.22 (m, 1H), 
7.11 (d, J = 8.3 Hz, 1H), 4.10 - 4.05 (m, 2H), 2.91 - 2.84 (m, 2H), 2.74 (tt, J = 12.2, 3.7 Hz, 1H), 2.31 
- 2.21 (m, 2H), 2.05 - 1.99 (m, 2H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 149.8, 148.7, 146.5, 143.5, 133.4, 128.6, 127.3, 127.1, 126.7, 
126.3, 124.0, 121.6, 116.1, 53.6, 43.1, 33.7. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 2357, 2006, 1496, 1389, 1219, 1008, 696. 
MS (EI, 70 eV): m/z = 322 (25), 266 (20), 203 (70), 189 (60), 163 (100), 128 (39). 
HRMS (EI) for C20H19ClN2 (322.1237): 322.1233 (M+). 
  
C. EXPERIMENTAL PART    165 
 
Synthesis of 8-(4-phenylpiperazin-1-yl)quinoline (102j) 
 
 
 
The aminopyridine 102j was prepared via TP6 using 99h (140 mg, 0.50 mmol), iPrMgCl·LiCl 
(0.99 mL, 1.50 mmol) and 4-phenylpiperazine (0.23 mL, 1.50 mmol). After stirring at 25 °C for 8 h, 
the reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) and 
dried over Na2SO4. After filtration, the solvents were removed in vacuo and the crude product purified 
via column chromatography (pentane:ethyl acetate = 9:1) to give 102j (88 mg, 0.30 mmol, 60%) as a 
yellow solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.93 (dd, J = 4.1, 1.8 Hz, 1H), 8.12 (dd, J = 8.3, 1.8 Hz, 1H), 
7.48 - 7.47 (m, 2H), 7.39 (dd, J = 8.3, 4.2 Hz, 1H), 7.35 - 7.30 (m, 2H), 7.21 (dd, J = 5.8, 3.1 Hz, 1H), 
7.08 - 7.04 (m, 2H), 6.93 - 6.89 (m, 1H), 3.64 - 3.53 (m, 8H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 151.6, 149.3, 148.3, 142.8, 136.6, 129.7, 129.2, 126.8, 121.9, 
121.0, 119.8, 116.3, 116.1, 52.2, 49.5. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 1598, 1499, 1469, 1445, 1382, 1329, 1228, 1115, 1021, 937, 906, 
824, 789, 755, 725, 689 
MS (EI, 70 eV): m/z = 183 (19), 169 (23), 157 (100), 155 (32), 144 (21), 129 (67), 104 (40), 77 (33) 
HRMS (EI) for C19H19N3 (289.1579): 289.1565 (M+). 
M.p. (°C): 125–127. 
  
C. EXPERIMENTAL PART    166 
 
Synthesis of 4-(quinolin-8-yl)morpholine (102k) 
 
 
 
The aminopyridine 102k was prepared via TP6 using 99h (140 mg, 0.50 mmol), iPrMgCl·LiCl 
(0.99 mL, 1.50 mmol) and morpholine (0.135 mL, 1.50 mmol). After stirring at 25 °C for 8 h, the 
reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) and dried 
over Na2SO4. After filtration, the solvents were removed in vacuo and the crude product purified via 
column chromatography (pentane:ethyl acetate = 9:1) to give 102k (56 mg, 0.261 mmol, 52%) as a 
yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.87 (dd, J = 4.1, 1.8 Hz, 1H), 8.11-8.09 (m, 1H), 7.44-7.42 
(m, 2H), 7.36 (dd, J = 8.3, 4.2 Hz, 1H), 7.12 (dd, J = 5.1, 3.8 Hz, 1H), 4.07 - 4.01 (m, 4H), 3.43 - 3.39 
(m, 4H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 149.3, 148.3, 142.7, 136.6, 129.7, 126.8, 122.0, 121.0, 115.8, 
67.3, 52.6. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 2813, 1567, 1499, 1469, 1443, 1387, 1373, 1264, 1239, 1114, 
1105, 1067, 1032, 1021, 921, 861, 824, 788, 752, 703. 
MS (EI, 70 eV): m/z = 195 (12), 183 (16), 169 (24), 168 (25), 157 (15), 156 (21), 155 (39), 129 (100), 
102 (14). 
HRMS (EI) for C13H14N2O (214.1106): 214.1093 (M+).  
C. EXPERIMENTAL PART    167 
 
Synthesis of N-butyl-N-methylquinolin-8-amine (102l) 
 
 
 
The aminopyridine 102l was prepared via TP6 using 99h (140 mg, 0.50 mmol), iPrMgCl·LiCl 
(0.99 mL, 1.50 mmol) and N-butyl-N-methylamine (0.18 mL, 1.50 mmol). After stirring at 25 °C for 
8 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) 
and dried over Na2SO4. After filtration, the solvents were removed in vacuo and the crude product 
purified via column chromatography (pentane:ethyl acetate = 9:1) to give 102l (62 mg, 0.29 mmol, 
57%) as a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.86 (dd, J = 4.1, 1.8 Hz, 1H), 8.07-8.05 (m, 1H), 7.40 (t, J = 
7.7, 1H), 7.34 - 7.31 (m, 2H), 7.09 (dd, J = 7.4, 1.4 Hz, 1H), 3.57 - 3.53 (m, 2H), 3.04 (s, 3H), 1.63 - 
1.56 (m, 2H), 1.27 (h, J = 7.4 Hz, 2H), 0.86 (t, J = 7.4 Hz, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 149.8, 147.6, 143.0, 136.3, 129.7, 126.6, 120.8, 120.3, 116.5, 
56.2, 41.3, 28.8, 20.6, 14.1. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 2954, 1564, 1500, 1469, 1388, 1361, 1310, 1095, 1062, 924, 821, 
804, 787, 746 
MS (EI, 70 eV): m/z = 171 (100), 157 (31), 156 (27), 155 (21), 129 (44). 
HRMS (EI) for C14H18N2 (214.1470): 214.1456 (M+). 
  
C. EXPERIMENTAL PART    168 
 
Synthesis of 2-(protriptylin-N-yl)quinoline (103a) 
 
 
 
The aminopyridine 103a was prepared via TP6 using 99i (140 mg, 0.50 mmol), iPrMgCl·LiCl 
(0.66 mL, 1.00 mmol) and protriptyline hydrochloride (0.18 mL, 1.50 mmol). After stirring at 25 °C 
for 8 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) 
and dried over Na2SO4. After filtration, the solvents were removed in vacuo and the crude product 
purified via column chromatography (isohexane:ethyl acetate = 9:1) to give 103a (175 mg, 0.445 mmol, 
89%) as a colorless oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.30 (s, 1H), 7.85-7.82 (m, 1H), 7.61-7.58 (m, 1H), 7.55-7.51 
(m, 1H), 7.35-7.31 (m, 1H), 7.15 - 7.11 (m, 4H), 7.09-7.07 (m, 2H), 6.96 - 6.92 (m, 2H), 3.85 (t, J = 6.5 
Hz, 2H), 3.71 (t, J = 6.5 Hz, 2H), 3.22 (s, 4H), 3.11 (s, 3H), 2.01-1.93 (m, 2H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 151.8, 148.1, 142.1, 136.4, 135.1, 134.3, 130.1, 130.0, 128.7, 
126.6, 126.4, 124.0, 122.8, 119.9, 48.1, 48.0, 36.3, 32.3, 25.8. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 2917, 2357, 1580, 1546, 1486, 758, 668. 
MS (EI, 70 eV): m/z = 394 (25), 208 (19), 193 (23), 173 (100), 144 (90). 
HRMS (EI) for C26H26N4 (394.2157): 394.2152 (M+). 
  
C. EXPERIMENTAL PART    169 
 
Synthesis of 2-(4-methyl-2-phenylpiperazin-1-yl)quinoxaline (103b) 
 
 
 
The aminopyridine 103b was prepared via TP6 using 99i (140 mg, 0.50 mmol), iPrMgCl·LiCl 
(0.46 mL, 0.70 mmol) and 2-phenyl-4-methylpiperazine (123 mg, 0.70 mmol). After stirring at 25 °C 
for 8 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) 
and dried over Na2SO4. After filtration, the solvents were removed in vacuo and the crude product 
purified via column chromatography (isohexane:ethyl acetate = 8:2) to give 103b (116 mg, 0.381 mmol, 
76%) as a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.52 (s, 1H), 7.87 - 7.85 (m, 1H), 7.69 - 7.66 (m, 1H), 7.59 - 
7.55 (m, 1H), 7.45 - 7.42 (m, 2H), 7.40-7.36 (m, 1H), 7.32 - 7.27 (m, 2H), 7.24 - 7.20 (m, 1H), 5.77 (s, 
1H), 4.49 - 4.45 (m, 1H), 3.55 - 3.48 (m, 1H), 3.39 (dt, J = 11.8, 2.0 Hz, 1H), 2.97 - 2.93 (m, 1H), 2.61 
(dd, J = 11.8, 4.3 Hz, 1H), 2.33 (s, 3H), 2.28 (td, J = 11.5, 3.5 Hz, 1H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 151.9, 141.7, 140.0, 136.8, 135.4, 130.1, 128.7, 128.6, 127.3, 
127.1, 126.5, 124.6, 58.7, 55.1, 54.1, 46.6, 41.0. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3057, 2936, 2844, 2791, 1673, 1576, 1547, 1433, 1299, 1022, 
931, 857, 757, 696. 
MS (EI, 70 eV): m/z = 304 (22), 234 (100), 159 (58), 146 (91), 130 (28), 104 (22), 71 (40), 43 (30). 
HRMS (EI) for C19H20N4 (304.1688): 304.1684 (M+). 
  
C. EXPERIMENTAL PART    170 
 
Synthesis of 2-(piperidin-1-yl)quinoxaline (103c) 
 
 
 
The aminopyridine 103c was prepared via TP6 using 99i (140 mg, 0.50 mmol), iPrMgCl·LiCl 
(0.46 mL, 0.70 mmol) and piperidine (0.07 mL, 0.70 mmol). After stirring at 25 °C for 8 h, the reaction 
mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) and dried over 
Na2SO4. After filtration, the solvents were removed in vacuo and the crude product purified via column 
chromatography (isohexane:ethyl acetate = 8:2) to give 103c (83 mg, 0.39 mmol, 78%) as a yellow oil. 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.58 (s, 1H), 7.85 (dd, J = 8.2, 1.5 Hz, 1H), 7.71 - 7.65 (m, 
1H), 7.55 (ddd, J = 8.4, 6.9, 1.5 Hz, 1H), 7.36 (ddd, J = 8.3, 6.9, 1.4 Hz, 1H), 3.78 (dd, J = 5.3, 3.1 Hz, 
4H), 1.75 - 1.67 (m, 6H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 152.5, 142.0, 136.5, 136.2, 130.0, 128.7, 126.4, 124.4, 45.9, 
25.8, 24.7. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3054, 2933, 2851, 1684, 1576, 1549, 1492, 1434, 1279, 1227, 
1128, 1017, 973, 930, 758.. 
MS (EI, 70 eV): m/z = 213 (100), 212 (22), 184 (71), 170 (28), 158 (40), 157 (27), 145 (22), 130 (60), 
129 (22), 102 (21), 84 (22), 44 (24). 
HRMS (EI) for C13H15N3 (213.1266): 213.1261 (M+). 
  
C. EXPERIMENTAL PART    171 
 
Synthesis of 2-(4-(pyridin-2-yl)piperazin-1-yl)quinoxaline (103d) 
 
 
 
The aminopyridine 103d was prepared via TP6 using 99i (140 mg, 0.50 mmol), iPrMgCl·LiCl 
(0.46 mL, 0.70 mmol) and 4-(pyridine-2-yl)piperazine (0.11 mL, 0.70 mmol). After stirring at 25 °C 
for 8 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) 
and dried over Na2SO4. After filtration, the solvents were removed in vacuo and the crude product 
purified via column chromatography (isohexane:ethyl acetate = 8:2) to give 103d (79 mg, 0.271 mmol, 
54%) as a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.62 (s, 1H), 8.24-8.22 (m, 1H), 7.91-7.89 (m, 1H), 7.72-7.70 
(m, 1H), 7.61-7.57 (m, 1H), 7.55-7.50 (m, 1H), 7.43-7.39 (m, 1H), 6.72-6.69 (m, 1H), 6.68 - 6.66 (m, 
1H), 3.95 - 3.92 (m, 4H), 3.76 - 3.73 (m, 4H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 159.3, 152.4, 148.2, 141.7, 137.8, 137.1, 135.8, 130.3, 128.9, 
126.7, 125.1, 113.9, 107.3, 45.0, 44.5. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 1590, 1577, 1550, 1478, 1431, 1241, 1225, 979, 942, 759, 731. 
MS (EI, 70 eV): m/z = 291 (25), 207 (40), 184 (45), 170 (45), 158 (32), 146 (46), 145 (78), 133 (100), 
129 (37), 121 (32), 119 (60), 107 (71), 78 (40). 
HRMS (EI) for C17H17N5 (291.1484): 291.1482 (M+). 
M.p. (°C): 136–139. 
  
C. EXPERIMENTAL PART    172 
 
Synthesis of 2-(4-methylpiperazin-1-yl)quinoxaline (103e) 
 
 
 
The aminopyridine 103e was prepared via TP6 using 99i (140 mg, 0.50 mmol), iPrMgCl·LiCl 
(0.46 mL, 0.70 mmol) and 4-methylpiperidine (0.08 mL, 0.70 mmol). After stirring at 25 °C for 8 h, 
the reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) and 
dried over Na2SO4. After filtration, the solvents were removed in vacuo and the crude product purified 
via column chromatography (isohexane:ethyl acetate = 9:1) to give 103e (97 mg, 0.427 mmol, 85%) as 
a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.58 (s, 1H), 7.85 (dd, J = 8.2, 1.5 Hz, 1H), 7.66 (ddd, J = 8.4, 
1.4, 0.6 Hz, 1H), 7.55 (ddd, J = 8.4, 6.9, 1.5 Hz, 1H), 7.36 (ddd, J = 8.3, 6.9, 1.4 Hz, 1H), 4.57 - 4.51 
(m, 2H), 3.00 (ddd, J = 13.3, 12.2, 2.7 Hz, 2H), 1.83 - 1.77 (m, 2H), 1.75 - 1.64 (m, 1H), 1.3 - 1.23 (m, 
2H), 0.99 (d, J = 6.5 Hz, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 152.6, 142.1, 136.6, 136.2, 130.1, 128.7, 126.5, 124.5, 45.4, 
34.0, 31.3, 22.0. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 1578, 1551, 1441, 1308, 1226, 1133, 928, 758. 
MS (EI, 70 eV): m/z = 227 (100), 158 (76), 130 (46), 103 (25). 
HRMS (EI) for C14H17N3 (227.1422): 227.1416 (M+). 
  
C. EXPERIMENTAL PART    173 
 
Synthesis of N-butyl-N-methylquinoxalin-2-amine (103f) 
 
 
 
The aminopyridine 103f was prepared via TP6 using 99i (140 mg, 0.50 mmol), iPrMgCl·LiCl 
(0.46 mL, 0.70 mmol) and N-methylbutane-1-amine (0.085 mL, 0.70 mmol). After stirring at 25 °C for 
8 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) 
and dried over Na2SO4. After filtration, the solvents were removed in vacuo and the crude product 
purified via column chromatography (isohexane:ethyl acetate = 8:2) to give 103f (95 mg, 0.44 mmol, 
88%) as a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.47 (s, 1H), 7.85 (dd, J = 8.2, 1.5 Hz, 1H), 7.67 (ddd, J = 8.4, 
1.5, 0.6 Hz, 1H), 7.54 (ddd, J = 8.4, 6.9, 1.5 Hz, 1H), 7.33 (ddd, J = 8.3, 6.9, 1.4 Hz, 1H), 3.69 - 3.61 
(m, 2H), 3.23 (s, 3H), 1.66 (tt, J = 8.8, 6.8 Hz, 2H), 1.39 (dq, J = 14.7, 7.4 Hz, 2H), 0.97 (t, J = 7.4 Hz, 
3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 152.0, 142.2, 136.3, 135.3, 130.0, 128.7, 126.3, 123.9, 49.9, 
36.2, 29.8, 20.3, 14.0. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3054, 2933, 2851, 1684, 1576, 1549, 1492, 1434, 1279, 1227, 
1128, 1017, 973, 930, 758. 
MS (EI, 70 eV): m/z = 213 (100), 212 (22), 184 (71), 170 (28), 158 (40), 157 (27), 145 (22), 130 (60), 
129 (22), 102 (21), 84 (22), 44 (24). 
HRMS (EI) for C13H17N3 (215.1422): 215.1416 (M+). 
  
C. EXPERIMENTAL PART    174 
 
Directed ortho-Metalation and Functionalization of Various Phosphorodiamidates, Followed by 
the Transition-Metal-Free Amination using Magnesium Amides: Synthesis of Aminated N-
heterocycles 106a–d, 107, 108a–c 
 
Synthesis of N-(2-bromobenzyl)-3-iodo-N-methylpyridin-2-amine (106a) 
 
N N
I
Me
Br
106a: 82%
N O P NMe2
O
NMe2
1) TMPMgCl·LiCl
(1.5 equiv)
0 °C, 1 h
2) I2
N O P NMe2
O
NMe2
I
R2NMgCl·LiCl
(2.0 equiv)
0 °C to 25 °C, 8 h
J: 75%
(62% over two steps)
99a
 
 
Synthesis of J 
 
Phosphorodiamidate J was prepared via TP7 using 99a (1.14 g, 5.00 mmol), TMPMgCl·LiCl 
(5.80 mL, 7.50 mmol) and iodine (2.02 g, 8.00 mmol). The reaction was complete after 12 h. After 
work-up, the crude product was purified via column chromatography (ethyl acetate) to give J (1.33 g, 
3.75 mmol, 75%) as a brown oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.22 (dd, J = 4.8, 1.8 Hz, 1H), 8.09 (ddd, J = 7.7, 1.8, 1.1 Hz, 
1H), 6.80 (dd, J = 7.7, 4.8 Hz, 1H), 2.79 (d, J = 10.6 Hz, 12H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 157.7, 157.6, 149.1, 147.6, 121.0, 81.8, 81.8, 37.0, 37.0. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 2925, 2851, 2809, 1570, 1414, 1300, 1214, 1067, 989, 908, 779, 
748, 671. 
MS (EI, 70 eV): 356 (100), 310 (30), 135 (15). 
HRMS (EI) for C9H16O2N3IP (356.0019): 356.0021 (M+). 
  
C. EXPERIMENTAL PART    175 
 
Synthesis of 106a 
 
The aminopyridine 106a was prepared via TP6 using J (1.03 mg, 2.91 mmol), iPrMgCl·LiCl (3.72 mL, 
5.82 mmol) and 1-(2-bromophenyl)-N-methylmethanamine (0.86 mL, 5.82 mmol). After stirring at 
25 °C for 8 h, the reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 
30 mL) and dried over Na2SO4. After filtration, the solvents were removed in vacuo and the crude 
product purified via column chromatography (isohexane:ethyl acetate = 99:1) to give 106a (961 mg, 
2.38 mmol, 82%) as a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.27 (dd, J = 4.7, 1.7 Hz, 1H), 8.08 (dd, J = 7.6, 1.7 Hz, 1H), 
7.64-7.62 (m, 1H), 7.55 (dd, J = 7.9, 1.3 Hz, 1H), 7.32 (td, J = 7.5, 1.3 Hz, 1H), 7.15 - 7.10 (m, 1H), 
6.63 (dd, J = 7.7, 4.7 Hz, 1H), 4.53 (s, 2H), 2.91 (s, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 162.8, 149.4, 147.0, 137.7, 132.8, 130.0, 128.4, 127.3, 123.8, 
118.9, 86.5, 58.4, 40.3. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 2920, 1566, 1439, 1402, 1002, 746. 
MS (EI, 70 eV): m/z = 402 (21), 474 (23), 323 (77), 307 (47), 233 (100), 195 (50), 169 (27), 90 (36) 
57 (30). 
HRMS (EI) for C13H12BrIN2 (401.9229): 401.9224 (M+). 
  
C. EXPERIMENTAL PART    176 
 
Synthesis of N-benzyl-3-iodo-N-methylpyridin-4-amine (106b) 
 
 
 
Synthesis of K 
 
Phosphorodiamidate K was prepared via TP7 using 99d (458 g, 2.00 mmol), TMPMgCl·LiCl 
(2.46 mL, 3.00 mmol) and iodine (761 mg, 3.00 mmol). The reaction was complete after 12 h. After 
work-up, the crude product was purified via column chromatography (ethyl acetate + 1% triethylamine) 
to give K (412 mg, 1.16 mmol, 58%) as an orange solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.82 (dd, J = 1.2, 0.4 Hz, 1H), 8.38 (d, J = 5.5 Hz, 1H), 7.49 
(ddd, J = 5.6, 0.8, 0.4 Hz, 1H), 2.74 (d, J = 10.3 Hz, 12H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 158.6, 158.2, 158.1, 150.9, 115.2, 115.1, 87.6, 87.5, 36.9, 
36.9. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3450, 2930, 2361, 1649, 1563, 1466, 1396, 1289, 1259, 1217, 
1170,992, 904, 840, 750, 683. 
MS (EI, 70 eV): 268 (24), 228 (95), 221 (56), 205 (13), 204 (12), 177 (37), 142 (23), 135 (72), 128 
(13), 127 (100), 92 (11). 
HRMS (EI) for C9H15O2N3IP (354.9947): 354.9941 (M+). 
M.p. (°C): 83–84. 
  
C. EXPERIMENTAL PART    177 
 
Synthesis of 106b 
 
The aminopyridine 106b was prepared via TP6 using K (226 mg, 0.70 mmol), iPrMgCl·LiCl (0.91 mL, 
1.40 mmol) and N-benzylmethylamine (0.18 mL, 1.40 mmol). After stirring at 25 °C for 8 h, the 
reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) and dried 
over Na2SO4. After filtration, the solvents were removed in vacuo and the crude product purified via 
column chromatography (isohexane:ethyl acetate = 10:0.5) to give 106b (176 mg, 0.55 mmol, 78%) as 
a colorless oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.83 (s, 1H), 8.32 (d, J = 5.5 Hz, 1H), 7.38 - 7.27 (m, 5H), 
6.84 (d, J = 5.5 Hz, 1H), 4.39 (s, 2H), 2.77 (s, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 160.2, 159.3, 149.5, 137.1, 128.6, 128.3, 127.6, 116.1, 90.8, 
59.1, 40.1. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3026, 2854, 2358, 1570, 1494, 1477, 1451, 1395, 1361, 1288, 
1106, 1009, 944, 733, 697. 
MS (EI, 70 eV): m/z = 198 (14), 197 (100), 195 (19), 182 (20), 181 (11), 91 (26). 
HRMS (EI) for C13H12N2I (323.0051): 323.0039 (M+). 
 
Synthesis of 2-(3-bromopyridin-2-yl)-1,2,3,4-tetrahydroisoquinoline (106c) 
 
 
 
Synthesis of L 
 
Phosphorodiamidate L was prepared via TP7 using 99a (229 g, 1.00 mmol), TMPMgCl·LiCl (1.33 mL, 
1.50 mmol) and dibromotetrachloroethane (488 mg, 1.50 mmol). The reaction was complete after 12 h. 
C. EXPERIMENTAL PART    178 
 
After work-up, the crude product was purified via column chromatography (ethyl acetate + 1% 
triethylamine) to give L (192 mg, 0.62 mmol, 62%) as a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.20 (dd, J = 4.8, 1.8 Hz, 1H), 7.87 (ddd, J = 7.8, 1.7, 1.1 Hz, 
1H), 6.94 (dd, J = 7.7, 4.8 Hz, 1H), 2.78 (d, J = 10.6 Hz, 12H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 155.3, 155.3, 146.7, 142.8, 120.9, 109.3, 109.3, 36.9, 36.9. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 2925, 2851, 2810, 1577, 1424, 1302, 1230, 1068, 1027, 997, 913, 
782, 756, 673. 
MS (EI, 70 eV): 310 (100), 308 (92), 265 (20), 176 (25), 135 (47). 
HRMS (EI) for C9H16O2N3BrP (308.0158): 308.0157 (M+). 
 
Synthesis of 106c 
 
The aminopyridine 106c was prepared via TP6 using L (170 mg, 0.55 mmol), iPrMgCl·LiCl (0.72 mL, 
1.10 mmol) and 1,2,3,4-tetrahydroisoquinoline (0.14 mL, 1.10 mmol). After stirring at 25 °C for 8 h, 
the reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) and 
dried over Na2SO4. After filtration, the solvents were removed in vacuo and the crude product purified 
via column chromatography (isohexane:ethyl acetate = 10:0.3) to give 106c (138 mg, 0.48 mmol, 87%) 
as a colorless oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.26 (dd, J = 4.8, 1.7 Hz, 1H), 7.82 (dd, J = 7.7, 1.7 Hz, 1H), 
7.20 - 7.14 (m, 4H), 6.78 (dd, J = 7.7, 4.7 Hz, 1H), 4.55 (s, 2H), 3.64 (t, J = 5.8 Hz, 2H), 3.11 (t, J = 
5.8 Hz, 2H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 159.6, 146.3, 142.6, 134.8, 134.7, 129.0, 126.9, 126.4, 126.0, 
118.3, 112.4, 51.3, 48.7, 29.5. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3049, 2922, 2830, 2350, 1667, 1574, 1431, 1375, 1230, 1113, 
1010, 933, 784, 746. 
MS (EI, 70 eV): m/z (%) = 288 (100). 
HRMS (EI) for C14H13N2Br (288.0262): 288.0253 (M+).  
C. EXPERIMENTAL PART    179 
 
Synthesis of (2-(butyl(methyl)amino)pyridin-3-yl)(4-chlorophenyl)methanone (106d) 
 
 
 
Synthesis of M 
 
Phosphorodiamidate N was prepared via TP7 using 99a (229 g, 1.00 mmol) and TMPMgCl·LiCl 
(1.33 mL, 1.50 mmol). After the metalation was complete, a 1 M ZnCl2 solution in THF (1.60 mL, 1.60 
mmol) was added at -40 °C. After stirring for 15 min, a 1 M CuCN·2LiCl solution in THF (0.10 mL, 
0.10 mmol) was added. After 10 min, 4-chlorobenzoyl chloride (0.19 mL, 1.50 mmol) was added and 
the reaction stirred for 12 h at 25 °C. After work-up, the crude product was purified via column 
chromatography (ethyl acetate + 1% triethylamine) to give M (254 mg, 0.69 mmol, 69%) as an orange 
oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.46 (ddd, J = 4.9, 2.1, 0.8 Hz, 1H), 7.82 (ddt, J = 10.8, 7.6, 
0.9 Hz, 3H), 7.50 - 7.44 (m, 2H), 7.22 (ddd, J = 7.5, 5.0, 0.7 Hz, 1H), 2.51 (dd, J = 10.6, 0.8 Hz, 12H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 192.8, 155.4, 155.4, 150.6, 140.3, 140.0, 135.3, 131.4, 129.1, 
124.1, 124.0, 119.9, 36.5, 36.4. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 2930, 2811, 2357, 2231, 1165, 1586, 1422, 1303, 1216, 1090. 
990. 935, 896, 763, 725. 
MS (EI, 70 eV): 325 (31), 324 (79), 323 (53), 280 (70), 260 (47), 231 (40), 202 (32), 139 (38), 122 
(32), 44 (100). 
HRMS (EI) for C16H19N3ClP (367.0853): 367.0846 (M+). 
 
C. EXPERIMENTAL PART    180 
 
Synthesis of 106d 
 
The aminopyridine 106d was prepared via TP6 using M (210 mg, 0.57 mmol), iPrMgCl·LiCl (0.74 mL, 
1.14 mmol) and N-methylbutane-1-amine (0.14 mL, 1.14 mmol). After stirring at 25 °C for 8 h, the 
reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) and dried 
over Na2SO4. After filtration, the solvents were removed in vacuo and the crude product purified via 
column chromatography (isohexane:ethyl acetate = 10:0.5) to give 106d (102 mg, 0.33 mmol, 59%) as 
a yellow solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.29 (dd, J = 4.8, 1.9 Hz, 1H), 7.81 - 7.75 (m, 2H), 7.57 (dd, 
J = 7.5, 2.0 Hz, 1H), 7.47 - 7.40 (m, 2H), 6.66 (dd, J = 7.5, 4.8 Hz, 1H), 3.49 - 3.41 (m, 2H), 2.75 (s, 
3H), 1.57 - 1.45 (m, 2H), 1.30 - 1.18 (m, 2H), 0.87 (t, J = 7.4 Hz, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 194.5, 158.2, 149.7, 140.3, 139.7, 135.8, 131.4, 129.0, 119.0, 
111.8, 52.0, 39.5, 29.4, 20.2, 14.0. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 2955, 2927, 2870, 2357. 1650, 1581, 1543, 1500, 1406, 1287, 
1243, 1222, 1088, 1013, 914, 845, 752. 
MS (EI, 70 eV): m/z (%) = 302 (25), 273 (17), 261 (26), 260 (16), 259 (92), 127 (27), 125 (100), 110 
(12). 
HRMS (EI) for C17H19ON2Cl (302.1186): 302.1179 (M+). 
M.p. (°C): 95–96. 
  
C. EXPERIMENTAL PART    181 
 
Synthesis of 4-(3-(methylthio)quinolin-2-yl)morpholine (107) 
 
 
 
Synthesis of N 
 
Phosphorodiamidate N was prepared via TP7 using 99f (215 g, 0.77 mmol) and TMPMgCl·LiCl 
(0.76 mL, 1.16 mmol) and S-methyl methanethiosulfonate (0.145 mL, 1.54 mmol). The reaction was 
complete after 12 h. After work-up, the crude product was purified via column chromatography (ethyl 
acetate + 1% triethylamine) to give N (169 mg, 0.518 mmol, 67%) as a yellow oil. The product 
contained 5% impurities and was used as is in the next step. 
 
Synthesis of 107 
 
The aminopyridine 107 was prepared via TP6 using N (169 mg, 0.519 mmol), iPrMgCl·LiCl (0.68 mL, 
1.04 mmol) and morpholine (0.09 mL, 1.04 mmol). After stirring at 25 °C for 8 h, the reaction mixture 
was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) and dried over Na2SO4. 
After filtration, the solvents were removed in vacuo and the crude product purified via column 
chromatography (pentane:ethyl acetate = 95:5) to give 107 (78 mg, 0.30 mmol, 39%) as a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 7.89 - 7.85 (m, 1H), 7.68 (s, 1H), 7.65 (dd, J = 8.1, 1.4 Hz, 
1H), 7.57-7.52 (m, 1H), 7.40-7.36 (m, 1H), 3.93 - 3.91 (m, 4H), 3.43 - 3.41 (m, 4H), 2.53 (s, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 158.2, 144.5, 131.3, 128.5, 128.3, 127.8, 126.2, 126.0, 125.1, 
67.1, 50.4, 15.1. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 2848, 1577, 1448, 1405, 1364, 1256, 1228, 1203, 1111, 942, 877, 
841, 779, 753, 730, 708. 
MS (EI, 70 eV): m/z (%) = 245 (100), 215 (12), 201 (25), 187 (41), 160 (10), 129 (14). 
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HRMS (EI) for C14H16N2OS (260.0983): 260.0979 (M+). 
 
Synthesis of 2-(4-(tert-butyl)phenyl)-3-(4-phenylpiperazin-1-yl)quinoxaline (108a) 
 
 
Synthesis of O 
 
Phosphorodiamidate O was prepared via TP7 using 99i (561 mg, 2.00 mmol) and TMP2Mg·2LiCl 
(5.40 mL, 3.00 mmol). After the metalation was complete, a 1.0 M ZnCl2 solution in THF (3.00 mL, 
3.00 mmol) was added dropwise at -40 °C and the reaction mixture stirred for 20 min. Then, Pd(dba)2 
(57 mg, 0.10 mmol), tfp (47 mg, 0.20 mol) and 4-tert-butyliodobenzene (425 mL, 2.40 mmol) were 
added, the reaction warmed to 25 °C and stirred for 12 h. After work-up, the crude product was purified 
via column chromatography (isohexane:ethyl acetate = 2:8) to give O (626 mg, 1.52 mmol, 76%) as a 
brown oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.11 - 8.08 (m, 1H), 7.94 - 7.91 (m, 3H), 7.71 - 7.64 (m, 2H), 
7.54 - 7.51 (m, 2H), 2.75 (d, J = 10.6 Hz, 12H), 1.36 (s, 9H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 153.2, 150.6, 150.5, 147.6, 147.5, 140.4, 139.7, 133.1, 130.0, 
129.5, 129.1, 128.5, 127.9, 125.4, 36.9, 36.9, 34.9, 31.4. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 2933, 1570, 1460, 1402, 1337, 1300, 1268, 1227, 1210, 1171, 
1135, 1124, 1067, 984, 926, 852, 833, 795, 761, 693 
MS (EI, 70 eV): 368 (12), 276 (65), 263 (51), 219 (100), 146 (45), 144 (82), 135 (41), 44 (82) 
HRMS (EI) for C22H30N4O2P (413.2106): 413.2081 (M++H). 
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Synthesis of 108a 
 
The aminopyridine 108a was prepared via TP6 using O (200 mg, 0.49 mmol), iPrMgCl·LiCl (0.59 mL, 
0.89 mmol) and 4-phenylpiperazine (0.14 mL, 0.89 mmol). After stirring at 25 °C for 8 h, the reaction 
mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) and dried over 
Na2SO4. After filtration, the solvents were removed in vacuo and the crude product purified via column 
chromatography (pentane:ethyl acetate = 99:1) to give 108a (179 mg, 0.424 mmol, 87%) as a yellow 
oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.00 - 7.95 (m, 3H), 7.86-7.84 (m, 1H), 7.64-7.59 (m, 1H), 
7.53 - 7.49 (m, 3H), 7.31 - 7.27 (m, 2H), 6.96 - 6.92 (m, 2H), 6.90-6.86 (m, 1H), 3.49 - 3.46 (m, 4H), 
3.24 - 3.21 (m, 4H), 1.37 (s, 9H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 154.3, 152.8, 151.4, 148.6, 140.3, 138.9, 136.7, 129.6, 129.3, 
128.9, 127.7, 127.1, 126.6, 125.9, 120.1, 116.3, 53.6, 48.8, 35.0, 31.4. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 2961, 1599, 1502, 1417, 1375, 1270, 1231, 1214, 1002, 946, 910, 
757, 734. 
MS (EI, 70 eV): m/z (%) = 422 (34), 290 (21), 234 (100), 145 (78), 132 (92), 104 (28), 57 (34). 
HRMS (EI) for C28H30N4 (422.2470): 422.2464 (M+). 
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Synthesis of N-butyl-3-(4-(tert-butyl)phenyl)-N-methylquinoxalin-2-amine (108b) 
 
 
Synthesis of O 
 
Phosphorodiamidate O was prepared via TP7 using 99i (561 mg, 2.00 mmol) and TMP2Mg·2LiCl 
(5.40 mL, 3.00 mmol). After the metalation was complete, a 1.0 M ZnCl2 solution in THF (3.00 mL, 
3.00 mmol) was added dropwise at -40 °C and the reaction mixture stirred for 20 min. Then, Pd(dba)2 
(57 mg, 0.10 mmol), tfp (47 mg, 0.20 mol) and 4-tert-butyliodobenzene (425 mL, 2.40 mmol) were 
added, the reaction warmed to 25 °C and stirred for 12 h. After work-up, the crude product was purified 
via column chromatography (isohexane:ethyl acetate = 2:8) to give O (626 mg, 1.52 mmol, 76%) as a 
brown oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.11 - 8.08 (m, 1H), 7.94 - 7.91 (m, 3H), 7.71 - 7.64 (m, 2H), 
7.54 - 7.51 (m, 2H), 2.75 (d, J = 10.6 Hz, 12H), 1.36 (s, 9H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 153.2, 150.6, 150.5, 147.6, 147.5, 140.4, 139.7, 133.1, 130.0, 
129.5, 129.1, 128.5, 127.9, 125.4, 36.9, 36.9, 34.9, 31.4. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 2933, 1570, 1460, 1402, 1337, 1300, 1268, 1227, 1210, 1171, 
1135, 1124, 1067, 984, 926, 852, 833, 795, 761, 693 
MS (EI, 70 eV): 368 (12), 276 (65), 263 (51), 219 (100), 146 (45), 144 (82), 135 (41), 44 (82) 
HRMS (EI) for C22H30N4O2P (413.2106): 413.2081 (M++H). 
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Synthesis of 108b 
 
The aminopyridine 108b was prepared via TP6 using O (208 mg, 0.50 mmol), iPrMgCl·LiCl (0.65 mL, 
1.00 mmol) and N-methylbutan-1-amine (0.12 mL, 1.00 mmol). After stirring at 25 °C for 8 h, the 
reaction mixture was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) and dried 
over Na2SO4. After filtration, the solvents were removed in vacuo and the crude product purified via 
column chromatography (isohexane:ethyl acetate = 10:0.3) to give 108b (153 mg, 0.44 mmol, 88%) as 
a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 7.94 (ddd, J = 8.2, 1.5, 0.6 Hz, 1H), 7.82 - 7.78 (m, 1H), 7.78 
- 7.73 (m, 2H), 7.56 (ddd, J = 8.4, 6.9, 1.5 Hz, 1H), 7.52 - 7.47 (m, 2H), 7.42 (ddd, J = 8.3, 6.9, 1.4 Hz, 
1H), 3.26 - 3.18 (m, 2H), 2.89 (s, 3H), 1.54 - 1.44 (m, 2H), 1.36 (s, 9H), 1.10 (h, J = 7.4 Hz, 2H), 0.79 
(t, J = 7.4 Hz, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 154.5, 152.1, 148.3, 140.4, 138.0, 137.5, 129.4, 128.7, 127.5, 
126.5, 125.8, 125.4, 52.6, 38.6, 34.9, 31.4, 29.4, 20.3, 13.9. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3060, 2958, 2865, 2357, 1543, 1460, 1398, 1260, 1133, 1119, 
1003, 907, 839, 756, 729. 
MS (EI, 70 eV): m/z (%) = 347 (68), 346 (100), 304 (18), 290 (18), 248 (93), 57 (18). 
HRMS (EI) for C23H28N3 (346.2289): 346.2277 (M+). 
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Synthesis of N,N-diallyl-3-(4-methoxyphenyl)quinoxalin-2-amine (108c) 
 
 
Synthesis of P 
 
Phosphorodiamidate P was prepared via TP7 using 99i (639 mg, 2.28 mmol) and TMP2Mg·2LiCl 
(6.16 mL, 3.42 mmol). After the metalation was complete, a 1.0 M ZnCl2 solution in THF (3.42 mL, 
3.42 mmol) was added dropwise at -40 °C and the reaction mixture stirred for 20 min. Then, Pd(dba)2 
66 mg, 0.114 mmol), tfp (52 mg, 0.228 mol) and 4-methoxyiodobenzene (641 mg, 2.74 mmol) were 
added, the reaction warmed to 25 °C and stirred for 12 h. After work-up, the crude product was purified 
via column chromatography (pentane:ethyl acetate = 1:9) to give P (667 mg, 1.73 mmol, 78%) as a 
brown oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.09 - 8.06 (m, 1H), 8.01 - 7.97 (m, 2H), 7.93 - 7.89 (m, 1H), 
7.69 - 7.63 (m, 2H), 7.04 - 7.00 (m, 2H), 3.88 (s, 3H), 2.77 (d, J = 10.7 Hz, 12H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 161.1, 150.5, 150.5, 147.1, 147.0, 140.5, 139.5, 131.4, 129.8, 
128.9, 128.5, 128.4, 127.9, 113.9, 55.5, 37.0, 36.9. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 2932, 1605, 1400, 1341, 1292, 1239, 1204, 1176, 998, 837, 811, 
763. 
MS (EI, 70 eV): 252 (59), 250 (100), 236 (21), 224 (31), 219 (33), 57 (28), 44 (30). 
HRMS (EI) for C19H23N4O3P (386.1508): 386.1498 (M+). 
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Synthesis of 108c 
 
The aminopyridine 108c was prepared via TP6 using P (195 mg, 0.50 mmol), iPrMgCl·LiCl (0.65 mL, 
1.00 mmol) and diallylamine (0.13 mL, 1.00 mmol). After stirring at 25 °C for 8 h, the reaction mixture 
was quenched with water (20 mL), extracted with ethyl acetate (3 x 30 mL) and dried over Na2SO4. 
After filtration, the solvents were removed in vacuo and the crude product purified via column 
chromatography (pentane:ethyl acetate = 99:1) to give 108c (75 mg, 0.226 mmol, 45%) as a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 7.96 - 7.93 (m, 1H), 7.89 - 7.85 (m, 2H), 7.81 - 7.78 (m, 1H), 
7.60 - 7.55 (m, 1H), 7.48 - 7.44 (m, 1H), 7.03 - 6.99 (m, 2H), 5.84 - 5.74 (m, 2H), 5.15 - 5.12 (m, 2H), 
5.10 - 5.09 (m, 2H), 3.90 (d, J = 6.3, 4H), 3.88 (s, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 160.5, 153.8, 148.2, 140.2, 138.5, 134.5, 132.4, 129.5, 129.3, 
128.6, 126.9, 126.1, 118.2, 114.3, 55.5, 52.1. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 1607, 1543, 1513, 1406, 1280, 1248, 1208, 1174, 1030, 923, 837, 
760. 
MS (EI, 70 eV): m/z (%) = 331 (15), 290 (100), 276 (54), 235 (21), 57 (24), 43 (38). 
HRMS (EI) for C21H21N30 (331.1685): 331.1678 (M+). 
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5 Zn-, Mg-, and Li-TMP Bases for the Successive Regioselective 
Metalations of the 1,5-Naphthyridine Scaffold 
5.1 Typical Procedures 
 
Typical Procedure 8: Metalation and functionalization of 1,5-naphthyridine (109) in the C4 position 
using TMP2Mg·2LiCl. 
 
To a solution of 1,5-naphthyridine in THF (5 mL/mmol 1,5-naphthyridine) was added dropwise a 
solution of TMP2Mg·2LiCl (1.1 equiv) at –78 °C. After full metalation (5 min, checked via GC / GC-
MS) the solution was cannulated dropwise to a solution of the electrophile in THF (5 mL/mmol 1,5-
naphthyridine) which was precooled to –78 °C. After warming to 25 °C the reaction mixture was stirred 
until completion. The reaction mixture was quenched with an aq. sat. NH4Cl solution (10 mL/mmol 
1,5-naphthyridine) and extracted with ethyl acetate (3 x 50 mL/mmol 1,5-naphthyridine). The organic 
phase was then dried over Na2SO4 and concentrated in vacuo. If the crude product needed purification, 
it was purified via flash chromatography on silica gel using the appropriate eluent. 
 
Typical Procedure 9: Metalation and functionalization of 110b and 110g in the C8 position using 
TMPMgCl·LiCl 
 
1,5-Naphthyridines 110b and 110g were dissolved in THF (5 mL/mmol 1,5-naphthyridine) and cooled 
to –40 °C. Then, TMPMgCl·LiCl (1.2 equiv) was added and the reaction stirred until full metalation 
was observed (1 h, checked via GC / GC-MS). Then, a solution of the electrophile in THF (5 mL/mmol 
1,5-naphthyridine) was added dropwise and the reaction stirred until completion. The reaction mixture 
was quenched with an aq. sat. NH4Cl solution (10 mL/mmol 1,5-naphthyridine) and extracted with ethyl 
acetate (3 x 50 mL/mmol 1,5-naphthyridine). The organic phase was then dried over Na2SO4 and 
concentrated in vacuo. If the crude product needed purification, it was purified via flash 
chromatography on silica gel using the appropriate eluent. 
 
Typical Procedure 10: Metalation and functionalization of 110c in the C8 position using 
TMPZnCl·LiCl 
 
1,5-Naphthyridine 110c was dissolved in THF (5 mL/mmol 1,5-naphthyridine), TMPZnCl·LiCl 
(1.5 equiv) added dropwise and the reaction stirred until full metalation was observed (1 h, checked via 
GC / GC-MS). Then, a solution of the electrophile in THF (5 mL/mmol 1,5-naphthyridine) was added 
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dropwise and the reaction stirred until completion. The reaction mixture was quenched with an aq. sat. 
NH4Cl solution (10 mL/mmol 1,5-naphthyridine) and extracted with ethyl acetate (3 x 50 mL/mmol 
1,5-naphthyridine). The organic phase was then dried over Na2SO4 and concentrated in vacuo. If the 
crude product needed purification, it was purified via flash chromatography on silica gel using the 
appropriate eluent. 
 
Typical Procedure 11: Metalation and functionalization of 110a, 110g, and 110f in the C2 position 
using BF3·OEt2 and TMPMgCl·LiCl 
 
1,5-Naphthyridines 110a, 110g, and 110f were dissolved in THF (5 mL/mmol 1,5-naphthyridine) and 
cooled to 0 °C. Then, BF3·OEt2 (1.1 equiv) was added dropwise and the reaction mixture stirred for 
10 min. After cooling to –40 °C, TMPMgCl·LiCl (1.2 equiv) was added and the reaction stirred until 
full metalation was observed (1 h, checked via GC / GC-MS). Then, a solution of the electrophile in 
THF (5 mL/mmol 1,5-naphthyridine) was added dropwise and the reaction stirred until completion. The 
reaction mixture was quenched with an aq. sat. NH4Cl solution (10 mL/mmol 1,5-naphthyridine) and 
extracted with ethyl acetate (3 x 50 mL/mmol 1,5-naphthyridine). The organic phase was then dried 
over Na2SO4 and concentrated in vacuo. If the crude product needed purification, it was purified via 
flash chromatography on silica gel using the appropriate eluent. 
 
Typical Procedure 12: Metalation and functionalization of 112g and 112h in the C8 position using 
TMPLi  
 
1,5-Naphthyridines 112g and 112h were dissolved in THF (5 mL/mmol 1,5-naphthyridine) and cooled 
to –78 °C. Then, TMPLi (1.1 equiv) was added dropwise and the reaction mixture stirred until full 
metalation was observed (30 min, checked via GC / GC-MS). Then, a solution of the electrophile in 
THF (5 mL/mmol 1,5-naphthyridine) was added dropwise and the reaction stirred until completion. The 
reaction mixture was quenched with an aq. sat. NH4Cl solution (10 mL/mmol 1,5-naphthyridine) and 
extracted with ethyl acetate (3 x 50 mL/mmol 1,5-naphthyridine). The organic phase was then dried 
over Na2SO4 and concentrated in vacuo. If the crude product needed purification, it was purified by 
flash chromatography on silica gel using the appropriate eluent. 
 
Typical Procedure 13: Metalation and functionalization of 113a in the C7 position using TMPLi 
 
1,5-Naphthyridine 113a was dissolved in THF (5 mL/mmol 1,5-naphthyridine) and cooled to  
–78 °C. Then, TMPLi (1.2 equiv) was added dropwise and the reaction mixture stirred until full 
metalation was observed (90 sec, checked via GC / GC-MS). Then, a solution of the electrophile in 
THF (5 mL/mmol 1,5-naphthyridine) was added dropwise and the reaction stirred until completion. The 
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reaction mixture was quenched with an aq. sat. NH4Cl solution (10 mL/mmol 1,5-naphthyridine) and 
extracted with ethyl acetate (3 x 50 mL/mmol 1,5-naphthyridine). The organic phase was then dried 
over Na2SO4 and concentrated in vacuo. If the crude product needed purification, it was purified via 
flash chromatography on silica gel using the appropriate eluent. 
  
C. EXPERIMENTAL PART    191 
 
5.2 Preparation of Compounds 109 to 126 
 
Synthesis of 1,5-naphthyridine (109) 
 
 
 
Adapted from a literature procedure,140 3-aminopyridine (5.00 g, 53.1 mmol) was dissolved in dioxane 
(30 mL) and water (30 mL). Then, glycerine (15.5 mL, 212 mmol) was added, followed by slow 
addition of conc. H2SO4 (55 mL) at 0 °C. After addition of iodine (4.04 g, 15.9 mmol), the reaction 
mixture was stirred at 150 °C for 15 h. After cooling to room temperature, the mixture was basified 
using a 50% aq. NaOH solution (250 mL). After addition of an aq. sat. Na2S2O3 solution (150 mL) and 
filtration over celite, the reaction mixture was diluted with water (500 mL), extracted with diethyl ether 
(3 x 500 mL) and dried over Na2SO4. After filtration, the solvent was removed in vacuo. The crude 
product was purified via column chromatography (isohexane:ethyl acetate:triethylamine = 7:3:0.1) to 
give 109 (3.78 g, 29.1 mmol, 55%) as an off-white solid. 
 
The spectra matched those of the literature.81d 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.99 (dd, J = 4.1, 1.6 Hz, 2H), 8.42 (dd, J = 8.5, 1.5 Hz, 2H), 
7.65 (dd, J = 8.5, 4.1 Hz, 2H). 
 
Synthesis of 4-phenyl-1,5-naphthyridine (110f) 
 
 
 
1,5-Naphthyridine 110f was prepared via TP8 using 109 (650 mg, 5.00 mmol), and TMP2Mg·2LiCl 
(8.75 mL, 5.50 mmol). After the metalation was complete, a 1.0 M ZnCl2 solution in THF (5.50 mL, 
5.50 mmol) was added and the reaction stirred at the same temperature for 20 min. Then, iodobenzene 
(0.56 mL, 5.00 mmol), Pd(dba)2 (86 mg, 150 µmol), and tfp (70 mg, 300 µmol) was added and the 
reaction slowly warmed to 25 °C over 12 h. After work-up, the crude product was purified via column 
                                                     
140
 K. C. Chunavala, S. Adimurthy, Synth. Commun. 2011, 41, 1843–1851. 
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chromatography (isohexane:ethyl acetate = 6:4) to give 110f (648 mg, 3.14 mmol, 63%) as a yellow 
solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 9.04 - 9.00 (m, 2H), 8.47 (dd, J = 8.5, 1.8 Hz, 1H), 7.81 - 7.75 
(m, 2H), 7.68 - 7.63 (m, 2H), 7.58 - 7.46 (m, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 151.1, 151.0, 148.7, 144.6, 142.1, 137.8, 136.8, 130.6, 128.9, 
128.4, 124.3, 124.3. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3078, 3022, 2356, 2322, 1611, 1589, 1572, 1489, 1456, 1394, 
1272, 1244, 876, 797, 699. 
MS (EI, 70 eV): m/z (%) = 206 (40), 200 (100), 103 (6). 
HRMS (EI) for C14H10N2 (206.0844): 206.0843 (M+). 
M.p. (°C): 75–76. 
 
Synthesis of 4-bromo-8-(4-methoxyphenyl)-1,5-naphthyridine (111b) 
 
 
 
1,5-Naphthyridine 111b was prepared via TP9 using 110g (31 mg, 0.13 mmol), TMPMgCl·LiCl 
(0.14 mL, 0.17 mmol), and dibromotetrachloroethane (85 mg, 0.26 mmol). The reaction was complete 
after 12 h. After work-up, the crude product was purified via column chromatography (isohexane:ethyl 
acetate:triethylamine = 8:2:0.1) to give 111b (25 mg, 79 μmol, 60%) as a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 9.08 (d, J = 4.5 Hz, 1H), 8.75 (d, J = 4.6 Hz, 1H), 7.98 (d, J = 
4.5 Hz, 1H), 7.77 - 7.71 (m, 2H), 7.68 (d, J = 4.5 Hz, 1H), 7.10 - 7.04 (m, 2H), 3.89 (s, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 160.6, 151.6, 150.1, 148.9, 143.1, 142.6, 136.6, 132.1, 128.7, 
128.1, 124.8, 114.1, 55.5. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3003, 2958, 2930, 2835, 1604, 1582, 1514, 1479, 1248, 1181, 
1028, 835, 726. 
MS (EI, 70 eV): m/z (%) = 316 (46), 315 (95), 314 (51), 313 (100), 301 (41), 285 (46), 283 (45), 272 
(48), 270 (50), 207 (53), 192 (57), 191 (66). 
HRMS (EI) for C15H10BrN2O (312.9977): 312.9971 (M+-1H). 
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M.p. (°C): 160–163. 
 
Synthesis of 4-(cyclohex-2-en-1-yl)-8-(4-methoxyphenyl)-1,5-naphthyridine (111c) 
 
 
 
1,5-Naphthyridine 111c was prepared via TP9 using 110g (93 mg, 0.39 mmol) and TMPMgCl·LiCl 
(0.40 mL, 0.51 mmol). After the metalation was complete, a 1.0 M CuCN·2LiCl solution in THF 
(0.51 mL, 0.51 mmol) was added and the reaction stirred at the same temperature for 20 min. Then, 3-
bromocyclohexene (0.07 mL, 0.59 mmol) was added and the reaction slowly warmed to 25 °C over 
12 h. After work-up, the crude product was purified via column chromatography (isohexane:ethyl 
acetate:triethylamine = 9:1:0.1) to give 111c (74 mg, 234 μmol, 60%) as a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.98 (d, J = 4.4 Hz, 1H), 8.92 (d, J = 4.4 Hz, 1H), 7.78 - 7.71 
(m, 2H), 7.59 (d, J = 4.4 Hz, 1H), 7.50 (d, J = 4.5 Hz, 1H), 7.09 - 7.03 (m, 2H), 6.10 - 6.03 (m, 1H), 
5.79 (dq, J = 10.1, 2.4 Hz, 1H), 4.94 - 4.87 (m, 1H), 3.88 (s, 3H), 2.34 - 2.24 (m, 1H), 2.21 - 2.12 (m, 
2H), 1.83 - 1.70 (m, 2H), 1.70 - 1.61 (m, 1H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 160.2, 154.3, 150.5, 149.6, 148.4, 143.2, 141.9, 132.0, 129.8, 
129.6, 129.1, 123.6, 122.4, 113.9, 55.5, 35.2, 30.8, 25.3, 21.0. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3016, 1928, 1858, 1835, 1607, 1583, 1496, 1248, 1175, 1036, 
906, 824, 726. 
MS (EI, 70 eV): m/z (%) = 316 (76). 315 (78), 287 (100), 275 (62), 243 (47), 230 (54), 217 (44). 
HRMS (EI) for C21H20N2O (316.1576): 316.1571 (M+). 
M.p. (°C): 129–131. 
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Synthesis of 2-iodo-4-phenyl-1,5-naphthyridine (112f)  
 
 
 
1,5-Naphthyridine 112f was prepared via TP11 using 110f (492 mg, 2.38 mmol), BF3·OEt2 (0.34 mL, 
2.62 mmol), TMPMgCl·LiCl (2.10 mL, 2.86 mmol), and iodine (1.21 g, 4.77 mmol). The reaction was 
complete after 12 h. After work-up, the crude product was purified via column chromatography 
(isohexane:ethyl acetate:triethyl amine = 9/2/0.1) and recrystallized from ethyl acetate / hexane to give 
112f (459 mg, 1.38 mmol, 58%) as a yellow solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 9.01 (dd, J = 4.1, 1.7 Hz, 1H), 8.38 (dd, J = 8.5, 1.7 Hz, 1H), 
7.98 (s, 1H), 7.76 - 7.72 (m, 2H), 7.64 (dd, J = 8.5, 4.1 Hz, 1H), 7.56 - 7.47 (m, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 151.1, 149.9, 146.0, 141.5, 137.0, 135.2, 135.0, 130.6, 129.4, 
128.5, 124.9, 119.8. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3028, 2972, 2932, 1569, 1466, 1332, 1167, 1020, 862, 761, 705, 
696. 
MS (EI, 70 eV): m/z (%) =332 (94), 206 (23), 204 (23), 102 (27), 44 (26), 43 (29). 
HRMS (EI) for C14H9N2I (331.9810): 331.9800 (M). 
M.p. (°C): 141–142. 
 
Synthesis of 2-bromo-4-phenyl-1,5-naphthyridine (112g) 
 
 
 
1,5-Naphthyridine 112g was prepared via TP11 using 110f (103 mg, 0.50 mmol), BF3·OEt2 (0.07 mL, 
0.55 mmol), TMPMgCl·LiCl (0.50 mL, 0.60 mmol), and 1,2-dibromotetrachloroethane (326 mg, 
1.00 mmol). The reaction was complete after 12 h. After work-up, the crude product was purified via 
column chromatography (isohexane:ethyl acetate = 8.5:1.5), recrystallized from hexane and hot filtered 
to give 112g (127 mg, 445 μmol, 89%) as a yellow solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 9.02 (dd, J = 4.1, 1.8 Hz, 1H), 8.38 (dd, J = 8.5, 1.7 Hz, 1H), 
7.80 - 7.72 (m, 3H), 7.66 (dd, J = 8.5, 4.1 Hz, 1H), 7.58 - 7.48 (m, 3H). 
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13C-NMR (101 MHz, CDCl3): δ / ppm = 151.1, 151.1, 145.1, 142.5, 141.3, 136.9, 135.4, 130.6, 129.5, 
128.7, 128.6, 125.1. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3063, 3044, 2360, 1565, 1546, 1479, 1303, 1133, 796, 695. 
MS (EI, 70 eV): m/z (%) = 286 (47), 285 (100), 284 (47), 283 (100), 204 (27), 203 (35), 202 (17)102 
(24), 43 (12). 
HRMS (EI) for C14H8N2Br (282.9871): 282.9854 (M+-H). 
M.p. (°C): 123–124. 
 
Synthesis of 2-(methylthio)-4-phenyl-1,5-naphthyridine (112h) 
 
 
 
1,5-Naphthyridine 112h was prepared via TP11 using 110f (52 mg, 0.25 mmol), BF3·OEt2 (35 μL, 
275 μmol), TMPMgCl·LiCl (0.97 mL, 1.20 mmol), and S-methyl methanethiosulfonate (0.08 mL, 
375 μmol). The reaction was complete after 12 h. After work-up, the crude product was purified via 
column chromatography (isohexane:ethyl acetate:triethylamine = 10:1:0.1) to give 112h (33 mg, 
131 μmol, 52%) as a light yellow solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.86 (dd, J = 4.2, 1.6 Hz, 1H), 8.28 (dd, J = 8.5, 1.7 Hz, 1H), 
7.73 (dd, J = 7.1, 1.5 Hz, 2H), 7.57 (dd, J = 8.5, 4.2 Hz, 1H), 7.54 - 7.45 (m, 4H), 2.74 (s, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 160.9, 149.0, 147.6, 144.7, 140.9, 136.6, 136.0, 130.4, 128.9, 
128.4, 124.3, 123.7, 13.3. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3062, 2924, 2365, 1585, 1543, 1480, 1321, 1137, 1092, 879, 794, 
696. 
MS (EI, 70 eV): m/z (%) = 253 (21), 252 (100), 251 (56), 219 (12), 218 (22), 206 (26), 205 (45), 43 
(18). 
HRMS (EI) for C15H12N2S (252.0721): 252.0716 (M+). 
M.p (°C): 107–108. 
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Synthesis of (4-chlorophenyl)(4-phenyl-1,5-naphthyridin-2-yl)methanone (112i) 
 
 
 
1,5-Naphthyridine 112i was prepared via TP11 using 110f (103 mg, 0.50 mmol), BF3·OEt2 (0.07 mL, 
0.55 mmol), and TMPMgCl·LiCl (0.50 mL, 0.60 mmol). After the metalation was complete, a 1.0 M 
CuCN·2LiCl solution in THF (0.60 mL, 0.60 mmol) was added and the reaction stirred at the same 
temperature for 20 min. Then, 4-chlorobenzoyl chloride (0.10 mL, 0.75 mmol) was added, and the 
reaction slowly warmed to 25 °C over 12 h. After work-up (the extraction was performed 6 times) the 
crude product was purified via column chromatography (isohexane:ethyl acetate = 8.5:1.5) and 
recrystallized from ethyl acetate / hexane to give 112i (102 mg, 296 μmol, 59%) as an off-white solid. 
 
1H-NMR (599 MHz, CDCl3): δ / ppm = 9.12 (dd, J = 4.0, 1.8 Hz, 1H), 8.53 (dd, J = 8.6, 1.7 Hz, 1H), 
8.36 (s, 1H), 8.24 (d, J = 8.6 Hz, 2H), 7.87 - 7.82 (m, 2H), 7.73 (dd, J = 8.6, 4.3 Hz, 1H), 7.59 - 7.54 
(m, 2H), 7.55 - 7.49 (m, 3H). 
13C-NMR (151 MHz, CDCl3): δ / ppm = 192.0, 154.7, 152.8, 149.9, 143.2, 142.5, 140.0, 138.7, 136.4, 
134.4, 133.0, 130.7, 129.3, 128.7, 128.5, 125.0, 124.1. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3063, 1662, 1585, 1486, 1255, 1091, 796, 695. 
MS (EI, 70 eV): m/z (%) = 346 (29), 345 (37), 344 (89), 343 (71), 317 (38), 316 (48), 315 (100), 309 
(20), 267 (18), 204 (13), 141 (14), 139 (40), 111 (34), 44 (13). 
HRMS (EI) for C21H13ON2Cl (344.0716): 344.0707 (M+). 
M.p. (°C): 153–154. 
 
Synthesis of ethyl 2-((4-phenyl-1,5-naphthyridin-2-yl)methyl)acrylate (112j) 
 
 
 
1,5-Naphthyridine 112j was prepared via TP11 using 110f (206 mg, 1.00 mmol), BF3·OEt2 (0.14 mL, 
1.10 mmol), and TMPMgCl·LiCl (0.97 mL, 1.20 mmol). After the metalation was complete, a 1.0 M 
CuCN·2LiCl solution in THF (1.20 mL, 1.20 mmol) was added and the reaction stirred at the same 
temperature for 20 min. Then, ethyl 2-(bromomethyl)acrylate (0.21 mL, 1.50 mmol) was added and the 
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reaction slowly warmed to 25 °C over 12 h. After work-up, the crude product was purified via column 
chromatography (isohexane:ethyl acetate:triethylamine = 7:3) to give 112j (202 mg, 630 μmol, 63%) 
as a light yellow oil. 
 
1H-NMR (400 MHz, C6D6 ): δ / ppm = 8.62 (dd, J = 4.1, 1.8 Hz, 1H), 8.23 (dd, J = 8.5, 1.8 Hz, 1H), 
7.82 - 7.78 (m, 2H), 7.47 (s, 1H), 7.32 - 7.26 (m, 2H), 7.24 - 7.18 (m, 1H), 6.87 (dd, J = 8.5, 4.1 Hz, 
1H), 6.38 - 6.35 (m, 1H), 5.50 - 5.46 (m, 1H), 4.04 (dd, J = 1.3, 0.6 Hz, 2H), 3.94 (q, J = 7.1 Hz, 2H), 
0.87 (t, J = 7.1 Hz, 3H). 
13C-NMR (101 MHz, C6D6): δ / ppm = 166.6, 160.7, 150.0, 148.7, 144.6, 141.6, 139.1, 137.6, 137.2, 
131.3, 128.6, 128.2, 127.0, 124.8, 124.0, 60.7, 41.7, 14.1. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3057, 2980, 2926, 2357, 1892, 1711, 1590, 1483, 1323, 1207, 
1181,1136, 1026, 945, 797, 696. 
MS (EI, 70 eV): m/z (%) = 318 (24), 289 (20), 246 (37), 245 (100), 244 (16), 243 (34), 123 (25). 
HRMS (EI) for C20H18N2O2 (318.1368): 318.1362 (M+). 
 
Synthesis of 2-bromo-8-iodo-4-phenyl-1,5-naphthyridine (113a) 
 
 
 
1,5-Naphthyridine 113a was prepared via TP12 using 112g (107 mg, 375 μmol), TMPLi (0.75 mL, 
0.45 mmol), and iodine (143 mg, 0.56 mmol). The reaction was complete after 12 h. After work-up, the 
crude product was purified via column chromatography (isohexane:ethyl acetate = 9.5:0.5) to give 113a 
(108 mg, 263 μmol, 70%) as a light-yellow solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.51 (d, J = 4.5 Hz, 1H), 8.25 (d, J = 4.5 Hz, 1H), 7.79 (s, 1H), 
7.74 - 7.68 (m, 2H), 7.58 - 7.48 (m, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 151.8, 150.5, 145.2, 143.5, 141.2, 135.9, 135.2, 130.6, 129.9, 
129.6, 128.5, 114.7. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3060, 1559, 1535, 1468, 1443, 1311, 1116, 1054, 989, 852, 751, 
695, 638, 616. 
MS (EI, 70 eV): m/z (%) = 412 (50), 411 (100), 410 (56), 409 (96), 204 (18), 203 (39), 165 (11), 164 
(12). 
HRMS (EI) for C14H7BrIN2 (408.8837): 409.8879 (M+-H). 
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M.p. (°C): 132–133. 
Synthesis of 2-bromo-8-methyl-4-phenyl-1,5-naphthyridine (113b) 
 
 
 
1,5-Naphthyridine 113b was prepared via TP12 using 112g (71 mg, 0.25 mmol), TMPLi (0.50 mL, 
0.30 mmol), and methyl iodide (23 μL, 375 μmol). The reaction was complete after 12 h. After work-
up, the crude product was purified via column chromatography (isohexane:ethyl acetate:triethylamine 
= 9:1:0.1) to give 113b (61 mg, 204 μmol, 82%) as a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.84 (d, J = 4.3 Hz, 1H), 7.75 - 7.71 (m, 3H), 7.55 - 7.48 (m, 
4H), 2.83 (d, J = 0.9 Hz, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 151.3, 150.7, 146.7, 145.2, 141.3, 141.0, 136.0, 130.6, 129.3, 
128.6, 128.5, 125.4, 17.8. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3056, 2967, 2911, 1549, 1498, 1394, 1294, 1064, 835, 754, 740, 
699, 670. 
MS (EI, 70 eV): m/z (%) = 300 (36), 299 (98), 298 (44), 297 (100), 219 (23), 218 (31), 217 (14), 216 
(14), 190 (13), 110 (17), 109 (13), 108 (13). 
HRMS (EI) for C15H10BrN2 (297.0033): 297.0027 (M+-H). 
M.p (°C): 137–138. 
 
Synthesis of 2-bromo-8-(methylthio)-4-phenyl-1,5-naphthyridine (113c) 
 
 
 
1,5-Naphthyridine 113c was prepared via TP12 using 112g (71 mg, 0.25 mmol), TMPLi (0.50 mL, 
0.30 mmol), and S-methyl methanethiosulfonate (36 μL, 375 μmol). The reaction was complete after 
12 h. After work-up, the crude product was purified via column chromatography (isohexane:ethyl 
acetate:triethylamine = 8:2:0.1) to give 113c (62 mg, 187 μmol, 75%) as a colorless solid. 
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1H-NMR (400 MHz, CDCl3): δ / ppm = 8.78 (d, J = 4.8 Hz, 1H), 7.77 (s, 1H), 7.75 - 7.70 (m, 2H), 
7.55 - 7.45 (m, 3H), 7.30 (d, J = 4.8 Hz, 1H), 2.56 (s, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 151.9, 151.4, 150.0, 142.9, 141.0, 140.0, 135.8, 130.6, 129.4, 
129.4, 128.5, 117.9, 13.9. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3051, 2986, 2920, 2854, 2236, 1563, 1538, 1474, 1433, 855, 784, 
696. 
MS (EI, 70 eV): m/z (%) = 333 (19), 332 (100), 331 (85), 330 (93), 328 (67), 298 (26), 296 (26), 285 
(24), 283 (20), 218 (34). 
HRMS (EI) for C15H12BrN2S (330.9899): 330.9904 (M++H). 
M.p (°C): 164–166. 
 
Synthesis of 2-bromo-8-(cyclohex-2-en-1-yl)-4-phenyl-1,5-naphthyridine (113d) 
 
 
 
1,5-Naphthyridine 113d was prepared via TP12 using 112g (71 mg, 0.25 mmol), and TMPLi (0.50 mL, 
0.30 mmol). After the metalation was complete, a 1.0 M CuCN·2LiCl solution in THF (0.30 mL, 
0.30 mmol) was added and the reaction stirred at the same temperature for 20 min. Then, 3-
bromocyclohexene (43 µL, 375 µmol) was added and the reaction slowly warmed to 25 °C over 12 h. 
After work-up, the crude product was purified via column chromatography (isohexane:ethyl 
acetate:triethylamine = 10:0.3:0.1) to give 113d (90 mg, 246 μmol, 99%) as a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.91 (d, J = 4.4 Hz, 1H), 7.76 - 7.70 (m, 3H), 7.56 - 7.45 (m, 
4H), 6.11 - 6.03 (m, 1H), 5.75 (dq, J = 10.1, 2.4 Hz, 1H), 4.85 - 4.77 (m, 1H), 2.33 - 2.23 (m, 1H), 2.21 
- 2.13 (m, 2H), 1.83 - 1.68 (m, 2H), 1.68 - 1.58 (m, 1H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 153.9, 151.4, 150.9, 143.8, 141.2, 141.1, 136.1, 130.5, 130.0, 
129.2, 128.6, 128.5, 128.4, 123.3, 35.1, 30.9, 25.2, 20.9. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3021, 2929, 1547, 1484, 1317, 1122, 855, 765, 697. 
MS (EI, 70 eV): m/z (%) = 367 (22), 366 (98), 365 (50), 364 (100), 363 (37), 337 (25), 335 (25), 325 
(21), 323 (29), 309 (20), 286 (21), 285 (82), 255 (23). 
HRMS (EI) for C20H17BrN2 (364.0575): 364.0567 (M+). 
M.p (°C): 103–104. 
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Synthesis of ethyl 2-((6-bromo-8-phenyl-1,5-naphthyridin-4-yl)methyl)acrylate (113e) 
 
 
 
1,5-Naphthyridine 113e was prepared via TP12 using 112g (71 mg, 0.25 mmol), and TMPLi (0.50 mL, 
0.30 mmol). After the metalation was complete, a 1.0 M CuCN·2LiCl solution in THF (0.30 mL, 
0.30 mmol) was added and the reaction stirred at the same temperature for 20 min. Then, 3-
bromocyclohexene (60 µL, 375 µmol) was added and the reaction slowly warmed to 25 °C over 12 h. 
After work-up, the crude product was purified via column chromatography (isohexane:ethyl 
acetate:triethylamine = 10:0.3:0.1) and HPLC (acetonitrile/water gradient) to give 113e (94 mg, 
236 μmol, 94%) as a colorless oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.88 (d, J = 4.4 Hz, 1H), 7.78 - 7.67 (m, 3H), 7.57 - 7.45 (m, 
4H), 6.40 (d, J = 1.3 Hz, 1H), 5.79 (q, J = 1.3 Hz, 1H), 4.33 (s, 2H), 4.20 (q, J = 7.1 Hz, 2H), 1.25 (t, J 
= 7.1 Hz, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 166.8, 151.4, 150.8, 147.2, 144.2, 141.4, 141.2, 138.2, 135.9, 
130.5, 129.3, 128.7, 128.5, 128.5, 124.5, 61.1, 32.8, 14.3. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3055, 2980, 2927, 1712, 1631, 1547, 1484, 1311, 1134, 1121, 
1026, 765, 696. 
MS (EI, 70 eV): m/z (%) = 396 (4), 369 (13), 167 (13), 326 (17), 325 (98), 324 (15), 321 (15), 244 
(14), 243 (38), 242 (38), 241 (12), 122 (11). 
HRMS (EI) for C20H17BrN2O2 (396.0473): 396.0466 (M+). 
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Synthesis of 2-bromo-8-(methylthio)-4-phenyl-1,5-naphthyridine (113f) 
 
 
 
1,5-Naphthyridine 113f was prepared via TP12 using 112g (71 mg, 0.25 mmol), TMPLi (0.50 mL, 
0.30 mmol), and benzaldehyde (38 µL, 375 µmol). The reaction was complete after 12 h. After work-
up, the crude product was purified via column chromatography (isohexane:ethyl acetate:triethylamine 
= 8:2:0.1) to give 113f (69 mg, 176 μmol, 71%) as a light yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.93 (d, J = 4.4 Hz, 1H), 7.76 (s, 1H), 7.72 - 7.68 (m, 2H), 
7.58 - 7.49 (m, 6H), 7.41 - 7.34 (m, 2H), 7.32 - 7.27 (m, 1H), 6.63 (s, 1H), 4.74 (s, 1H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 151.7, 151.1, 149.3, 143.0, 141.9, 141.2, 141.0, 135.4, 130.4, 
129.4, 128.6, 128.5, 128.4, 127.8, 126.9, 122.2, 73.3. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3365, 3061, 2360, 1549, 1485, 1309, 1058, 765, 727, 698. 
MS (EI, 70 eV): m/z (%) = 393 (27), 392 (100), 391 (77), 390 (99), 389 (47), 315 (20), 313 (19), 287 
(18), 286 (17), 285 (35), 284 (22), 283 (22), 206 (29), 205 (36), 147 (16), 77 (20). 
HRMS (EI) for C21H15BrN2O (390.0368): 390.0372 (M+). 
 
Synthesis of 8-bromo-2-(methylthio)-4-phenyl-1,5-naphthyridine (113g) 
 
 
 
1,5-Naphthyridine 113g was prepared via TP12 using 112h (39 mg, 154 µmol), TMPLi (0.32 mL, 
185 µmol), and 1,2-dibromotetrachloroethane (76 mg, 232 µmol). The reaction was complete after 
12 h. After work-up, the crude product was purified via column chromatography (isohexane:ethyl 
acetate:triethylamine = 9.5:0.5:0.1) to give 113g (24 mg, 73 μmol, 47%) as a light yellow solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.59 (d, J = 4.6 Hz, 1H), 7.89 (d, J = 4.6 Hz, 1H), 7.72 - 7.66 
(m, 2H), 7.55 - 7.46 (m, 4H), 2.80 (s, 3H). 
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13C-NMR (101 MHz, CDCl3): δ / ppm = 162.0, 148.0, 147.9, 142.1, 141.6, 136.2, 134.8, 130.3, 128.9, 
128.3, 128.0, 124.6, 13.4. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3050, 2922, 2358, 1941, 1588, 1574, 1532, 1476, 1349, 1120, 
878, 756, 692. 
MS (EI, 70 eV): m/z (%) = 333 (21), 332 (100), 330 (91), 329 (48), 298 (15), 287 (24), 285 (26), 284 
(16), 283 (21), 204 (16), 203 (21), 177 (16), 44 (25), 43 (24). 
HRMS (EI) for C15H11BrN2S (329.9826): 329.9813 (M+). 
M.p (°C): 164–166. 
 
Synthesis of 2-bromo-7-iodo-4-phenyl-1,5-naphthyridine (114a) 
 
 
 
1,5-Naphthyridine 114a was prepared via TP13 using 113a (41 mg, 0.10 mmol), TMPLi (0.20 mL, 
0.12 mmol), and H2O (0.9 mL, 5.00 mmol). The reaction was complete after 2 h. After work-up, the 
crude product was purified via column chromatography (isohexane:ethyl acetate:triethylamine = 
9.5:0.5:0.1) to give 114a (32 mg, 78 μmol, 78%) as a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 9.12 (d, J = 2.0 Hz, 1H), 8.77 (d, J = 2.1 Hz, 1H), 7.78 (s, 1H), 
7.74 - 7.69 (m, 2H), 7.57 - 7.51 (m, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 156.4, 151.3, 145.5, 144.7, 143.3, 139.8, 134.9, 130.5, 129.7, 
129.1, 128.6, 94.8. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3059, 2236, 1560, 1537, 1463, 1442, 1295, 1100, 971, 895, 885, 
838, 763, 717, 694. 
MS (EI, 70 eV): m/z (%) = 412 (8), 411 (21), 410 (9), 409 (21), 281 (28), 225 (27), 209 (13), 208 (13), 
207 (100), 203 (16), 191 (18). 
HRMS (EI) for C14H7N2BrI (408.8837): 408.8834 (M+-H). 
M.p. (°C): 136–137. 
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Synthesis of 2-bromo-7-iodo-8-(methylthio)-4-phenyl-1,5-naphthyridine (114b) 
 
 
 
1,5-Naphthyridine 114b was prepared via TP13 using 113a (55 mg, 134 µmol), TMPLi (0.27 mL, 
160 µmol), and S-methyl methanethiosulfonate (20 µL, 200 µmol). The reaction was complete after 
12 h. After work-up, the crude product was purified via column chromatography (isohexane:ethyl 
acetate:triethylamine = 9.8:0.2:0.1) to give 114b (38 mg, 83 μmol, 62%) as a light yellow solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 9.08 (s, 1H), 7.76 (s, 1H), 7.70 - 7.64 (m, 2H), 7.55 - 7.49 (m, 
3H), 3.02 (d, J = 0.6 Hz, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 156.6, 152.2, 152.2, 144.4, 140.8, 140.8, 135.4, 130.5, 129.6, 
129.0, 128.5, 101.9, 21.5. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3062, 2925, 2853, 2362, 1558, 1533, 1458, 1403, 1376, 1309, 
1094, 876, 785, 758, 692. 
MS (EI, 70 eV): m/z (%) = 458 (42), 456 (36), 330 (25), 329 (100), 285 (29), 283 (34), 85 (20), 71 
(30), 57 (51), 44 (34), 43 (68). 
HRMS (EI) for C15H10BrIN2S (455.8793): 455.8789 (M+). 
M.p (°C): 169–170. 
 
Synthesis of 2-bromo-7-iodo-8-(trimethylsilyl)-4-phenyl-1,5-naphthyridine (114c) 
 
 
 
1,5-Naphthyridine 114c was prepared via TP13 using 113a (41 mg, 0.10 mmol), TMPLi (0.20 mL, 
0.12 mmol), and trimethylsilyl chloride (30 µL, 0.30 mmol). The reaction was complete after 12 h. 
After work-up, the crude product was purified via column chromatography (isohexane:ethyl 
acetate:triethylamine = 10:0.1:0.1) to give 114c (36 mg, 74 μmol, 74%) as a yellow oil. 
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1H-NMR (400 MHz, CDCl3): δ / ppm = 9.19 (s, 1H), 7.71 (s, 1H), 7.69 - 7.65 (m, 2H), 7.55 - 7.48 (m, 
3H), 0.64 (s, 9H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 158.9, 155.6, 151.6, 149.9, 139.8, 139.0, 135.6, 130.5, 129.4, 
128.5, 128.3, 104.6, 3.1. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3060, 2952, 2895, 1580, 1562, 1537, 1466, 1316, 1247, 1170, 
1084, 997, 876, 848, 768, 695. 
MS (EI, 70 eV): m/z (%) = 480 (2), 470 (21), 469 (199), 468 (20), 467 (100), 357 (24), 355 (24), 343 
(32), 245 (21), 207 (15). 
HRMS (EI) for C17H15N2BrISi (480.9233): 480.9227 (M+-H). 
 
Synthesis of 8-allyl-2-bromo-7-iodo-4-phenyl-1,5-naphthyridine (114d) 
 
 
 
1,5-Naphthyridine 114d was prepared via TP13 using 113a (39 mg, 95 μmol), and TMPLi (190 µL, 
114 µmol). After the metalation was complete, a 1.0 M CuCN·2LiCl solution in THF (114 µL, 
114 µmol) was added and the reaction stirred at the same temperature for 20 min. Then, allyl bromide 
(15 µL, 143 µmol) was added and the reaction slowly warmed to 25 °C over 12 h. After work-up, the 
crude product was purified via column chromatography (isohexane:ethyl acetate:triethylamine = 
10:0.2:0.1) to give 114d (27 mg, 60 μmol, 63%) as a yellow oil. 
 
1H-NMR (400 MHz, C6D6): δ / ppm = 8.94 (s, 1H), 7.50 - 7.43 (m, 2H), 7.37 (s, 1H), 7.26 - 7.17 (m, 
3H), 6.05 - 5.92 (m, 1H), 5.25 (dq, J = 17.1, 1.6 Hz, 1H), 5.04 (dq, J = 10.1, 1.5 Hz, 1H), 4.07 (dt, J = 
6.5, 1.5 Hz, 2H). 
13C-NMR (101 MHz, C6D6): δ / ppm = 157.3, 151.5, 150.6, 144.3, 142.2, 140.4, 135.7, 133.7, 131.1, 
129.2, 128.8, 128.3, 117.6, 101.6, 39.9. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3078, 2979, 1635, 1562, 1538, 1470, 1318, 1304, 1185, 1168, 
1094, 1049, 920, 879, 830, 765, 695, 617. 
MS (EI, 70 eV): m/z (%) = 452 (100), 450 (79), 437 (91), 434 (82), 322 (16), 243 (22), 241 (24). 
HRMS (EI) for C17H12N2BrI (449.9229): 449.9222 (M+). 
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Synthesis of 2-bromo-8-(cyclopropanecarbonyl)-7-iodo-4-phenyl-1,5-naphthyridine (114e) 
 
 
 
1,5-Naphthyridine 114f was prepared via TP13 using 113a (62 mg, 0.15 mmol), and TMPLi (0.30 mL, 
0.18 mmol). After the metalation was complete, a 1.0 M CuCN·2LiCl solution in THF (0.18 mL, 
0.18 mmol) was added and the reaction stirred at the same temperature for 20 min. Then, 
cyclopropanecarbonyl chloride (30 µL, 225 µmol) was added and the reaction slowly warmed to 25 °C 
over 12 h. After work-up, the crude product was purified via column chromatography (isohexane:ethyl 
acetate:triethylamine = 9.5:0.5:0.1) to give 114f (50 mg, 104 μmol, 70%) as a light yellow oil. 
 
1H-NMR (599 MHz, CDCl3): δ / ppm = 9.20 (s, 1H), 7.80 (s, 1H), 7.73 - 7.68 (m, 2H), 7.56 - 7.51 (m, 
3H), 2.36 - 2.30 (m, 1H), 1.60 - 1.56 (m, 2H), 1.28 - 1.23 (m, 2H). 
13C-NMR (151 MHz, CDCl3): δ / ppm = 204.2, 157.1, 153.0, 150.9, 143.0, 141.9, 140.0, 134.6, 130.3, 
129.6, 129.4, 128.5, 91.0, 22.7, 13.5. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3010, 2925, 1696, 1562, 1537, 1469, 1371, 1204, 1093, 982, 765, 
730, 697. 
MS (EI, 70 eV): m/z (%) = 453 (18), 452 (96), 451 (25), 450 (100), 399 (20), 216 (18), 203 (31), 176 
(19), 69 (29), 41 (43). 
HRMS (EI) for C18H12BrIN2O (477.9178): 477.9167 (M+). 
 
Synthesis of 4,8-dibromo-1,5-naphthyridine (123) 
 
N
N
Br
Br
 
 
1,5-Naphthyridine (109, 1.04 g, 8.00 mmol) was dissolved in THF (40 mL) and cooled to -40 °C. Then, 
TMPMgCl·LiCl (20.5 mL, 24.0 mmol) was added and the reaction mixture stirred for 4 h whilst 
warming to -20 °C slowly. After adding a solution of 1,2-dibromotetrachloroethane (10.4 g, 32.0 mmol) 
in THF (40 mL), the reaction was slowly warmed to 25 °C and stirred for 12 h. After work-up, the crude 
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product was purified via column chromatography (isohexane:ethyl acetate:triethylamine = 9:1:0.1) to 
give 123 (1.23 g, 4.27 mmol, 53%) as an off-white solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.85 (d, J = 4.6 Hz, 2H), 8.06 (d, J = 4.6 Hz, 2H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 151.3, 142.9, 136.9, 129.4. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3062, 3019, 1576, 1474, 1456, 1376, 1264, 1180, 1041, 866, 711. 
MS (EI, 70 eV): m/z (%) = 290 (48), 288 (100), 286 (53), 209 (46), 207 (47), 128 (17), 100 (15). 
HRMS (EI) for C8H4N2Br2 (285.8741): 285.8736 (M+). 
M.p. (°C): Compound sublimes at 220 °C followed by degradation. 
 
Synthesis of 4-(4-(tert-butyl)phenyl)-8-methyl-1,5-naphthyridine (124) 
 
 
 
Synthesis of 4-(4-(tert-butyl)phenyl)-1,5-naphthyridine (126) 
 
1,5-Naphthyridine 109 (1.04 g, 8.00 mmol) was dissolved in THF (40 mL), cooled to -78 °C, and 
TMP2Mg·2LiCl (7.62 mL, 4.80 mmol) was added dropwise. After the metalation was complete (5 min, 
checked via GC / GC-MS), a 1.0 M ZnCl2 solution in THF (4.80 mL, 4.80 mmol) was added and the 
reaction stirred at the same temperature for 20 min. Then, 4-tert-butyliodobenzene (1.14 mL, 
6.40 mmol), Pd(dba)2 (138 mg, 240 µmol), and tfp (111 mg, 480 µmol) was added and the reaction 
slowly warmed to 25 °C over 12 h. After work-up, the crude product was purified via column 
chromatography (isohexane:ethyl acetate:triethylamine = 8:2:0.1) to give 126 (1.11 g, 4.23 mmol, 88%) 
as a yellow solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 9.03 (dd, J = 4.1, 1.8 Hz, 1H), 9.00 (d, J = 4.5 Hz, 1H), 8.46 
(dd, J = 8.5, 1.8 Hz, 1H), 7.78 - 7.73 (m, 2H), 7.68 - 7.62 (m, 2H), 7.60 - 7.54 (m, 2H), 1.40 (s, 9H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 151.8, 151.0, 150.7, 148.3, 144.5, 142.1, 137.7, 133.7, 130.2, 
125.4, 124.1, 34.8, 31.3. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3015, 2962, 2903, 2868, 1611, 1582, 1492, 1404, 1363, 1268, 
1106, 866, 834, 822, 792, 662. 
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MS (EI, 70 eV): m/z (%) = 262 (139, 261 (19), 247 (43), 232 (15), 231 (16), 218 (22), 206 (14), 205 
(100). 
HRMS (EI) for C18H17N2 (261.1392): 261.1385 (M+-H). 
M.p. (°C): 146-148. 
 
Synthesis of 4-(4-(tert-butyl)phenyl)-8-methyl-1,5-naphthyridine (124) 
 
1,5-Naphthyridine 126 (100 mg, 0.38 mmol) was dissolved in THF (3 mL) and cooled to –78 °C. After 
addition of TMPLi (0.63 mL, 0.40 mmol) and stirring for 10 min, methyl trifluoromethanesulfonate 
(0.06 mL, 0.57 mmol) was added dropwise. After stirring at the same temperature for one hour, the 
solvent was removed rapidly from the reaction mixture and the crude ‘wet loaded’ on a pre packed 
column by dissolving in DCM. Elution in isohexane:ethyl acetate:triethylamine = 9:1:0.1 gave 124 (56 
mg, 0.20 mmol, 53%) as an off-white solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 9.00 (d, J = 4.4 Hz, 1H), 8.87 (d, J = 4.2 Hz, 1H), 7.73 (d, J = 
8.1 Hz, 2H), 7.63 (d, J = 4.4 Hz, 1H), 7.55 (d, J = 8.1 Hz, 2H), 7.49 (d, J = 4.3 Hz, 1H), 2.88 (s, 3H), 
1.39 (s, 9H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 151.7, 150.5, 149.7, 148.7, 147.1, 144.5, 141.7, 134.3, 130.4, 
125.5, 124.6, 124.2, 34.9, 31.5, 18.1. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3017, 2957, 2930, 2903, 2860, 1581, 1500, 1472, 1462, 1396, 
1363, 1240, 1097, 1075, 1063, 864, 832, 772, 669. 
MS (EI, 70 eV): m/z (%) = 276 (19), 175 (58), 261 (40), 259 (11), 245 (21), 232 (12), 231 (12), 220 
(15), 219 (100), 218 (12), 207 (18), 116 (19). 
HRMS (EI) for C19H19N2 (275.1548): 275.1545 (M+-H). 
M.p. (°C): 141–143. 
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5.3 Regioselectivity Investigations 
 
To confirm the regioselectivity for each metalation (Typical Procedure TP8–13), the resulting metal 
species of type 115, 116, 117, 120 and 122 were quenched with D2O / THF solutions and the obtained 
deuterium-incorporated products analyzed via 1H NMR spectroscopy. The measured spectra were also 
compared with the respective starting material spectra. 
 
Synthesis of 1,5-naphthyridine-4-d 
 
 
 
1,5-Naphthyridine-4-d was prepared via TP8 using 109 (130 mg, 1.00 mmol) and TMP2Mg·2LiCl 
(1.75 mL, 1.10 mmol). The metalated species was then slowly cannulated into a solution of D2O 
(0.1 mL, 5.56 mmol) in THF (2 mL), warmed to room temperature and stirred for 1 h. After work-up, 
the crude product was purified via column chromatography (isohexane:ethyl acetate:triethylamine = 
8:2:0.1) to give 1,5-Naphthyridine-4-d (60 mg, 458 μmol, 46%) as an off-white solid. NMR-
spectroscopy revealed an incorporation of deuterium at position C4 with a 2H:1H ratio of 89:11. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.98 (d, J = 4.2 Hz, 2H), 8.40 (dd, J = 8.5, 1.7 Hz, 1H), 7.67-
7.61 (m, 2H). 
 
Synthesis of 4-iodo-1,5-naphthyridine-8-d 
 
 
 
4-Iodo-1,5-naphthyridine-8-d was prepared via TP9 using 110a (139 mg, 0.50 mmol) and 
TMPMgCl·LiCl (0.52 mL, 0.60 mmol). Then, a solution of D2O (0.05 mL, 2.78 mmol) in THF (2 mL) 
was added dropwise and the reaction mixture warmed to room temperature and stirred for 1 h. After 
work-up, the crude product was purified via column chromatography (isohexane:ethyl 
acetate:triethylamine = 9:1:0.1) to give 4-iodo-1,5-naphthyridine-8-d (100 mg, 389 μmol, 78%) as an 
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off-white solid. NMR-spectroscopy revealed an incorporation of deuterium at position C8 with a 2H:1H 
ratio of 63:37. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 9.06 (d, J = 4.2 Hz, 1 H), 8.53 (d, J = 4.5 Hz, 1 H), 8.28 (d, J 
= 4.5 Hz, 1H), 7.70 (dd, J = 8.4, 4.2 Hz, 1 H). 
 
Synthesis of 4-iodo-1,5-naphthyridine-2-d 
 
 
 
4-Iodo-1,5-naphthyridine-2-d was prepared via TP11 using 110a (128 mg, 0.50 mmol), BF3·OEt2 
(0.07 mL, 0.55 mmol) and TMPMgCl·LiCl (0.52 mL, 0.60 mmol). Then, a solution of D2O (0.05 mL, 
2.78 mmol) in THF (2 mL) was added dropwise and the reaction mixture warmed to room temperature 
and stirred for 1 h. After work-up, the crude product was purified via column chromatography (ethyl 
acetate) to give 4-iodo-1,5-naphthyridine-2-d (86 mg, 334 μmol, 67%) as an off-white solid. NMR-
spectroscopy revealed an incorporation of deuterium at position C2 with a 2H:1H ratio of 76:24. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 9.05 (dd, J = 4.2 Hz, 1.6 Hz, 1 H), 8.35 (dd, J = 8.5 Hz, 1.6 
Hz, 1 H), 8.29-8.24 (m, 1H), 7.69 (dd, J = 8.5 Hz, 4.2 Hz, 1 H). 
  
C. EXPERIMENTAL PART    210 
 
Synthesis of 2-bromo-4-phenyl-1,5-naphthyridine-8-d 
 
 
 
2-Bromo-4-phenyl-1,5-naphthyridine-8-d was prepared via TP12 using 112g (57 mg, 0.20 mmol), and 
TMPLi (0.40 mL, 0.24 mmol). Then, a solution of D2O (0.05 mL, 2.78 mmol) in THF (2 mL) was 
added dropwise and the reaction mixture warmed to room temperature and stirred for 1 h. After work-
up, the crude product was purified via column chromatography (isohexane:ethyl acetate = 1:1) to give 
2-bromo-4-phenyl-1,5-naphthyridine-8-d (45 mg, 157 μmol, 79%) as a colorless solid. NMR-
spectroscopy revealed an incorporation of deuterium at position C2 with a 2H:1H ratio of 98:12. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 9.01 (d, J = 4.1 Hz, 1H), 7.79 - 7.73 (m, 3H), 7.66 (d, J = 4.2 
Hz, 1H), 7.58 - 7.48 (m, 3H). 
 
Synthesis of 2-bromo-7-iodo-4-phenyl-1,5-naphthyridine-8-d 
 
 
 
2-bromo-7-iodo-4-phenyl-1,5-naphthyridine-8-d was prepared via TP13 using 113a (41 mg, 
0.10 mmol), and TMPLi (0.20 mL, 0.12 mmol). Then, a solution of D2O (0.05 mL, 2.78 mmol) in THF 
(2 mL) was added dropwise and the reaction mixture warmed to room temperature and stirred for 1 h. 
After work-up, the crude product was purified via column chromatography (isohexane:ethyl 
acetate:triethylamine = 9.5:0.5:0.1) to give 2-bromo-7-iodo-4-phenyl-1,5-naphthyridine-8-d (25 mg, 61 
μmol, 61%) as a colorless solid. NMR-spectroscopy revealed an incorporation of deuterium at position 
C2 with a 2H:1H ratio of 95:05. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 9.12 (s, 1H), 7.78 (s, 1H), 7.75 - 7.69 (m, 2H), 7.57 - 7.49 (m, 
3H). 
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1H NMR spectrum of 1,5-naphthyridine-4-d 
 
1H NMR spectrum of 4-iodo-1,5-naphthyridine-8-d 
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1H NMR spectrum of 4-iodo-1,5-naphthyridine-2-d 
 
1H NMR spectrum of 2-bromo-4-phenyl-1,5-naphthyridine-8-d 
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1H NMR spectrum of 2-bromo-7-iodo-4-phenyl-1,5-naphthyridine-8-d 
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6 Regioselective Metalation and Functionalization of the 
Pyrazolo[1,5-a]pyridine Scaffold using Mg- and Zn-TMP Bases 
6.1 Typical Procedures 
 
Typical Procedure 14: Metalation and functionalization of pyrazolo[1,5-a]pyridine (128) in the C7 
position using TMPMgCl·LiCl (inverse addition). 
 
To a solution of pyrazolo[1,5-a]pyridine 128, in THF (5 mL/mmol pyrazolo[1,5-a]pyridine) was added 
dropwise a solution of TMPMgCl·LiCl (1.2 equiv) at –78 °C. After full metalation (15 min, checked 
via GC / GC-MS), the solution was canulated dropwise to a precooled solution of the corresponding 
electrophile in THF at –78 °C (5 mL/mmol pyrazolo[1,5-a]pyridine) and the reaction slowly warmed 
to 25 °C and stirred until completion. The reaction mixture was quenched with an aq. sat. NH4Cl 
solution (10 mL/mmol pyrazolo[1,5-a]pyridine) and extracted with ethyl acetate (3 x 50 mL/mmol 
pyrazolo[1,5-a]pyridine). The organic phase was then dried over Na2SO4, filtered and concentrated in 
vacuo. If the crude product needed purification, it was purified via flash chromatography on silica gel 
using the appropriate eluent. 
 
Typical Procedure 15: Metalation and functionalization of pyrazolo[1,5-a]pyridines in the C7 position 
using TMPMgCl·LiCl (normal addition). 
 
To a solution of the pyrazolo[1,5-a]pyridine in THF (5 mL/mmol pyrazolo[1,5-a]pyridine) was added 
dropwise a solution of TMPMgCl·LiCl (1.2 equiv) at –78 °C. After full metalation (15 min, checked 
via GC / GC-MS analysis of iodolyzed reaction aliquots), a solution of the corresponding electrophile 
in THF (2 mL/mmol pyrazolo[1,5-a]pyridine) was added dropwise and the reaction slowly warmed to 
25 °C and stirred until completion. The reaction mixture was quenched with an aq. sat. NH4Cl solution 
(10 mL/mmol pyrazolo[1,5-a]pyridine) and extracted with ethyl acetate (3 x 50 mL/mmol 
pyrazolo[1,5-a]pyridine). The organic phase was then dried over Na2SO4, filtered and concentrated in 
vacuo. If the crude product needed purification, it was purified via flash chromatography on silica gel 
using the appropriate eluent. 
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Typical Procedure 16: Metalation and functionalization of pyrazolo[1,5-a]pyridine 128 in the C7 
position using TMPZnCl·LiCl. 
 
To a solution of pyrazolo[1,5-a]pyridine 128 in THF (5 mL/mmol pyrazolo[1,5-a]pyridine) was added 
dropwise a solution of TMPZnCl·LiCl (1.2 equiv) at 0 °C. After full metalation (15 min, checked via 
GC / GC-MS analysis of iodolyzed reaction aliquots), a solution of the corresponding electrophile in 
THF (2 mL/mmol pyrazolo[1,5-a]pyridine) was added dropwise and the reaction slowly warmed to 
25 °C and stirred until completion. The reaction mixture was quenched with an aq. sat. NH4Cl solution 
(10 mL/mmol pyrazolo[1,5-a]pyridine) and extracted with ethyl acetate (3 x 50 mL/mmol 
pyrazolo[1,5-a]pyridine). The organic phase was then dried over Na2SO4, filtered and concentrated in 
vacuo. If the crude product needed purification, it was purified via flash chromatography on silica gel 
using the appropriate eluent. 
 
Typical Procedure 17: Metalation and functionalization of pyrazolo[1,5-a]pyridine (128) in the C2 
position using BF3·OEt2 and TMPMgCl·LiCl. 
 
Pyrazolo[1,5-a]pyridine 128 was dissolved in THF (5 mL/mmol pyrazolo[1,5-a]pyridine) and cooled 
to 0 °C. Then, BF3·OEt2 (1.1 equiv) was added dropwise and the reaction mixture stirred for 10 min. 
After cooling to –78 °C, TMPMgCl·LiCl (1.2 equiv) was added and the reaction stirred until full 
metalation was observed (10 min, checked via GC / GC-MS). Then, a solution of the electrophile in 
THF (2 mL/mmol pyrazolo[1,5-a]pyridine) was added dropwise and the reaction slowly warmed to 
25 °C and stirred until completion. The reaction mixture was quenched with an aq. sat. NH4Cl solution 
(10 mL/mmol pyrazolo[1,5-a]pyridine) and extracted with ethyl acetate (3 x 50 mL/mmol 
pyrazolo[1,5-a]pyridine). The organic phase was then dried over Na2SO4, filtered and concentrated in 
vacuo. If the crude product needed purification, it was purified via flash chromatography on silica gel 
using the appropriate eluent. 
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6.2 Preparation of Compounds 128 to 149 
 
Synthesis of pyrazolo[1,5-a]pyridine-3-carboxylate (139) 
 
 
 
Adapted from a literature procedure,141 1-aminopyridinium iodide (21.4 g, 96.6 mmol) and K2CO3 
(19.5 g, 141 mmol) were dissolved in DMF (100 mL). Then, ethyl propiolate (10.4 mL, 106 mmol) was 
added dropwise at room temperature. Air was introduced to the reaction mixture via a gas inlet and the 
reaction mixture was stirred for 2 h. DMF was removed in vacuo, and the reaction mixture was extracted 
with diethylether (3 x 100 mL). The organic phase was washed with an aq. 5% LiOH solution 
(3x100 mL) and dried over Na2SO4. After filtration, the solvents were removed in vacuo and the crude 
product purified via column chromatography (isohexane:ethyl acetate = 7:3) to give 139 (12.3 g, 
64.8 mmol, 67%) as an orange oil. 
 
The spectra matched those of the literature.142 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.49 (dt, J = 6.9, 1.1 Hz, 1H), 8.38 (s, 1H), 8.13 (dt, J = 8.9, 
1.2 Hz, 1H), 7.37 (ddd, J = 8.9, 6.8, 1.1 Hz, 1H), 6.91 (td, J = 6.9, 1.4 Hz, 1H), 4.36 (q, J = 7.1 Hz, 
2H), 1.39 (t, J = 7.1 Hz, 3H). 
  
                                                     
141
 (a) P. Gmeiner, J. Sommer, Arch. Pharm. 1988, 321, 505–507. (b) Löber, S.; Hübner, H.; Utz, W.; Gmeiner, 
P., J. Med. Chem. 2001, 44, 2691–2694. 
142
 R. Chitrakar, S. Supravat, C. M. Darapaneni, K. R. N. Naresh, A. Subbarayappa, Synthesis 2017, 49, 2513–
2522. 
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Synthesis of pyrazolo[1,5-a]pyridine (128) 
 
 
 
Adapted from a literature procedure,141 pyrazolo[1,5-a]pyridine-3-carboxylate 139 (9.01 g, 47.4 mmol) 
was dissolved in H2SO4 (50% v/v, 30.0 mL). Then, the reaction mixture was heated at 110 °C for 2 h. 
After cooling to 0 °C, an aq. 50% NaOH solution was added until basification. Then, the reaction 
mixture was extracted with diethylether (3 x 100 mL) and dried over Na2SO4. After filtration, the 
solvents were removed in vacuo and the crude product purified via column chromatography 
(isohexane:ethyl acetate:triethylamine = 9:1:0.1) to give 128 (4.16 g, 35.2 mmol, 74%) as a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.46 (d, J = 7.0 Hz, 1H), 7.94 (d, J = 2.1 Hz, 1H), 7.52 (d, J 
= 8.9 Hz, 1H), 7.10 - 7.04 (m, 1H), 6.72 (t, J = 6.8 Hz, 1H), 6.50 (d, J = 2.0 Hz, 1H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 141.9, 140.2, 128.7, 123.2, 118.2, 111.7, 96.8. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3432, 3108, 1633, 1515, 1460, 1434, 1370, 1338, 1252, 1225, 
1176, 1140, 1008, 920, 890, 759. 
MS (EI, 70 eV): m/z = 119 (8), 118 (100), 91 (19), 78 (10). 
HRMS (EI) for C7H6N2 (118.0531): 118.0525 (M+). 
 
Synthesis of 7-iodopyrazolo[1,5-a]pyridine (134a) 
 
 
 
Pyrazolo[1,5-a]pyridine 134a was prepared via TP1 using 128 (59 mg, 0.50 mmol), TMPMgCl·LiCl 
(0.48 mL, 0.60 mmol) and iodine (190 mg, 0.75 mmol). The reaction was complete after 1 h. After 
quenching with a sat. aq. Na2S2O3 solution (10 mL) followed by standard work-up, the crude product 
was purified via column chromatography (isohexane:ethyl acetate:triethylamine = 95:5:1) to give 134a 
(84 mg, 344 µmol, 69%) as a yellow solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.04 (d, J = 2.3 Hz, 1H), 7.54 (dd, J = 8.8, 1.2 Hz, 1H), 7.32 
(dd, J = 7.1, 1.2 Hz, 1H), 6.83 (dd, J = 8.8, 7.1 Hz, 1H), 6.75 (d, J = 2.3 Hz, 1H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 141.2, 140.5, 123.9 (2C), 118.2, 99.5, 91.6. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3074, 1617, 1528, 1490, 1440, 1359, 1294, 1200, 900, 778, 714. 
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MS (EI, 70 eV): 244 (100), 127 (36), 117 (31), 90 (27), 63 (10). 
HRMS (EI) for C7H5N2I (243.9497): 243.9493 (M+). 
M.p. (°C): 53–55. 
 
Synthesis of 7-bromopyrazolo[1,5-a]pyridine (134b) 
 
 
 
Pyrazolo[1,5-a]pyridine 134b was prepared via TP14 using 128 (591 mg, 5.00 mmol), TMPMgCl·LiCl 
(5.04 mL, 6.00 mmol) and 1,2-dibromotetrachloroethane (2.44 g, 7.50 mmol). The reaction was 
complete after 5 h. After work-up, the crude product was purified via column chromatography 
(isohexane:ethyl acetate:triethylamine = 9:1:0.1) to give 134b (917 mg, 4.65 mmol, 93%) as a yellow 
oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.05 (d, J = 2.3 Hz, 1H), 7.55 (dd, J = 8.7, 1.3 Hz, 1H), 7.07 
(dd, J = 7.2, 1.3 Hz, 1H), 6.98 (dd, J = 8.7, 7.0 Hz, 1H), 6.68 (d, J = 2.3 Hz, 1H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 142.0, 141.7, 123.7, 118.7, 117.3, 116.1, 99.1. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3079, 1624, 1498, 1444, 1360, 1297, 1200, 950, 901, 779, 713. 
MS (EI, 70 eV): 198 (98), 196 (100), 134 (10), 116 (80), 90 (38), 63 (20). 
HRMS (EI) for C7H5N2Br (195.9636): 195.9629 (M+). 
 
Synthesis of 7-(methylthio)pyrazolo[1,5-a]pyridine (134c) 
 
 
 
Pyrazolo[1,5-a]pyridine 134c was prepared via TP14 using 128 (62 mg, 0.52 mmol), TMPMgCl·LiCl 
(0.50 mL, 0.62 mmol) and S-methyl methanethiosulfonate (60 µL, 0.64 mmol). The reaction was 
complete after 12 h. After work-up, the crude product was purified via column chromatography 
(isohexane:ethyl acetate:triethylamine = 9:1:0.1) to give 134c (39 mg, 237 µmol, 46%) as a colorless 
oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.03 (d, J = 2.3 Hz, 1H), 7.39 (dd, J = 8.8, 1.1 Hz, 1H), 7.11 
(dd, J = 8.8, 7.2 Hz, 1H), 6.58 - 6.53 (m, 2H), 2.61 (s, 3H). 
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13C-NMR (101 MHz, CDCl3): δ / ppm = 13C NMR (101 MHz, CDCl3) δ 141.7, 140.5, 140.1, 123.4, 
113.7, 107.1, 97.2, 14.3. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3082, 2922, 1616, 1500, 1436, 1356, 1307, 1208, 1147, 908, 774, 
718. 
MS (EI, 70 eV): 164 (97), 163 (14), 131 (100), 104 (10), 91 (12). 
HRMS (EI) for C8H8N2S (164.0408): 164.0402 (M+). 
 
Synthesis of 7-(cyclohex-2-en-1-yl)pyrazolo[1,5-a]pyridine (134d) 
 
 
 
Pyrazolo[1,5-a]pyridine 134d was prepared via TP15 using 128 (118 mg, 1.00 mmol) and 
TMPMgCl·LiCl (1.01 mL, 1.20 mmol). After the metalation was complete, a 1.0 M CuCN·2LiCl 
solution in THF (1.20 mL, 1.20 mmol) was added and the reaction warmed to –40 °C and stirred for 10 
min. Then, 3-bromocyclohexene (0.15 mL, 1.30 mmol) was added dropwise, and the reaction slowly 
warmed to 25 °C and stirred for 2 h. After work-up, the crude product was purified via column 
chromatography (isohexane:ethyl acetate:triethylamine = 95:5:1) to give 134d (171 mg, 862 µmol, 
86%) as a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 7.99 (d, J = 2.3 Hz, 1H), 7.45 (dd, J = 8.9, 1.4 Hz, 1H), 7.09 
(dd, J = 8.8, 6.9 Hz, 1H), 6.63 (dd, J = 6.9, 1.4 Hz, 1H), 6.54 (d, J = 2.3 Hz, 1H), 6.09 - 6.02 (m, 1H), 
5.83 - 5.75 (m, 1H), 4.52 - 4.45 (m, 1H), 2.31 - 2.20 (m, 1H), 2.18 - 2.10 (m, 2H), 1.88 - 1.78 (m, 1H), 
1.74 - 1.61 (m, 2H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 144.8, 141.1, 140.8, 130.5, 126.8, 123.3, 115.9, 110.1, 97.0, 
35.8, 26.7, 25.4, 20.3. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3022, 2927, 1632, 1546, 1524, 1449, 1314, 1215, 1178, 1148, 
914, 787, 724. 
MS (EI, 70 eV): 198 (53), 197 (56), 183 (12), 170 (11), 169 (100), 168 (17), 157 (24), 156 (16), 155 
(30), 143 (43), 132 (23), 131 (12). 
HRMS (EI) for C13H14N2 (198.1157): 198.1149 (M+). 
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Synthesis of ethyl 2-(pyrazolo[1,5-a]pyridin-7-ylmethyl)acrylate (134e) 
 
 
 
Pyrazolo[1,5-a]pyridine 134e was prepared via TP15 using 128 (59 mg, 0.50 mmol) and 
TMPMgCl·LiCl (0.48 mL, 0.60 mmol). After the metalation was complete, a 1.0 M CuCN·2LiCl 
solution in THF (0.60 mL, 0.60 mmol) was added and the reaction warmed to –40 °C and stirred for 10 
min. Then, ethyl 2-(bromomethyl)acrylate (0.09 mL, 0.65 mmol) was added dropwise, and the reaction 
slowly warmed to 25 °C and stirred for 2 h. After work-up, the crude product was purified via column 
chromatography (isohexane:ethyl acetate:triethylamine = 9:1:0.1) to give 134e (84 mg, 364 µmol, 73%) 
as a colorless oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 7.98 (d, J = 2.3 Hz, 1H), 7.48 (dd, J = 8.8, 1.3 Hz, 1H), 7.06 
(dd, J = 8.9, 6.9 Hz, 1H), 6.60 (dd, J = 6.8, 1.1 Hz, 1H), 6.55 (d, J = 2.3 Hz, 1H), 6.37 - 6.35 (m, 1H), 
5.65 (q, J = 1.3 Hz, 1H), 4.26 - 4.16 (m, 4H), 1.24 (t, J = 7.1 Hz, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 166.7, 141.3, 140.7, 138.9, 136.0, 127.9, 123.2, 116.4, 111.0, 
97.3, 61.1, 33.3, 14.2. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 2981, 1710, 1635, 1548, 1526, 1454, 1369, 1299, 1204, 1141, 
1026, 955, 785, 725. 
MS (EI, 70 eV): 230 (11), 201 (40), 185 (11), 158 (11), 157 (100), 156 (34), 155 (35), 130 (13). 
HRMS (EI) for C13H14N2O2 (230.1055): 230.1048 (M+). 
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Synthesis of (2-chlorophenyl)(pyrazolo[1,5-a]pyridin-7-yl)methanone (134f) 
 
 
 
Pyrazolo[1,5-a]pyridine 134f was prepared via TP15 using 128 (59 mg, 0.50 mmol) and 
TMPMgCl·LiCl (0.50 mL, 0.60 mmol). After the metalation was complete, a 1.0 M CuCN·2LiCl 
solution in THF (0.60 mL, 0.60 mmol) was added and the reaction warmed to –40 °C and stirred for 10 
min. Then, 2-chlorobenzoyl chloride (85 µL, 0.65 mmol) was added dropwise, and the reaction slowly 
warmed to 25 °C and stirred for 12 h. After work-up, the crude product was purified via column 
chromatography (isohexane:ethyl acetate:triethylamine = 8.1:1.9:0.1) to give 134f (68 mg, 265 µmol, 
53%) as a red solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = δ 7.98 (d, J = 2.3 Hz, 1H), 7.80 - 7.73 (m, 1H), 7.68 - 7.64 (m, 
1H), 7.50 - 7.43 (m, 1H), 7.43 - 7.36 (m, 2H), 7.19 - 7.14 (m, 2H), 6.65 (d, J = 2.3 Hz, 1H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = δ 188.3, 142.4, 141.1, 137.8, 136.7, 132.6, 132.5, 130.7, 
130.4, 127.2, 122.7, 122.2, 117.9, 98.1. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3078, 1674, 1622, 1589, 1434, 1306, 1202, 1074, 1035, 892, 798, 
746. 
MS (EI, 70 eV): 229 (10), 227 (31), 225 (9), 222 (15), 221 (100), 204 (10), 139 (11), 75 (9). 
HRMS (EI) for C14H9N2OCl (256.0403): 256.0403 (M+). 
M.p. (°C): 120–123. 
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Synthesis of (2-iodophenyl)(pyrazolo[1,5-a]pyridin-7-yl)methanone (134g) 
 
 
 
Pyrazolo[1,5-a]pyridine 134g was prepared via TP15 using 128 (59 mg, 0.50 mmol) and 
TMPMgCl·LiCl (0.50 mL, 0.60 mmol). After the metalation was complete, a 1.0 M CuCN·2LiCl 
solution in THF (0.60 mL, 0.60 mmol) was added and the reaction warmed to –40 °C and stirred for 10 
min. Then, 2-iodobenzoyl chloride (175 mg, 0.65 mmol) was added dropwise, and the reaction slowly 
warmed to 25 °C and stirred for 12 h. After work-up, the crude product was purified via column 
chromatography (isohexane:ethyl acetate:triethylamine = 8:2:0.1) to give 134g (117 mg, 336 µmol, 
67%) as a yellow solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.06 (d, J = 2.4 Hz, 1H), 7.92 (dd, J = 8.0, 1.1 Hz, 1H), 7.79 
(dd, J = 8.2, 1.9 Hz, 1H), 7.54 - 7.41 (m, 2H), 7.25 - 7.16 (m, 1H), 7.18 - 7.07 (m, 2H), 6.68 (d, J = 2.3 
Hz, 1H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 190.1, 143.1, 142.7, 141.3, 140.3, 135.0, 132.3, 130.2, 128.3, 
123.0, 122.0, 119.4, 98.3, 93.3. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3079, 2924, 1673, 1622, 1580, 1454, 1305, 1202, 1066, 1014, 
885, 797, 740.  
MS (EI, 70 eV): 348 (2), 322 (13), 222 (16), 221 (100), 220 (6), 203 (9), 192 (9), 166 (4), 90 (3), 76 
(5). 
HRMS (EI) for C14H9N2OI (347.9760): 347.9745 (M+). 
M.p. (°C): 150–154. 
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Synthesis of (4-chloroophenyl)(pyrazolo[1,5-a]pyridin-7-yl)methanone (134h) 
 
 
 
Pyrazolo[1,5-a]pyridine 134h was prepared via TP15 using 128 (59 mg, 0.50 mmol) and 
TMPMgCl·LiCl (0.50 mL, 0.60 mmol). After the metalation was complete, a 1.0 M CuCN·2LiCl 
solution in THF (0.60 mL, 0.60 mmol) was added and the reaction warmed to –40 °C and stirred for 10 
min. Then, 4-chlorobenzoyl chloride (85 µL, 0.65 mmol) was added dropwise, and the reaction slowly 
warmed to 25 °C and stirred for 12 h. After work-up, the crude product was purified via column 
chromatography (isohexane:ethyl acetate:triethylamine = 8:2:0.1) to give 134h (90 mg, 351 µmol, 
70%) as a yellow solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 7.95 (d, J = 2.3 Hz, 1H), 7.83 (t, J = 1.9 Hz, 1H), 7.73 (dd, J 
= 8.9, 1.3 Hz, 1H), 7.66 (ddd, J = 7.8, 1.6, 1.1 Hz, 1H), 7.57 (ddd, J = 8.0, 2.1, 1.1 Hz, 1H), 7.38 (t, J = 
7.9 Hz, 1H), 7.20 (dd, J = 8.9, 6.9 Hz, 1H), 6.98 (dd, J = 6.8, 1.3 Hz, 1H), 6.65 (d, J = 2.3 Hz, 1H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 188.4, 142.5, 140.9, 137.8, 136.3, 135.2, 134.0, 130.1, 129.8, 
128.2, 122.4, 121.1, 114.3, 97.8. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3068, 1672, 1626, 1570, 1520, 1454, 1423, 1303, 1264, 1203, 
1176, 1149, 1058, 904, 791, 738, 675. 
MS (EI, 70 eV): 256 (8), 255 (13), 229 (33), 228 (13), 227 (100), 192 (8). 
HRMS (EI) for C14H8N2OCl (255.0325): 255.0318 (M+-H). 
M.p. (°C): 80–83. 
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Synthesis of 7-(piperidin-1-ylsulfonyl)pyrazolo[1,5-a]pyridine (134i) 
 
 
 
Adapted from a literature procedure,100 DABSO (608 mg, 2.52 mmol) was dried in vacuo for 15 min, 
suspended in THF (10 mL) and then cooled to –40 °C. In a separate flask, pyrazolo[1,5-a]pyridine 1 
(119 mg, 1.00 mmol) was dissolved in THF (4 mL) and cooled to –78 °C. Then TMPMgCl·LiCl 
(0.96 mL, 1.2 mmol) was added dropwise and the reaction stirred for 15 min. The formed magnesium 
species was then added dropwise to the DABSO suspension, and the reaction mixture stirred for 1 h at 
–40 °C. Then, sulfuryl chloride (0.105 mL, 1.30 mmol) was added dropwise to the reaction mixture and 
stirred for 20 min. Then, piperidine (1.00 mL, 10 mmol) was added to the reaction mixture, which was 
then slowly warmed to 25 °C and stirred for 12 h. After quenching with water (40 mL) and extraction 
with ethyl acetate (3 x 25 mL), the organic phase was dried over Na2SO4, filtered and concentrated in 
vacuo. The crude product was purified via column chromatography (isohexane:ethyl 
acetate:triethylamine = 7.5:2.5:0.1) to give 134i (146 mg, 0.55 mmol, 55%) as a brown solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.07 (d, J = 2.3 Hz, 1H), 7.72 (dd, J = 8.9, 1.3 Hz, 1H), 7.57 
(dd, J = 7.1, 1.3 Hz, 1H), 7.16 (dd, J = 8.8, 7.1 Hz, 1H), 6.68 (d, J = 2.3 Hz, 1H), 3.50 - 3.45 (m, 4H), 
1.63 - 1.55 (m, 4H), 1.54 - 1.47 (m, 2H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 142.3, 141.5, 136.5, 122.2, 121.9, 116.8, 98.4, 47.4, 26.0, 
23.8. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 2939, 2856, 1626, 1508, 1444, 1340, 12961164, 1139, 1052, 946, 
795, 712. 
MS (EI, 70 eV): 265 (1), 118 (100), 91 (11), 88 (10), 84 (42), 70 (15), 61 (22), 45 (16), 43 (76). 
HRMS (EI) for C12H15N3O2S (265.0885): 265.0863 (M+). 
M.p. (°C): 147–148. 
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Synthesis of 7-(p-tolyl)pyrazolo[1,5-a]pyridine (134j) 
 
 
 
Pyrazolo[1,5-a]pyridine 134j was prepared via TP15 using 128 (59 mg, 0.50 mmol) and 
TMPMgCl·LiCl (0.48 mL, 0.60 mmol). After the metalation was complete, a 1.0 M ZnCl2 solution in 
THF (0.60 mL, 0.60 mmol) was added dropwise and the reaction mixture stirred for 20 min. Then, 
Pd(dba)2 (9 mg, 15 µmol), tfp (7 mg, 30 µmol) and 4-iodotoluene (98 mg, 0.45 mmol) were added, the 
reaction warmed to 25 °C and stirred for 12 h. After work-up, the crude product was purified via column 
chromatography (isohexane:ethyl acetate:triethylamine = 9:1:0.1) to give 134j (65 mg, 312 µmol, 69%) 
as a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 7.98 (d, J = 2.3 Hz, 1H), 7.82 - 7.76 (m, 2H), 7.54 (dd, J = 
8.8, 1.4 Hz, 1H), 7.36 - 7.31 (m, 2H), 7.17 (dd, J = 8.8, 6.9 Hz, 1H), 6.80 (dd, J = 6.9, 1.4 Hz, 1H), 6.60 
(d, J = 2.3 Hz, 1H), 2.44 (s, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 141.5, 141.3, 140.8, 139.5, 131.1, 129.2, 129.2, 123.5, 116.9, 
112.2, 97.2, 21.5. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3031, 2920, 1629, 1544, 1504, 1449, 1302, 1196, 1154, 908, 818, 
778, 728. 
MS (EI, 70 eV): 208 (41), 208 (10), 207 (100), 192 (6), 103 (7). 
HRMS (EI) for C14H11N2 (207.0922): 207.0916 (M+-H). 
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Synthesis of ethyl 4-(pyrazolo[1,5-a]pyridin-7-yl)benzoate (134k) 
 
 
 
Pyrazolo[1,5-a]pyridine 134k was prepared via TP16 using 128 (59 mg, 0.50 mmol) and 
TMPZnCl·LiCl (0.79 mL, 0.60 mmol). After the metalation was complete, Pd(dba)2 (9 mg, 15 µmol), 
tfp (7 mg, 30 µmol) and ethyl 4-iodobenzoate (70 µL, 0.40 mmol) were added and the reaction warmed 
to 25 °C and stirred for 12 h. After work-up, the crude product was purified via column chromatography 
(isohexane:ethyl acetate:triethylamine = 9:1:0.1) to give 134k (103 mg, 387 µmol, 97%) as a yellow 
oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.24 - 8.14 (m, 2H), 8.03 - 7.96 (m, 3H), 7.59 (dd, J = 8.9, 1.3 
Hz, 1H), 7.19 (dd, J = 8.9, 6.9 Hz, 1H), 6.86 (dd, J = 6.9, 1.3 Hz, 1H), 6.63 (d, J = 2.3 Hz, 1H), 4.42 
(q, J = 7.1 Hz, 2H), 1.42 (t, J = 7.1 Hz, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 166.3, 141.6, 141.3, 139.6, 138.1, 131.2, 129.8, 129.2, 123.4, 
118.0, 113.0, 97.6, 61.2, 14.5. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 2981, 1711, 1268, 1182, 1103, 1021, 791, 769, 698. 
MS (EI, 70 eV): 267 (13), 266 (81), 265 (70), 238 (14), 237 (100), 221 (19), 193 (45), 192 (35), 191 
(15), 164 (10), 139 (9). 
HRMS (EI) for C16H14N2O2 (266.1055): 266.1047 (M+). 
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Synthesis of 7-(3-methoxyphenyl)pyrazolo[1,5-a]pyridine (134l) 
 
 
 
Pyrazolo[1,5-a]pyridine 134l was prepared via TP16 using 128 (59 mg, 0.50 mmol) and 
TMPZnCl·LiCl (0.79 mL, 0.60 mmol). After the metalation was complete, Pd(dba)2 (9 mg, 15 µmol), 
tfp (7 mg, 30 µmol) and 3-iodoanisole (50 µL, 0.42 mmol) were added and the reaction warmed to 
25 °C and stirred for 12 h. After work-up, the crude product was purified via column chromatography 
(isohexane:ethyl acetate:triethylamine = 9:1:0.1) to give 134l (70 mg, 312 µmol, 74%) as a colorless 
oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 7.98 (d, J = 2.3 Hz, 1H), 7.55 (dd, J = 8.8, 1.3 Hz, 1H), 7.49 - 
7.41 (m, 3H), 7.17 (ddd, J = 8.8, 6.8, 0.5 Hz, 1H), 7.03 (ddd, J = 7.8, 2.6, 1.5 Hz, 1H), 6.82 (dd, J = 
6.9, 1.4 Hz, 1H), 6.61 (d, J = 2.3 Hz, 1H), 3.87 (s, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 159.6, 141.6, 141.3, 140.5, 135.2, 129.6, 123.4, 121.7, 117.3, 
115.2, 114.9, 112.6, 97.3, 55.5. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 2937, 1579, 1522, 1485, 1447, 1305, 1230, 1179, 1045, 852, 778, 
728, 694. 
MS (EI, 70 eV): 225 (13), 224 (87), 223 (100), 209 (23), 208 (16), 194 (13), 192 (10), 180 (17), 43 
(35). 
HRMS (EI) for C14H12N2O (224.0950): 224.0918 (M+). 
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Synthesis of 2-iodopyrazolo[1,5-a]pyridine (136a) 
 
 
 
Pyrazolo[1,5-a]pyridine 136a was prepared via TP17 using 128 (59 mg, 0.50 mmol), BF3·OEt2 (70 µL, 
0.55 mmol), TMPMgCl·LiCl (0.48 mL, 0.60 mmol) and iodine (195 mg, 0.75 mmol). The reaction was 
complete after 12 h. After quenching with a sat. aq. Na2S2O3 solution (10 mL) followed by standard 
work-up, the crude product was purified via column chromatography (isohexane:ethyl 
acetate:triethylamine = 9:1:0.1) to give 136a (67 mg, 274 µmol, 55%) as a colorless oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.44 - 8.38 (m, 1H), 7.48 - 7.42 (m, 1H), 7.14 - 7.07 (m, 1H), 
6.72 - 6.64 (m, 2H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 13C NMR (101 MHz, CDCl3) δ 141.9, 128.2, 124.4, 116.8, 
112.0, 105.9, 100.9. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3107, 2922, 1632, 1508, 1452, 1365, 1328, 1285, 1245, 1142, 
937, 762, 735. 
MS (EI, 70 eV): 244 (81), 135 (8), 127 (100), 117 (40), 90 (23), 63 (6). 
HRMS (EI) for C7H5N2I (243.9497): 243.9490 (M+). 
 
Synthesis of 2-bromopyrazolo[1,5-a]pyridine (136b) 
 
 
 
Pyrazolo[1,5-a]pyridine 136b was prepared via TP17 using 128 (590 mg, 5.00 mmol), BF3·OEt2 
(0.70 mL, 5.50 mmol), TMPMgCl·LiCl (4.80 mL, 6.00 mmol) and dibromotetrachloroethane (3.26 g, 
10 mmol). The reaction was complete after 12 h. After work-up, the crude product was purified via 
column chromatography (isohexane:ethyl acetate:triethylamine = 9:1:0.1) to give 136b (908 mg, 
4.61 mmol, 92%) as a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.37 (dq, J = 7.1, 1.0 Hz, 1H), 7.44 (dt, J = 9.0, 1.2 Hz, 1H), 
7.13 (ddd, J = 9.0, 6.8, 1.1 Hz, 1H), 6.74 (td, J = 6.9, 1.4 Hz, 1H), 6.52 (d, J = 0.9 Hz, 1H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 141.8, 130.9, 128.4, 124.6, 117.1, 112.1, 99.3. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3111, 1633, 1512, 1456, 1371, 1330, 1309, 1249, 1144, 946, 760, 
735. 
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MS (EI, 70 eV): 198 (98), 196 (100), 135 (18), 117 (86), 90 (54), 81 (18), 79 (17), 63 (12). 
HRMS (EI) for C7H5N2Br (195.9636): 195.9628 (M+). 
M.p. (°C): 44–46. 
 
Synthesis of ethyl 4-(pyrazolo[1,5-a]pyridin-2-yl)benzoate (136c) 
 
 
 
Pyrazolo[1,5-a]pyridine 136c was prepared via TP17 using 128 (59 mg, 0.50 mmol), BF3·OEt2 (70 µL, 
0.55 mmol) and TMPMgCl·LiCl (0.50 mL, 0.60 mmol). After the metalation was complete, a 1.0 M 
ZnCl2 solution in THF (0.60 mL, 0.60 mmol) was added dropwise and the reaction mixture stirred for 
20 min. Then, Pd(dba)2 (9 mg, 15 µmol), tfp (7 mg, 30 µmol) and ethyl 4-iodobenzoate (70 µL, 
0.42 mmol) were added, the reaction warmed to 25 °C and stirred for 12 h. After work-up, the crude 
product was purified via column chromatography (isohexane:ethyl acetate:triethylamine = 8.5:1.5:0.1) 
to give 136c (75 mg, 282 µmol, 67%) as a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.47 (dq, J = 7.0, 1.1 Hz, 1H), 8.16 - 8.08 (m, 2H), 8.06 - 8.00 
(m, 2H), 7.52 (dt, J = 8.9, 1.3 Hz, 1H), 7.10 (ddd, J = 8.9, 6.7, 1.1 Hz, 1H), 6.85 (d, J = 0.9 Hz, 1H), 
6.76 (td, J = 6.9, 1.4 Hz, 1H), 4.40 (q, J = 7.1 Hz, 2H), 1.41 (t, J = 7.1 Hz, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 166.6, 152.5, 141.8, 137.6, 130.3, 130.2, 128.7, 126.3, 123.8, 
118.3, 112.4, 94.6, 61.1, 14.5. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3082, 2982, 1708, 1611, 1518, 1431, 1366, 1270, 1180, 1105, 
1022, 862, 766, 734, 702. 
MS (EI, 70 eV): 281 (11), 267 (16), 266 (100), 238 (48), 237 (17), 225 (19), 222 (11), 221 (80), 207 
(35), 193 (37), 192 (35), 166 (23). 
HRMS (EI) for C16H14N2O2 (266.1055): 266.1046 (M+). 
M.p. (°C): 144–146. 
 
Synthesis of 2-phenylpyrazolo[1,5-a]pyridine (136d) 
 
 
 
Pyrazolo[1,5-a]pyridine 136d was prepared via TP17 using 128 (59 mg, 0.50 mmol), BF3·OEt2 (70 µL, 
0.55 mmol) and TMPMgCl·LiCl (0.50 mL, 0.60 mmol). After the metalation was complete, a 1.0 M 
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ZnCl2 solution in THF (0.60 mL, 0.60 mmol) was added dropwise and the reaction mixture stirred for 
20 min. Then, Pd(dba)2 (9 mg, 15 µmol), tfp (7 mg, 30 µmol) and iodobenzene (45 µL, 0.40 mmol) 
were added, the reaction warmed to 25 °C and stirred for 12 h. After work-up, the crude product was 
purified via column chromatography (isohexane:ethyl acetate:triethylamine = 9:1:0.1) to give 136d 
(53 mg, 273 µmol, 68%) as a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.48 (dq, J = 7.0, 1.0 Hz, 1H), 8.01 - 7.93 (m, 2H), 7.54 - 7.42 
(m, 3H), 7.41 - 7.33 (m, 1H), 7.08 (ddd, J = 8.9, 6.7, 1.1 Hz, 1H), 6.80 (d, J = 0.9 Hz, 1H), 6.73 (td, J 
= 6.9, 1.4 Hz, 1H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 153.7, 141.8, 133.4, 128.9, 128.7, 128.5, 126.6, 123.5, 118.1, 
111.8, 93.8. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3086, 2927, 1631, 1509, 1468, 1328, 1252, 1143, 1125, 764, 695. 
MS (EI, 70 eV): 195 (13), 194 (100), 193 (52), 192 (12), 166 (12), 103 (18). 
HRMS (EI) for C13H10N2 (194.0844): 194.0835 (M+). 
M.p. (°C): 104–107. 
 
Synthesis of (2-chlorophenyl)(pyrazolo[1,5-a]pyridin-2-yl)methanone (136e) 
 
 
 
Pyrazolo[1,5-a]pyridine 136e was prepared via TP17 using 128 (59 mg, 0.50 mmol), BF3·OEt2 (70 µL, 
0.55 mmol) and TMPMgCl·LiCl (0.50 mL, 0.60 mmol). After the metalation was complete, a 1.0 M 
CuCN·2LiCl solution in THF (0.60 mL, 0.60 mmol) was added and the reaction warmed to –40 °C and 
stirred for 10 min. Then, 2-chlorobenzoyl chloride (85 µL, 0.65 mmol) was added dropwise, and the 
reaction slowly warmed to 25 °C and stirred for 12 h. After work-up, the crude product was purified 
via column chromatography (isohexane:ethyl acetate:triethylamine = 8:2:0.1) to give 136e (77 mg, 
300 µmol, 60%) as a colorless oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.46 (dq, J = 7.1, 1.0 Hz, 1H), 7.65 - 7.57 (m, 2H), 7.50 - 7.42 
(m, 2H), 7.41 - 7.35 (m, 1H), 7.17 (ddd, J = 9.0, 6.7, 1.1 Hz, 1H), 7.09 (d, J = 1.0 Hz, 1H), 6.89 (ddd, 
J = 6.7, 1.4 Hz, 1H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 190.0, 151.2, 141.1, 138.6, 132.0, 131.6, 130.4, 130.0, 129.2, 
126.5, 124.2, 119.8, 114.6, 100.3. 
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IR (Diamond-ATR, neat): ?̃ / cm-1 = 3089, 1669, 1590, 1492, 1433, 1388, 1329, 1271, 1223, 1121, 
1060, 1023, 899, 752. 
MS (EI, 70 eV): 256 (7), 225 (8), 222 (14), 221 (100), 141 (11), 139 (11), 139 (33). 
HRMS (EI) for C14H9N2O (221.0715): 221.0708 (M+-Cl). 
 
Synthesis of (3-fluorophenyl)(pyrazolo[1,5-a]pyridin-2-yl)methanone (136f) 
 
 
 
Pyrazolo[1,5-a]pyridine 136f was prepared via TP17 using 128 (59 mg, 0.50 mmol), BF3·OEt2 (70 µL, 
0.55 mmol) and TMPMgCl·LiCl (0.50 mL, 0.60 mmol). After the metalation was complete, a 1.0 M 
CuCN·2LiCl solution in THF (0.60 mL, 0.60 mmol) was added and the reaction warmed to –40 °C and 
stirred for 10 min. Then, 3-fluorobenzoyl chloride (80 µL, 0.65 mmol) was added dropwise, and the 
reaction slowly warmed to 25 °C and stirred for 12 h. After work-up, the crude product was purified 
via column chromatography (isohexane:ethyl acetate:triethylamine = 8:2:0.1) to give 136f (52 mg, 
216 µmol, 43%) as a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.52 (dq, J = 7.1, 1.1 Hz, 1H), 8.13 (dt, J = 7.7, 1.3 Hz, 1H), 
8.07 (ddd, J = 9.7, 2.7, 1.5 Hz, 1H), 7.64 (dt, J = 9.0, 1.3 Hz, 1H), 7.53 - 7.45 (m, 1H), 7.34 - 7.27 (m, 
1H), 7.22 - 7.15 (m, 2H), 6.92 (td, J = 6.9, 1.4 Hz, 1H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 187.6, 187.5, 163.8, 161.4, 151.2, 140.7, 139.4, 139.3, 130.0, 
129.9, 129.1, 126.6, 126.6, 124.2, 120.1, 119.9, 119.6, 117.8, 117.6, 114.4, 100.7. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3074, 2926, 1645, 1585, 1515, 1480, 1442, 1347, 1331, 1258, 
1180, 899, 852, 832, 781, 755. 
MS (EI, 70 eV): 240 (46), 123 (26), 123 (100), 113 (12), 95 (10), 75 (11). 
HRMS (EI) for C14H9N2OF (240.0699): 240.0692 (M+). 
M.p. (°C): 92–96. 
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Synthesis of pyrazolo[1,5-a]pyridin-2-yl(thiophen-2-yl)methanone (136g) 
 
 
 
Pyrazolo[1,5-a]pyridine 136g was prepared via TP17 using 128 (59 mg, 0.50 mmol), BF3·OEt2 (70 µL, 
0.55 mmol) and TMPMgCl·LiCl (0.50 mL, 0.60 mmol). After the metalation was complete, a 1.0 M 
CuCN·2LiCl solution in THF (0.60 mL, 0.60 mmol) was added and the reaction warmed to –40 °C and 
stirred for 10 min. Then, 2-thiophenecarbonyl chloride (70 µL, 0.65 mmol) was added dropwise, and 
the reaction slowly warmed to 25 °C and stirred for 12 h. After work-up, the crude product was purified 
via column chromatography (isohexane:ethyl acetate:triethylamine = 8:2:0.1) to give 136g (69 mg, 
302 µmol, 60%) as a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.58 (dd, J = 3.8, 1.2 Hz, 1H), 8.52 (dq, J = 6.8, 0.9 Hz, 1H), 
7.74 (dd, J = 4.9, 1.2 Hz, 1H), 7.63 (dt, J = 9.0, 1.2 Hz, 1H), 7.25 - 7.13 (m, 3H), 6.91 (td, J = 6.9, 1.4 
Hz, 1H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 180.1, 151.5, 143.0, 140.8, 136.1, 134.9, 129.1, 128.3, 124.1, 
119.6, 114.2, 100.0. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3108, 2925, 1626, 1514, 1411, 1347, 1250, 1107, 1052, 834, 778, 
755, 726. 
MS (EI, 70 eV): 228 (43), 225 (19), 209 (7), 207 (8), 111 (100). 
HRMS (EI) for C12H8N2OS (228.0357): 228.0351 (M+). 
M.p. (°C): 111–114. 
 
Synthesis of furan-2-yl(pyrazolo[1,5-a]pyridin-2-yl)methanone (136h) 
 
 
 
Pyrazolo[1,5-a]pyridine 136h was prepared via TP17 using 128 (59 mg, 0.50 mmol), BF3·OEt2 (70 µL, 
0.55 mmol) and TMPMgCl·LiCl (0.50 mL, 0.60 mmol). After the metalation was complete, a 1.0 M 
CuCN·2LiCl solution in THF (0.60 mL, 0.60 mmol) was added and the reaction warmed to –40 °C and 
stirred for 10 min. Then, 2-furoyl chloride (65 µL, 0.65 mmol) was added dropwise, and the reaction 
slowly warmed to 25 °C and stirred for 12 h. After work-up, the crude product was purified via column 
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chromatography (isohexane:ethyl acetate:triethylamine = 7:3:0.1) to give 136h (50 mg, 236 µmol, 
47%) as a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.51 (dq, J = 7.1, 1.1 Hz, 1H), 8.03 (dd, J = 3.6, 0.8 Hz, 1H), 
7.75 (dd, J = 1.7, 0.8 Hz, 1H), 7.62 (dt, J = 8.9, 1.3 Hz, 1H), 7.28 - 7.22 (m, 1H), 7.17 (ddd, J = 9.0, 
6.7, 1.1 Hz, 1H), 6.90 (td, J = 6.9, 1.4 Hz, 1H), 6.63 (dd, J = 3.6, 1.7 Hz, 1H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 175.2, 151.9, 150.7, 147.6, 140.8, 129.0, 124.1, 122.5, 119.6, 
114.3, 112.5, 100.1. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3138, 2925, 1637, 1564, 1494, 1463, 1390, 1330, 1271, 1166, 
1118, 1018, 936, 862, 764. 
MS (EI, 70 eV): 225 (23), 212 (50), 209 (9), 207 (10), 95 (100), 61 (9), 43 (9). 
HRMS (EI) for C12H8N2O2 (212.0586): 212.0578 (M+). 
M.p. (°C): 109–112. 
 
Synthesis of N,N-dimethyl-1-(pyrazolo[1,5-a]pyridin-2-yl)methanamine (136i) 
 
 
 
Adapted from a literature procedure,101b pyrazolo[1,5-a]pyridine 128 (117 mg, 1.00 mmol) was 
dissolved in THF (5 mL) and cooled to 0 °C. Then, BF3·O2Et (0.16 mL, 1.2 mmol) was added to the 
mixture and the reaction stirred for 10 min. After cooling to –78 °C, TMPMgCl·LiCl (0.97 mL, 
1.30 mmol) was added dropwise and the mixture stirred for 15 min. In a separate flask, N,N,N',N'-
tetramethylmethanediamine (0.19 mL, 1.50 mmol) was dissolved in DCM (2 mL) and cooled to 0 °C. 
Then, trifluoroacetic anhydride (0.21 mL, 1.50 mmol) was added dropwise to the diamine and the 
reaction mixture stirred for 15 min. The formed species was then added dropwise to the 
organomagnesium solution prepared in the first step, and the resulting reaction mixture stirred for 1.5 h 
at –78 °C. The reaction was quenched with water (40 mL) and extracted with ethyl acetate (3 x 25 mL). 
The organic phase was dried over Na2SO4, filtered, concentrated in vacuo and the crude product purified 
via column chromatography (dichloromethane:methanol:triethylamine = 9:1:0.1) to give 136i (89 mg, 
0.508 µmol, 51%) as a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.42 - 8.35 (m, 1H), 7.51 - 7.44 (m, 1H), 7.09 (ddd, J = 9.0, 
6.7, 1.1 Hz, 1H), 6.74 (td, J = 6.9, 1.4 Hz, 1H), 6.60 (s, 1H), 3.98 (s, 2H), 2.55 (s, 6H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 148.9, 141.3, 128.5, 123.8, 118.2, 112.2, 97.8, 56.3, 44.5. 
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IR (Diamond-ATR, neat): ?̃ / cm-1 = 3398, 2958, 2781, 1636, 1519, 1466, 1330, 1254, 1054, 1030, 
836, 778, 745. 
MS (EI, 70 eV): 175 (2), 146 (3), 133 (9), 132 (100), 131 (41), 105 (7), 104 (6), 79 (4), 78 (7), 58 (1). 
HRMS (EI) for C10H13N3 (175.1109): 175.1101 (M+). 
 
Synthesis of 2-bromo-7-iodopyrazolo[1,5-a]pyridine (138a) 
 
 
 
Pyrazolo[1,5-a]pyridine 138a was prepared via TP15 using 136b (99 mg, 0.50 mmol), TMPMgCl·LiCl 
(0.50 mL, 0.60 mmol) and iodine (200 mg, 0.79 mmol). The reaction was complete after 2 h. After 
quenching with a sat. aq. Na2S2O3 solution (10 mL) followed by standard work-up, the crude product 
was purified via column chromatography (isohexane:ethyl acetate:triethylamine = 92:8:1) to give 138a 
(105 mg, 325 µmol, 65%) as a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 7.46 (dd, J = 8.8, 1.2 Hz, 1H), 7.31 (dd, J = 7.2, 1.2 Hz, 1H), 
6.88 (dd, J = 8.8, 7.2 Hz, 1H), 6.76 (s, 1H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 141.9, 130.5, 125.0, 124.2, 116.9, 102.0, 91.0. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3132, 2902, 1618, 1522, 1485, 1425, 1350, 13001180, 1140, 950, 
926, 778, 708. 
MS (EI, 70 eV): 324 (99), 322 (100), 261 (14), 243 (59), 134 (17), 127 (32), 116 (62). 
HRMS (EI) for C7H4N2IBr (321.8603): 321.8598 (M+). 
M.p. (°C): 65–68. 
 
Synthesis of 2-iodo-7-iodopyrazolo[1,5-a]pyridine (138b) 
 
 
 
Pyrazolo[1,5-a]pyridine 138b was prepared via TP15 using 136a (122 mg, 0.50 mmol), 
TMPMgCl·LiCl (0.50 mL, 0.60 mmol) and iodine (190 mg, 0.75 mmol). The reaction was complete 
after 12 h. After quenching with a sat. aq. Na2S2O3 solution (10 mL) followed by standard work-up, the 
crude product was purified via column chromatography (isohexane:ethyl acetate:triethylamine = 
96:4:1) to give 138b (90 mg, 243 µmol, 49%) as an orange oil.  
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1H-NMR (400 MHz, CDCl3): δ / ppm = 7.46 (dd, J = 8.8, 1.2 Hz, 1H), 7.26 (dd, J = 7.2, 1.2 Hz, 1H), 
6.90 (s, 1H), 6.85 (dd, J = 8.8, 7.2 Hz, 1H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 142.1, 124.8, 124.1, 116.5, 108.7, 100.5, 90.6. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3128, 1613, 1482, 1419, 1343, 1295, 1180, 941, 922, 780, 709. 
MS (EI, 70 eV): 370 (46), 261 (17), 243 (17), 127 (100), 116 (16), 42 (31). 
HRMS (EI) for C7H4N2I2 (369.8464): 369.8457 (M+). 
 
Synthesis of 7-iodo-2-phenylpyrazolo[1,5-a]pyridine (138c) 
 
 
 
Pyrazolo[1,5-a]pyridine 138c was prepared similar to TP15 using 136d (78 mg, 0.40 mmol), 
TMPMgCl·LiCl (0.78 mL, 1.00 mmol) and iodine (254 mg, 1.00 mmol). The reaction was complete 
after 12 h. After quenching with a sat. aq. Na2S2O3 solution (10 mL) followed by standard work-up, the 
crude product was purified via column chromatography (isohexane:ethyl acetate:triethylamine = 
94:6:1) to give 138c (99 mg, 309 µmol, 77%) as a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.06 - 8.01 (m, 2H), 7.53 - 7.43 (m, 3H), 7.42 - 7.34 (m, 1H), 
7.29 (dd, J = 7.1, 1.2 Hz, 1H), 7.02 (s, 1H), 6.81 (dd, J = 8.7, 7.1 Hz, 1H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 152.8, 141.8, 133.0, 128.8, 128.7, 126.8, 124.0, 123.8, 117.8, 
96.2, 91.7. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3067, 1617, 1536, 1486, 1462, 1290, 1194, 928, 767, 691. 
MS (EI, 70 eV): 321 (14), 320 (100), 192 (10), 90 (15), 61 (12), 43 (61). 
HRMS (EI) for C13H9N2I (319.9810): 319.9806 (M+). 
 
Synthesis of 2,7-dibromopyrazolo[1,5-a]pyridine (138d) 
 
 
 
Pyrazolo[1,5-a]pyridine 138d was prepared via TP15 using 136b (100 mg, 0.50 mmol), 
TMPMgCl·LiCl (0.50 mL, 0.60 mmol) and 1,2-dibromotetrachloroethane (250 mg, 0.75 mmol). The 
reaction was complete after 2 h. After work-up, the crude product was purified via column 
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chromatography (isohexane:ethyl acetate:triethylamine = 92:8:1) to give 138d (94 mg, 341 mmol, 
68%) as a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 7.47 (dd, J = 8.2, 1.9 Hz, 1H), 7.10 - 7.01 (m, 2H), 6.70 (s, 
1H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 143.1, 131.3, 124.9, 118.4, 116.4, 116.0, 101.6. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3136, 1624, 1494, 1433, 1355, 1302, 1187, 940, 780, 708. 
MS (EI, 70 eV): 278 (49), 276 (100), 274 (51), 215 (17), 213 (18), 197 (76), 195 (79), 116 (67), 115 
(10). 
HRMS (EI) for C7H4N2Br2 (273.8741): 273.8738 (M+). 
M.p. (°C): 97–101. 
 
Synthesis of 2-bromo-7-phenylpyrazolo[1,5-a]pyridine (138e) 
 
 
 
Pyrazolo[1,5-a]pyridine 138e was prepared via TP15 using 136b (100 mg, 0.50 mmol) and 
TMPMgCl·LiCl (0.50 mL, 0.60 mmol). After the metalation was complete, a 1.0 M ZnCl2 solution in 
THF (0.60 mL, 0.60 mmol) was added dropwise and the reaction mixture stirred for 20 min. Then, 
Pd(dba)2 (9 mg, 15 µmol), tfp (7 mg, 30 µmol) and iodobenzene (50 µL, 0.45 mmol) were added, the 
reaction warmed to 25 °C and stirred for 12 h. After work-up, the crude product was purified via column 
chromatography (isohexane:ethyl acetate:triethylamine = 95:5:1) to give 138e (78 mg, 286 µmol, 64%) 
as a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 7.94 - 7.86 (m, 2H), 7.54 - 7.47 (m, 3H), 7.45 (dd, J = 8.8, 1.4 
Hz, 1H), 7.22 (dd, J = 8.9, 7.0 Hz, 1H), 6.82 (dd, J = 7.0, 1.4 Hz, 1H), 6.62 (s, 1H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 142.9, 140.5, 133.1, 130.7, 129.8, 129.3, 128.6, 124.8, 115.9, 
112.8, 99.9. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3060, 1630, 1544, 1520, 1489, 1450, 1424, 1352, 1310, 1169, 
952, 790, 760, 691. 
MS (EI, 70 eV): 274 (55), 273 (97), 272 (58), 271 (100), 193 (12), 192 (54), 166 (47), 164 (16), 140 
(22), 139 (24), 97 (26). 
HRMS (EI) for C13H8N2Br (270.9871): 270.9866 (M+-H). 
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M.p. (°C): 112–113. 
 
Synthesis of ethyl 4-(2-bromopyrazolo[1,5-a]pyridin-7-yl)benzoate (138f) 
 
 
 
Pyrazolo[1,5-a]pyridine 138f was prepared via TP15 using 136b (100 mg, 0.50 mmol) and 
TMPMgCl·LiCl (0.50 mL, 0.60 mmol). After the metalation was complete, a 1.0 M ZnCl2 solution in 
THF (0.60 mL, 0.60 mmol) was added dropwise and the reaction mixture stirred for 20 min. Then, 
Pd(dba)2 (9 mg, 15 µmol), tfp (7 mg, 30 µmol) and ethyl 4-iodobenzoate (76 µL, 0.45 mmol) were 
added, the reaction warmed to 25 °C and stirred for 12 h. After work-up, the crude product was purified 
via column chromatography (isohexane:ethyl acetate:triethylamine = 9:1:0.1) to give 138f (102 mg, 
295 µmol, 66%) as a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.21 - 8.15 (m, 2H), 8.01 - 7.96 (m, 2H), 7.48 (dd, J = 8.9, 1.4 
Hz, 1H), 7.23 (dd, J = 8.9, 7.1 Hz, 1H), 6.86 (dd, J = 7.1, 1.4 Hz, 1H), 6.64 (s, 1H), 4.42 (q, J = 7.1 Hz, 
2H), 1.42 (t, J = 7.1 Hz, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 166.2, 142.8, 139.4, 137.2, 131.5, 130.8, 129.8, 129.3, 124.7, 
116.7, 113.3, 100.2, 61.3, 14.5. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 2980, 1713, 1630, 1435, 1350, 1271, 1170, 1105, 1021, 952, 858, 
791, 769, 699. 
MS (EI, 70 eV): 346 (13), 344 (14), 343 (10), 317 (10), 315 (11), 299 (17), 281 (23), 227 (10), 227 
(16), 226 (13), 225 (100), 209 (38), 207 (65), 192 (14), 191 (11), 191 (14), 164 (14), 151 (12), 73 (14), 
43 (17). 
HRMS (EI) for C16H13N2O2Br (344.0160): 344.0154 (M+). 
M.p. (°C): 121–124. 
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Synthesis of 2-bromo-7-(4-methoxyphenyl)pyrazolo[1,5-a]pyridine (138g) 
 
 
 
Pyrazolo[1,5-a]pyridine 138g was prepared via TP15 using 136b (99 mg, 0.50 mmol) and 
TMPMgCl·LiCl (0.50 mL, 0.60 mmol). After the metalation was complete, a 1.0 M ZnCl2 solution in 
THF (0.60 mL, 0.60 mmol) was added dropwise and the reaction mixture stirred for 20 min. Then, 
Pd(dba)2 (9 mg, 15 µmol), tfp (7 mg, 30 µmol) and ethyl 4-iodoanisole (96 mg, 0.40 mmol) were added, 
the reaction warmed to 25 °C and stirred for 12 h. After work-up, the crude product was purified via 
column chromatography (isohexane:ethyl acetate:triethylamine = 9:1:0.1) to give 138g (120 mg, 
396 µmol, 99%) as a yellow solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 7.87 (d, J = 8.5 Hz, 2H), 7.40 (d, J = 8.9 Hz, 1H), 7.20 (t, J = 
7.9 Hz, 1H), 7.02 (d, J = 8.5 Hz, 2H), 6.78 (dd, J = 7.0, 1.5 Hz, 1H), 6.60 (s, 1H), 3.88 (s, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 160.8, 142.9, 140.3, 130.7, 130.6, 125.4, 124.8, 115.3, 114.0, 
112.2, 99.7, 55.5. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 2932, 1607, 1501, 1435, 1349, 1297, 1251, 1180, 1031, 939, 830, 
785, 729. 
MS (EI, 70 eV): 305 (16), 304 (99), 303 (13), 303 (82), 302 (100), 301 (86), 223 (21), 208 (37), 207 
(21), 196 (21), 192 (19), 180 (26), 179 (57), 153 (20), 152 (12), 81 (23), 79 (22). 
HRMS (EI) for C14H11N2OBr (302.0055): 302.0051 (M+). 
M.p. (°C): 82–86. 
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Synthesis of 7-allyl-2-iodopyrazolo[1,5-a]pyridine (138h) 
 
 
 
Pyrazolo[1,5-a]pyridine 138h was prepared via TP15 using 136a (61 mg, 0.25 mmol) and 
TMPMgCl·LiCl (0.25 mL, 0.30 mmol). After the metalation was complete, a 1.0 M CuCN·2LiCl 
solution in THF (0.30 mL, 0.30 mmol) was added and the reaction stirred for 10 min. Then, allyl 
bromide (40 mg, 0.33 mmol) was added dropwise, and the reaction slowly warmed to 25 °C and stirred 
for 12 h. After work-up, the crude product was purified via column chromatography (isohexane:ethyl 
acetate:triethylamine = 95:5:1) to give 138h (46 mg, 162 µmol, 65%) as a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 7.41 - 7.34 (m, 1H), 7.09 (dd, J = 8.8, 7.0 Hz, 1H), 6.72 (s, 
1H), 6.60 - 6.52 (m, 1H), 6.20 - 6.07 (m, 1H), 5.34 - 5.23 (m, 2H), 3.93 - 3.87 (m, 2H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 142.2, 140.0, 132.2, 124.3, 119.1, 114.5, 110.1, 106.4, 100.5, 
35.1. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3078, 2922, 1633, 1546, 1516, 1436, 1408, 1355, 1313, 1283, 
1247, 1203, 1158, 1100, 1029. 
MS (EI, 70 eV): 284 (57), 283 (41), 269 (39), 157 (100), 156 (42), 155 (29), 130 (45), 104 (17), 78 
(14), 77 (21), 63 (18), 51 (13). 
HRMS (EI) for C10H9IN2 (283.9810): 283.9805 (M+). 
 
Synthesis of 2-bromo-7-(cyclohex-2-en-1-yl)pyrazolo[1,5-a]pyridine (138i) 
 
 
 
Pyrazolo[1,5-a]pyridine 138i was prepared via TP15 using 136b (40 mg, 0.20 mmol) and 
TMPMgCl·LiCl (0.20 mL, 0.24 mmol). After the metalation was complete, a 1.0 M CuCN·2LiCl 
solution in THF (0.24 mL, 0.24 mmol) was added and the reaction stirred for 10 min. Then, 3-
bromocyclohexene (30 µL, 0.27 mmol) was added dropwise, and the reaction slowly warmed to 25 °C 
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and stirred for 4 h. After work-up, the crude product was purified via column chromatography 
(isohexane:ethyl acetate:triethylamine = 98:2:1) to give 138i (31 mg, 112 µmol, 56%) as a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 7.34 (dd, J = 8.9, 1.4 Hz, 1H), 7.12 (dd, J = 8.8, 7.0 Hz, 1H), 
6.62 (dd, J = 7.0, 1.4 Hz, 1H), 6.55 (s, 1H), 6.09 - 6.00 (m, 1H), 5.78 - 5.68 (m, 1H), 4.47 - 4.39 (m, 
1H), 2.30 - 2.19 (m, 1H), 2.16 - 2.09 (m, 2H), 1.83 - 1.56 (m, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 144.9, 142.3, 130.8, 130.3, 126.4, 124.6, 114.6, 110.3, 99.5, 
35.5, 26.7, 25.3, 20.2. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 2928, 1632, 1546, 1518, 1433, 1361, 1314, 946, 788, 722. 
MS (EI, 70 eV): 278 (42), 277 (31), 276 (41), 275 (34), 249 (33), 247 (38), 223 (35), 221 (35), 212 
(23), 210 (25), 197 (100), 169 (22), 155 (21), 81 (40), 79 (23), 79 (42). 
HRMS (EI) for C13H13N2Br (276.0262): 276.0252 (M+). 
 
Synthesis of 2-iodo-7-(methylthio)pyrazolo[1,5-a]pyridine (138j) 
 
 
 
Pyrazolo[1,5-a]pyridine 138j was prepared via TP15 using 136a (61 mg, 0.25 mmol), TMPMgCl·LiCl 
(0.25 mL, 0.30 mmol) and S-methyl methanethiosulfonate (42 mg, 0.33 mmol). The reaction was 
complete after 12 h. After work-up, the crude product was purified via column chromatography 
(isohexane:ethyl acetate:triethylamine = 15:1:0.1) to give 138j (38 mg, 131 mmol, 52%) as a colorless 
solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 7.31 - 7.29 (m, 1H), 7.15 - 7.11 (m, 1H), 6.72 (s, 1H), 6.50 (d, 
J = 7.3, 1H), 2.60 (s, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 142.1, 139.9, 124.3, 112.1, 107.2, 106.4, 100.9, 14.3. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 2987, 2915, 1905, 1688, 1609, 1532, 1489, 1437, 1416, 1341, 
1308, 1280, 1221, 1198, 1152, 1096, 1059. 
MS (EI, 70 eV): 291 (11), 290 (100), 257 (46), 163 (31), 136 (29), 117 (16), 90 (33), 63 (13), 62 (11), 
45 (14), 43 (40). 
HRMS (EI) for C8H7IN2S (289.9375): 289.9369 (M+). 
M.p. (°C): 131–133. 
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Synthesis of 2-iodo-7-(phenylthio)pyrazolo[1,5-a]pyridine (138k) 
 
 
 
Pyrazolo[1,5-a]pyridine 138k was prepared via TP15 using 136a (61 mg, 0.25 mmol), TMPMgCl·LiCl 
(0.25 mL, 0.30 mmol) and S-phenyl benzenethiosulfonate (83 mg, 0.33 mmol). The reaction was 
complete after 12 h. After work-up, the crude product was purified via column chromatography 
(isohexane:ethyl acetate:triethylamine = 15:1:0.1 to 15:10:0.1) to give 138k (56 mg, 159 mmol, 64%) 
as a yellow solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 7.71 - 7.66 (m, 2H), 7.56 - 7.46 (m, 3H), 7.27 (dd, J = 8.8, 1.2 
Hz, 1H), 6.95 (dd, J = 8.8, 7.4 Hz, 1H), 6.74 (s, 1H), 6.00 (dd, J = 7.4, 1.2 Hz, 1H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 142.2, 140.5, 136.2, 130.4, 130.2, 128.4, 124.5, 112.2, 108.6, 
106.4, 100.9. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3134, 3058, 2916, 1614, 1529, 1489, 1440, 1420, 1340, 1308, 
1281, 1194, 1148, 1102, 1068, 1024. 
MS (EI, 70 eV): 353 (15), 352 (100), 225 (41), 224 (14), 43 (11). 
HRMS (EI) for C13H9IN2S (351.9531): 351.9526 (M+). 
M.p. (°C): 119–120. 
 
Synthesis of ethyl 7-iodopyrazolo[1,5-a]pyridine-3-carboxylate (141a) 
 
 
 
Pyrazolo[1,5-a]pyridine 141a was prepared via TP15 using 139 (190 mg, 1.00 mmol), TMPMgCl·LiCl 
(0.96 mL, 1.20 mmol) and iodine (381 mg, 1.50 mmol). The reaction was complete after 12 h. After 
quenching with a sat. aq. Na2S2O3 solution (10 mL) followed by standard work-up, the crude product 
was purified via column chromatography (isohexane:ethyl acetate = 9:1) to give 141a (189 mg, 
0.60 mmol, 60%) as a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.48 (s, 1H), 8.20 (dd, J = 8.8, 1.3 Hz, 1H), 7.51 (dd, J = 7.2, 
1.3 Hz, 1H), 7.13 (dd, J = 8.8, 7.2 Hz, 1H), 4.39 (q, J = 7.1 Hz, 2H), 1.42 (t, J = 7.1 Hz, 3H). 
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13C-NMR (101 MHz, CDCl3): δ / ppm = 163.6, 144.1, 141.6, 127.7, 125.9, 119.2, 106.4, 92.7, 60.4, 
14.6. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3098, 2980, 1701, 1622, 1507, 1239, 1198, 1136, 1063, 787. 
MS (EI, 70 eV): m/z = 316 (47), 288 (51), 271 (100), 244 (25), 207 (13), 144 (13). 
HRMS (EI) for C10H9N2O2I (315.9709): 315.9702 (M+). 
M.p. (°C): 105–108. 
 
Synthesis of ethyl 7-bromopyrazolo[1,5-a]pyridine-3-carboxylate (141b) 
 
 
 
Pyrazolo[1,5-a]pyridine 141b was prepared via TP15 using 139 (196 mg, 1.03 mmol), TMPMgCl·LiCl 
(0.96 mL, 1.20 mmol) and 1,2-dibromotetrachloroethane (520 mg, 1.60 mmol). The reaction was 
complete after 12 h. After work-up, the crude product was purified via column chromatography 
(isohexane:ethyl acetate = 9:1) to give 141b (189 mg, 0.70 mmol, 68%) as a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm 8.51 (s, 1H), 8.21 (dd, J = 8.1, 2.0 Hz, 1H), 7.34 - 7.26 (m, 2H), 
4.41 (q, J = 7.1 Hz, 2H), 1.43 (t, J = 7.1 Hz, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 163.3, 144.7, 142.6, 127.6, 119.8, 118.3, 118.2, 106.0, 60.4, 
14.6. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3102, 2980, 1700, 1626, 1510, 1376, 1304, 1239, 1199, 1146, 
1067, 910, 787, 722. 
MS (EI, 70 eV): 270 (32), 268 (32), 242 (44), 240 (46), 225 (95), 223 (100), 198 (19), 196 (20), 116 
(16). 
HRMS (EI) for C10H9N2O2Br (267.9847): 267.9841 (M+). 
M.p. (°C): 70–72. 
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Synthesis of ethyl 7-(methylthio)pyrazolo[1,5-a]pyridine-3-carboxylate (141c) 
 
 
 
Pyrazolo[1,5-a]pyridine 141c was prepared via TP15 using 139 (95 mg, 0.50 mmol), TMPMgCl·LiCl 
(0.50 mL, 0.60 mmol) and S-methyl methanethiosulfonate (70 µL, 0.75 mmol). The reaction was 
complete after 6 h. After work-up, the crude product was purified via column chromatography 
(isohexane:ethyl acetate = 7:3) and HPLC to give 141c (63 mg, 267 µmol, 53%) as a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.48 - 8.40 (m, 1H), 7.95 (d, J = 8.9 Hz, 1H), 7.41 - 7.32 (m, 
1H), 6.69 (d, J = 7.4 Hz, 1H), 4.36 (q, J = 7.0 Hz, 2H), 2.61 (s, 3H), 1.39 (t, J = 7.0 Hz, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 163.6, 144.5, 141.7, 141.3, 127.3, 114.3, 108.8, 104.2, 60.1, 
14.6, 14.3. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3115, 3086, 3000, 2981, 2930, 2904, 2861, 1692, 1617, 1507, 
1395, 1385, 1345, 1196, 1077, 1024, 924, 810, 779, 726. 
MS (EI, 70 eV): 236 (100), 203 (41), 191 (72), 176 (19), 175 (58), 163 (21), 159 (43), 132 (14), 131 
(14), 47 (13), 45 (31), 44 (21). 
HRMS (EI) for C11H12N2O2S (236.0619): 236.0613 (M+). 
M.p. (°C): 112–123. 
 
Synthesis of ethyl 7-formylpyrazolo[1,5-a]pyridine-3-carboxylate (141d) 
 
 
 
Pyrazolo[1,5-a]pyridine 141d was prepared via TP15 using 139 (95 mg, 0.50 mmol), TMPMgCl·LiCl 
(0.50 mL, 0.60 mmol) and 4-formylmorpholine (65 µL, 0.65 mmol). The reaction was complete after 
12 h. After work-up, the crude product was purified via column chromatography (isohexane:ethyl 
acetate = 8:2) to give 141d (50 mg, 0.229 mmol, 46%) as a yellow solid. 
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1H-NMR (400 MHz, CDCl3): δ / ppm = 10.91 (d, J = 0.6 Hz, 1H), 8.48 (s, 1H), 8.43 (dd, J = 8.8, 1.5 
Hz, 1H), 7.62 (dd, J = 7.1, 1.5 Hz, 1H), 7.50 (ddd, J = 8.9, 7.1, 0.7 Hz, 1H), 4.41 (q, J = 7.1 Hz, 2H), 
1.43 (t, J = 7.1 Hz, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 184.6, 163.3, 144.9, 141.4, 134.1, 126.3, 124.7, 116.1, 105.7, 
60.5, 14.6. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3110, 2979, 2884, 1692, 1628, 1532, 1422, 1374, 1352, 1242, 
1169, 1084, 849, 799, 782, 727. 
MS (EI, 70 eV): 218 (24), 207 (15), 205 (15), 191 (10), 190 (100), 173 (81), 162 (23), 145 (47), 144 
(12), 118 (18), 117 (13), 117 (47), 91 (11), 90 (28). 
HRMS (EI) for C11H10N2O3 (218.0691): 218.0684 (M+). 
M.p. (°C): 104–106. 
 
Synthesis of ethyl 7-allylpyrazolo[1,5-a]pyridine-3-carboxylate (141e) 
 
 
 
Pyrazolo[1,5-a]pyridine 141e was prepared via TP15 using 139 (95 mg, 0.50 mmol) and 
TMPMgCl·LiCl (0.50 mL, 0.60 mmol). After the metalation was complete, a 1.0 M CuCN·2LiCl 
solution in THF (0.60 mL, 0.60 mmol) was added and the reaction warmed to –40 °C and stirred for 
10 min. Then, allyl bromide (55 µL, 0.65 mmol) was added dropwise, and the reaction slowly warmed 
to 25 °C and stirred for 2 h. After work-up, the crude product was purified via column chromatography 
(isohexane:ethyl acetate:triethylamine = 9:1:0.1) to give 141e (85 mg, 369 µmol, 74%) as a colorless 
solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.42 (s, 1H), 8.12 - 8.04 (m, 1H), 7.36 (dd, J = 8.9, 7.0 Hz, 
1H), 6.85 - 6.76 (m, 1H), 6.20 - 6.06 (m, 1H), 5.31 - 5.20 (m, 2H), 4.38 (q, J = 7.1 Hz, 2H), 3.94 (d, J 
= 6.7 Hz, 2H), 1.41 (t, J = 7.1 Hz, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 163.8, 144.3, 141.4, 141.2, 132.1, 127.4, 119.0, 117.1, 112.4, 
104.2, 60.0, 35.1, 14.7. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3103, 2983, 2926, 2899, 1690, 1636, 1532, 1477, 1376, 1292, 
1231, 1204, 1141, 1087, 999, 976, 918, 846, 794. 
MS (EI, 70 eV): 230 (39), 229 (100), 215 (13), 202 (10), 201 (97), 187 (40), 185 (56), 183 (12), 157 
(25), 156 (12), 155 (16), 130 (21). 
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HRMS (EI) for C13H13N2O2 (229.0977): 229.0971 (M+-H). 
M.p. (°C): 64–65. 
 
Synthesis of ethyl 7-(cyclohex-2-en-1-yl)pyrazolo[1,5-a]pyridine-3-carboxylate (141f) 
 
 
 
Pyrazolo[1,5-a]pyridine 141f was prepared via TP15 using 139 (95 mg, 0.50 mmol) and 
TMPMgCl·LiCl (0.50 mL, 0.60 mmol). After the metalation was complete, a 1.0 M CuCN·2LiCl 
solution in THF (0.60 mL, 0.60 mmol) was added and the reaction warmed to –40 °C and stirred for 10 
min. Then, 3-bromocyclohexene (75 µL, 0.65 mmol) was added dropwise, and the reaction slowly 
warmed to 25 °C and stirred for 2.5 h. After work-up, the crude product was purified via column 
chromatography (isohexane:ethyl acetate:triethylamine = 10:0.6) to give 141f (112 mg, 414 µmol, 
83%) as a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.43 (s, 1H), 8.07 (dd, J = 8.8, 1.4 Hz, 1H), 7.38 (dd, J = 8.8, 
7.1 Hz, 1H), 6.83 (dd, J = 7.1, 1.4 Hz, 1H), 6.12 - 6.03 (m, 1H), 5.82 - 5.72 (m, 1H), 4.54 - 4.45 (m, 
1H), 4.39 (q, J = 7.1 Hz, 2H), 2.31 - 2.19 (m, 1H), 2.18 - 2.10 (m, 2H), 1.84 - 1.56 (m, 3H), 1.41 (t, J = 
7.1 Hz, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 163.9, 146.0, 144.2, 141.6, 131.1, 127.5, 126.2, 116.8, 112.2, 
104.0, 60.0, 35.8, 27.0, 25.3, 20.2, 14.7. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 2930, 1702, 1635, 1531, 1378, 1234, 1094, 795. 
MS (EI, 70 eV): 271 (13), 270 (81), 269 (38), 241 (100), 229 (24), 227 (14), 225 (22), 215 (20), 213 
(45), 204 (32), 201 (14), 199 (12), 195 (11), 187 (18), 169 (11). 
HRMS (EI) for C16H18N2O2 (270.1368): 270.1366 (M+). 
M.p. (°C): 53–57. 
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Synthesis of ethyl 7-(cyclopropanecarbonyl)pyrazolo[1,5-a]pyridine-3-carboxylate (141g) 
 
 
 
Pyrazolo[1,5-a]pyridine 141g was prepared via TP15 using 139 (95 mg, 0.50 mmol) and 
TMPMgCl·LiCl (0.50 mL, 0.60 mmol). After the metalation was complete, a 1.0 M CuCN·2LiCl 
solution in THF (0.60 mL, 0.60 mmol) was added and the reaction warmed to –40 °C and stirred for 10 
min. Then, cyclopropanecarbonyl chloride (70 µL, 0.75 mmol) was added dropwise, and the reaction 
slowly warmed to 25 °C and stirred for 1.5 h. After work-up, the crude product was purified via column 
chromatography (isohexane:ethyl acetate = 8.5:1.5) to give 141g (70 mg, 271 µmol, 54%) as a colorless 
solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.47 (s, 1H), 8.35 (dd, J = 8.8, 1.5 Hz, 1H), 7.47 (dd, J = 8.8, 
7.1 Hz, 1H), 7.38 (dd, J = 7.1, 1.5 Hz, 1H), 4.40 (q, J = 7.1 Hz, 2H), 3.23 - 3.13 (m, 1H), 1.46 - 1.40 
(m, 5H), 1.25 - 1.18 (m, 2H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 196.8, 163.5, 144.7, 141.8, 138.5, 126.7, 122.3, 115.9, 104.8, 
60.4, 21.5, 14.6, 14.1. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3103, 2981, 2165, 1701, 1624, 1529, 1481, 1414, 1377, 1306, 
1238, 1197, 1172, 1083, 1008, 930, 797, 741, 710. 
MS (EI, 70 eV): 259 (12), (258 (57), 257 (12), 230 (16), 229 (100), 228 (31), 228 (27), 214 (12), 213 
(38), 202 (37), 201 (15), 185 (11), 145 (17). 
HRMS (EI) for C14H14N2O3 (258.1004): 258.1038 (M+). 
M.p. (°C): 52–54. 
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Synthesis of ethyl 7-(4-(ethoxycarbonyl)phenyl)pyrazolo[1,5-a]pyridine-3-carboxylate (141h) 
 
 
 
Pyrazolo[1,5-a]pyridine 141h was prepared via TP15 using 139 (95 mg, 0.50 mmol) and 
TMPMgCl·LiCl (0.50 mL, 0.60 mmol). After the metalation was complete, a 1.0 M ZnCl2 solution in 
THF (0.60 mL, 0.60 mmol) was added dropwise and the reaction mixture stirred for 20 min. Then, 
Pd(dba)2 (9 mg, 15 µmol), tfp (7 mg, 30 µmol) and ethyl 4-iodobenzoate (76 µL, 0.45 mmol) were 
added, the reaction warmed to 25 °C and stirred for 12 h. After work-up, the crude product was purified 
via column chromatography (isohexane:ethyl acetate = 8.5:1.5) to give 141h (60 mg, 177 µmol, 39%) 
as a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.42 (s, 1H), 8.27 - 8.18 (m, 3H), 7.98 - 7.91 (m, 2H), 7.50 
(dd, J = 8.9, 7.1 Hz, 1H), 7.05 (dd, J = 7.1, 1.4 Hz, 1H), 4.49 - 4.34 (m, 4H), 1.48 - 1.37 (m, 6H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 166.1, 163.7, 144.6, 142.0, 140.5, 137.2, 131.7, 129.8, 129.5, 
127.5, 118.8, 115.0, 104.5, 61.4, 60.2, 14.7, 14.5. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 2981, 1701, 1632, 1532, 1507, 1376, 1271, 1242, 1182, 1118, 
1049, 917, 859, 798, 772, 736, 700. 
MS (EI, 70 eV): 339 (21), 338 (100), 337 (11), 310 (10), 293 (43), 266 (10), 265 (19). 
HRMS (EI) for C19H18N2O4 (338.1267): 338.1263 (M+). 
M.p. (°C): 94–97. 
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Synthesis of ethyl 7-(4-methoxyphenyl)pyrazolo[1,5-a]pyridine-3-carboxylate (141i) 
 
 
 
Pyrazolo[1,5-a]pyridine 141i was prepared via TP15 using 139 (95 mg, 0.50 mmol) and 
TMPMgCl·LiCl (0.50 mL, 0.60 mmol). After the metalation was complete, a 1.0 M ZnCl2 solution in 
THF (0.60 mL, 0.60 mmol) was added dropwise and the reaction mixture stirred for 20 min. Then, 
Pd(dba)2 (9 mg, 15 µmol), tfp (7 mg, 30 µmol) and 4-iodoanisole (105 mg, 0.45 mmol) were added, the 
reaction warmed to 25 °C and stirred for 12 h. After work-up, the crude product was purified via column 
chromatography (isohexane:ethyl acetate = 8.5:1.5) to give 141i (100 mg, 337 µmol, 75%) as a 
colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.40 (s, 1H), 8.13 (dd, J = 8.8, 1.4 Hz, 1H), 7.84 - 7.75 (m, 
2H), 7.41 (dd, J = 8.8, 7.1 Hz, 1H), 7.06 - 6.98 (m, 2H), 6.92 (dd, J = 7.1, 1.4 Hz, 1H), 4.38 (q, J = 7.1 
Hz, 2H), 3.84 (s, 3H), 1.41 (t, J = 7.1 Hz, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 163.6, 160.7, 144.3, 141.9, 141.3, 130.8, 127.5, 125.1, 117.2, 
113.9, 113.9, 103.9, 59.9, 55.4, 14.6. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 2988, 2926, 1692, 1611, 1552, 1509, 1439, 1408, 1379, 1346, 
1297, 1254, 1231, 1182, 1126, 1112, 1054, 1016, 914, 828, 789, 741. 
MS (EI, 70 eV): 297 (18), 296 (100), 295 (14), 268 (17), 267 (41), 251 (56), 224 (18), 223 (26), 179 
(14). 
HRMS (EI) for C17H16N2O3 (296.1161): 296.1156 (M+). 
M.p. (°C): 125–126. 
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Synthesis of ethyl 5-ethylpyrazolo[1,5-a]pyridine-3-carboxylate (142) and ethyl 5-((tert-
butoxycarbonyl)amino)pyrazolo[1,5-a]pyridine-3-carboxylate (143) 
 
 
 
O-(2,4-dinitrophenyl)hydroxylamine was synthesized according to a literature procedure.143 
 
Synthesis of ethyl 5-ethylpyrazolo[1,5-a]pyridine-3-carboxylate (142) 
 
 
 
Adapted from a literature procedure,95i 4-ethylpyridine (0.57 mL, 5.00 mmol) was dissolved in 
acetonitrile (30 mL) and then O-(2,4-dinitrophenyl)hydroxylamine (996 mg, 5.00 mmol) added. The 
resulting solution was then stirred at 40 °C for 22 h. Then, the solvent was removed in vacuo and the 
crude redissolved in DMF (15 mL). Then, K2CO3 (1.38 g, 10 mmol) and ethyl propiolate (0.51 mL, 
5.00 mmol) were added and an air inlet introduced to the solution. After stirring for 3 h at room 
temperature, an aq. 5% LiCl solution (100 mL) was added and the reaction mixture transferred to a 
separating funnel. After extraction with ethyl acetate (4 x 100 mL), the organic phase was dried over 
Na2SO4, filtered, and the solvent removed in vacuo. The crude product was then purified via column 
chromatography (isohexane:ethyl acetate = 9:1) to give 142 (620 mg, 2.84 mmol, 57%) as a light yellow 
solid. 
 
The spectra matched those of the literature.95i  
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.40 (dd, J = 7.1, 0.9 Hz, 1H), 8.34 (s, 1H), 7.94 (m, J = 2.3, 
1.1 Hz, 1H), 6.80 (dd, J = 7.1, 1.9 Hz, 1H), 4.37 (q, J = 7.1 Hz, 2H), 2.75 (q, J = 7.6, 2H), 1.41 (t, J = 
7.1 Hz, 3H), 1.31 (t, J = 7.6 Hz, 3H). 
  
                                                     
143
 Legault, C.; Charette, A. B., J. Org. Chem. 2003, 68, 7119–7122. 
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Synthesis of ethyl 5-((tert-butoxycarbonyl)amino)pyrazolo[1,5-a]pyridine-3-carboxylate (143) 
 
 
 
Adapted from a literature procedure,95i tert-butyl pyridin-4-ylcarbamate (0.971 mg, 5.00 mmol) was 
dissolved in acetonitrile (30 mL) and then O-(2,4-dinitrophenyl)hydroxylamine (996 mg, 5.00 mmol) 
added. The resulting solution was then stirred at 40 °C for 22 h. Then, the solvent was removed in vacuo 
and the crude redissolved in DMF (15 mL). Then, K2CO3 (1.38 g, 10 mmol) and ethyl propiolate 
(0.51 mL, 5.00 mmol) were added and an air inlet introduced to the solution. After stirring for 3 h at 
room temperature, an aq. 5%LiCl solution (100 mL) was added and the reaction mixture transferred to 
a separating funnel. After extraction with ethyl acetate (4 x 100 mL), the organic phase was dried over 
Na2SO4, filtered, and the solvent removed in vacuo. The crude product was then purified via column 
chromatography (isohexane:ethyl acetate:triethylamine = 7:3:0.1) to give 143 (564 mg, 1.85 mmol, 
37%) as yellow solid. 
 
The spectra matched those of the literature.95i 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.39 (dd, J = 7.6, 0.8 Hz, 1H), 8.32 (s, 1H), 7.98 (dd, J = 2.5, 
0.8 Hz, 1H), 7.34 - 7.28 (m, 1H), 6.91 (s, 1H), 4.36 (q, J = 7.1 Hz, 2H), 1.54 (s, 9H), 1.40 (t, J = 7.1 
Hz, 3H). 
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Synthesis of ethyl 5-ethyl-7-iodopyrazolo[1,5-a]pyridine-3-carboxylate (144a) 
 
 
 
Pyrazolo[1,5-a]pyridine 144a was prepared via TP15 using 142 (22 mg, 0.10 mmol), TMPMgCl·LiCl 
(0.09 mL, 0,12 mmol) and iodine (40 mg, 0.15 mmol). The reaction was stirred at -78 °C and complete 
after 40 min. After quenching with a sat. aq. Na2S2O3 solution (10 mL) followed by standard work-up, 
the crude product was purified via column chromatography (isohexane:ethyl acetate:triethylamine = 
9:1:0.1) to give 144a (30 mg, 87 µmol, 86%) as a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.41 (s, 1H), 7.99 - 7.95 (m, 1H), 7.37 (d, J = 1.8 Hz, 1H), 
4.38 (q, J = 7.1 Hz, 2H), 2.72 (q, J = 7.5, 2H), 1.41 (t, J = 7.1 Hz, 3H), 1.31 (t, J = 7.6 Hz, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 163.8, 145.4, 144.3, 141.8, 127.2, 116.5, 105.3, 92.2, 60.2, 
28.3, 14.6, 14.5. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3098, 2971, 2935, 1697, 1629, 1531, 1507, 1375, 1318, 1234, 
1121, 1052, 930, 853, 834, 776. 
MS (EI, 70 eV): m/z = 345 (12), 344 (100), 316 (18), 299 (77), 272 (18). 
HRMS (EI) for C12H13IN2O2 (344.0022): 344.0011 (M+). 
M.p. (°C): 77–79. 
 
Synthesis of ethyl 7-(4-(tert-butyl)phenyl)-5-ethylpyrazolo[1,5-a]pyridine-3-carboxylate (144b) 
 
 
 
Pyrazolo[1,5-a]pyridine 144b was prepared via TP15 using 142 (85 mg, 0.39 mmol) and 
TMPMgCl·LiCl (0.35 mL, 0.47 mmol). After the metalation was complete, a 1.0 M ZnCl2 solution in 
THF (0.47 mL, 0.47 mmol) was added dropwise and the reaction mixture stirred for 20 min. Then, 
Pd(dba)2 (7 mg, 12 µmol), tfp (5 mg, 24 µmol) and 4-tert-butyliodobenzene (81 mg, 0.31 mmol) were 
added, the reaction warmed to 25 °C and stirred for 12 h. After work-up, the crude product was purified 
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via column chromatography (isohexane:ethyl acetate:triethylamine = 9.5:0.5:0.1) to give 144b (87 mg, 
248 µmol, 80%) as a colorless oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.37 (s, 1H), 8.00 - 7.95 (m, 1H), 7.82 - 7.76 (m, 2H), 7.59 - 
7.52 (m, 2H), 6.86 (d, J = 2.0 Hz, 1H), 4.40 (q, J = 7.1 Hz, 2H), 2.80 (q, J = 7.6, 2H), 1.43 (t, J = 7.1 
Hz, 3H), 1.38 (s, 9H), 1.34 (t, J = 7.6 Hz, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 164.0, 153.0, 145.0, 144.7, 142.3, 141.0, 130.2, 129.1, 125.7, 
116.0, 115.1, 103.1, 60.0, 35.0, 31.4, 28.8, 14.7, 14.7. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 2965, 2905, 2871, 1699, 1640, 1534, 1512, 1377, 1235, 1187, 
1121, 1056, 834, 779. 
MS (EI, 70 eV): m/z = 351 (24), 350 (100), 336 (12), 335 (43), 305 (19). 
HRMS (EI) for C22H26N2O2 (350.1994): 350.1991 (M+). 
 
Synthesis of ethyl 5-ethyl-7-(pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carboxylate (144c) 
 
 
 
Pyrazolo[1,5-a]pyridine 144c was prepared via TP15 using 142 (92 mg, 0.42 mmol) and 
TMPMgCl·LiCl (0.40 mL, 0.50 mmol). After the metalation was complete, a 1.0 M ZnCl2 solution in 
THF (0.50 mL, 0.50 mmol) was added dropwise and the reaction mixture stirred for 20 min. Then, 
Pd(dba)2 (7 mg, 13 µmol), tfp (6 mg, 26 µmol) and 3-iodopyridine (70 mg, 0.34 mmol) were added, the 
reaction warmed to 25 °C and stirred for 12 h. After work-up, the crude product was purified via column 
chromatography (isohexane:ethyl acetate:triethylamine = 5:5:0.1) to give 144c (50 mg, 169 µmol, 50%) 
as a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.99 (d, J = 2.3 Hz, 1H), 8.71 (dd, J = 5.0, 1.6 Hz, 1H), 8.33 
(s, 1H), 8.29 (dt, J = 8.0, 2.0 Hz, 1H), 8.02 (d, J = 1.0 Hz, 1H), 7.47 - 7.41 (m, 1H), 6.88 (d, J = 1.9 Hz, 
1H), 4.38 (q, J = 7.1 Hz, 2H), 2.79 (q, 2H), 1.40 (t, J = 7.1 Hz, 3H), 1.34 (t, J = 7.6 Hz, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 163.7, 150.7, 149.8, 144.8, 144.6, 142.2, 137.6, 137.0, 129.2, 
123.1, 116.3, 116.2, 103.6, 60.0, 28.7, 14.6, 14.5. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3110, 3030, 2971, 1935, 2883, 1693, 1642, 1533, 1487, 1378, 
1237, 1185, 1118, 1059, 1026, 907, 868, 730, 705. 
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MS (EI, 70 eV): 295 (58), 281 (21), 266 (29), 250 (49), 225 (83), 222 (30), 209 (38), 207 (100), 191 
(33), 78 (28), 44 (28). 
HRMS (EI) for C17H17N3O2 (295.1321): 295.1315 (M+). 
M.p. (°C): 108–110. 
 
Synthesis of ethyl 5-ethyl-7-(methylthio)pyrazolo[1,5-a]pyridine-3-carboxylate (144d) 
 
 
 
Pyrazolo[1,5-a]pyridine 144d was prepared via TP15 using 142 (70 mg, 0.32 mmol), TMPMgCl·LiCl 
(0.29 mL, 0.39 mmol) and S-methyl methanethiosulfonate (61 mg, 0.48 mmol). The reaction was 
complete after 12 h. After work-up, the crude product was purified via column chromatography 
(isohexane:ethyl acetate:triethylamine = 8:2:0.1) and HPLC to give 144d (53 mg, 0.20 mmol, 62%) as 
a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.41 (s, 1H), 7.80 - 7.76 (m, 1H), 6.56 (d, J = 1.6 Hz, 1H), 
4.37 (q, J = 7.1 Hz, 2H), 2.77 (q, J = 7.6, 2H), 2.63 (s, 3H), 1.41 (t, J = 7.1 Hz, 3H), 1.33 (t, J = 7.6 Hz, 
3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 163.9, 144.9, 144.7, 141.8, 140.8, 112.2, 110.5, 103.3, 60.0, 
29.1, 14.8, 14.7, 14.4. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3077, 2985, 2962, 2934, 1961, 1626, 1516, 1380, 1217, 1177, 
1128, 1081, 943, 858, 774. 
MS (EI, 70 eV): 264 (100), 231 (58), 219 (44), 203 (50), 187 (31), 118 (10), 49 (12). 
HRMS (EI) for C13H16N2O2S (264.0932): 264.0924 (M+). 
M.p. (°C): 114–116. 
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Synthesis of ethyl 5-((tert-butoxycarbonyl)amino)-7-iodopyrazolo[1,5-a]pyridine-3-carboxylate 
(145a) 
 
 
 
Pyrazolo[1,5-a]pyridine 145a was prepared via TP15 using 143 (20 mg, 66 µmol), TMPMgCl·LiCl 
(0.11 mL, 144 µmol) and iodine (50 mg, 197 µmol). The reaction was stirred at –78 °C and complete 
after 50 min. After quenching with a sat. aq. Na2S2O3 solution (10 mL) followed by standard work-up, 
the crude product was purified via column chromatography (isohexane:ethyl acetate = 9:1) to give 145a 
(13 mg, 30 µmol, 46%) as a yellow solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.37 (s, 1H), 7.98 (s, 2H), 6.86 (s, 1H), 4.37 (q, J = 7.1 Hz, 
2H), 1.54 (s, 9H), 1.40 (t, J = 7.1 Hz, 4H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 163.8, 152.0, 144.9, 141.7, 138.6, 118.6, 105.2, 104.1, 93.2, 
82.3, 60.2, 28.4, 14.7. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3312, 3124, 2979, 2931, 1732, 1703, 1676, 1629, 1561, 1520, 
1239, 1223, 1198, 1153, 1132, 1055, 849, 774. 
MS (ESI, 70 eV): m/z = 432 (55), 376 (100), 279 (10). 
HRMS (ESI) for C15H19IN3O4 (432.0420): 432.0412 (M++H). 
M.p. (°C): 172–174. 
 
Synthesis of ethyl 7-bromo-5-((tert-butoxycarbonyl)amino)pyrazolo[1,5-a]pyridine-3-
carboxylate (145b) 
 
 
 
Pyrazolo[1,5-a]pyridine 145b was prepared via TP15 using 143 (62 mg, 0.20 mmol), TMPMgCl·LiCl 
(0.32 mL, 0.40 mmol) and 1,2-dibromotetrachloroethane (98 mg, 0.30 mmol). The reaction was 
complete after 12 h. After work-up, the crude product was purified via column chromatography 
(isohexane:ethyl acetate:triethylamine = 8:2:0.1) to give 145b (65 mg, 169 µmol, 83%) as a yellow 
solid. 
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1H-NMR (400 MHz, CDCl3): δ / ppm = 8.39 (s, 1H), 7.95 (d, J = 2.3 Hz, 1H), 7.81 (s, 1H), 6.95 (s, 
1H), 4.37 (q, J = 7.1 Hz, 2H), 1.54 (s, 9H), 1.40 (t, J = 7.1 Hz, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 163.6, 152.0, 145.4, 142.7, 138.9, 120.3, 111.2, 104.7, 103.1, 
82.3, 60.2, 28.3, 14.7. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3310, 2981, 2365, 1734, 1702, 1674, 1636, 1567, 1529, 1242, 
1224, 1156, 1134, 1067, 858, 730. 
MS (ESI, 70 eV): 386 (55), 330 (100), 328 (98), 302 (15), 282 (5). 
HRMS (ESI) for C15H19BrN3O4 (384.0559): 384.0560 (M++H). 
M.p. (°C): 159–161. 
 
Synthesis of ethyl 5-((tert-butoxycarbonyl)amino)-7-(4-(tert-butyl)phenyl)pyrazolo[1,5-
a]pyridine-3-carboxylate (145c) 
 
 
 
Pyrazolo[1,5-a]pyridine 145c was prepared via TP15 using 143 (81 mg, 0.26 mmol) and 
TMPMgCl·LiCl (0.42 mL, 0.57 mmol). After the metalation was complete, a 1.0 M ZnCl2 solution in 
THF (0.57 mL, 0.57 mmol) was added dropwise and the reaction mixture stirred for 20 min. Then, 
Pd(dba)2 (5 mg, 8 µmol), tfp (4 mg, 16 µmol) and 4-tert-butyliodobenzene (55 mg, 0.21 mmol) were 
added, the reaction warmed to 25 °C and stirred for 12 h. After work-up, the crude product was purified 
via column chromatography (isohexane:ethyl acetate:triethylamine = 8.5:1.5:0.1) to give 145c (90 mg, 
206 µmol, 98%) as a yellow solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.34 (s, 1H), 8.03 (d, J = 2.4 Hz, 1H), 7.80 - 7.75 (m, 2H), 
7.54 - 7.49 (m, 2H), 7.42 (s, 1H), 7.26 (s, 1H), 4.37 (q, J = 7.1 Hz, 2H), 1.53 (s, 9H), 1.39 (t, J = 7.1 
Hz, 3H), 1.34 (s, 9H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 164.0, 153.2, 152.3, 145.1, 142.7, 142.0, 139.1, 129.8, 129.1, 
125.6, 107.6, 102.8, 81.7, 59.9, 34.9, 31.3, 28.4, 14.7. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3316, 2967, 1733, 1674, 1639, 1544, 1514, 1235, 1215, 1189, 
1153, 1127, 1053, 907, 834, 727. 
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MS (ESI, 70 eV): 439 (25), 438 (100), 382 (25) 
HRMS (ESI) for C25H32N3O4 (438.2393): 438.2387 (M++H). 
M.p. (°C): 167–168. 
 
Synthesis of ethyl 5-((tert-butoxycarbonyl)amino)-7-(quinolin-2-yl)pyrazolo[1,5-a]pyridine-3-
carboxylate (145d) 
 
 
 
Pyrazolo[1,5-a]pyridine 145d was prepared via TP15 using 143 (81 mg, 0.26 mmol) and 
TMPMgCl·LiCl (0.42 mL, 0.57 mmol). After the metalation was complete, a 1.0 M ZnCl2 solution in 
THF (0.57 mL, 0.57 mmol) was added dropwise and the reaction mixture stirred for 20 min. Then, 
Pd(dba)2 (5 mg, 8 µmol), tfp (4 mg, 16 µmol) and 2-bromoquinoline (43 mg, 0.21 mmol) were added, 
the reaction warmed to 25 °C and stirred for 12 h. After work-up, the crude product was purified via 
column chromatography (isohexane:ethyl acetate:triethylamine = 8:2:0.1) to give 145d (50 mg, 
116 µmol, 55%) as a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.45 (d, J = 8.6 Hz, 1H), 8.37 (s, 1H), 8.33 (d, J = 2.5 Hz, 1H), 
8.31 (d, J = 8.6 Hz, 1H), 8.16 (d, J = 8.4 Hz, 1H), 7.88 (d, J = 8.2 Hz, 1H), 7.85 (d, J = 2.5 Hz, 1H), 
7.79 - 7.71 (m, 1H), 7.64 - 7.57 (m, 1H), 7.44 (s, 1H), 4.39 (q, J = 7.1 Hz, 2H), 1.48 (s, 9H), 1.41 (t, J 
= 7.1 Hz, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 163.8, 152.2, 150.8, 148.2, 145.2, 142.9, 140.2, 139.0, 136.3, 
130.1, 129.9, 128.3, 127.7, 127.7, 122.5, 109.6, 104.5, 103.3, 81.7, 60.1, 28.3, 14.7. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3314, 2979, 2932, 1733, 1701, 1679, 1642, 1561, 1542, 1524, 
1505, 1243, 1190, 1156, 1115, 1064, 775, 760, 731. 
MS (ESI, 70 eV): 434 (25), 433 (100), 377 (10). 
HRMS (ESI) for C24H25N4O4 (433.1876): 433.1870 (M++H). 
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Synthesis of 6-phenyl-7-(piperidin-1-yl)pyrazolo[1,5-a]pyridine (149) 
 
 
 
Synthesis of 7-(phenylthio)pyrazolo[1,5-a]pyridine (Q) 
 
 
 
Pyrazolo[1,5-a]pyridine Q was prepared via TP15 using 128 (1.18 g, 10.0 mmol), TMPMgCl·LiCl 
(9.60 mL, 12.0 mmol) and S-phenyl benzenethiosulfonate (3.76 µL, 15.0 mmol). The reaction was 
complete after 12 h. After work-up, the crude product was purified via column chromatography 
(isohexane:ethyl acetate:triethylamine = 10:0.8:0.1) to give Q (1.98 g, 8.75 mmol, 88%) as a light 
yellow solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.07 (d, J = 2.3 Hz, 1H), 7.71 - 7.64 (m, 2H), 7.58 - 7.42 (m, 
3H), 7.37 (dd, J = 8.8, 1.2 Hz, 1H), 6.95 (dd, J = 8.8, 7.3 Hz, 1H), 6.58 (d, J = 2.3 Hz, 1H), 6.10 (dd, J 
= 7.3, 1.1 Hz, 1H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 141.7, 140.6, 140.3, 135.8, 130.1, 130.1, 129.0, 123.5, 114.1, 
109.1, 97.2. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3076, 1615, 1583, 1531, 1495, 1475, 1440, 1411, 1356, 1306, 
1290, 1234, 1206, 1146, 1068, 1055, 1024, 1000. 
MS (EI, 70 eV): 226 (100), 225 (90), 198 (15), 193 (50), 192 (12). 
HRMS (EI) for C13H10N2S (226.0565): 226.0559 (M+). 
M.p. (°C): 80–81. 
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Synthesis of 7-(phenylsulfinyl)pyrazolo[1,5-a]pyridine (146) 
 
 
 
Pyrazolo[1,5-a]pyridine Q (1.93 g, 8.52 mmol) was dissolved in DCM (20 mL) and cooled to -30 °C. 
Then, mCPBA (70% in H2O, 2.31 g, 9.372 mmol) was dissolved in DCM (30 mL) and dried over 
Na2SO4. After drying, the mCPBA solution was added dropwise and the reaction mixture stirred for 5 h 
at –30 °C. The reaction was then quenched with water (50 mL) and extracted with DCM (3 x 50 mL), 
dried over Na2SO4, filtered, and the solvents removed in vacuo. The crude product was purified via 
column chromatography (isohexane:ethyl acetate:triethylamine = 7:3:0.1) to give 146 (1.80 g, 
7.43 mmol, 87%) as a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.05 - 7.98 (m, 2H), 7.94 (d, J = 2.3 Hz, 1H), 7.63 (dd, J = 
8.8, 1.3 Hz, 1H), 7.55 (dd, J = 7.1, 1.3 Hz, 1H), 7.46 - 7.40 (m, 3H), 7.32 (dd, J = 8.8, 7.0 Hz, 1H), 6.60 
(d, J = 2.3 Hz, 1H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 143.1, 142.4, 142.1, 140.8, 132.0, 129.2, 126.4, 123.4, 119.9, 
109.0, 97.9. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3059, 1624, 1506, 1476, 1444, 1368, 1296, 1225, 119, 1169, 
1140, 1082, 1054, 1033. 
MS (EI, 70 eV): 242 (100), 225 (17), 194 (50), 193 (90), 167 (10), 149 (11), 133 (56), 105 (11), 77 
(21), 42 (42). 
HRMS (EI) for C13H10N2SO (242.0514): 242.0507 (M+). 
M.p. (°C): 110–111. 
 
Synthesis of 6-phenyl-7-(phenylsulfinyl)pyrazolo[1,5-a]pyridine (147) 
 
 
 
Pyrazolo[1,5-a]pyridine 146 (484 mg, 2.00 mmol) was dissolved in THF (10 mL) and cooled to –30 °C. 
Then, TMPMgCl·LiCl (1.76 mL, 2.20 mmol) was added dropwise and the reaction stirred for 15 min 
at the same temperature. Then, a 1.0 M ZnCl2 solution in THF (2.20 mL, 2.20 mmol) was added 
dropwise and the reaction mixture stirred for 20 min. Then, Pd(dba)2 (35 mg, 60 µmol), tfp (28 mg, 
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120 µmol) and iodobenzene (224 µL, 2.20 mmol) were added, the reaction warmed to 25 °C and stirred 
for 12 h. After quenching with water, the mixture was extracted with ethyl acetate (3 x 50 mL), dried 
over Na2SO4, filtered and the solvent removed in vacuo. The crude product was purified via column 
chromatography (isohexane:ethyl acetate:triethylamine = 7:3:0.1) to give 147 (568 mg, 1.77 mmol, 
89%) as a yellow-orange solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 7.95 (d, J = 2.3 Hz, 1H), 7.72 (d, J = 9.0 Hz, 1H), 7.69 - 7.64 
(m, 2H), 7.56 - 7.45 (m, 5H), 7.41 - 7.35 (m, 3H), 7.16 (d, J = 9.0 Hz, 1H), 6.62 (d, J = 2.4 Hz, 1H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 142.3, 141.1, 140.0, 136.2, 135.9, 132.3, 130.3, 130.0, 128.5, 
128.4, 125.9, 125.1, 121.3, 98.2. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3056, 1731, 1615, 1475, 1443, 1408, 1281, 1199, 1086, 1050, 
814, 746, 727, 696, 693. 
MS (EI, 70 eV): 319 (18), 318 (82), 302 (15), 301 (46), 270 (38), 269 (100), 225 (54), 224 (52), 209 
(20), 198 (17), 192 (19), 182 (29), 166 (18), 140 (25), 139 (24), 77 (18). 
HRMS (EI) for C19H14N2SO (318.0827): 318.0831 (M+). 
M.p. (°C): 66–70. 
 
Synthesis of 6-phenyl-7-(piperidin-1-yl)pyrazolo[1,5-a]pyridine (149) 
 
 
 
Pyrazolo[1,5-a]pyridine 147 (64 mg, 0.20 mmol) was dissolved in THF (1 mL) and cooled to  
-78 °C. In a separate flask, piperidine (24 µL, 0.24 mmol) was dissolved in THF (1 mL) and cooled to 
0 °C. Then, iPrMgCl·LiCl (0.15 mL, 0.24 mmol) was added and the reaction stirred for 15 min at 0 °C 
and then 15 min at 25 °C The formed magnesium amide was then transferred dropwise to the solution 
of 147 and stirred at the same temperature for 40 min. The reaction was quenched with water and 
extracted with ethyl acetate (3 x 10 mL), dried over Na2SO4, filtered and the solvent removed in vacuo. 
The crude product was purified via column chromatography (isohexane:ethyl acetate:triethylamine = 
10:0.2:0.1) to give 149 (30.4 mg, 110 µmol, 55%) as a colorless oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 7.92 (d, J = 2.2 Hz, 1H), 7.44 - 7.32 (m, 2H), 7.31 - 7.24 (m, 
3H), 7.21 (d, J = 8.9 Hz, 1H), 7.01 (d, J = 8.9 Hz, 1H), 6.45 (d, J = 2.3 Hz, 1H), 2.98 (s, 4H), 1.52 (m, 
6H). 
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13C-NMR (101 MHz, CDCl3): δ / ppm = 143.8, 141.4, 141.2, 139.6, 129.9, 128.4, 128.3, 126.9, 118.4, 
112.1, 96.8, 51.2, 26.2, 24.4. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3053, 3026, 2930, 2848, 1622, 1599, 1520, 1491, 1443, 1292, 
1276, 1100, 1029, 919, 798, 768, 700. 
MS (EI, 70 eV): 277 (48), 276 (100), 248 (15), 220 (16), 209 (14), 208 (13), 194 (70), 193 (17), 166 
(19), 139 (11). 
HRMS (EI) for C18H19N3 (277.1579): 277.1580 (M+). 
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6.3 Regioselectivity Investigations 
 
To determine the regioselectivity of the metalation, both X-Ray crystallography (see chapter 9) and 
deuteration experiments were carried out. 
 
Regioselectivity Investigations 
 
Starting from pyrazolo[1,5-a]pyridines 128, 139, and 143, the corresponding metal species, which were 
prepared according to TP15, were quenched with a D2O / THF solution and the obtained deuterium-
incorporated product analyzed via 1H NMR spectroscopy. The measured spectra were also compared 
with the respective starting material spectra. 
 
Synthesis of pyrazolo[1,5-a]pyridine-7-d 
 
 
 
Pyrazolo[1,5-a]pyridine-7-d was prepared via TP15 using 128 (59 mg, 0.50 mmol) and 
TMPMgCl·LiCl (0.51 mL, 0.60 mmol). Then, a solution of D2O (0.05 mL, 2.78 mmol) in THF (2 mL) 
was added dropwise and the reaction mixture warmed to room temperature and stirred for 1 h. After 
work-up and purification via column chromatography (isohexane:ethyl acetate:triethylamine = 8:2:0.1) 
pyrazolo[1,5-a]pyridine-7-d was obtained (39 mg, 330 μmol, 66%) as a light yellow oil. NMR-
spectroscopy revealed an incorporation of deuterium at position C7 with a 2H:1H ratio of 75:25. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.48 (d, J = 7.0 Hz, 1D), 7.95 (d, J = 2.2 Hz, 1H), 7.54 (d, J = 
8.9 Hz, 1H), 7.09 (dd, J = 8.9, 6.7 Hz, 1H), 6.74 (d, J = 6.2 Hz, 1H), 6.51 (d, J = 2.2 Hz, 1H). 
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Synthesis of ethyl pyrazolo[1,5-a]pyridine-3-carboxylate-7-d 
 
 
 
Ethyl pyrazolo[1,5-a]pyridine-3-carboxylate-7-d was prepared via TP15 using 139 (95 mg, 0.50 mmol) 
and TMPMgCl·LiCl (0.51 mL, 0.60 mmol). Then, a solution of D2O (0.05 mL, 2.78 mmol) in THF 
(2 mL) was added dropwise and the reaction mixture warmed to room temperature and stirred for 1 h. 
After work-up, ethyl pyrazolo[1,5-a]pyridine-3-carboxylate-7-d was obtained (85 mg, 445 μmol, 89%) 
as a light yellow oil. NMR-spectroscopy revealed an incorporation of deuterium at position C7 with a 
2H:1H ratio of 80:20. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.53 (d, J = 6.9 Hz, 1D), 8.41 (s, 1H), 8.17 (d, J = 8.9 Hz, 1H), 
7.41 (dd, J = 8.9, 6.8 Hz, 1H), 6.95 (d, J = 6.8 Hz, 1H), 4.39 (q, J = 7.1 Hz, 2H), 1.42 (t, J = 7.1 Hz, 
3H). 
 
 
Synthesis of ethyl 5-((tert-butoxycarbonyl)amino)pyrazolo[1,5-a]pyridine-3-carboxylate-7-d 
 
 
 
Ethyl 5-((tert-butoxycarbonyl)amino)pyrazolo[1,5-a]pyridine-3-carboxylate-7-d was prepared via 
TP15 using 143 (19 mg, 33 μmol) and TMPMgCl·LiCl (0.06 mL, 75 μmol). Then, a solution of D2O 
(0.05 mL, 2.78 mmol) in THF (2 mL) was added dropwise and the reaction mixture warmed to room 
temperature and stirred for 1 h. After work-up, Ethyl 5-((tert-butoxycarbonyl)amino)pyrazolo[1,5-
a]pyridine-3-carboxylate-7-d was obtained (10 mg, 33 μmol, 52%) as a light yellow solid. NMR-
spectroscopy revealed an incorporation of deuterium at position C7 with a 2H:1H ratio of 81:19. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.39 (d, J = 7.6 Hz, 1D), 8.32 (s, 1H), 7.98 (d, J = 2.5 Hz, 1H), 
7.32 (s, 1H), 7.03 (s, 1H), 4.36 (q, J = 7.1 Hz, 2H), 1.53 (s, 9H), 1.40 (t, J = 7.1 Hz, 3H). 
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1H NMR spectrum of pyrazolo[1,5-a]pyridine-7-d 
  
1H NMR spectrum of pyrazolo[1,5-a]pyridine 
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1H NMR spectrum of ethyl pyrazolo[1,5-a]pyridine-3-carboxylate-7-d 
 
1H NMR spectrum of ethyl 5-((tert-butoxycarbonyl)amino)pyrazolo[1,5-a]pyridine-3-carboxylate 12 
(for comparison) 
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1H NMR spectrum of ethyl 5-((tert-butoxycarbonyl)amino)pyrazolo[1,5-a]pyridine-3-carboxylate-7-d  
 
1H NMR spectrum of ethyl 5-((tert-butoxycarbonyl)amino)pyrazolo[1,5-a]pyridine-3-carboxylate 16 
(for comparison) 
 
  
CDCl3, 400 MHz
143
N N
H
BocHN
CO2Et
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7 Lewis Acid Directed Regioselective Metalations of Pyridazine 
7.1 Typical Procedures 
 
Typical Procedure 18: Metalation and functionalization of pyridazine in the C3 position using 
BF3·OEt2 and TMPZnCl·LiCl. 
 
Pyridazine (150) was dissolved in THF (5 mL/mmol pyridazine) and cooled to 0 °C. BF3·OEt2 
(1.1 equiv) was added dropwise and the reaction mixture stirred for 10 min. TMPZnCl·LiCl (1.5 equiv) 
was added and the reaction warmed to 25 °C and stirred for 6 h. Then, a solution of the electrophile in 
THF (5 mL/mmol pyridazine) was added dropwise and the reaction stirred until completion. The 
reaction mixture was quenched with an aq. sat. NH4Cl solution (10 mL) and extracted with ethyl acetate 
(3 x 30 mL). The organic phase was dried over Na2SO4, filtered, and concentrated in vacuo. If the crude 
product needed purification, it was purified via flash chromatography on silica gel using the appropriate 
eluent. 
 
Typical Procedure 19: Metalation and functionalization of pyridazine (150) via cross-coupling 
reactions in the C3 position using BF3·OEt2 and TMPZnCl·LiCl 
 
Pyridazine (150) was dissolved in THF (5 mL/mmol pyridazine) and cooled to 0 °C. BF3·OEt2 
(1.1 equiv) was added dropwise and the reaction mixture stirred for 10 min. TMPZnCl·LiCl (1.5 equiv), 
Pd(dba)2 (4 mol%), tfp (8 mol%) and the aryl iodide (0.8 equiv) were added and the reaction warmed 
to 25 °C and stirred for 12 h. The reaction mixture was quenched with an aq. sat. NH4Cl solution 
(10 mL) and extracted with ethyl acetate (3 x 30 mL). The organic phase was then dried over Na2SO4, 
filtered, and concentrated in vacuo. If the crude product needed purification, it was purified via flash 
chromatography on silica gel using the appropriate eluent. 
 
Typical Procedure 20: Metalation and functionalization of 3-phenylpyridazine (153) in the C6 position 
using TMPLi 
 
Pyridazine 153 was dissolved in THF (5 mL/mmol pyridazine) and cooled to -78 °C. TMPLi 
(0.95 equiv) was added dropwise and the reaction mixture stirred until full metalation was observed 
(5 min, checked via TLC). A solution of the electrophile in THF (5 mL/mmol pyridazine) was added 
dropwise and the reaction slowly warmed to room temperature and stirred until completion. The 
reaction mixture was quenched with an aq. sat. NH4Cl solution (10 mL) and extracted with ethyl acetate 
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(3 x 30 mL). The organic phase was then dried over Na2SO4, filtered and concentrated in vacuo. If the 
crude product needed purification, it was purified by flash chromatography on silica gel using the 
appropriate eluent. 
 
Typical Procedure 21: meta-Metalation and functionalization of pyridazines in the C5 position using 
BF3·OEt2 and TMPMgCl·LiCl. 
 
The pyridazine was dissolved in THF (5 mL/mmol pyridazine) and cooled to 0 °C. BF3·OEt2 (1.1 equiv) 
was added dropwise and the reaction mixture stirred for 10 min. The reaction was cooled to –78 °C and 
TMPMgCl·LiCl (2.0 equiv) was added and the reaction stirred for 20 min at the same temperature. A 
solution of the electrophile in THF (5 mL/mmol pyridazine) was added dropwise and the reaction stirred 
until completion. The reaction mixture was quenched with an aq. sat. NH4Cl solution (10 mL) and 
extracted with ethyl acetate (3 x 30 mL). The organic phase was then dried over Na2SO4, filtered, and 
concentrated in vacuo. If the crude product needed purification, it was purified via flash 
chromatography on silica gel using the appropriate eluent. 
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7.2 Optimization of Reaction Conditions for the Directed ortho- and meta-Metalation of the 
Pyridazine Scaffold 
 
Table 17: Optimization of the reaction conditions for the directed ortho-metalation of 
pyridazine.  
 
 
entry TMP base equiv time Temp [°C] yield[a] ratio (153: 154)[b] 
1 TMPMgCl·LiCl[c] 1.05 15 min –78 12% 32:68 
2 TMPMgCl·LiCl 1.05 15 min –78 1% 96:4 
3 TMPZnCl·LiCl[c] 1.1 2 h 25 45% 60:40 
4 TMPZnCl·LiCl 1.3 2 h 25 45% 96:4 
5 TMPZnCl·LiCl 1.5 6 h 25 72% (57%)[d] 97:3 
6 TMPZnCl·LiCl 1.1 6 h 25 48% n.d. 
7 TMPZnCl·LiCl 1.3 6 h 25 64% n.d. 
8 TMPZnCl·LiCl 1.4 6 h 25 69% n.d. 
[a] NMR yield using trimethoxybenzene as standard. [b] Determined by NMR analysis.
[c] BF3·OEt2 was omitted. [d] Isolated yield of 153. 
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Table 18: Optimization of the reaction conditions for the directed ortho-and meta-metalation 
of 3-phenylpyridazine. 
 
 
entry TMP base BF3·OEt2 time equiv yield ratio (155:156)[a] 
1 TMPLi - 5 min 1.1 43%[b] 95:5 
2 TMPLi - 5 min 0.95 72%[b] 96:4 
3 TMPMgCl·LiCl - 20 min 1.1 0%[c] - 
4 TMPMgCl·LiCl  1.1 equiv 20 min 1.1 65%[c] 44:56 
5 TMPMgCl·LiCl  1.1 equiv 20 min 2.0 82%[c] (58%)[b] 27:73 
6 TMPMgCl·LiCl  1.1 equiv 20 min 3.0 45%[c] 26:74 
[a] Determined by NMR analysis. [b] Isolated yield of the main regioisomer. [c] NMR yield using trimethoxybenzene as standard. 
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Table 19: Optimization of the reaction conditions for the directed meta-metalation of 
pyridazine. 
 
 
entry equiv temp. conc. yield[a] ratio (meta:ortho)[b] 
1 1.3 0 °C 0.1 M 40%[c] 99:1 
2 1.3 –78 °C 0.1 M 52% 99:1 
3 1.3 –78 °C 0.05 M 62% 99:1 
4 2.0 –78 °C 0.07 M 69% 99:1 
5 1.7  –78 °C 0.07 M 86% (63%)[c] 99:1 
6 1.3 –78 °C 0.1 M 0%[d] - 
[a] NMR yield using trimethoxybenzene as standard. [b] Determined by NMR analysis. [c] Isolated yield. [d] The 
Lewis acid 157 was omitted. 
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7.3 Preparation of Compounds 150 to 160 
 
Synthesis of 3-iodopyridazine (153) 
 
 
 
Pyridazine 153 was prepared via TP18 using pyridazine (92 mg, 1.15 mmol), BF3·OEt2 (0.16 mL, 
1.26 mmol), TMPZnCl·LiCl (2.08 mL, 1.73 mmol), and iodine (438 mg, 1.72 mmol). The reaction was 
complete after 1 h. After work-up, the crude product was purified via column chromatography 
(isohexane:ethyl acetate:triethylamine = 6:4:0.1) to give 153 (134 mg, 0.65 mmol, 57%) as a light 
yellow solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 9.15 (dd, J = 4.8, 1.6 Hz, 1H), 7.88 (dd, J = 8.5, 1.5 Hz, 1H), 
7.16 (dd, J = 8.6, 4.8 Hz, 1H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 150.6, 137.3, 127.2, 125.8. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3020, 1554, 1409, 1362, 1108, 1068, 980, 806, 710. 
MS (EI, 70 eV): m/z (%) = 206 (100), 128 (10), 125 (5). 
HRMS (EI) for C4H4IN2 (206.9419): 206.9414 (M++H+). 
M.p. (°C): 122–124. 
 
The spectra matched those of the literature.104b 
 
Synthesis of 3-phenylpyridazine (153a) 
 
 
 
Pyridazine 153a was prepared via TP19 using pyridazine (45 mg, 0.56 mmol), BF3·OEt2 (0.08 mL, 
0.62 mmol), and TMPZnCl·LiCl (1.01 mL, 0.84 mmol). After the metalation was complete, 
iodobenzene (93 mg, 0.457 µmol), Pd(dba)2 (13 mg, 22 µmol), and tfp (11 mg, 45 µmol) was added 
and the reaction stirred at 25 °C for 12 h. After work-up, the crude product was purified via column 
chromatography (isohexane:ethyl acetate:triethylamine = 6:4:0.1) to give 153a (48 mg, 0.31 mmol, 
68%) as a light yellow solid.  
C. EXPERIMENTAL PART    272 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 9.15 (dd, J = 4.9, 1.6 Hz, 1H), 8.10 - 8.05 (m, 2H), 7.85 (dd, 
J = 8.6, 1.6 Hz, 1H), 7.56 - 7.48 (m, 4H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 159.6, 150.1, 136.5, 130.2, 129.2, 127.3, 126.9, 124.0. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3080, 3053, 3034, 1575, 1452, 1433, 1374, 1316, 1156, 1100, 
981, 824, 760, 746, 698. 
MS (EI, 70 eV): m/z (%) = 157 (10), 156 (100), 128 (17), 102 (79), 76 (7). 
HRMS (EI) for C10H8N2 (156.0687): 156.0681 (M+). 
M.p. (°C): 106–107. 
 
Synthesis of ethyl 4-(pyridazin-3-yl)benzoate (153b) 
 
 
 
Pyridazine 153b was prepared via TP19 using pyridazine (83 mg, 1.04 mmol), BF3·OEt2 (0.15 mL, 
1.14 mmol), TMPZnCl·LiCl (1.88 mL, 1.56 mmol), ethyl 4-iodobenzoate (230 mg, 0.83 mmol), 
Pd(dba)2 (23 mg, 40 µmol), and tfp (19 mg, 80 µmol). After work-up, the crude product was purified 
via column chromatography (isohexane:ethyl acetate:triethylamine = 7:3:0.1) to give 153b (110 mg, 
0.48 mmol, 58%) as a light brown solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 9.21 (dt, J = 5.0, 1.6 Hz, 1H), 8.18 (qd, J = 8.7, 1.7 Hz, 4H), 
7.92 (dt, J = 8.6, 1.4 Hz, 1H), 7.59 (ddd, J = 8.6, 4.9, 1.2 Hz, 1H), 4.41 (qd, J = 7.1, 1.2 Hz, 2H), 1.42 
(td, J = 7.1, 1.1 Hz, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 166.3, 158.7, 150.5, 140.4, 132.0, 130.3, 127.2, 127.0, 124.4, 
61.4, 14.5. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3056, 2984, 2963, 2904, 1707, 1610, 1575, 1416, 1273, 1178, 
1112, 1022, 824, 767, 752, 697. 
MS (EI, 70 eV): m/z (%) = 228 (72), 227 (15), 200 (70), 184 (11), 183 (100), 155 (35), 146 (45), 129 
(14), 129 (51). 
HRMS (EI) for C13H12N2O2 (228.0899): 228.0894 (M+). 
M.p. (°C): 89–91. 
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Synthesis of 3-(4-chlorophenyl)pyridazine (153c) 
 
 
 
Pyridazine 153c was prepared via TP19 using pyridazine (85 mg, 1.06 mmol), BF3·OEt2 (0.15 mL, 
1.17 mmol), and TMPZnCl·LiCl (1.92 mL, 1.59 mmol). After the metalation was complete, 1-chloro-
4-iodobenzene (202 mg, 0.85 mmol), Pd(dba)2 (24 mg, 42 µmol), and tfp (20 mg, 85 µmol) was added 
and the reaction stirred at 25 °C for 12 h. After work-up, the crude product was purified via column 
chromatography (isohexane:ethyl acetate:triethylamine = 5:5:0.1) to give 153c (111 mg, 0.58 mmol, 
69%) as a yellow solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 9.17 (dd, J = 4.9, 1.6 Hz, 1H), 8.07 - 8.01 (m, 2H), 7.84 (dd, 
J = 8.6, 1.6 Hz, 1H), 7.57 - 7.48 (m, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 158.6, 150.3, 136.7, 134.9, 129.5, 128.5, 127.0, 123.7. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3080, 3047, 2926, 2854, 1593, 1577, 1488, 1433, 1105, 1092, 
1015, 851, 806, 689. 
MS (EI, 70 eV): m/z (%) = 192 (18), 190 (55), 162 (10), 138 (32), 136 (100), 75 (6). 
HRMS (EI) for C10H7ClN2 (190.0298): 190.0291 (M+). 
M.p. (°C): 127–129. 
 
Synthesis of 3-(4-chlorophenyl)pyridazine (153d) 
 
 
 
Pyridazine 153d was prepared via TP19 using pyridazine (95 mg, 1.18 mmol), BF3·OEt2 (0.17 mL, 
1.38 mmol), and TMPZnCl·LiCl (2.30 mL, 1.77 mmol). After the metalation was complete, 4-
iodobenzonitrile (216 mg, 0.94 mmol), Pd(dba)2 (27 mg, 47 µmol), and tfp (22 mg, 94 µmol) was added 
and the reaction stirred at 25 °C for 12 h. After work-up, the crude product was purified via column 
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chromatography (isohexane:ethyl acetate:triethylamine = 7:3:0.1) to give 153d (91 mg, 0.50 mmol, 
53%) as a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 9.22 (dd, J = 5.0, 1.6 Hz, 1H), 8.23 - 8.17 (m, 2H), 7.91 (dd, 
J = 8.7, 1.6 Hz, 1H), 7.84 - 7.78 (m, 2H), 7.62 (dd, J = 8.6, 4.9 Hz, 1H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 157.7, 150.8, 140.5, 132.9, 127.8, 127.2, 124.2, 118.5, 113.8. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 2918, 2888, 2229, 1579, 1505, 1434, 1179, 987, 854, 806, 751. 
MS (EI, 70 eV): m/z (%) = 182 (12), 181 (91), 128 (13), 127 (100), 126 (6), 76 (5), 63 (10), 50 (8). 
HRMS (EI) for C11H7N3 (181.0640): 181.0639 (M+). 
M.p. (°C): 152–154. 
 
Synthesis of 3-(4-methoxyphenyl)pyridazine (153e) 
 
 
 
Pyridazine 153e was prepared via TP19 using pyridazine (45 mg, 0.56 mmol), BF3·OEt2 (0.08 mL, 
0.62 mmol), and TMPZnCl·LiCl (1.01 mL, 0.84 mmol). After the metalation was complete, 4-
iodoanisole (107 mg, 0.457 µmol), Pd(dba)2 (13 mg, 22 µmol), and tfp (11 mg, 45 µmol) was added 
and the reaction stirred at 25 °C for 12 h. After work-up, the crude product was purified via column 
chromatography (isohexane:ethyl acetate:triethylamine = 7:3:0.1) to give 153e (62 mg, 0.33 mmol, 
72%) as a light brown solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 9.08 (dd, J = 4.9, 1.6 Hz, 1H), 8.07 - 8.01 (m, 2H), 7.78 (dd, 
J = 8.6, 1.6 Hz, 1H), 7.47 (dd, J = 8.6, 4.9 Hz, 1H), 7.06 - 6.99 (m, 2H), 3.86 (s, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 161.4, 159.0, 149.5, 128.8, 128.5, 126.7, 123.1, 114.5, 55.4. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3051, 3014, 2964, 2936, 2845, 1606, 1578, 1512, 1435, 1251, 
1173, 1028, 844, 807, 754, 728. 
MS (EI, 70 eV): m/z (%) = 186 (62), 158 (11), 133 (10), 132 (100), 117 (18), 89 (25), 63 (12). 
HRMS (EI) for C11H10N2O (186.0793): 186.0783 (M+). 
M.p. (°C): 111–112. 
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Synthesis of 3-(4-(tert-butyl)phenyl)pyridazine (153f) 
 
 
 
Pyridazine 153f was prepared via TP19 using pyridazine (84 mg, 1.05 mmol), BF3·OEt2 (0.15 mL, 
1.21 mmol), and TMPZnCl·LiCl (1.95 mL, 1.58 mmol). After the metalation was complete, 1-(tert-
butyl)-4-iodobenzene (0.15 mL, 0.85 mmol), Pd(dba)2 (24 mg, 42 µmol), and tfp (20 mg, 85 µmol) was 
added and the reaction stirred at 25 °C for 12 h. After work-up, the crude product was purified via 
column chromatography (isohexane:ethyl acetate:triethylamine = 8:2:0.1) to give 153f (117 mg, 
0.55 mmol, 65%) as a brown solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = (dd, J = 5.0, 1.6 Hz, 1H), 8.06 - 8.01 (m, 2H), 7.87 (dd, J = 
8.6, 1.6 Hz, 1H), 7.59 - 7.51 (m, 3H), 1.38 (s, 9H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 159.5, 153.6, 149.9, 133.6, 127.0, 126.9, 126.2, 123.8, 34.9, 
31.4. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 1565, 1548, 1481, 1459, 1393, 1376, 1279, 1181, 1028, 961, 841, 
782. 
MS (EI, 70 eV): m/z (%) = 212 (22), 198 (12), 197 (100), 169 (7), 143 (5), 115 (8). 
HRMS (EI) for C14H16N2 (212.1313): 212.1310 (M+). 
M.p. (°C): 118–122. 
 
Synthesis of 3-iodo-6-phenylpyridazine (155) 
 
 
 
Pyridazine 155 was prepared via TP20 using 153a (17 mg, 109 µmol), TMPLi (0.17 mL, 104 µmol), 
and I2 (41 mg, 0.16 mmol). The reaction was complete after 2 h. After work-up, the crude product was 
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purified via column chromatography (isohexane:ethyl acetate:triethylamine = 9:1:0.1) to give 155 (22 
mg, 73 µmol, 70%) as a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.07 - 8.01 (m, 2H), 7.90 (d, J = 8.9 Hz, 1H), 7.56 - 7.49 (m, 
4H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 158.7, 137.6, 135.4, 130.7, 129.3, 127.1, 125.1, 123.6. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3036, 2920, 1559, 1444, 1392, 1328, 1310, 1255, 1117, 1075, 
1026, 856, 777, 741, 694. 
MS (EI, 70 eV): m/z (%) = 281 (100), 254 (26), 127 (16), 102 (37), 77 (9). 
HRMS (EI) for C10H7IN2 (281.9654): 281.9649 (M+). 
M.p. (°C): 170–172. 
 
Synthesis of 3-phenylpyridazine-6-d (155a) 
 
 
 
Pyridazine 155a was prepared via TP20 using 153a (15 mg, 96 µmol), TMPLi (0.15 mL, 91 µmol), 
and D2O (0.05 mL, 2.78 mmol). The reaction was complete after 1 h. After work-up, the crude product 
was purified via column chromatography (isohexane:ethyl acetate:triethylamine = 6:4:0.1) to give 155a 
(14 mg, 89 µmol, 93%) as a colorless solid. The NMR-spectrum reveals an incorporation of deuterium 
at position C6 with a 2H:1H ratio of 85:15. Hence, the yield of fully deuterated 3-phenylpyridazine-6-d 
can be estimated to be 79%. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 9.17 (dd, J = 4.9, 1.6 Hz, 1D), 8.12 - 8.05 (m, 2H), 7.87 (d, J 
= 8.6 Hz, 1H), 7.59 - 7.47 (m, 4H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 159.7, 150.2, 136.5, 130.3, 129.2, 127.3, 126.8, 124.1. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3046, 2935, 1569, 1448, 1406, 1312, 1120, 1068, 1024, 974, 908, 
878, 749, 698. 
MS (EI, 70 eV): m/z (%) = 157 (92), 129 (15), 103 (15), 102 (100), 76 (12). 
HRMS (EI) for C10H7DN2 (157.0750): 157.0745 (M+). 
M.p. (°C): 103–105. 
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Synthesis of 3-chloro-6-phenylpyridazine (155b) 
 
 
 
Pyridazine 155b was prepared via TP20 using 153a (39 mg, 0.25 mmol), TMPLi (0.37 mL, 238 µmol), 
and a precooled solution (-40 °C) of hexachloroethane (93 mg, 0.38 mmol) in THF (1 mL). The reaction 
was complete after 12 h. After work-up, the crude product was purified via column chromatography 
(isohexane:ethyl acetate:triethylamine = 8:2:0.1) to give 155b (20 mg, 105 µmol, 44%) as a colorless 
solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.07 - 8.01 (m, 2H), 7.83 (d, J = 8.9 Hz, 1H), 7.56 (d, J = 9.0 
Hz, 1H), 7.55 - 7.50 (m, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 158.7, 155.7, 135.2, 130.6, 129.3, 128.6, 127.2, 126.3. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3059, 2924, 2853, 1562, 1446, 1386, 1100, 766, 697. 
MS (EI, 70 eV): m/z (%) = 190 (27), 103 (22), 102 (75), 77 (18), 57 (23), 55 (29), 50 (15), 44 (67), 43 
(27), 43 (100), 41 (34). 
HRMS (EI) for C10H7ClN2 (190.0298): 190.0297 (M+). 
M.p. (°C): 159–161. 
 
Synthesis of 3-(methylthio)-6-phenylpyridazine (155c) 
 
 
 
Pyridazine 155c was prepared via TP20 using 153a (39 mg, 0.25 mmol), TMPLi (0.36 mL, 238 µmol), 
and S-methyl methanethiosulfonate (35 µL, 0.38 mmol). The reaction was complete after 12 h. After 
work-up, the crude product was purified via column chromatography (isohexane:ethyl 
acetate:triethylamine = 9:1:0.1) to give 155c (31 mg, 153 µmol, 64%) as a colorless solid. 
 
C. EXPERIMENTAL PART    278 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.06 - 8.02 (m, 2H), 7.63 (d, J = 9.1 Hz, 1H), 7.53 - 7.44 (m, 
3H), 7.38 (d, J = 9.1 Hz, 1H), 2.76 (s, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 161.3, 156.0, 136.2, 129.9, 129.1, 126.7, 126.2, 123.1, 13.4. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3058, 3038, 2923, 2853, 1581, 1569, 1446, 1402, 1162, 1094, 
846, 776, 740. 
MS (EI, 70 eV): m/z (%) = 203 (11), 202 (100), 201 (29), 159 (8), 157 (22), 115 (43), 102 (27). 
HRMS (EI) for C11H10N2S (202.0565): 202.0558 (M+). 
M.p. (°C): 136–138. 
 
Synthesis of 3-phenyl-6-(phenylthio)pyridazine (155d) 
 
 
 
Pyridazine 155d was prepared via TP20 using 153a (39 mg, 0.25 mmol), TMPLi (0.36 mL, 238 µmol), 
and S-phenyl benzenethiosulfonate (94 mg, 0.38 mmol). The reaction was complete after 12 h. After 
work-up, the crude product was purified via column chromatography (isohexane:ethyl 
acetate:triethylamine = 9:1:0.1) to give 155d (44 mg, 166 µmol, 70%) as a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.05 - 8.00 (m, 2H), 7.68 - 7.64 (m, 2H), 7.62 (d, J = 9.1 Hz, 
1H), 7.53 - 7.44 (m, 6H), 7.13 (d, J = 9.0 Hz, 1H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 164.1, 156.5, 136.0, 135.4, 130.1, 130.1, 129.8, 129.5, 129.1, 
126.9, 125.5, 124.2. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3049, 2924, 2852, 1474, 1447, 1389, 1138, 1000, 846, 754, 745, 
689. 
MS (EI, 70 eV): m/z (%) = 264 (15), 263 (100), 135 (15), 115(7). 
HRMS (EI) for C16H11N2S (263.0643): 263.0639 (M+-H+). 
M.p. (°C): 156–158. 
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Synthesis of 6-phenylpyridazine-3-carbaldehyde (155e) 
 
 
 
Pyridazine 155e was prepared via TP20 using 153a (39 mg, 0.25 mmol), TMPLi (0.36 mL, 238 µmol), 
and 4-formylmorpholine (0.04 mL, 0.38 mmol). The reaction was complete after 12 h. After work-up, 
the crude product was purified via column chromatography (isohexane:ethyl acetate:triethylamine = 
8:2:0.1) to give 155e (20 mg, 109 µmol, 46%) as a yellow solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 10.44 (d, J = 0.9 Hz, 1H), 8.21 - 8.16 (m, 2H), 8.10 (d, J = 8.8 
Hz, 1H), 8.04 (dd, J = 8.8, 0.9 Hz, 1H), 7.63 - 7.53 (m, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 192.3, 161.4, 154.2, 135.3, 131.4, 129.4, 127.9, 124.9, 124.5. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3065, 2926, 2836, 1715, 1571, 1452, 1419, 1348, 1116, 779, 743, 
689. 
MS (EI, 70 eV): m/z (%) = 184 (100), 156 (13), 128 (26), 104 (22), 102 (74), 77 (13), 76 (12), 51 (14). 
HRMS (EI) for C11H8N2O (184.0637): 184.0628 (M+). 
M.p. (°C): 160–162. 
 
Synthesis of ethyl 2-((6-phenylpyridazin-3-yl)methyl)acrylate (155f) 
 
 
 
Pyridazine 155f was prepared via TP20 using 153a (39 mg, 0.25 mmol), and TMPLi (0.36 mL, 
238 µmol). After the metalation was complete, a 1.0 M CuCN·2LiCl solution in THF (0.03 mL, 
0.25 mmol) was added and the reaction stirred at the same temperature for 20 min. Then, ethyl 2-
(bromomethyl)acrylate (72 mg, 0.38 mmol) was added and the reaction slowly warmed to 25 °C over 
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12 h. After work-up, the crude product was purified via column chromatography (isohexane:ethyl 
acetate:triethylamine = 9:1:0.1) to give 155f (28 mg, 104 μmol, 44%) as a brown oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.10 - 8.05 (m, 2H), 7.81 (dd, J = 8.8, 1.6 Hz, 1H), 7.55 - 7.46 
(m, 4H), 6.39 (d, J = 1.1 Hz, 1H), 5.83 (p, J = 1.4 Hz, 1H), 4.19 (q, J = 7.1 Hz, 2H), 4.07 (d, J = 1.4 
Hz, 2H), 1.26 (t, J = 7.1 Hz, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 166.7, 159.8, 157.7, 137.7, 136.4, 130.0, 129.1, 128.4, 127.4, 
127.1, 124.1, 61.1, 38.6, 14.3. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3031, 2898, 1638, 1458, 1421, 1298, 1200, 1142, 1027, 860, 757, 
739, 690. 
MS (EI, 70 eV): m/z (%) = 268 (13), 239 (19), 223 (9), 196 (32), 195 (100),194 (9), 102 (13). 
HRMS (EI) for C16H16N2O2 (268.1212): 268.1204 (M+). 
 
Synthesis of 3-(cyclohex-2-en-1-yl)-6-phenylpyridazine (155g) 
 
 
Pyridazine 155g was prepared via TP20 using 153a (39 mg, 0.25 mmol), and TMPLi (0.36 mL, 
238 µmol). After the metalation was complete, a 1.0 M CuCN·2LiCl solution in THF (0.03 mL, 
0.25 mmol) was added and the reaction stirred at the same temperature for 20 min. Then, 3-
bromocyclohexene (61 mg, 0.38 mmol) was added and the reaction slowly warmed to 25 °C over 12 h. 
After work-up, the crude product was purified via column chromatography (isohexane:ethyl 
acetate:triethylamine = 8:2:0.1) to give 155g (26 mg, 110 μmol, 46%) as a light brown solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.14 - 8.08 (m, 2H), 7.81 (d, J = 8.8 Hz, 1H), 7.57 - 7.48 (m, 
3H), 7.46 (d, J = 8.8 Hz, 1H), 6.07 - 6.00 (m, 1H), 5.87 - 5.80 (m, 1H), 4.02 - 3.93 (m, 1H), 2.27 - 2.13 
(m, 3H), 1.88 - 1.71 (m, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 165.6, 157.6, 136.6, 130.2, 129.9, 129.1, 127.6, 127.0, 125.9, 
124.2, 42.0, 30.7, 25.0, 21.1. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3059, 3020, 2922, 2856, 2833, 1545, 1449, 1420, 1014, 861, 750, 
693. 
MS (EI, 70 eV): m/z (%) = 236 (12), 235 (11), 221 (13), 208 (14), 207 (100), 170 (28), 102 (10). 
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HRMS (EI) for C16H16N2 (236.1313): 236.1308 (M+). 
M.p. (°C): 86–88. 
 
Synthesis of 5-iodo-3-phenylpyridazine (156) 
 
 
 
Pyridazine 156 was prepared via TP21 using 153a (17 mg, 109 µmol), BF3·OEt2 (0.015 mL, 
0.12 mmol), TMPMgCl·LiCl (0.18 mL, 0.22 mmol) and iodine (83 mg, 0.33 mmol). The reaction was 
complete after 1 h. After work-up, the crude product was purified via column chromatography 
(isohexane:ethyl acetate:triethylamine = 9:1:0.1) to give 156 (17.7 mg, 63 µmol, 58%) as a light brown 
solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 9.39 (d, J = 2.0 Hz, 1H), 8.27 (d, J = 2.0 Hz, 1H), 8.07 - 8.01 
(m, 2H), 7.56 - 7.50 (m, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 159.7, 156.4, 135.2, 133.0, 130.8, 129.3, 127.4, 101.5. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3054, 3019, 1546, 1493, 1386, 1364, 1038, 921, 89, 786, 772, 
690. 
MS (EI, 70 eV): m/z (%) = 283 (10), 282 (100), 155 (25), 127 (60), 126 (21), 77 (9). 
HRMS (EI) for C10H7IN2 (281.9654): 281.9649 (M+). 
M.p. (°C): 129–131. 
 
Synthesis of 3-phenyl-5-(phenylthio)pyridazine (156a) 
 
 
 
Pyridazine 156a was prepared via TP21 using 153a (40 mg, 256 µmol), BF3·OEt2 (0.035 mL, 
0.28 mmol), TMPMgCl·LiCl (0.42 mL, 0.51 mmol) and a precooled solution (-40 °C) of S-phenyl 
benzenethiosulfonate (193 mg, 0.77 mmol) in THF (1 mL). The reaction was complete after 10 h. After 
work-up, the crude product was purified via column chromatography (isohexane:ethyl 
acetate:triethylamine = 8:2:0.1) to give 156a (26 mg, 98 µmol, 38%) as a brown solid. 
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1H-NMR (400 MHz, CDCl3): δ / ppm = 8.82 (d, J = 2.2 Hz, 1H), 7.97 - 7.90 (m, 2H), 7.66 - 7.60 (m, 
2H), 7.56 - 7.51 (m, 3H), 7.51 - 7.46 (m, 3H), 7.39 (d, J = 2.2 Hz, 1H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 158.3, 147.3, 144.0, 136.2, 135.4, 130.5, 130.5, 130.2, 129.0, 
127.4, 127.3, 119.7. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 2999, 2902, 2840, 1552, 1499, 1439, 1375, 1003, 898, 780, 760, 
746. 
MS (EI, 70 eV): m/z (%) = 265 (12), 264 (70), 263 (100), 235 (13), 234 (27), 202 (17), 134 (41), 127 
(12), 126 (13), 121 (17), 77 (10). 
HRMS (EI) for C16H12N2S (264.0721): 264.0722 (M+). 
M.p. (°C): 104–106. 
 
Synthesis of 5-iodo-3-(4-methoxyphenyl)pyridazine (156b) 
 
 
 
Pyridazine 156b was prepared via TP21 using 153e (18 mg, 97 µmol), BF3·OEt2 (0.015 mL, 
0.11 mmol), TMPMgCl·LiCl (0.16 mL, 0.195 mmol) and iodine (74 mg, 0.29 mmol). The reaction was 
complete after 1 h. After work-up, the crude product was purified via column chromatography 
(isohexane:ethyl acetate:triethylamine = 8:2:0.1) to give 156b (15 mg, 48 µmol, 50%) as a light brown 
solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 9.31 (d, J = 2.0 Hz, 1H), 8.21 (d, J = 2.0 Hz, 1H), 8.05 - 7.98 
(m, 2H), 7.07 - 7.01 (m, 2H), 3.89 (s, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 161.9, 159.3, 155.7, 132.2, 128.8, 127.5, 114.7, 101.5, 55.6. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3021, 3004, 2925, 2854, 1607, 1550, 1515, 1503, 1384, 1245, 
1181, 1036, 1025, 989, 835, 826, 813, 673. 
MS (EI, 70 eV): m/z (%) = 313 (11), 312 (100), 207 (17), 158 (10), 157 (89), 142 (30), 128 (27), 127 
(38), 114 (21), 113 (14). 
HRMS (EI) for C11H9IN2O (311.9760): 311.9753 (M+). 
M.p. (°C): 152–156 (decomposition). 
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Synthesis of 3-(4-chlorophenyl)-5-iodopyridazine (156c) 
 
 
 
Pyridazine 156c was prepared via TP21 using 153c (18 mg, 94 µmol), BF3·OEt2 (0.015 mL, 103 µmol), 
TMPMgCl·LiCl (0.155 mL, 0.19 mmol) and iodine (72 mg, 0.28 mmol). The reaction was complete 
after 1 h. After work-up, the crude product was purified via column chromatography (isohexane:ethyl 
acetate:triethylamine = 9:1:0.1) to give 156c (15 mg, 47 µmol, 50%) as a light brown solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 9.39 (d, J = 2.0 Hz, 1H), 8.24 (d, J = 2.0 Hz, 1H), 8.03 - 7.97 
(m, 2H), 7.53 - 7.47 (m, 2H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 158.6, 156.5, 137.2, 133.5, 132.7, 129.6, 128.6, 101.6. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3016, 2923, 2854, 1594, 1548, 1489, 1092, 1032, 1012, 898, 831, 
796, 704, 671. 
MS (EI, 70 eV): m/z (%) = 316 (24), 299 (15), 281 (37), 225 (66), 209 (23), 208 (13), 207 (100), 193 
(10), 191 (15), 161 (19), 127 (17), 126 (21), 73 (14). 
HRMS (EI) for C10H6ClIN2 (315.9264): 315.9256 (M+). 
M.p. (°C): 160–164 (decomposition). 
 
Synthesis of the bidentate Lewis acid 157 
 
 
 
The highly moisture and air sensitive Lewis acid 157 was prepared according to literature procedures 
and stored in a glove box under argon.144 
 
                                                     
144
 S. N. Kessler, M. Neuburger, H. A. Wegner, Eur. J. Org. Chem. 2011, 3238–3245. 
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The starting material 1,2-bis(trimethylsilyl)benzene can also be synthesized via an alternative pathway 
which does not require the use of DMI as solvent:145 
 
 
 
LiCl (17.07 g, 400 mmol) was added to a dry Schlenk flask and flame dried in vacuo using a heat gun 
at 400 °C for 10 min. After cooling to room temperature, the flask was flushed with argon and 
magnesium turnings (9.70 g, 400 mmol) were added and the mixture once more flame dried under 
vacuo for 5 min. After cooling to room temperature, the flask was again flushed with argon and THF 
(200 mL) was added. TMSCl (76.2 mL, 600 mmol) was added and the mixture stirred for 5 min. Then, 
1,2-dibromobenzene (12.0 mL, 100 mmol) was added dropwise and the temperature of the reaction held 
at 25 °C using an ice bath for 20 min. After stirring at 25 °C for 12 h the reaction was quenched with 
water (300 mL) and extracted with hexane (3 x 200 mL). The organic phase was dried over Na2SO4, 
filtered, and the solvents removed in vacuo. The crude product was purified first via column 
chromatography (isohexane) and then via distillation (7 mbar, 130 °C) to give 1,2-
bis(trimethylsilyl)benzene (4.68 g, 21.1 mmol, 21%) as a colorless oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 7.74 - 7.63 (m, 2H), 7.34 (dt, J = 5.5, 3.3 Hz, 2H), 0.38 (d, J 
= 3.3 Hz, 18H). 
 
The spectrum matched the one of the literature.145  
 
Synthesis of 4-iodopyridazine (154) 
 
 
 
 
                                                     
145
 T. Kitamura, R. Yamada, K. Gondo, N. Eguchi, J. Oyamada, Synthesis 2017, 49, 2495–2500. 
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The bidentate Lewis acid 157 (93 mg, 0.38 mmol) was dissolved in THF (5 mL) and cooled to 0 °C. 
Then, a solution of pyridazine in THF (0.82 mL, 0.38 mmol, 0.462 mM) was added dropwise and the 
reaction stirred at the same temperature for 10 min. After cooling to –78 °C, TMPZnCl·LiCl (0.68 mL, 
0.65 mmol) was added dropwise and the reaction stirred at the same temperature for 20 min. Then, a 
solution of iodine (193 mg, 0.76 mmol) in THF (2 mL) was added and the reaction stirred for 10 min 
at –78 °C and then warmed to 25 °C and stirred for additional 20 min. After quenching with a sat. aq. 
Na2S2O3 solution (10 mL), the reaction was extracted with ethyl acetate (3 x 30 mL), dried over Na2SO4, 
filtered, and the solvents removed in vacuo. The crude product was purified via column chromatography 
(isohexane:ethyl acetate:triethylamine = 6.5:3.5:0.1) to give 154 (49 mg, 238 µmol, 63%) as a light 
brown solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 9.45 (dd, J = 2.3, 1.2 Hz, 1H), 8.84 (dd, J = 5.4, 1.2 Hz, 1H), 
7.89 (dd, J = 5.4, 2.3 Hz, 1H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 158.4, 151.2, 135.5, 101.0. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3084, 3009, 1534, 1346, 1280, 1104, 1042, 982, 913, 855, 741, 
698, 668, 660. 
MS (EI, 70 eV): m/z (%) = 206 (100), 152 (14), 127 (45), 79 (7). 
HRMS (EI) for C4H3IN2 (205.9341): 205.9336 (M+). 
M.p. (°C): 116–118. 
 
The spectra matched those of the literature.104c 
 
Synthesis of 3-(o-tolyloxy)pyridazine (credazine) (160) 
 
 
 
3-Iodopyridazine (153, 63 mg, 0.306 mmol) was dissolved in toluene (2 mL) and o-cresol (40 mg, 
0.37 mmol), Pd(OAc)2 (1.4 mg, 6 µmol), tBuXPhos (3.9 mg, 9 µmol), and K3PO4 (129 mg, 0.61 mmol) 
were added. The reaction was stirred at 100 °C for 14 h. After addition of water (10 mL), the reaction 
was extracted with ethyl acetate (3 x 30 mL), dried over Na2SO4, filtered, and the solvents removed in 
vacuo. The crude product was purified via column chromatography (isohexane:ethyl 
acetate:triethylamine = 6:4:0.1) to give 160 (53 mg, 285 µmol, 93%) as a colorless solid. 
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1H-NMR (400 MHz, CDCl3): δ / ppm = 8.92 (dd, J = 4.5, 1.3 Hz, 1H), 7.47 (dd, J = 8.9, 4.5 Hz, 1H), 
7.30 - 7.27 (m, 1H), 7.24 (dd, J = 7.7, 1.9 Hz, 1H), 7.20 - 7.12 (m, 2H), 7.10 (dd, J = 7.9, 1.4 Hz, 1H), 
2.19 (s, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 165.8, 151.8, 148.1, 131.7, 130.6, 129.7, 127.4, 125.9, 121.7, 
116.6, 16.5. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3058, 2993, 1579, 1463, 1425, 1394, 1280, 1177, 1111, 1042, 
1005, 878, 815, 776, 743. 
MS (EI, 70 eV): m/z (%) = 186 (20), 185 (21), 171 (19), 169 (46), 127 (19), 113 (19), 111 (23), 99 
(30), 97 (36), 85 (74), 83 (40), 71 (97), 57 (100), 55 (20), 43 (38). 
HRMS (EI) for C11H10N2O (186.0793): 186.0796 (M+). 
M.p. (°C): 79–80. 
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7.4 Regioselectivity Investigations 
 
Given is A) the 1H-NMR of the mixture of regioisomers from Table 1, entry 6 (optimized reaction 
conditions), indicating a ratio of 3-iodopyridazine (6) to 4-iodopyridazine (7) of 97:3 and B) the 1H-
NMR of the mixture of regioisomers from Table 3, entry 3 (optimized reaction conditions), indicating 
a ratio of 3-iodopyridazine (6) to 4-iodopyridazine (7) of 1:99. 
A) 1H-NMR of the mixture of regioisomers from Table 5, entry 6. 
 
B) 1H-NMR of the mixture of regioisomers from Table 7, entry 3. 
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To confirm the regioselectivity of the metalation on pyridazine, the resulting metal species of the ortho-
and meta-metalation using either A) BF3·OEt2 and TMPZnCl·LiCl (TP18) or B) the bidentate Lewis 
acid 157 and TMPZnCl·LiCl were quenched with D2O and the obtained deuterium-incorporated 
products analyzed via 1H NMR spectroscopy. The measured spectra were also compared with the 
respective starting material spectra. 
 
Synthesis of pyridazine-3-d 
 
 
 
Pyridazine (80 mg, 1.00 mmol) was dissolved in THF (5 mL) and cooled to 0 °C. Then, BF3·OEt2 
(0.14 mL, 1.10 mmol) was added dropwise and the reaction stirred for 10 min. TMPZnCl·LiCl 
(1.74 mL, 1.5 mmol) was added dropwise and the reaction stirred for 6 h at 25 °C. The reaction was 
quenched with D2O (5 mL) and the phases were separated. The aqueous phase was filtered and 
submitted to NMR spectroscopy, indicating an incorporation of deuterium at position C4 with a 2H:1H 
ratio of 33:67. 
 
1H-NMR (400 MHz, D2O): δ / ppm = 9.16 (t, J = 3.5 Hz, 1H), 7.81 (d, J = 3.5 Hz, 1H). 
 
Synthesis of pyridazine-4-d 
 
 
 
The bidentate Lewis acid 157 (99 mg, 0.41 mmol) was dissolved in THF (5 mL) and cooled to 0 °C. 
Then, a solution of pyridazine in THF (0.90 mL, 0.41 mmol, 0.454 mM) was added dropwise and the 
reaction stirred at the same temperature for 10 min. After cooling to –78 °C, TMPZnCl·LiCl (0.81 mL, 
0.70 mmol) was added dropwise and the reaction stirred at the same temperature for 20 min. The 
reaction was quenched with D2O (5 mL), stirred at room temperature for 10 min and the phases were 
separated. The aqueous phase was filtered and submitted to NMR spectroscopy, indicating an 
incorporation of deuterium at position C3 with a 2H:1H ratio of 45:55. 
 
1H-NMR (400 MHz, D2O): δ / ppm = 9.20 - 9.15 (m, 1H), 7.82 (t, J = 3.4 Hz, 1H). 
 
C. EXPERIMENTAL PART    289 
 
1H NMR spectrum of pyridazine-3-d 
 
1H NMR spectrum of pyridazine-4-d 
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7.5 NMR Investigations Towards the Lewis Acid-Pyridazine Complex 158 
 
To investigate the Lewis acid - pyridazine complex 158, several NMR experiments were performed. 1H 
and 13C spectra of pyridazine (150), 1H, 13C, 11B spectra of the Lewis acid 157, and 1H, 13C, 11B spectra 
of the Lewis acid - pyridazine complex 158 were measured and are displayed below. Pyridazine was 
dissolved in THF (0.07 M) and measured as is. The Lewis acid 157 and the complex 158 were dissolved 
in THF (0.07 M) and a C6D6 capillary was added to the NMR tube. All NMRs were referenced to the 
THF peak at 1.73 ppm (1H NMR) and 25.37 ppm (13C NMR). 
 
Pyridazine (150) in THF. 
 
1H-NMR (400 MHz, THF): δ / ppm = 9.1 (q, J = 3.5 Hz, 1H), 7.5 (q, J = 3.6 Hz, 1H). 
13C-NMR (101 MHz, THF): δ / ppm = 151.4, 125.7. 
 
Bidentate Lewis acid 157: 
 
1H-NMR (400 MHz, THF): δ / ppm = 7.9 (dd, J = 5.5, 3.3 Hz, 1H), 7.2 (dd, J = 5.6, 3.2 Hz, 1H). 
13C-NMR (101 MHz, THF): δ / ppm = 132.3, 126.5. 
11B-NMR (128 MHz, THF): δ / ppm = 16.6. 
 
Lewis acid - pyridazine complex 158: 
 
1H-NMR (400 MHz, THF): δ / ppm = 10.1 - 10.1 (m, 1H), 8.2 - 8.1 (m, 1H), 7.6 - 7.5 (m, 2H), 6.9 - 
6.8 (m, 2H). 
13C-NMR (101 MHz, THF): δ / ppm = 147.3, 135.0, 127.2, 124.6. 
11B-NMR (128 MHz, THF): δ / ppm = 10.7.  
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1H NMR spectrum of pyridazine (150) in THF 
 
13C NMR spectrum of pyridazine (150) in THF 
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1H NMR spectrum of the bidentate Lewis acid 157 in THF 
 
13C NMR spectrum of the bidentate Lewis acid 157 in THF 
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11B NMR spectrum of the bidentate Lewis acid 157 in THF 
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1H NMR spectrum of the Lewis acid - pyridazine complex 158 in THF 
 
13C NMR spectrum of the Lewis acid - pyridazine complex 158 in THF 
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11B NMR spectrum of the Lewis acid - pyridazine complex 158 in THF 
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Stacked 1H spectra of pyridazine (150; red), the bidentate Lewis acid 157 (blue), and the Lewis acid - 
pyridazine complex 158 (green) with THF set as a reference to 1.73 ppm.[a] 
 
Stacked 1H NMR spectra of 150 (red), 157 (blue), and 158 (green) from 10.4–6.40 ppm.[a] 
 
[a]The peak at 7.26 ppm in the spectrum of 157 (blue) and 158 (green) corresponds to the C6D6 solvent 
residual peak. 
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Stacked 13C spectra of pyridazine (150; red), the bidentate Lewis acid 157 (blue), and the Lewis acid - 
pyridazine complex 158 (green) with THF set as a reference to 1.73 ppm.[b] 
 
Stacked 1H NMR spectra of 150 (red), 157 (blue), and 158 (green) from 10.4–6.40 ppm.[b] 
 
[b] The peak at 128 ppm in the spectrum of 157 (blue) corresponds to the C6D6 solvent residual peak. 
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8 Preparation of Polyfunctional Arylzinc Organometallics in Toluene via 
Halogen/Zinc Exchange Reactions 
8.1 Screening Tables 
Variation of the alkoxide residue 
 
 
 
Nr. R1 Exchange reagent GC-yield (%)a 
1 
 
1a 99 
2 
 
1b 97 
3 
 
1c 23 
3 
 
1d 91 
4 
 
1e 95 
[a] Yield determined by GC-analysis of water quenched reaction aliquots 
 
Variation of the alkyl residue 
 
 
 
Nr. R2 GC-yield (%)a 
1 nBu 80 
2 sBu 99 
3 tBu 89 
[a] Yield determined by GC-analysis of water quenched reaction aliquots 
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Solvent screening 
 
 
Nr. Solvent 
GC Yield (%)a 
Hydrolysis Iodolysis 
1 Et2O 99 91 
2 THF 99 87 
3 2-MeTHF 99 85 
4 Dioxane 99 86 
5 MTBE 99 89 
6 Acetone 9 0 
7 MeCN 99 36 
8 DMF 99 31 
9 Ethylacetate 99 19 
10 1,2-Dichlorethane 99 80 
11 Chlorbenzene 99 60 
12 Toluene 99 86 
13 Hexane 99 90 
[a] Yield determined by GC-analysis of water quenched reaction aliquots (hydrolysis), or iodine quenched reaction aliquots (iodolysis) 
 
Reaction time screening 
 
 
 
Nr. time (min) GC-yield (%) 
1 0.5 93 
2 1 99 
3 60 99 
[a] Yield determined by GC-analysis of water quenched reaction aliquots 
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8.2 Preparation of Reagents of Type R2Zn·2LiOR 
 
Preparation of nBu2Zn·2LiOR: 
 
 
 
A dry and argon-flushed Schlenk-flask, equipped with a magnetic stirring bar and a septum, was charged 
with Et2Zn (1.11 M in toluene, 9.01 mL, 10.0 mmol) and the reaction mixture was cooled to –40 °C. 
Then, 2-((2-(dimethylamino)ethyl)(methyl)amino)ethane-1-ol (2.925 g, 20.0 mmol) was added 
dropwise and the reaction stirred for 2 h. Then, the reaction mixture was cooled to –40 °C and nBuLi 
(2.4 M in hexane, 8.33 mL, 20.0 mmol)) added dropwise. After the addition was complete, the reaction 
mixture was allowed to warm to room temperature and stir for 2 h. The solvents were removed in vacuo 
affording a light yellow oil. Freshly distilled toluene (8 mL) was added under vigorous stirring. The 
prepared nBu2Zn·2LiO(CH2)2N(Me)(CH2)2N(Me)2 was titrated prior to use at 0 °C by iodometric 
titration. The nBu2Zn·2LiO(CH2)2N(Me)(CH2)2N(Me)2 concentration of the resulting clear solution 
was 0.68 M 
 
Preparation of sBu2Zn·2LiOR (161c): 
 
 
 
A dry and argon-flushed Schlenk-flask, equipped with a magnetic stirring bar and a septum, was charged 
with Et2Zn (1.11 M in toluene, 9.01 mL, 10.0 mmol) and the reaction mixture was cooled to –40 °C. 
Then, 2-((2-(dimethylamino)ethyl)(methyl)amino)ethane-1-ol (2.925 g, 20.0 mmol) was added 
dropwise and the reaction stirred for 2 h. Then, the reaction mixture was cooled to –40 °C and sBuLi 
(1.32 M in hexane, 15.15 mL, 20.0 mmol)) added dropwise. After the addition was complete, the 
reaction mixture was allowed to warm to room temperature and stir for 2 h. The solvents were removed 
in vacuo affording a light yellow oil. Freshly distilled toluene (8 mL) was added under vigorous stirring. 
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The prepared sBu2Zn·2LiO(CH2)2N(Me)(CH2)2N(Me)2 was titrated prior to use at 0 °C by iodometric 
titration. The sBu2Zn·2LiO(CH2)2N(Me)(CH2)2N(Me)2 concentration of the resulting clear solution was 
0.60–1.00 M. 
 
Preparation of tBu2Zn·2LiOR (168): 
 
 
 
A dry and argon-flushed Schlenk-flask, equipped with a magnetic stirring bar and a septum, was charged 
with Et2Zn (1.11 M in toluene, 9.01 mL, 10.0 mmol) and the reaction mixture was cooled to –40 °C. 
Then, 2-((2-(dimethylamino)ethyl)(methyl)amino)ethane-1-ol (2.925 g, 20.0 mmol) was added 
dropwise and the reaction stirred for 2 h. Then, the reaction mixture was cooled to –40 °C and tBuLi 
(1.93 M in pentane, 10.36 mL, 20.0 mmol)) added dropwise. After the addition was complete, the 
reaction mixture was allowed to warm to room temperature and stir for 2 h. The solvents were removed 
in vacuo affording a light yellow oil. Freshly distilled toluene (8 mL) was added under vigorous stirring. 
The prepared tBu2Zn·2LiO(CH2)2N(Me)(CH2)2N(Me)2 was titrated prior to use at 0 °C by iodometric 
titration. The tBu2Zn·2LiO(CH2)2N(Me)(CH2)2N(Me)2 concentration of the resulting clear solution was 
0.68 M 
 
Titration Using Iodine146 
A dry flask was charged with accurately weighed I2 (128 mg, 0.504 mmol), fitted with a rubber septum, 
and flushed with argon. THF (2 mL) was added and stirring was started. After the iodine was completely 
dissolved, the resulting brown solution was cooled to 0 °C in an ice bath and the organozinc reagent 
was added dropwise via a 1.00-mL syringe (0.01-mL graduations) until the brown color disappeared. 
The obtained concentration needs to be divided by 2 to obtain the concentration of the dialkyl zinc 
species. 
  
                                                     
146
 A. Krasovskiy, P. Knochel, Synthesis 2006, 890. 
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Preparation of Tol2Zn·2LiOR (Tol = p-tolyl-, 167) 
 
 
 
A dry and argon-flushed Schlenk-flask, equipped with a magnetic stirring bar and a septum, was charged 
with Et2Zn (1.11 M in toluene, 9.01 mL, 10.0 mmol) and the reaction mixture was cooled to –40 °C. 
Then, 2-((2-(dimethylamino)ethyl)(methyl)amino)ethane-1-ol (2.925 g, 20.0 mmol) was added 
dropwise and the reaction stirred for 2 h. Then, the reaction mixture was cooled to –40 °C and TolLi 
(0.98 M in Et2O, 20.4 mL, 20.0 mmol)) added dropwise. After the addition was complete, the reaction 
mixture was allowed to warm to room temperature and stir for 2 h. The solvents were removed in vacuo 
affording a light yellow oil. Freshly distilled toluene (8 mL) was added under vigorous stirring. The 
prepared Tol2Zn·2LiO(CH2)2N(Me)(CH2)2N(Me)2 was titrated prior to use at 0 °C by iodometric 
titration. The Tol2Zn·2LiO(CH2)2N(Me)(CH2)2N(Me)2 concentration of the resulting clear solution was 
0.69 M. 
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8.3 Typical Procedures 
 
Typical Procedure 22: Preparation of diarylzinc alkoxides via an iodine/zinc Exchange followed by 
electrophilic functionalization 
 
A dry and argon-flushed Schlenk flask, equipped with a magnetic stirring bar and a septum, was charged 
with the corresponding aryl halide (1.0 equiv) and dissolved in dry toluene (0.5 M): Then, the exchange 
reagent R2Zn·2LiO(CH2)2N(Me)(CH2)2N(Me)2 (161c, 167 or 168) (0.6–0.8 equiv) was added dropwise 
and the reaction stirred for 10 minutes at 25 °C unless otherwise stated. The completion of the 
halogen/zinc exchange was checked by GC-analysis of reaction aliquots quenched with water, using 
undecane as internal standard. Subsequent reactions with electrophiles were carried out under the 
indicated conditions. After complete conversion, the mixture was quenched with a sat. aq. NH4Cl 
solution (10 mL), diluted with water (10 mL) and extracted with ethyl acetate (3 x 30 mL). The 
combined organic extracts were dried over Na2SO4, filtered and concentrated in vacuo. If the crude 
product needed purification, it was purified by flash chromatography on silica gel using the appropriate 
eluent. 
 
Typical Procedure 23: Preparation of diarylzinc alkoxides via a bromine/zinc exchange followed by 
electrophilic functionalization 
 
A dry and argon-flushed Schlenk flask, equipped with a magnetic stirring bar and a septum, was charged 
with the corresponding aryl halide (1.0 equiv) and dissolved in dry toluene (1.0 M): Then, 
sBu2Zn·2LiO(CH2)2N(Me)(CH2)2N(Me)2 (161c, 0.8 equiv) was added dropwise and the reaction stirred 
for 5 h at 25 °C unless otherwise stated. The completion of the halogen/zinc exchange was checked by 
GC-analysis of reaction aliquots quenched with water, using undecane as internal standard. Subsequent 
reactions with electrophiles were carried out under the indicated conditions. After complete conversion, 
the mixture was quenched with a sat. aq. NH4Cl solution (10 mL), diluted with water (10 mL) and 
extracted with ethyl acetate (3 x 30 mL). The combined organic extracts were dried over Na2SO4, 
filtered and concentrated in vacuo. If the crude product needed purification, it was purified by flash 
chromatography on silica gel using the appropriate eluent. 
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8.4 Preparation of Compounds 166 to 170 
 
Synthesis of methyl(4'-(trifluoromethoxy)-[1,1'-biphenyl]-4-yl)sulfane (166d) 
 
F3CO
SMe
 
 
Biaryl 166d was prepared via TP22 using 1-iodo-4-(trifluoromethoxy)benzene (139 mg, 0.48 mmol) 
and sBu2Zn·2LiOR (161c, 0.30 mL, 0.29 mmol). After the exchange was complete, Pd(OAc)2 (3 mg, 
14 µmol), SPhos (12 mg, 29 µmol) and 4-iodothioanisole (100 mg, 0.40 mmol) were added and the 
reaction stirred for 12 h at room temperature. After work-up, the crude product was purified via column 
chromatography (pentane:ethyl acetate = 10:0.04) to give 166d (55 mg, 193 µmol, 48%) as a colorless 
solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 7.60 – 7.55 (m, 2H), 7.51 – 7.47 (m, 2H), 7.36 – 7.31 (m, 2H), 
7.30 – 7.26 (m, 2H), 2.53 (s, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 148.7 (q, J = 2 Hz), 139.4, 138.4, 136.6, 128.2, 127.5, 127.0, 
121.4, 120.6 (q, J = 257 Hz), 15.9. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 2623, 1594, 1523, 1484, 1205, 1155, 1100, 805. 
MS (EI, 70 eV): m/z (%) = 284 (100), 269 (42), 236 (10), 184 (9), 139 (14). 
HRMS (EI) for C14H11F3OS (284.0483): 284.0475 (M+). 
M.p. (°C): 103–105. 
 
Synthesis of 2',4'-dichloro-1,2,3,4-tetrahydro-1,1'-biphenyl (166e) 
 
 
 
Arene 166e was prepared via TP22 using 1-iodo-4-(trifluoromethoxy)benzene (139 mg, 0.48 mmol) 
and sBu2Zn·2LiOR (161c, 0.30 mL, 0.29 mmol). After the exchange was complete, the reaction was 
cooled to 0 °C and CuI (19 mg, 0.1 mmol) was added. After stirring at 0 °C for 30 min, ethyl 2-
(bromomethyl)acrylate (139 mg, 0.72 mmol) was added and the reaction stirred for 12 h at room 
temperature. After work-up, the crude product was purified via column chromatography (pentane:ethyl 
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acetate = 1000:1 to 9:1) to give 166e (88 mg, 321 µmol, 67%) as a colorless oil. The product was 
detected by GC-analysis. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 7.25 – 7.19 (m, 2H), 7.16 – 7.11 (m, 2H), 6.25 (q, J = 0.9 Hz, 
1H), 5.49 (q, J = 1.4 Hz, 1H), 4.18 (q, J = 7.1 Hz, 2H), 3.63 (d, J = 1.2 Hz, 2H), 1.26 (t, J = 7.1 Hz, 
3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 166.8, 147.9, 140.0, 137.7, 130.4, 126.5, 121.1, 61.0, 37.6, 
14.3. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 2984, 2932, 1716, 1634, 1508, 1257, 1222, 1196, 1161, 1021, 
950, 813. 
MS (EI, 70 eV): m/z (%) = 274 (25), 229 (12), 201 (24), 200 (100), 199 (17), 161 (11), 131 (15), 115 
(47), 103 (15). 
HRMS (EI) for C13H13F3O3 (274.0817): 274.0811 (M+). 
 
Synthesis of (4-((tert-butyldimethylsilyl)oxy)phenyl)(cyclopropyl)methanone (166f) 
 
 
 
Arene 166f was prepared via TP22 using tert-butyl(4-iodophenoxy)dimethylsilane (154 mg, 
0.46 mmol) and sBu2Zn·2LiOR (161c, 0.29 mL, 0.28 mmol). After the exchange was complete, the 
reaction was cooled to 0 °C and CuI (53 mg, 0.28 mmol) was added. After stirring at 0 °C for 30 min, 
cyclopropanecarbonyl chloride (0.13 mL, 1.38 mmol) was added and the reaction stirred for 12 h at 
room temperature. After work-up, the crude product was purified via column chromatography 
(pentane:ethyl acetate = 10:0.5) to give 166f (77 mg, 279 µmol, 61%) as a colorless oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 7.98 – 7.92 (m, 2H), 6.92 – 6.86 (m, 2H), 2.63 (tt, J = 7.8, 4.5 
Hz, 1H), 1.20 (dt, J = 4.5, 3.4 Hz, 2H), 0.99 (s, 11H), 0.23 (s, 6H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 199.4, 160.2, 131.7, 130.3, 120.0, 25.7, 18.4, 16.8, 11.4, -4.2. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3008, 2955, 2930, 2858, 1664, 1599, 1508, 1415, 1272, 1257, 
1225, 1164, 994, 910, 840, 782. 
MS (ESI): m/z (%) = 277 (100). 
HRMS (ESI) for C16H25O2Si (277.1624): 277,1620 (M++H+). 
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Synthesis of ethyl 2-(2-((triisopropylsilyl)oxy)benzyl)acrylate (166g) 
 
 
 
Arene 166g was prepared via TP22 using (2-iodophenoxy)triisopropylsilane (376 mg, 1.00 mmol) and 
sBu2Zn·2LiOR (161c, 0.62 mL, 0.60 mmol). After the exchange was complete, the reaction was cooled 
to 0 °C and CuI (38 mg, 0.2 mmol) was added. After stirring at 0 °C for 30 min, ethyl 2-
(bromomethyl)acrylate (289 mg, 1.50 mmol) was added and the reaction stirred for 12 h at room 
temperature. After work-up, the crude product was purified via column chromatography (pentane:ethyl 
acetate = 10:0.5) to give 166g (300 mg, 827 µmol, 83%) as a colorless oil.  
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 7.09 (dd, J = 8.2, 6.5 Hz, 2H), 6.87 (td, J = 7.4, 1.2 Hz, 1H), 
6.80 (dt, J = 7.3, 1.1 Hz, 1H), 6.20 (q, J = 1.4 Hz, 1H), 5.22 (q, J = 1.7 Hz, 1H), 4.22 (q, J = 7.1 Hz, 
2H), 3.64 (t, J = 1.6 Hz, 2H), 1.34 – 1.23 (m, 6H), 1.08 (d, J = 7.3 Hz, 18H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 167.4, 154.2, 139.7, 131.0, 128.9, 127.6, 125.5, 120.8, 118.1, 
60.7, 32.6, 18.2, 14.4, 13.2. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 2945, 2867, 1718, 1491, 1453, 1265, 1132, 1108, 910, 755, 683. 
MS (EI, 70 eV): m/z (%) = 319 (100), 291 (33), 175 (23), 161 (24), 159 (17), 149 (18), 131 (35), 115 
(18), 103 (46), 89 (14), 75 (55), 61 (11). 
HRMS (EI) for C18H27O3Si (319.1729): 319.1725 (M+-iPr). 
 
Synthesis of 2',4'-dichloro-1,2,3,4-tetrahydro-1,1'-biphenyl (166j) 
 
 
 
Arene 166j was prepared via TP22 using 2,4-dichloro-1-iodobenzene (273 mg, 1.00 mmol) and 
sBu2Zn·2LiOR (161c, 0.85 mL, 0.60 mmol). After the exchange was complete, the reaction was cooled 
to 0 °C and CuI (38 mg, 0.20 mmol) was added. After stirring at 0 °C for 30 min, 3-bromo cyclohexene 
(0.17 mL, 1.50 mmol) was added and the reaction stirred for 12 h at room temperature. After work-up, 
the crude product was purified via column chromatography (pentane:ethyl acetate = 1000:1) to give 
166j (202 mg, 889 µmol, 89%) as a colorless oil. 
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1H-NMR (400 MHz, CDCl3): δ / ppm = 7.36 (dd, J = 1.7, 0.8 Hz, 1H), 7.22 – 7.17 (m, 2H), 5.98 (m, 
1H), 5.66 – 5.56 (m, 1H), 3.84 (m, 1H), 2.15 – 2.01 (m, 3H), 1.65 (m, 2H), 1.52 – 1.41 (m, 1H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 142.1, 134.4, 132.3, 130.2, 129.8, 129.2, 128.8, 127.0, 37.7, 
30.0, 25.1, 20.7. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3020, 2928, 2858, 2834, 2360, 1587, 1557, 1468, 1378, 1101, 
1052, 881, 865, 819, 804, 728, 681, 670. 
MS (EI, 70 eV): m/z (%) = 226 (57), 211 (23), 192 (41), 165 (32), 163 (100), 155 (20), 128 (55), 127 
(20). 
HRMS (EI) for C12H12Cl2 (226.0316): 226.0311 (M+). 
 
Synthesis of 1-((4-allylphenyl)diazenyl)pyrrolidine (166q) 
 
 
 
Arene 166q was prepared via TP22 using 1-((4-iodophenyl)diazenyl)pyrrolidine (301 mg, 1.00 mmol) 
and sBu2Zn·2LiOR (161c, 0.58 mL, 0.60 mmol). After the exchange was complete, the reaction was 
cooled to 0 °C and CuI (38 mg, 0.20 mmol) was added. After stirring at 0 °C for 30 min, allyl bromide 
(0.13 mL, 1.50 mmol) was added and the reaction stirred for 12 h at room temperature. After work-up, 
the crude product was purified via column chromatography (pentane:ethyl acetate = 10:0.2) to give 
166q (166 mg, 771 µmol, 77%) as a light yellow solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 7.38 – 7.33 (m, 2H), 7.18 – 7.13 (m, 2H), 5.99 (m, 1H), 5.13 
– 5.02 (m, 2H), 3.79 (s, 4H), 3.38 (dt, J = 6.6, 1.6 Hz, 2H), 2.06 – 1.96 (m, 4H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 149.9, 137.9, 136.9, 129.1, 120.4, 115.6, 48.8, 39.9, 23.9. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3025, 2986, 2972, 2921, 2874, 1500, 1427, 1404, 1347, 1319, 
1261, 1154, 886, 923, 849, 810, 689. 
MS (EI, 70 eV): m/z (%) = 215 (9), 145 (92), 117 (7), 115 (100), 91 (29). 
HRMS (EI) for C13H17N3 (215.1422): 215.1416 (M+). 
M.p. (°C): 50–52. 
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Synthesis of 2',4'-dinitro-1,2,3,4-tetrahydro-1,1'-biphenyl (166s) 
 
 
 
Arene 166s was prepared via TP22 using 1-iodo-2,4-dinitrobenzene (294 mg, 1.00 mmol) and 
Tol2Zn·2LiOR (167, 0.76 mL, 0.60 mmol). After the exchange was complete, the reaction was cooled 
to 0 °C and CuI (38 mg, 0.20 mmol) was added. After stirring at 0 °C for 30 min, 3-bromocyclohexene 
(0.17 mL, 1.50 mmol) was added and the reaction stirred for 2 h at the same temperature. After work-
up, the crude product was purified via column chromatography (isohexane:ethyl acetate = 9.8:0.2) to 
give 166s (196 mg, 0.79 mmol, 79%) as a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.62 (d, J = 2.4 Hz, 1H), 8.38 – 8.31 (m, 1H), 7.69 (d, J = 8.7 
Hz, 1H), 6.10 – 6.01 (m, 1H), 5.57 (m, 1H), 4.02 (m, 1H), 2.27 – 2.18 (m, 1H), 2.17 – 2.10 (m, 2H), 
1.80 – 1.61 (m, 2H), 1.51 (m, 1H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 149.6, 147.9, 146.2, 131.9, 131.2, 127.3, 126.7, 119.8, 37.3, 
31.6, 24.8, 20.9. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3105, 3025, 2930, 1603, 1526, 1447, 1341, 1065, 901, 834, 788, 
743, 724, 661. 
MS (EI, 70 eV): m/z (%) = 231 (56), 214 (32), 203 (32), 191 (94), 185 (61), 184 (51), 175 (35), 168 
(43), 167 (100), 166 (28), 157 (64), 156 (61), 155 (21), 154 (26), 153 (41), 152 (58), 145 (39), 139 (34), 
130 (31), 129 (24), 129 (38), 128 (77), 127 (30), 126 (23), 117 (27), 115 (96), 102 (28), 89 (36), 77 
(39). 
HRMS (EI) for C12H12N2O4 (248.0797): 248.0746 (M+). 
 
Synthesis of 3-allyl-4-nitrobenzonitrile (166t) 
 
 
 
Arene 166t was prepared via TP22 using 3-iodo-4-nitrobenzonitrile (132 mg, 0.48 mmol) and 
Tol2Zn·2LiOR (167, 0.42 mL, 0.29 mmol) at -15 °C for 15 min. After the exchange was complete, the 
reaction was cooled to -40 °C and CuI (19 mg, 0.10 mmol) and allyl bromide (0.06 mL, 0.72 mmol) 
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were added and the reaction stirred for 30 min at the same temperature. After work-up, the crude product 
was purified via column chromatography (pentane:ethyl acetate = 9:1) to give 166t (64 mg, 340 µmol, 
71%) as a yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.21 (d, J = 1.8 Hz, 1H), 7.82 (dd, J = 8.1, 1.8 Hz, 1H), 7.62 
– 7.53 (m, 1H), 5.93 (m, 1H), 5.29 – 5.08 (m, 2H), 3.75 (dt, J = 6.5, 1.5 Hz, 2H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 149.5, 140.4, 135.9, 133.5, 133.3, 128.5, 118.9, 116.7, 111.9, 
37.1. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3058, 2983, 2236, 1616, 1531, 1412, 1352, 1195, 1074, 995, 922, 
902, 845, 812, 678. 
MS (EI, 70 eV): m/z (%) = 187 (24), 171 (98), 154 (40), 143 (49), 142 (57), 141 (40), 140 (100), 129 
(55), 116 (82), 114 (32), 113 (36), 89 (40). 
HRMS (EI) for C10H7N2O2 (187.0508): 187.0498 (M+-H+). 
 
Synthesis of 5,6-dimethoxy-1',2',3',4'-tetrahydro-[1,1'-biphenyl]-3-carbaldehyde (166u) 
 
 
 
Arene 166u was prepared via TP22 using 3-iodo-4,5-dimethoxybenzaldehyde (115 mg, 0.394 mmol) 
and tBu2Zn·2LiOR (168, 0.35 mL, 0.24 mmol) at 0 °C for 10 min. After the exchange was complete, 
CuI (15 mg, 0.08 mmol) and 3-bromo cyclohexene (0.07 mL, 0.59 mmol) were added and the reaction 
stirred for 30 min at the same temperature. After work-up, the crude product was purified via column 
chromatography (pentane:ethyl acetate = 9:1) to give 166u (47 mg, 191 µmol, 48%) as a colorless oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 9.87 (s, 1H), 7.34 (dd, J = 13.0, 1.9 Hz, 2H), 5.96 (dtd, J = 
9.9, 3.7, 2.4 Hz, 1H), 5.65 – 5.57 (m, 1H), 3.97 – 3.78 (m, 7H), 2.18 – 1.95 (m, 3H), 1.78 – 1.59 (m, 
2H), 1.50 (m, 1H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 191.8, 153.3, 152.4, 140.7, 132.3, 129.6, 129.4, 125.7, 108.6, 
61.2, 56.0, 34.9, 31.2, 25.1, 21.3. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3018, 2932, 2858, 2835, 2736, 1689, 1583, 1482, 1455, 1426, 
1386, 1296, 1134, 1086, 1002, 977, 859, 723, 670. 
MS (EI, 70 eV): m/z (%) = 246 (100), 231 (42), 217 (31), 192 (28), 165 (22), 137 (17), 115 (15). 
HRMS (EI) for C15H18O3 (246.1256): 246.1249 (M+).  
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Synthesis of 1-benzyl-4-(cyclohex-2-en-1-yl)-1H-pyrazole (169c) 
 
 
 
Pyrazole 169c was prepared via TP22 using 1-benzyl-4-iodopyrazole (142 mg, 0.50 mmol) and 
sBu2Zn·2LiOR (161c, 0.38 mL, 0.30 mmol). After the exchange was complete, the reaction was cooled 
to 0 °C and CuI (19 mg, 0.10 mmol) was added. After stirring at 0 °C for 30 min, 3-bromo cyclohexene 
(0.09 mL, 0.75 mmol) was added and the reaction stirred for 2 h at room temperature. After work-up, 
the crude product was purified via column chromatography (pentane:ethyl acetate:triethylamine = 
9:1:0.1) to give 169c (95 mg, 0.40 mmol, 80%) as a colorless oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 7.32 (s, 1H), 7.28 – 7.17 (m, 3H), 7.14 – 7.10 (m, 2H), 7.09 
(s, 1H), 5.71 – 5.59 (m, 2H), 5.17 (s, 2H), 3.27 – 3.23 (m, 1H), 1.97 – 1.84 (m, 3H), 1.67 – 1.41 (m, 
3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 138.3, 137.0, 130.3, 128.8, 128.0, 127.7, 127.6, 127.1, 127.1, 
56.1, 31.7, 31.6, 25.0, 20.8. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 2933, 1709, 1649, 1455, 1431, 1358, 1221, 1177, 1072, 996, 848, 
714. 
MS (EI, 70 eV): m/z (%) = 238 (48), 147 (17), 119 (29), 91 (100), 65 (16). 
HRMS (EI) for C16H18N2 (238.1470): 238.1465 (M+). 
 
Synthesis of (4-fluorophenyl)(2-fluoropyridin-3-yl)methanone (169d) 
 
 
 
Pyridine 169d was prepared via TP22 using 2-fluoro-3-iodopyridine (118 mg, 0.53 mmol) and 
sBu2Zn·2LiOR (161c, 0.38 mL, 0.32 mmol). After the exchange was complete, the reaction was cooled 
to 0 °C and CuI (61 mg, 0.32 mmol) was added. After stirring at 0 °C for 30 min,  
4-fluorobenzoyl chloride (0.19 mL, 1.59 mmol) was added and the reaction stirred for 12 h at room 
temperature. After work-up, the crude product was purified via column chromatography (pentane:ethyl 
acetate = 8:2) to give 169d (111 mg, 506 µmol, 96%) as a colorless solid. 
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1H-NMR (400 MHz, CDCl3): δ / ppm = 8.41 (ddd, J = 4.9, 2.1, 1.1 Hz, 1H), 8.03 (ddd, J = 9.2, 7.4, 
2.0 Hz, 1H), 7.88 – 7.81 (m, 2H), 7.37 (ddd, J = 7.3, 4.9, 1.9 Hz, 1H), 7.20 – 7.12 (m, 2H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 190.2 (d, J = 5 Hz), 166.2 (d, J = 257 Hz), 156.0 (d, J = 243 
Hz), 150.6 (d, pJ = 15 Hz), 141.8 (d, J = 3 Hz), 132.9 (t, J = 3, 1 Hz), 132.4 (dd, J = 10, 1 Hz), 121.8 
(d, J = 5 Hz), 121.3 (d, J = 30 Hz), 116.0 (d, J = 22 Hz). 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3071, 2360, 2343, 1664, 1596, 1573, 1412, 1430, 1229, 1150, 
930, 855, 772. 
MS (EI, 70 eV): m/z (%) = 219 (28), 123 (12), 123 (100), 96 (5), 75 (6). 
HRMS (EI) for C12H7F2NO (219.0496): 219.0490 (M+). 
M.p. (°C): 77–78. 
 
Synthesis of 4-allyl-3-fluoro-6-methoxyquinoline (169l) 
 
 
 
Quinoline 169l was prepared via TP22 using 3-fluoro-4-iodo-6-methoxyquinoline (155 mg, 
0.51 mmol) and sBu2Zn·2LiOR (161c, 0.37 mL, 0.31 mmol) at 0 °C for 10 min. After the exchange 
was complete, CuI (19 mg, 0.09 mmol) was added. After stirring at 0 °C for 30 min, allyl bromide 
(0.07 mL, 0.77 mmol) was added and the reaction stirred for 12 h at room temperature. After work-up, 
the crude product was purified via column chromatography (pentane:ethyl acetate = 9:1) to give 169l 
(102 mg, 0.47 mmol, 92%) as a colorless oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.61 (d, J = 1.2 Hz, 1H), 7.98 (d, J = 9.2 Hz, 1H), 7.31 – 7.27 
(m, 1H), 7.14 (d, J = 2.8 Hz, 1H), 5.97 (ddt, J = 17.2, 10.1, 6.0 Hz, 1H), 5.11 (dq, J = 10.1, 1.6 Hz, 1H), 
5.05 (dq, J = 17.0, 1.7 Hz, 1H), 3.90 (s, 3H), 3.77 (dq, J = 6.1, 1.7 Hz, 2H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 158.62, 154.91 (d, J = 252.6 Hz), 141.60 (d, J = 2.5 Hz), 
138.35 (d, J = 29.3 Hz), 133.72, 131.68, 129.33 (d, J = 3.6 Hz), 127.10 (d, J = 12.8 Hz), 120.52 (d, J = 
2.7 Hz), 117.09, 102.09 (d, J = 5.5 Hz), 55.58, 28.39 (d, J = 4.0 Hz). 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3081, 3007, 2938, 2831, 2360, 1620, 1506, 1468, 1360, 1320, 
1263, 1216, 1136, 1029, 908, 827, 784, 699, 674. 
MS (ESI): m/z (%) = 218 (100). 
HRMS (ESI) for C13H13FNO (218.0981): 218.0974 (M++H+). 
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Synthesis of 4-(3-fluoro-6-methoxyquinolin-4-yl)butan-2-one (169m) 
 
 
 
Step 1: Synthesis of R 
 
 
 
Quinoline R was prepared via TP22 using 3-fluoro-4-iodo-6-methoxyquinoline (155 mg, 0.51 mmol) 
and sBu2Zn·2LiOR (161c, 0.44 mL, 0.31 mmol) at 0 °C for 10 min. After the exchange was complete, 
CuI (19 mg, 0.09 mmol) was added. After stirring at 0 °C for 30 min, a solution of methyl vinyl ketone 
(MVK, 0.13 mL, 0.53 mL) and TMSCl (0.28 mL, 2.15 mmol) was added and the reaction stirred for 
12 h at room temperature. After work-up, the crude product was obtained as a yellow oil and used as is 
in the next step. 
 
Step 2: Synthesis of 169m 
 
The crude product R was dissolved in THF (2.5 mL) and TBAF (1 M in THF, 0.6 mL, 0.6 mmol) added 
dropwise. The reaction was stirred at room temperature for 1 h. Then, a sat. aq. NH4Cl solution (10 mL) 
was added and the reaction mixture extracted with ethyl acetate (3 x 30 mL). After purification via 
column chromatography (pentane:ethyl acetate = 7:3) 169m (71 mg, 287 µmol, 56%) was obtained as 
a colorless solid over two steps. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.56 (d, J = 1.3 Hz, 1H), 7.96 (d, J = 9.2 Hz, 1H), 7.29 (dd, J 
= 9.2, 2.7 Hz, 1H), 7.16 (d, J = 2.7 Hz, 1H), 3.92 (s, 3H), 3.28 (td, J = 8.3, 7.9, 1.8 Hz, 2H), 2.83 – 2.77 
(m, 2H), 2.17 (s, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 206.93, 158.87, 155.05 (d, J = 252.2 Hz), 141.63 (d, J = 2.4 
Hz), 138.15 (d, J = 29.0 Hz), 131.85, 128.96 (d, J = 3.7 Hz), 128.81 (d, J = 12.7 Hz), 120.59 (d, J = 2.8 
Hz), 101.57 (d, J = 5.4 Hz), 55.73, 42.45 (d, J = 1.3 Hz), 30.01, 18.20 (d, J = 3.5 Hz). 
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IR (Diamond-ATR, neat): ?̃ / cm-1 = 3003, 2958, 2835, 1712, 1620, 1508, 1469, 1359, 1229, 1207, 
1027, 907, 829, 788, 731. 
MS (EI): m/z (%) = 247 (100), 205 (11), 204 (91), 190 (60), 173 (19), 172 (20), 161 (11), 160 (11). 
HRMS (EI) for C14H14FNO2 (247.1009): 247.1003 (M+). 
 
Synthesis of 5-(cyclohex-2-en-1-yl)-1,3-dimethylpyrimidine-2,4(1H,3H)-dione (169n) 
 
 
 
Uracil 169n was prepared via TP22 using 5-iodo-1,3-dimethyluracil (137 mg, 0.515 mmol) and 
sBu2Zn·2LiOR (161c, 0.37 mL, 0.31 mmol) in THF (1 mL) at 0 °C for 10 min. After the exchange was 
complete, CuI (19 mg, 0.10 mmol) was added. After stirring at 0 °C for 30 min, 3-bromo cyclohexene 
(0.09 mL, 0.77 mmol) was added and the reaction stirred for 12 h at room temperature. After work-up, 
the crude product was purified via column chromatography (pentane:ethyl acetate:triethylamine = 
6:4:0.1) to give 169n (91 mg, 413 µmol, 80%) as a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 6.87 (d, J = 0.8 Hz, 1H), 5.93 (dtd, J = 9.8, 3.7, 2.1 Hz, 1H), 
5.49 (ddt, J = 10.1, 4.0, 2.2 Hz, 1H), 3.54 – 3.47 (m, 1H), 3.38 (s, 3H), 3.35 (s, 3H), 2.06 – 1.99 (m, 
2H), 1.97 – 1.87 (m, 1H), 1.59 (m, 1H), 1.55 – 1.42 (m, 2H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 163.4, 151.8, 139.9, 130.6, 127.6, 117.2, 37.1, 32.4, 28.3, 
28.1, 25.2, 19.5. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3062, 3019, 2927, 2860, 2836, 1696, 1656, 1632, 1449, 1338, 
1238, 1089, 784, 756. 
MS (EI, 70 eV): m/z (%) = 220 (90), 205 (43), 192 (13), 191 (41), 179 (19), 166 (100), 165 (23), 153 
(20), 148 (12), 134 (14), 107 (10). 
HRMS (EI) for C12H16N2O2 (220.1212): 220.1205 (M+). 
M.p. (°C): 79–82. 
  
C. EXPERIMENTAL PART    314 
 
Synthesis of 1,3-dimethyl-5-(thiophene-2-carbonyl)pyrimidine-2,4(1H,3H)-dione (169o) 
 
 
 
Uracil 169o was prepared via TP22 using 5-iodo-1,3-dimethyluracil (136 mg, 0.51 mmol) and 
sBu2Zn·2LiOR (161c, 0.44 mL, 0.31 mmol) in THF (1 mL) at 0 °C for 10 min. After the exchange was 
complete, CuI (58 mg, 0.31 mmol) was added. After stirring at 0 °C for 30 min, 2-thiophenecarbonyl 
chloride (0.17 mL, 1.53 mmol) was added and the reaction stirred for 12 h at room temperature. After 
work-up, the crude product was purified via column chromatography (pentane:ethyl acetate = 4:6) to 
give 169o (99 mg, 396 µmol, 77%) as a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 7.88 (s, 1H), 7.78 (dd, J = 3.9, 1.1 Hz, 1H), 7.68 (dd, J = 5.0, 
1.2 Hz, 1H), 7.13 (dd, J = 4.9, 3.9 Hz, 1H), 3.51 (s, 3H), 3.41 (s, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 181.8, 160.4, 151.2, 148.2, 143.5, 135.0, 134.8, 128.1, 113.5, 
37.9, 28.5. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3105, 301, 2953, 1706, 1648, 1635, 1599, 1410, 1335, 1220, 
1056, 794, 748, 670. 
MS (EI, 70 eV): m/z (%) = 250 (61), 222 (21), 221 (100), 207 (15), 167 (27), 124 (11), 111 (58). 
HRMS (EI) for C11H10N2O3S (250.0412): 250.0409 (M+). 
M.p. (°C): 193–196. 
 
Synthesis of ethyl 2-((1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)methyl)acrylate 
(169p) 
 
 
 
Antipyrine 169p was prepared via TP22 using iodoantipyrine (145 mg, 0.46 mmol) and sBu2Zn·2LiOR 
(161c, 0.33 mL, 0.28 mmol) in THF (1 mL) at 0 °C for 10 min. After the exchange was complete, CuI 
(19 mg, 0.09 mmol) was added. After stirring at 0 °C for 30 min, ethyl 2-(bromomethyl)acrylate 
(134 mg, 0.69 mmol) was added and the reaction stirred for 12 h at room temperature. After work-up, 
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the crude product was purified via column chromatography (pentane:ethyl acetate = 4:6) to give 169p 
(103 mg, 343 µmol, 74%) as a colorless oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 7.44 – 7.37 (m, 4H), 7.22 (ddt, J = 6.6, 5.7, 2.6 Hz, 1H), 6.22 
(q, J = 1.0 Hz, 1H), 5.71 (q, J = 1.5 Hz, 1H), 4.19 (q, J = 7.1 Hz, 2H), 3.30 (t, J = 1.2 Hz, 2H), 3.01 (s, 
3H), 2.21 (s, 3H), 1.28 (t, J = 7.1 Hz, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 167.1, 166.0, 154.4, 137.3, 135.5, 129.1, 126.3, 126.1, 123.4, 
107.6, 60.8, 36.4, 24.8, 14.3, 11.4. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 2982, 2906, 1713, 1667, 1595, 1496, 1292, 1254, 1025, 946, 757, 
696. 
MS (EI, 70 eV): m/z (%) = 300 (31), 299 (31), 271 (89), 255 (19), 254 (20), 227 (100), 226 (19), 208 
(18), 207 (29), 201 (19), 196 (18), 152 (22), 124 (18). 
HRMS (EI) for C17H20N2O3 (300.1474): 300.1471 (M+). 
 
Synthesis of 1-(4-allylphenyl)-3-(piperidin-1-yl)-5,6-dihydropyridin-2(1H)-one (169q) 
 
 
 
Quinoline 169q was prepared via TP22 using 1-(4-iodophenyl)-3-(piperidin-1-yl)-5,6-dihydropyridin-
2(1H)-one (76 mg, 0.20 mmol) and sBu2Zn·2LiOR (161c, 0.17 mL, 0.12 mmol) at 0 °C for 10 min. 
After the exchange was complete, CuI (8 mg, 0.04 mmol) was added. After stirring at 0 °C for 30 min, 
allyl bromide (0.03 mL, 0.30 mmol) was added and the reaction stirred for 2 h at room temperature. 
After work-up, the crude product was purified via column chromatography (pentane:ethyl acetate = 6:4) 
to give 169q (50 mg, 168 µmol, 85%) as a colorless oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 7.37 – 7.26 (m, 4H), 6.09 – 5.97 (m, 1H), 5.71 (t, J = 4.7 Hz, 
1H), 5.21 – 5.11 (m, 2H), 3.93 – 3.88 (m, 4H), 3.85 (t, J = 6.7 Hz, 2H), 3.48 – 3.43 (m, 2H), 3.01 – 2.96 
(m, 4H), 2.60 – 2.52 (m, 2H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 161.5, 143.9, 141.0, 138.0, 137.3, 129.0, 125.1, 116.0, 114.2, 
66.9, 50.6, 48.7, 39.9, 23.5. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 2957, 2924, 2892, 2854, 2818, 1659, 1620, 1511, 1219, 1118, 
924, 811, 782. 
MS (EI): m/z (%) = 298 (5), 280 (100), 279 (29), 239 (34), 212 (55), 146 (39), 117 (18), 115 (27). 
HRMS (EI) for C19H24N2O (298.1681): 298.1681 (M+).  
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Synthesis of 4-iodobenzonitrile (170a) 
 
 
 
Benzonitrile 170a was prepared via TP23 using 4-bromobenzonitrile (94 mg, 516 µmol) and 
sBu2Zn·2LiOR (161c, 0.55 mL, 413 µmol). After the exchange was complete, a solution of I2 (262 mg, 
1.03 mmol) in THF (2 mL) was added and the reaction stirred for 30 min. After work-up, the crude 
product was purified via column chromatography (isohexane:ethyl acetate = 9:1) to give 170a (91 mg, 
397 µmol, 77%) as a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 7.88 – 7.81 (m, 2H), 7.40 – 7.32 (m, 2H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 138.6, 133.3, 118.3, 111.8, 100.5. 
 
The spectra matched those of the literature.147 
 
Synthesis of 4'-methoxy-[1,1'-biphenyl]-4-carbonitrile (170b) 
 
 
 
Biaryl 170b was prepared via TP23 using 4-bromobenzonitrile (52 mg, 286 µmol) and sBu2Zn·2LiOR 
(161c, 0.305 mL, 229 µmol). After the exchange was complete, Pd(OAc)2 (2 mg, 9 µmol), SPhos 
(7 mg, 17 µmol) and 4-iodoanisole (53 mg, 0.23 mmol) were added and the reaction stirred for 12 h at 
room temperature. After work-up, the crude product was purified via column chromatography 
(isohexane:ethyl acetate = 9:1) to give 170b (31 mg, 148 µmol, 64%) as a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 7.72 – 7.61 (m, 4H), 7.57 – 7.50 (m, 2H), 7.04 – 6.97 (m, 2H), 
3.87 (s, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 160.3, 145.3, 132.7, 131.6, 128.5, 127.2, 119.3, 114.7, 110.2, 
55.5. 
 
                                                     
147
 Y.-H. Chen, M. Sun, P. Knochel, Angew. Chem. Int. Ed. 2009, 48, 2236–2239. 
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The spectra matched those of the literature.148 
 
Synthesis of ethyl 2-(2-cyanobenzyl)acrylate (170c) 
 
 
 
Benzonitrile 170c was prepared via TP23 using 2-bromobenzonitrile (89 mg, 0.49 mmol) and 
sBu2Zn·2LiOR (161c, 0.47 mL, 0.39 mmol). After the exchange was complete, the reaction was cooled 
to 0 °C and CuI (19 mg, 0.10 mmol) was added. After stirring at 0 °C for 30 min, ethyl 2-
(bromomethyl)acrylate (171 mg, 0.74 mmol) was added and the reaction stirred for 2 h at the same 
temperature. After work-up, the crude product was purified via column chromatography (pentane:ethyl 
acetate = 7:3) to give 170c (66 mg, 0.31 mmol, 63%) as a colorless oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 7.63 (ddd, J = 7.8, 1.5, 0.6 Hz, 1H), 7.51 (td, J = 7.7, 1.4 Hz, 
1H), 7.37 (ddd, J = 7.9, 1.2, 0.6 Hz, 1H), 7.32 (td, J = 7.6, 1.2 Hz, 1H), 6.33 (q, J = 0.9 Hz, 1H), 5.57 
(q, J = 1.3 Hz, 1H), 4.18 (q, J = 7.1 Hz, 2H), 3.86 (s, 2H), 1.25 (t, J = 7.1 Hz, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 166.3, 142.8, 138.3, 133.0, 132.9, 130.3, 127.6, 127.2, 118.0, 
113.1, 61.1, 36.7, 14.2. 
 
The spectra matched those of the literature.149 
 
Synthesis of 2-(cyclopropanecarbonyl)benzonitrile (170d) 
 
 
 
Benzonitrile 170d was prepared via TP23 using 2-bromobenzonitrile (85 mg, 0.47 mmol) and 
sBu2Zn·2LiOR (161c, 0.48 mL, 0.38 mmol). After the exchange was complete, the reaction was cooled 
to 0 °C and CuI (71 mg, 0.38 mmol) was added. After stirring at 0 °C for 30 min, cyclopropanecarbonyl 
chloride (147 mg, 1.41 mmol) was added and the reaction stirred for 12 h at room temperature. After 
                                                     
148
 S. Bernhardt, G. Manolikakes, T. Kunz, P. Knochel, Angew. Chem. Int. Ed. 2011, 50, 9205–9209. 
149
 M. Ketels, M. A. Ganiek, N. Weidmann, P. Knochel, Angew. Chem. Int. Ed. 2017, 56, 12770–12773. 
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work-up, the crude product was purified via column chromatography (pentane:ethyl acetate = 7:3) to 
give 170d (54 mg, 315 µmol, 67%) as a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 7.99 (dd, J = 7.9, 1.3 Hz, 1H), 7.79 (dd, J = 7.6, 1.4 Hz, 1H), 
7.71 (td, J = 7.7, 1.4 Hz, 1H), 7.62 (td, J = 7.6, 1.3 Hz, 1H), 2.59 (tt, J = 7.7, 4.5 Hz, 1H), 1.35 (p, J = 
3.8 Hz, 2H), 1.16 (dq, J = 7.4, 3.7 Hz, 2H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 199.6, 141.5, 134.8, 132.7, 132.0, 129.3, 118.1, 110.8, 19.4, 
13.3. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3076, 3006, 2220, 1673, 1590, 1571, 1486, 1383, 1223, 989, 871, 
756. 
MS (EI, 70 eV): m/z (%) = 170 (10), 143 (13), 130 (100), 115 (8), 75 (6). 
HRMS (EI) for C11H9NO (171.0684): 171.0678 (M+). 
M.p. (°C): 66-67. 
 
Synthesis of 4'-(tert-butyl)-[1,1'-biphenyl]-2-carbonitrile (170e) 
 
 
 
Biaryl 170e was prepared via TP23 using 2-bromobenzonitrile (93 mg, 0.51 mmol) and sBu2Zn·2LiOR 
(161c, 0.49 mL, 0.41 mmol). After the exchange was complete, the reaction was cooled to 0 °C and 
TMSCl (0.05 mL, 0.41 mmol) added at 0 °C and stirred for 10 min. Then, Pd(OAc)2 (4 mg, 15 µmol), 
SPhos (13 mg, 31 µmol) and 4-tertbutyliodobenzene (107 mg, 0.41 mmol) were added and the reaction 
stirred for 12 h at room temperature. After work-up, the crude product was purified via column 
chromatography (isohexane:ethyl acetate = 10:0.2) to give 170e (62 mg, 263 µmol, 64%) as a colorless 
oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 7.76 (ddd, J = 7.7, 1.4, 0.6 Hz, 1H), 7.63 (ddd, J = 7.5, 1.4 Hz, 
1H), 7.54 – 7.50 (m, 5H), 7.42 (td, J = 7.6, 1.3 Hz, 1H), 1.38 (s, 9H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 151.9, 145.6, 135.3, 133.9, 132.9, 130.2, 128.6, 127.4, 125.8, 
119.1, 111.2, 34.8, 31.4. 
 
The spectra matched those of the literature.150 
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Synthesis of 2'-(trifluoromethyl)-1,2,3,4-tetrahydro-1,1'-biphenyl (170f) 
 
 
 
Arene 170f was prepared via TP23 using 1-bromo-2-(trifluoromethyl)benzene (238 mg, 1.06 mmol) 
and sBu2Zn·2LiOR (161c, 1.15 mL, 0.85 mmol). After the exchange was complete, the reaction was 
cooled to 0 °C and a 1 M CuCN·2LiCl solution in THF (0.21 mL, 0.21 mmol) was added. After stirring 
at 0 °C for 10 min, 3-bromocyclohexene (0.18 mL, 1.59 mmol) was added and the reaction stirred for 
2 h at the same temperature. After work-up, the crude product was purified via column chromatography 
(isohexane:diethyl ether = 1000:1) to give 170f (185 mg, 818 µmol, 77%) as a colorless oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 7.61 (dd, J = 7.9, 1.3 Hz, 1H), 7.52 – 7.40 (m, 2H), 7.29 (t, J 
= 7.6 Hz, 1H), 5.97 – 5.87 (m, 1H), 5.64 – 5.55 (m, 1H), 3.86 – 3.77 (m, 1H), 2.17 – 2.03 (m, 3H), 1.86 
– 1.76 (m, 1H), 1.74 – 1.61 (m, 1H), 1.53 – 1.41 (m, 1H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 145.84 (d, J = 1.5 Hz), 131.90, 130.02 (d, J = 29.3 Hz), 
128.71, 128.03 (q, J = 29.2 Hz), 126.18, 126.04, 125.70 (q, J = 5.9 Hz), 123.45, 37.93 (d, J = 2.0 Hz), 
32.84, 24.96, 21.79. 
 
The spectra matched those of the literature.151 
 
Synthesis of 5-fluoro-3'-methoxy-[1,1'-biphenyl]-3-carbonitrile (170g) 
 
 
 
Biaryl 170g was prepared via TP23 using 3-bromo-5-fluorobenzonitrile (193 mg, 0.96 mmol) and 
sBu2Zn·2LiOR (161c, 1.04 mL, 0.77 mmol). After stirring at 25 °C for 30 min the exchange was 
complete, the reaction cooled to 0 °C and TMSCl (0.08 mL, 0.77 mmol) added at 0 °C and stirred for 
10 min. Then, Pd(OAc)2 (7 mg, 29 µmol), SPhos (25 mg, 58 µmol) and 3-iodoanisole (157 mg, 
0.67 mmol) were added and the reaction stirred for 12 h at room temperature. After work-up, the crude 
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product was purified via column chromatography (pentane:ethyl acetate = 10:0.5) to give 170g (93 mg, 
409 µmol, 60%) as a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 7.66 (t, J = 1.5 Hz, 1H), 7.51 (ddd, J = 9.6, 2.5, 1.6 Hz, 1H), 
7.40 (t, J = 8.0 Hz, 1H), 7.32 (ddd, J = 7.7, 2.5, 1.4 Hz, 1H), 7.12 (ddd, J = 7.6, 1.8, 0.9 Hz, 1H), 7.05 
(t, J = 2.1 Hz, 1H), 6.98 (ddd, J = 8.3, 2.6, 0.9 Hz, 1H), 3.88 (s, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 162.6 (d, J = 250.1 Hz), 160.3, 145.0 (d, J = 8.1 Hz), 139.2 
(d, J = 2.1 Hz), 130.5, 126.9 (d, J = 3.2 Hz), 119.5, 119.1 (d, J = 21.8 Hz), 117.8 (d, J = 3.5 Hz), 117.7 
(d, J = 24.7 Hz), 114.4, 114.2 (d, J = 10.0 Hz), 112.9, 55.5. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3081, 2928, 2234, 1580, 1460, 1440, 1403, 1332, 1287, 1240, 
1193, 1134, 1046, 966, 865, 776, 685. 
MS (EI, 70 eV): m/z (%) = 228 (15), 227 (100), 197 (49), 196 (15), 184 (26), 158 (29). 
HRMS (EI) for C14H10FNO (227.0746): 227.0740 (M+). 
M.p. (°C): 109-110. 
 
Synthesis of 5-allyl-2-chlorobenzonitrile (170h) 
 
 
 
Arene 170h was prepared via TP23 using 5-bromo-2-chlorobenzonitrile (222 mg, 1.03mmol) and 
sBu2Zn·2LiOR (161c, 1.11 mL, 0.82 mmol). After stirring at 25 °C for 1 h the exchange was complete 
and the reaction cooled to 0 °C and a 1 M CuCN·2LiCl solution in THF (0.21 mL, 0.21 mmol) was 
added. After stirring at 0 °C for 10 min, allyl bromide (0.13 mL, 1.55 mmol) was added and the reaction 
stirred for 1 h at the same temperature. After work-up, the crude product was purified via column 
chromatography (pentane:ethyl acetate = 10:0.2) to give 170h (144 mg, 811 µmol, 79%) as a colorless 
oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm =  7.5 (d, J = 2.1 Hz, 1H), 7.4 (d, J = 8.4 Hz, 1H), 7.4 (dd, J = 
8.4, 2.1 Hz, 1H), 5.9 (ddt, J = 16.8, 10.1, 6.7 Hz, 1H), 5.2 – 5.1 (m, 2H), 3.4 – 3.3 (m, 2H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 139.8, 135.4, 134.6, 134.4, 134.0, 130.0, 117.8, 116.2, 113.3, 
39.0. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3082, 3981, 2902, 2837, 1711, 1640, 1472, 1432, 1359, 1221, 
1155, 1055, 994, 919, 829, 822. 
MS (EI, 70 eV): m/z (%) = 179 (17), 177 (54), 150 (10), 143 (10), 142 (100), 141 (11), 140 (33); 115 
(70). 
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HRMS (EI) for C10H8NCl (177.0345): 177.0338 (M+). 
 
Synthesis of ethyl 4-chloro-1',2',3',4'-tetrahydro-[1,1'-biphenyl]-3-carboxylate (170i) 
 
 
 
Arene 170i was prepared via TP23 using ethyl 5-bromo-2-chlorobenzoate (130 mg, 0.49 mmol) and 
sBu2Zn·2LiOR (161c, 0.46 mL, 0.39 mmol). After the exchange was complete, the reaction was cooled 
to 0 °C and CuI (18 mg, 0.10 mmol) was added. After stirring at 0 °C for 30 min, 3-bromo cyclohexene 
(0.09 mL, 0.74 mmol) was added and the reaction stirred for 12 h at the same temperature. After work-
up, the crude product was purified via column chromatography (pentane:ethyl acetate = 10:0.05) to give 
170i (95 mg, 359 µmol, 73%) as a colorless oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 7.55 (d, J = 2.3 Hz, 1H), 7.29 (d, J = 8.3 Hz, 1H), 7.20 – 7.17 
(m, 1H), 5.90 – 5.82 (m, 1H), 5.61 – 5.55 (m, 1H), 4.33 (q, J = 7.2 Hz, 2H), 3.39 – 3.30 (m, 1H), 2.06 
– 1.98 (m, 2H), 1.98 – 1.90 (m, 1H), 1.69 – 1.59 (m, 1H), 1.59 – 1.49 (m, 1H), 1.49 – 1.39 (m, 1H), 
1.34 (t, J = 7.1 Hz, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 166.3, 145.6, 131.9, 131.0, 130.9, 130.6, 130.5, 129.5, 129.1, 
61.7, 41.2, 32.5, 25.0, 21.0, 14.4. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3020, 2981, 2930, 2858, 1731, 1472, 1294, 1251, 1189, 1118, 
1045, 827. 
MS (EI, 70 eV): m/z (%) = 264 (100), 219 (48), 191 (46), 183 (52), 163 (67), 129 (55), 128 (98), 115 
(50). 
HRMS (EI) for C15H17ClO2 (264.0917): 264.0912 (M+). 
 
Synthesis of 3-allylquinoline (170j) 
 
 
 
Quinoline 170j was prepared via TP23 using 3-bromoquinoline (100 mg, 0.48 mmol) and 
sBu2Zn·2LiOR (161c, 0.45 mL, 0.38 mmol). After the exchange was complete, the reaction was cooled 
to 0 °C and CuI (18 mg, 0.10 mmol) was added. After stirring at 0 °C for 30 min, allyl bromide 
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(0.07 mL, 0.72 mmol) was added and the reaction stirred for 2 h at the same temperature. After work-
up, the crude product was purified via column chromatography (isohexane:ethyl acetate = 9:1) to give 
170j (57 mg, 337 µmol, 70%) as a light yellow oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.77 (d, J = 2.2 Hz, 1H), 8.09 (dq, J = 8.4, 0.9 Hz, 1H), 7.92 
(dd, J = 2.2, 1.0 Hz, 1H), 7.76 (dd, J = 8.1, 1.5 Hz, 1H), 7.66 (ddd, J = 8.4, 6.9, 1.5 Hz, 1H), 7.51 (ddd, 
J = 8.1, 6.9, 1.2 Hz, 1H), 6.11 – 5.95 (m, 1H), 5.21 – 5.09 (m, 2H), 3.62 – 3.53 (m, 2H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 152.1, 147.1, 136.2, 134.7, 132.7, 129.3, 128.9, 128.3, 127.5, 
126.8, 117.2, 37.5. 
 
The spectra matched those of the literature.152 
 
Synthesis of 2-(cyclohex-2-en-1-yl)pyridine (170k) 
 
 
 
Pyridine 170k was prepared via TP23 using 2-bromopyridine (82 mg, 0.52 mmol) and sBu2Zn·2LiOR 
(161c, 0.56 mL, 0.42 mmol). After the exchange was complete, the reaction was cooled to 0 °C and CuI 
(18 mg, 0.10 mmol) was added. After stirring at 0 °C for 30 min, 3-bromo cyclohexene (0.09 mL, 
0.78 mmol) was added and the reaction stirred for 12 h at room temperature. After work-up, the crude 
product was purified via column chromatography (isohexane:ethyl acetate = 9:1) to give 170k (51 mg, 
0.32 mmol, 62%) as a colorless oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.53 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.59 (td, J = 7.6, 1.9 Hz, 
1H), 7.18 (dt, J = 7.9, 1.1 Hz, 1H), 7.09 (ddd, J = 7.5, 4.9, 1.2 Hz, 1H), 5.96 – 5.89 (m, 1H), 5.81 – 5.75 
(m, 1H), 3.62 – 3.51 (m, 1H), 2.18 – 1.97 (m, 3H), 1.79 – 1.58 (m, 3H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 165.5, 149.4, 136.5, 129.1, 128.8, 121.9, 121.2, 44.1, 30.8, 
25.0, 21.2. 
IR (Diamond-ATR, neat): ?̃ / cm-1 = 3018, 2928, 2859, 2835, 2360, 1587, 1568, 1469, 1432, 1150, 
880, 774, 749, 723, 686. 
MS (EI, 70 eV): m/z (%) = 159 (2), 158 (20), 144 (16), 131 (10), 130 (100), 117 (14). 
HRMS (EI) for C11H13N (159.1048): 159.1041 (M+). 
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Synthesis of 3-allyl-5-bromopyridine (170l) 
 
 
 
Pyridine 170l was prepared via TP23 using 3,5-dibromopyridine (235 mg, 1.00 mmol) and 
sBu2Zn·2LiOR (161c, 0.76 mL, 0.60 mmol). After the exchange was complete, the reaction was cooled 
to 0 °C and CuI (38 mg, 0.20 mmol) was added. After stirring at 0 °C for 30 min, allyl bromide 
(0.13 mL, 1.50 mmol) was added and the reaction stirred for 12 h at room temperature. After work-up, 
the crude product was purified via column chromatography (isohexane:ethyl acetate = 9.7:0.3) to give 
170l (120 mg, 0.61 mmol, 61%) as a colorless oil. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.56 (d, J = 2.1 Hz, 1H), 8.40 (d, J = 1.5 Hz, 1H), 7.69 (t, J = 
2.0 Hz, 1H), 5.99 – 5.89 (m, 1H), 5.23 – 5.11 (m, 2H), 3.40 (d, J = 6.6 Hz, 2H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 148.7, 148.1, 138.8, 137.2, 135.2, 120.7, 117.7, 36.7. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 2923, 2356, 1640, 1580, 1555, 1421, 1096, 1022, 993, 921, 884, 
851. 
MS (EI, 70 eV): m/z (%) = 199 (36), 198 (99), 197 (36), 196 (100), 118 (39), 117 (84), 91 (23). 
HRMS (EI) for C8H8BrN (196.9840): 196.9833 (M+). 
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Synthesis of 2-iodobenzothiazole (170m) 
 
 
 
Benzothiazole 170m was prepared via TP23 using 2-bromobenzothiazole (110 mg, 0.51 mmol) and 
sBu2Zn·2LiOR (161c, 0.55 mL, 41 mmol). After the exchange was complete, a solution of I2 (261 mg, 
1.02 mmol) in THF (2 mL) was added and the reaction stirred for 30 min. After work-up, the crude 
product was purified via column chromatography (isohexane:ethyl acetate = 9:1) to give 170m (100 mg, 
383 µmol, 75%) as a colorless solid. 
 
1H-NMR (400 MHz, CDCl3): δ / ppm = 8.06 – 8.00 (m, 1H), 7.87 – 7.81 (m, 1H), 7.48 – 7.34 (m, 2H). 
13C-NMR (101 MHz, CDCl3): δ / ppm = 154.3, 139.2, 126.5, 125.7, 122.7, 120.6, 105.9. 
IR (Diamond-ATR, neat): ? ̃ / cm-1 = 3054, 3026, 2965, 2927, 2831, 1451, 1416, 1308, 1228, 951, 940, 
750, 722.  
MS (EI, 70 eV): m/z (%) = 260 (100), 134 (35), 90 (6). 
HRMS (EI) for C7H4INS (260.9109): 260.9103 (M+). 
M.p. (°C): 79–80. 
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9 Single Crystal X-Ray Diffraction Studies 
 
Single crystals of compound 134f, 134g, 137g, 138g, 141i, and 155c suitable for X-ray diffraction, were 
obtained by slow evaporation of dichloromethane solutions. Single crystals of compound 114b,153a, 
and 156c suitable for X-ray diffraction, were obtained by vapour diffusion: 114b, 153a, and 156c were 
dissolved in dichloromethane in a small vial which was placed in a larger vial containing isohexane 
which was then closed and left standing for several days. Single crystals of 151 was obtained by the 
following procedure: In a Schlenk tube under argon, pyridazine (46 mg, 0.58 mmol) was dissolved in 
THF (1.45 mL) to obtain a 0.4 M solution. Then, BF3 (0.08 mL, 0.58 mmol) was added and the mixture 
shaken for 5 seconds. After closing the Schlenk tube with a glass stopper, crystals formed after 1 week 
at room temperature. The crystals were introduced into perfluorinated oil and a suitable single crystal 
was carefully mounted on the top of a thin glass wire. Data collection was performed with an Oxford 
Xcalibur 3 diffractometer equipped with a Spellman generator (50 kV, 40 mA) and a Kappa CCD 
detector, operating with Mo-Kα radiation (λ = 0.71071 Ǻ).  
Data collection was performed with the CrysAlis CCD software;a) CrysAlis RED softwareb) was used 
for data reduction. Absorption correction using the SCALE3 ABSPACK multiscan methodc) was 
applied. The structures were solved with SHELXS-97,d) refined with SHELXL-97e) and finally checked 
using PLATON.f) Details for data collection and structure refinement are summarized in Table 20, 24, 
28, 32, 36, 40, 44, 48, 52 and 56. 
CCDC 1559514 (114b), CCDC 1836478 (134f), CCDC 1836477 (134g), CCDC 1836476 (136g), 
CCDC 1836475 (138g), CCDC 1836479 (141i), CCDC 1906337 (156c), CCDC 1906338 (155c), 
CCDC 1906339 (153a), and CCDC 1906340 (151) contain the supplementary crystallographic data for 
this thesis. These data are provided free of charge by The Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
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Table 20. Details for X-ray data collection and structure refinement for compound 114b. 
 
 114b 
Empirical formula C15H10BrIN2S 
Formula mass 457.12 
T[K] 173(2) 
Crystal size [mm] 0.47 × 0.04 × 0.03 
Crystal description colorless rod 
Crystal system orthorhombic 
Space group Pbcn 
a [Ǻ] 12.7276(4) 
b [Ǻ] 7.3359(3) 
c [Ǻ] 31.9815(9) 
α [°] 90.0 
β [°] 90.0 
γ [°] 90.0 
V [Ǻ3] 2986.06(18) 
Z 8 
ρcalcd. [g cm-3] 2.034 
μ [mm-1] 4.951 
F(000) 1744 
Θ range [°] 4.29 – 25.24 
Index ranges -16 ≤ h ≤ 16 
 -9 ≤ k ≤ 9 
 -42 ≤ l ≤ 42 
Reflns. collected 42322 
Reflns. obsd. 2706 
Reflns. unique 3681 
(Rint = 0.0717) 
R1, wR2 (2σ data) 0.0366, 0.0670 
R1, wR2 (all data) 0.0601, 0.0750 
GOOF on F2 1.082 
Peak/hole [e Ǻ-3] 0.884 / -0.520 
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Figure 6. Molecular structure of compound 114b in the crystal, DIAMONDg) representation; thermal 
ellipsoids are drawn at 50 % probability level.   
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Figure 7. Crystal structure of compound 114b showing Br∙∙∙Br interactions within pairs of molecules 
in the crystal, DIAMONDg) representation; thermal ellipsoids are drawn at 50 % probability level. 
Symmetry code for the unlabeled molecule: 2-x, y, -0.5-z. 
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Table 21. Selected bond lengths (Å) of compound 114b. 
I1 – C2 2.097(3) C9 – C14 1.389(5)
Br1 – C6 1.905(4) C9 – C8 1.489(5)
S1 – C1 1.758(3) C4 – C5 1.427(4)
S1 – C15 1.792(4) C4 – C8 1.440(5)
C10 – C11 1.379(5) C6 – N2 1.295(5)
C10 – C9 1.391(5) C6 – C7 1.404(5)
C13 – C14 1.385(5) C3 – C2 1.415(5)
C13 – C12 1.387(6) C8 – C7 1.371(5)
N1 – C3 1.310(5) N2 – C5 1.364(4)
N1 – C4 1.358(4) C2 – C1 1.383(5)
C11 – C12 1.386(6) C5 – C1 1.425(5)
 
Table 22. Selected bond angles (°) of compound 114b. 
C1 – S1 – C15 108.2(2) N1 – C3 – C2 124.0(3)
C11 – C10 – C9 120.9(4) C7 – C8 – C4 117.7(3)
C14 – C13 – C12 120.1(4) C7 – C8 – C9 119.0(3)
C3 – N1 – C4 117.6(3) C4 – C8 – C9 123.3(3)
C10 – C11 – C12 120.1(4) C6 – N2 – C5 116.9(3)
C14 – C9 – C10 118.7(3) C13 – C14 – C9 120.6(4)
C14 – C9 – C8 122.0(3) C1 – C2 – C3 120.4(3)
C10 – C9 – C8 119.2(3) C1 – C2 – I1 121.7(3)
N1 – C4 – C5 122.6(3) C3 – C2 – I1 117.9(3)
N1 – C4 – C8 119.2(3) N2 – C5 – C1 119.2(3)
C5 – C4 – C8 118.2(3) N2 – C5 – C4 122.0(3)
N2 – C6 – C7 126.7(3) C1 – C5 – C4 118.8(3)
N2 – C6 – Br1 116.8(3) C2 – C1 – C5 116.4(3)
C7 – C6 – Br1 116.5(3) C2 – C1 – S1 117.6(3)
C11 – C12 – C13 119.6(4) C5 – C1 – S1 125.7(3)
  C8 – C7 – C6 118.3(3)
 
Table 23. Selected torsion angles (°) of compound 114b. 
C9 – C10 – C11 – C12 -0.4(6) C6 – N2 – C5 – C4 -1.6(5) 
C11 – C10 – C9 – C14 0.1(5) N1 – C4 – C5 – N2 -172.6(3) 
C11 – C10 – C9 – C8 178.2(3) C8 – C4 – C5 – N2 4.3(5) 
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C3 – N1 – C4 – C5 -1.0(5) N1 – C4 – C5 – C1 4.9(5) 
C3 – N1 – C4 – C8 -177.9(3) C8 – C4 – C5 – C1 -178.3(3) 
C4 – N1 – C3 – C2 -1.8(5) C3 – C2 – C1 – C5 3.0(5) 
N1 – C4 – C8 – C7 173.8(3) I1 – C2 – C1 – C5 -175.7(2) 
C5 – C4 – C8 – C7 -3.2(5) C3 – C2 – C1 – S1 177.8(2) 
N1 – C4 – C8 – C9 -4.8(5) I1 – C2 – C1 – S1 -0.9(4) 
C5 – C4 – C8 – C9 178.2(3) N2 – C5 – C1 – C2 172.0(3) 
C14 – C9 – C8 – C7 139.5(4) C4 – C5 – C1 – C2 -5.6(5) 
C10 – C9 – C8 – C7 -38.6(5) N2 – C5 – C1 – S1 -2.4(5) 
C14 – C9 – C8 – C4 -41.9(5) C4 – C5 – C1 – S1 -179.9(2) 
C10 – C9 – C8 – C4 140.0(4) C15 – S1 – C1 – C2 153.3(3) 
C7 – C6 – N2 – C5 -2.3(6) C15 – S1 – C1 – C5 -32.5(3) 
Br1 – C6 – N2 – C5 177.7(2) C4 – C8 – C7 – C6 -0.1(5) 
C12 – C13 – C14 – C9 -0.9(6) C9 – C8 – C7 – C6 178.6(3) 
C10 – C9 – C14 – C13 0.6(5) N2 – C6 – C7 – C8 3.1(6) 
C8 – C9 – C14 – C13 -177.5(3) Br1 – C6 – C7 – C8 -176.8(3) 
N1 – C3 – C2 – C1 0.8(5) C10 – C11 – C12 – C13 0.1(6) 
N1 – C3 – C2 – I1 179.5(3) C14 – C13 – C12 – C11 0.5(6) 
C6 – N2 – C5 – C1 -179.1(3)   
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Table 24. Details for X-ray data collection and structure refinement for compound 134f. 
 
 134f 
Empirical formula C14H9ClN2O 
Formula mass 256.68 
T[K] 143(2) 
Crystal size [mm] 0.41 × 0.36 × 0.24 
Crystal description pale yellow block 
Crystal system orthorhombic 
Space group P212121 
a [Ǻ] 6.6737(2) 
b [Ǻ] 7.5084(2) 
c [Ǻ] 23.4225(7) 
α [°] 90.0 
β [°] 90.0 
γ [°] 90.0 
V [Ǻ3] 1173.67(6) 
Z 4 
ρcalcd. [g cm-3] 1.453 
μ [mm-1] 0.312 
F(000) 528 
Θ range [°] 4.18 – 25.24 
Index ranges -9 ≤ h ≤ 7 
 -10 ≤ k ≤ 9 
 -28 ≤ l ≤ 33 
Reflns. collected 12137 
Reflns. obsd. 3280 
Reflns. unique 3567 
(Rint = 0.0275) 
R1, wR2 (2σ data) 0.0323, 0.0732 
R1, wR2 (all data) 0.0368, 0.0759 
GOOF on F2 1.057 
Peak/hole [e Ǻ-3] 0.215 / -0.183 
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Figure 8. Molecular structure of compound 134f in the crystal, DIAMONDg) representation; thermal 
ellipsoids are drawn at 50 % probability level.  
 
Table 25. Selected bond lengths (Å) of compound 134f.  
Cl1 – C10 1.741(2) C6 – C5 1.415(3) 
O1 – C8 1.220(2) N2 – C1 1.341(2) 
N1 – N2 1.357(2) C10 – C11 1.392(2) 
N1 – C7 1.377(2) C10 – C9 1.397(2) 
N1 – C3 1.386(2) C9 – C14 1.400(2) 
C8 – C7 1.489(2) C11 – C12 1.383(3) 
C8 – C9 1.494(2) C1 – C2 1.390(3) 
C13 – C14 1.379(3) C3 – C4 1.417(3) 
C13 – C12 1.391(3) C4 – C5 1.364(3) 
C3 – C2 1.384(3) C6 – C7 1.366(2) 
 
Table 26. Selected bond angles (°) of compound 134f. 
N2 – N1 – C7 124.1(1) C10 – C9 – C8 126.1(2) 
N2 – N1 – C3 112.8(1) C14 – C9 – C8 115.8(2) 
C7 – N1 – C3 123.0(2) C12 – C11 – C10 119.6(2) 
O1 – C8 – C7 118.5(2) C4 – C5 – C6 120.1(2) 
O1 – C8 – C9 119.5(2) C6 – C7 – N1 118.4(2) 
C7 – C8 – C9 122.0(1) C6 – C7 – C8 121.9(2) 
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C14 – C13 – C12 120.0(2) N1 – C7 – C8 119.7(2) 
C2 – C3 – N1 105.5(2) C13 – C14 – C9 121.1(2) 
C2 – C3 – C4 136.9(2) N2 – C1 – C2 113.3(2) 
N1 – C3 – C4 117.7(2) C3 – C2 – C1 105.1(2) 
C5 – C4 – C3 120.1(2) C11 – C12 – C13 120.2(2) 
C7 – C6 – C5 120.7(2) C11 – C10 – Cl1 116.9(1) 
C1 – N2 – N1 103.3(2) C9 – C10 – Cl1 121.8(1) 
C11 – C10 – C9 121.1(2) C10 – C9 – C14 118.0(2) 
 
Table 27. Selected torsion angles (°) of compound 134f. 
N2 – N1 – C3 – C2 -1.1(2) C5 – C6 – C7 – N1 -3.2(3) 
C7 – N1 – C3 – C2 -178.0(2) C5 – C6 – C7 – C8 174.9(2) 
N2 – N1 – C3 – C4 179.1(2) N2 – N1 – C7 – C6 -175.9(2) 
C7 – N1 – C3 – C4 2.1(3) C3 – N1 – C7 – C6 0.7(3) 
C2 – C3 – C4 – C5 177.6(2) N2 – N1 – C7 – C8 6.0(2) 
N1 – C3 – C4 – C5 -2.5(3) C3 – N1 – C7 – C8 -177.4(2) 
C7 – N1 – N2 – C1 177.8(2) O1 – C8 – C7 – C6 48.4(2) 
C3 – N1 – N2 – C1 0.8(2) C9 – C8 – C7 – C6 -130.1(2) 
C11 – C10 – C9 – C14 0.6(2) O1 – C8 – C7 – N1 -133.5(2) 
Cl1 – C10 – C9 – C14 -175.7(1) C9 – C8 – C7 – N1 47.9(2) 
C11 – C10 – C9 – C8 178.0(2) C12 – C13 – C14 – C9 0.9(3) 
Cl1 – C10 – C9 – C8 1.7(2) C10 – C9 – C14 – C13 -1.4(3) 
O1 – C8 – C9 – C10 -144.1(2) C8 – C9 – C14 – C13 -179.0(2) 
C7 – C8 – C9 – C10 34.4(2) N1 – N2 – C1 – C2 -0.3(2) 
O1 – C8 – C9 – C14 33.3(2) N1 – C3 – C2 – C1 0.8(2) 
C7 – C8 – C9 – C14 -148.2(2) C4 – C3 – C2 – C1 -179.4(2) 
C9 – C10 – C11 – C12 0.6(3) N2 – C1 – C2 – C3 -0.3(3) 
Cl1 – C10 – C11 – C12 177.1(2) C10 – C11 – C12 – C13 -1.2(3) 
C3 – C4 – C5 – C6 0.2(3) C14 – C13 – C12 – C11 0.4(3) 
C7 – C6 – C5 – C4 2.8(3)   
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Table 28. Details for X-ray data collection and structure refinement for compound 134g. 
 
 134g 
Empirical formula C14H9IN2O 
Formula mass 348.13 
T[K] 143(2) 
Crystal size [mm] 0.43 × 0.26 × 0.15 
Crystal description pale yellow block 
Crystal system triclinic 
Space group P-1 
a [Ǻ] 7.9150(4) 
b [Ǻ] 8.6083(4) 
c [Ǻ] 9.1999(5) 
α [°] 103.172(4) 
β [°] 93.199(4) 
γ [°] 95.217(4) 
V [Ǻ3] 605.92(5) 
Z 2 
ρcalcd. [g cm-3] 1.908 
μ [mm-1] 2.630 
F(000) 336 
Θ range [°] 4.27 – 25.24 
Index ranges -11 ≤ h ≤ 11 
 -12 ≤ k ≤ 12 
 -13 ≤ l ≤ 13 
Reflns. collected 12199 
Reflns. obsd. 3227 
Reflns. unique 3678 
(Rint = 0.0405) 
R1, wR2 (2σ data) 0.0292, 0.0575 
R1, wR2 (all data) 0.0371, 0.0607 
GOOF on F2 1.039 
Peak/hole [e Ǻ-3] 1.240 / -0.630 
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Figure 9. Molecular structure of compound 134g in the crystal, DIAMONDg) representation; thermal 
ellipsoids are drawn at 50 % probability level.  
 
Figure 10. View of a I · · ·  N halogen bonded dimers of compound 134g in the crystal, DIAMONDg) 
representation; thermal ellipsoids are drawn at 50 % probability level. Symmetry code for the second 
molecule (not labeled): -x, 1-y, -z. 
C. EXPERIMENTAL PART    336 
 
 
Table 29. Selected bond lengths (Å) of compound 134g. 
I1 – C14 2.104(2) C10 – C11 1.389(4) 
O1 – C8 1.216(3) C5 – C4 1.367(4) 
N1 – N2 1.364(3) C1 – C2 1.407(4) 
N1 – C7 1.379(3) C3 – C2 1.387(4) 
N1 – C3 1.385(3) C3 – C4 1.416(4) 
N2 – C1 1.305(4) C11 – C12 1.377(4) 
C9 – C10 1.393(4) C7 – C6 1.362(3) 
C9 – C14 1.408(3) C14 – C13 1.386(3) 
C9 – C8 1.490(3) C6 – C5 1.412(4) 
C8 – C7 1.502(3) C13 – C12 1.387(4) 
 
Table 30. Selected bond angles (°) of compound 134g. 
N2 – N1 – C7 124.7(2) C4 – C5 – C6 120.2(2) 
N2 – N1 – C3 112.1(2) N2 – C1 – C2 113.4(2) 
C7 – N1 – C3 123.0(2) N1 – C3 – C2 105.4(2) 
C1 – N2 – N1 104.4(2) N1 – C3 – C4 118.2(2) 
C10 – C9 – C14 118.5(2) C2 – C3 – C4 136.4(2) 
C10 – C9 – C8 117.6(2) C5 – C4 – C3 119.3(2) 
C14 – C9 – C8 123.7(2) C12 – C11 – C10 119.6(3) 
O1 – C8 – C9 122.3(2) C3 – C2 – C1 104.6(2) 
O1 – C8 – C7 118.2(2) C11 – C12 – C13 120.2(2) 
C9 – C8 – C7 119.1(2) C13 – C14 – I1 116.3(2) 
C6 – C7 – N1 117.9(2) C9 – C14 – I1 123.9(2) 
C6 – C7 – C8 120.9(2) C7 – C6 – C5 121.3(2) 
N1 – C7 – C8 121.1(2) C14 – C13 – C12 120.6(3) 
C13 – C14 – C9 119.8(2) C11 – C10 – C9 121.2(3) 
 
Table 31. Selected torsion angles (°) of compound 134g. 
C7 – N1 – N2 – C1 -176.2(2) C9 – C14 – C13 – C12 -2.5(4) 
C3 – N1 – N2 – C1 -0.6(3) I1 – C14 – C13 – C12 179.0(2) 
C10 – C9 – C8 – O1 146.8(2) C14 – C9 – C10 – C11 0.8(4) 
C14 – C9 – C8 – O1 -28.8(4) C8 – C9 – C10 – C11 -175.0(2) 
C10 – C9 – C8 – C7 -26.2(3) C7 – C6 – C5 – C4 -0.3(4) 
C14 – C9 – C8 – C7 158.2(2) N1 – N2 – C1 – C2 0.1(3) 
N2 – N1 – C7 – C6 174.5(2) N2 – N1 – C3 – C2 0.8(3) 
C3 – N1 – C7 – C6 -0.7(3) C7 – N1 – C3 – C2 176.6(2) 
N2 – N1 – C7 – C8 -6.4(3) N2 – N1 – C3 – C4 -176.9(2) 
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C3 – N1 – C7 – C8 178.4(2) C7 – N1 – C3 – C4 -1.2(4) 
O1 – C8 – C7 – C6 -46.8(3) C6 – C5 – C4 – C3 -1.6(4) 
C9 – C8 – C7 – C6 126.4(3) N1 – C3 – C4 – C5 2.4(4) 
O1 – C8 – C7 – N1 134.0(2) C2 – C3 – C4 – C5 -174.5(3) 
C9 – C8 – C7 – N1 -52.7(3) C9 – C10 – C11 – C12 -2.3(4) 
C10 – C9 – C14 – C13 1.6(3) N1 – C3 – C2 – C1 -0.7(3) 
C8 – C9 – C14 – C13 177.1(2) C4 – C3 – C2 – C1 176.4(3) 
C10 – C9 – C14 – I1 179.9(2) N2 – C1 – C2 – C3 0.4(3) 
C8 – C9 – C14 – I1 -4.6(3) C10 – C11 – C12 – C13 1.3(4) 
N1 – C7 – C6 – C5 1.5(4) C14 – C13 – C12 – C11 1.1(4) 
C8 – C7 – C6 – C5 -177.7(2)   
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Table 32. Details for X-ray data collection and structure refinement for compound 136g. 
 
 136g 
Empirical formula C12H8N2OS 
Formula mass 228.26 
T[K] 143(2) 
Crystal size [mm] 0.47 × 0.24 × 0.19 
Crystal description colorless block 
Crystal system monoclinic 
Space group P21/c 
a [Ǻ] 10.3883(6) 
b [Ǻ] 11.4775(5) 
c [Ǻ] 8.7580(5) 
α [°] 90.0 
β [°] 99.608(5) 
γ [°] 90.0 
V [Ǻ3] 1029.58(10) 
Z 4 
ρcalcd. [g cm-3] 1.473 
μ [mm-1] 0.290 
F(000) 472 
Θ range [°] 4.26 – 25.24 
Index ranges -14 ≤ h ≤ 14 
 -14 ≤ k ≤ 16 
 -10 ≤ l ≤ 12 
Reflns. collected 10783 
Reflns. obsd. 2412 
Reflns. unique 3129 
(Rint = 0.0307) 
R1, wR2 (2σ data) 0.0409, 0.0984 
R1, wR2 (all data) 0.0579, 0.1097 
GOOF on F2 1.046 
Peak/hole [e Ǻ-3] 0.340 / -0.309 
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Figure 11. Molecular structure of compound 136g in the crystal, DIAMONDg) representation; thermal 
ellipsoids are drawn at 50 % probability level.  
 
Table 33. Selected bond lengths (Å) of compound 136g. 
S1 – C12 1.710(2) C10 – C11 1.417(2)
S1 – C9 1.728(1) C12 – C11 1.358(2)
C9 – C10 1.376(2) C6 – C5 1.360(2)
C9 – C1 1.465(2) C6 – C7 1.420(2)
N1 – C2 1.348(2) C8 – C7 1.355(2)
N1 – N2 1.353(2) C5 – C4 1.419(2)
O1 – C1 1.228(2) C2 – C3 1.402(2)
N2 – C8 1.375(2) C2 – C1 1.484(2)
N2 – C4 1.387(2) C3 – C4 1.390(2)
 
Table 34. Selected bond angles (°) of compound 136g. 
C12 – S1 – C9 91.5(1) C5 – C6 – C7 120.3(1) 
C10 – C9 – C1 129.8(1) C7 – C8 – N2 118.1(2) 
C10 – C9 – S1 111.3(1) C12 – C11 – C10 112.8(1) 
C1 – C9 – S1 118.6(1) C6 – C5 – C4 119.4(2) 
C2 – N1 – N2 103.6(1) C8 – C7 – C6 121.1(2) 
N1 – N2 – C8 123.8(1) N2 – C4 – C3 105.5(1) 
N1 – N2 – C4 113.1(1) N2 – C4 – C5 118.0(1) 
C8 – N2 – C4 123.1(1) C3 – C4 – C5 136.5(1) 
N1 – C2 – C3 112.8(1) O1 – C1 – C9 121.0(1) 
N1 – C2 – C1 122.2(1) O1 – C1 – C2 119.1(1) 
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C3 – C2 – C1 125.0(1) C9 – C1 – C2 119.9(1) 
C4 – C3 – C2 105.0(1) C11 – C12 – S1 112.3(1) 
C9 – C10 – C11 112.2(1)   
 
Table 35. Selected torsion angles (°) of compound 136g. 
C12 – S1 – C9 – C10 0.3(1) C3 – C2 – C1 – C9 154.7(1) 
C12 – S1 – C9 – C1 174.2(1) C9 – S1 – C12 – C11 -0.3(1) 
C2 – N1 – N2 – C8 177.8(1) N1 – N2 – C8 – C7 -179.2(1) 
C2 – N1 – N2 – C4 -0.3(2) C4 – N2 – C8 – C7 -1.3(2) 
N2 – N1 – C2 – C3 0.3(2) S1 – C12 – C11 – C10 0.3(2) 
N2 – N1 – C2 – C1 -177.7(1) C9 – C10 – C11 – C12 -0.1(2) 
N1 – C2 – C3 – C4 -0.1(2) C7 – C6 – C5 – C4 0.0(3) 
C1 – C2 – C3 – C4 177.7(1) N2 – C8 – C7 – C6 0.8(2) 
C1 – C9 – C10 – C11 -173.2(1) C5 – C6 – C7 – C8 -0.2(3) 
S1 – C9 – C10 – C11 -0.2(2) N1 – N2 – C4 – C3 0.2(2) 
C10 – C9 – C1 – O1 162.7(2) C8 – N2 – C4 – C3 -177.9(1) 
S1 – C9 – C1 – O1 -9.9(2) N1 – N2 – C4 – C5 179.3(1) 
C10 – C9 – C1 – C2 -15.3(2) C8 – N2 – C4 – C5 1.1(2) 
S1 – C9 – C1 – C2 172.1(1) C2 – C3 – C4 – N2 -0.1(2) 
N1 – C2 – C1 – O1 154.3(1) C2 – C3 – C4 – C5 -178.8(2) 
C3 – C2 – C1 – O1 -23.3(2) C6 – C5 – C4 – N2 -0.5(2) 
N1 – C2 – C1 – C9 -27.7(2) C6 – C5 – C4 – C3 178.2(2) 
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Table 36. Details for X-ray data collection and structure refinement for compound 138g. 
 
 138g 
Empirical formula C14H11BrN2O 
Formula mass 303.16 
T[K] 143(2) 
Crystal size [mm] 0.31 × 0.22 × 0.09 
Crystal description colorless block 
Crystal system triclinic 
Space group P-1 
a [Ǻ] 5.9056(4) 
b [Ǻ] 7.2277(5) 
c [Ǻ] 15.8858(11) 
α [°] 96.483(6) 
β [°] 96.206(6) 
γ [°] 112.954(7) 
V [Ǻ3] 611.75(8) 
Z 2 
ρcalcd. [g cm-3] 1.646 
μ [mm-1] 3.348 
F(000) 304 
Θ range [°] 4.22 – 25.24 
Index ranges -8 ≤ h ≤ 8 
 -9 ≤ k ≤ 10 
 -22 ≤ l ≤ 22 
Reflns. collected 6325 
Reflns. obsd. 3162 
Reflns. unique 3715 
(Rint = 0.0262) 
R1, wR2 (2σ data) 0.0381, 0.0820 
R1, wR2 (all data) 0.0482, 0.0886 
GOOF on F2 1.037 
Peak/hole [e Ǻ-3] 1.034 / -0.694 
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Figure 12. Molecular structure of compound 138g in the crystal, DIAMONDg) representation; thermal 
ellipsoids are drawn at 50 % probability level.  
 
Table 37. Selected bond lengths (Å) of compound 138g. 
Br1 – C1 1.873(2) C7 – C8 1.476(3)
O1 – C11 1.369(3) C8 – C9 1.391(3)
O1 – C14 1.428(3) C8 – C13 1.399(3)
N1 – N2 1.371(2) C9 – C10 1.385(3)
N1 – C7 1.383(3) C10 – C11 1.393(3)
N1 – C3 1.391(3) C11 – C12 1.391(3)
N2 – C1 1.338(3) C12 – C13 1.383(3)
C1 – C2 1.383(3) C4 – C5 1.361(3)
C2 – C3 1.394(3) C5 – C6 1.415(3)
C3 – C4 1.414(3) C6 – C7 1.368(3)
 
Table 38. Selected bond angles (°) of compound 138g. 
C11 – O1 – C14 117.5(2) N1 – C7 – C8 119.6(2) 
N2 – N1 – C7 124.1(2) C9 – C8 – C13 118.3(2) 
N2 – N1 – C3 112.4(2) C9 – C8 – C7 119.2(2) 
C7 – N1 – C3 123.4(2) C13 – C8 – C7 122.4(2) 
C1 – N2 – N1 102.1(2) C10 – C9 – C8 121.8(2) 
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N2 – C1 – C2 115.7(2) C9 – C10 – C11 119.0(2) 
N2 – C1 – Br1 118.5(2) O1 – C11 – C12 115.9(2) 
C2 – C1 – Br1 125.7(2) O1 – C11 – C10 124.1(2) 
C1 – C2 – C3 103.6(2) C12 – C11 – C10 120.0(2) 
N1 – C3 – C2 106.2(2) C13 – C12 – C11 120.2(2) 
N1 – C3 – C4 118.3(2) C12 – C13 – C8 120.6(2) 
C2 – C3 – C4 135.4(2) C7 – C6 – C5 121.8(2) 
C5 – C4 – C3 119.3(2) C6 – C7 – N1 116.9(2) 
C4 – C5 – C6 120.4(2) C6 – C7 – C8 123.5(2) 
 
Table 39. Selected torsion angles (°) of compound 138g. 
C7 – N1 – N2 – C1 -176.6(2) C3 – N1 – C7 – C6 0.4(3) 
C3 – N1 – N2 – C1 -0.6(2) N2 – N1 – C7 – C8 -2.7(3) 
N1 – N2 – C1 – C2 -0.1(2) C3 – N1 – C7 – C8 -178.3(2) 
N1 – N2 – C1 – Br1 179.7(1) C6 – C7 – C8 – C9 -49.0(3) 
N2 – C1 – C2 – C3 0.7(3) N1 – C7 – C8 – C9 129.5(2) 
Br1 – C1 – C2 – C3 -179.0(2) C6 – C7 – C8 – C13 127.2(2) 
N2 – N1 – C3 – C2 1.0(2) N1 – C7 – C8 – C13 -54.2(3) 
C7 – N1 – C3 – C2 177.1(2) C13 – C8 – C9 – C10 -1.2(3) 
N2 – N1 – C3 – C4 -176.3(2) C7 – C8 – C9 – C10 175.3(2) 
C7 – N1 – C3 – C4 -0.3(3) C8 – C9 – C10 – C11 -0.7(3) 
C1 – C2 – C3 – N1 -1.0(2) C14 – O1 – C11 – C12 -166.9(2) 
C1 – C2 – C3 – C4 175.7(2) C14 – O1 – C11 – C10 14.7(3) 
N1 – C3 – C4 – C5 0.3(3) C9 – C10 – C11 – O1 -179.4(2) 
C2 – C3 – C4 – C5 -176.1(2) C9 – C10 – C11 – C12 2.2(3) 
C3 – C4 – C5 – C6 -0.4(3) O1 – C11 – C12 – C13 179.7(2) 
C4 – C5 – C6 – C7 0.6(3) C10 – C11 – C12 – C13 -1.8(3) 
C5 – C6 – C7 – N1 -0.5(3) C11 – C12 – C13 – C8 -0.1(3) 
C5 – C6 – C7 – C8 178.1(2) C9 – C8 – C13 – C12 1.6(3) 
N2 – N1 – C7 – C6 176.0(2) C7 – C8 – C13 – C12 -174.7(2) 
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Table 40. Details for X-ray data collection and structure refinement for compound 141i. 
 
 141i 
Empirical formula C17H16N2O3 
Formula mass 296.32 
T[K] 143(2) 
Crystal size [mm] 0.40 × 0.12 × 0.08 
Crystal description colorless block 
Crystal system monoclinic 
Space group P21/n 
a [Ǻ] 3.9038(2) 
b [Ǻ] 28.3121(10) 
c [Ǻ] 12.6695(5) 
α [°] 90.0 
β [°] 93.301(4) 
γ [°] 90.0 
V [Ǻ3] 1397.97(10) 
Z 4 
ρcalcd. [g cm-3] 1.408 
μ [mm-1] 0.098 
F(000) 624 
Θ range [°] 4.31 – 25.24 
Index ranges -5 ≤ h ≤ 5 
 -37 ≤ k ≤ 40 
 -18 ≤ l ≤ 17 
Reflns. collected 14363 
Reflns. obsd. 3472 
Reflns. unique 4260 
(Rint = 0.0275) 
R1, wR2 (2σ data) 0.0407, 0.1013 
R1, wR2 (all data) 0.0528, 0.1092 
GOOF on F2 1.036 
Peak/hole [e Ǻ-3] 0.400 / -0.189 
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Figure 13. Molecular structure of compound 141i in the crystal, DIAMONDg) representation; thermal 
ellipsoids are drawn at 50 % probability level.  
 
Table 41. Selected bond lengths (Å) of compound 141i. 
O2 – C8 1.350(1) C15 – C16 1.380(2) 
O2 – C9 1.455(1) C12 – C13 1.394(1) 
O3 – C14 1.365(1) C4 – C3 1.367(2) 
O3 – C17 1.435(1) C4 – C5 1.409(1) 
C11 – C12 1.393(1) C9 – C10 1.505(2) 
C11 – C16 1.406(2) N2 – N1 1.376(1) 
C11 – C1 1.471(1) N1 – C1 1.382(1) 
O1 – C8 1.214(1) N1 – C5 1.385(1) 
C6 – C7 1.402(1) C2 – C1 1.372(1) 
C6 – C5 1.403(1) C2 – C3 1.415(2) 
C6 – C8 1.455(1) C14 – C13 1.395(2) 
N2 – C7 1.331(1) C14 – C15 1.398(2) 
 
Table 42. Selected bond angles (°) of compound 141i. 
C8 – O2 – C9 115.4(1) C15 – C16 – C11 120.2(1)
C14 – O3 – C17 116.5(1) C3 – C4 – C5 118.7(1)
C12 – C11 – C16 118.7(1) O2 – C9 – C10 106.9(1)
C12 – C11 – C1 119.8(1) N1 – C5 – C6 105.3(1)
C16 – C11 – C1 121.4(1) N1 – C5 – C4 118.4(1)
C7 – C6 – C5 104.8(1) C6 – C5 – C4 136.2(1)
C7 – C6 – C8 124.7(1) C4 – C3 – C2 121.0(1)
C5 – C6 – C8 130.4(1) C12 – C13 – C14 119.0(1)
C7 – N2 – N1 103.6(1) O1 – C8 – C6 123.9(1)
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N2 – N1 – C1 123.4(1) O2 – C8 – C6 112.9(1)
N2 – N1 – C5 112.6(1) C16 – C15 – C14 120.6(1)
C1 – N1 – C5 124.0(1) C11 – C12 – C13 121.5(1)
C1 – C2 – C3 121.2(1) N2 – C7 – C6 113.6(1)
O3 – C14 – C13 124.1(1) C2 – C1 – N1 116.6(1)
O3 – C14 – C15 115.9(1) C2 – C1 – C11 123.9(1)
C13 – C14 – C15 120.0(1) N1 – C1 – C11 119.5(1)
O1 – C8 – O2 123.2(1)   
 
Table 43. Selected torsion angles (°) of compound 141i. 
C7 – N2 – N1 – C1 178.8(1) C12 – C11 – C1 – C2 48.1(2) 
C7 – N2 – N1 – C5 0.1(1) C16 – C11 – C1 – C2 -126.6(1) 
C17 – O3 – C14 – C13 -1.3(1) C12 – C11 – C1 – N1 -133.8(1) 
C17 – O3 – C14 – C15 178.3(1) C16 – C11 – C1 – N1 51.5(1) 
C9 – O2 – C8 – O1 -8.3(2) C14 – C15 – C16 – C11 1.6(2) 
C9 – O2 – C8 – C6 170.7(1) C12 – C11 – C16 – C15 0.1(2) 
C7 – C6 – C8 – O1 1.1(2) C1 – C11 – C16 – C15 174.8(1) 
C5 – C6 – C8 – O1 179.0(1) C8 – O2 – C9 – C10 176.9(1) 
C7 – C6 – C8 – O2 -177.9(1) N2 – N1 – C5 – C6 -0.6(1) 
C5 – C6 – C8 – O2 0.0(2) C1 – N1 – C5 – C6 -179.3(1) 
O3 – C14 – C15 – C16 178.2(1) N2 – N1 – C5 – C4 177.5(1) 
C13 – C14 – C15 – C16 -2.2(2) C1 – N1 – C5 – C4 -1.2(2) 
C16 – C11 – C12 – C13 -1.2(2) C7 – C6 – C5 – N1 0.8(1) 
C1 – C11 – C12 – C13 -176.0(1) C8 – C6 – C5 – N1 -177.4(1) 
N1 – N2 – C7 – C6 0.5(1) C7 – C6 – C5 – C4 -176.7(1) 
C5 – C6 – C7 – N2 -0.9(1) C8 – C6 – C5 – C4 5.1(2) 
C8 – C6 – C7 – N2 177.5(1) C3 – C4 – C5 – N1 -2.1(2) 
C3 – C2 – C1 – N1 -2.8(2) C3 – C4 – C5 – C6 175.1(1) 
C3 – C2 – C1 – C11 175.3(1) C5 – C4 – C3 – C2 2.9(2) 
N2 – N1 – C1 – C2 -174.8(1) C1 – C2 – C3 – C4 -0.4(2) 
C5 – N1 – C1 – C2 3.7(2) C11 – C12 – C13 – C14 0.7(2) 
N2 – N1 – C1 – C11 6.9(2) O3 – C14 – C13 – C12 -179.3(1) 
C5 – N1 – C1 – C11 -174.5(1) C15 – C14 – C13 – C12 1.1(2) 
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Table 44. Details for X-ray data collection and structure refinement for compound 151. 
 
 
151 
Empirical formula C4H4BF3N2 
Formula mass 147.90 
T[K] 143(2) 
Crystal size [mm] 0.15 × 0.15 × 0.10 
Crystal description colorless block 
Crystal system monoclinic 
Space group P21/n 
a [Ǻ] 4.9485(2) 
b [Ǻ] 9.1216(4) 
c [Ǻ] 12.7420(5) 
α [°] 90.0 
β [°] 93.815(4) 
γ [°] 90.0 
V [Ǻ3] 573.88(4) 
Z 4 
ρcalcd. [g cm-3] 1.712 
μ [mm-1] 0.173 
F(000) 296 
Θ range [°] 4.53 – 25.24 
Index ranges -7 ≤ h ≤ 7 
 -13 ≤ k ≤ 13 
 -18 ≤ l ≤ 18 
Reflns. collected 10726 
Reflns. obsd. 1430 
Reflns. unique 1734 
(Rint = 0.0342) 
R1, wR2 (2σ data) 0.0340, 0.0769 
R1, wR2 (all data) 0.0443, 0.0832 
GOOF on F2 1.038 
Peak/hole [e Ǻ-3] 0.315 / -0.213 
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Figure 14. Molecular structure of compound 151 in the crystal, DIAMONDe) representation; 
thermal ellipsoids are drawn at 50 % probability level.  
 
Table 45. Selected bond lengths (Å) of compound 151. 
N1 – C1 1.320(1) C3 – C2 1.364(2)
N1 – N2 1.345(1) C3 – C4 1.399(2)
N1 – B1 1.610(2) C1 – C2 1.393(2)
F3 – B1 1.378(1) F2 – B1 1.377(1)
F1 – B1 1.378(1) N2 – C4 1.319(2)
 
Table 46. Selected bond angles (°) of compound 151. 
C1 – N1 – N2 123.0(1) F2 – B1 – F1 111.3(1) 
C1 – N1 – B1 123.6(1) F2 – B1 – F3 111.7(1) 
N2 – N1 – B1 113.4(1) F1 – B1 – F3 111.6(1) 
C4 – N2 – N1 117.0(1) F2 – B1 – N1 107.4(1) 
C2 – C3 – C4 117.8(1) F1 – B1 – N1 107.0(1) 
N1 – C1 – C2 120.9(1) F3 – B1 – N1 107.6(1) 
N2 – C4 – C3 123.7(1) C3 – C2 – C1 117.7(1) 
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Table 47. Selected torsion angles (°) of compound 151. 
C1 – N1 – N2 – C4 0.7(2) N2 – N1 – B1 – F2 -72.0(1) 
B1 – N1 – N2 – C4 -179.5(1) C1 – N1 – B1 – F1 -132.5(1) 
N2 – N1 – C1 – C2 -0.6(2) N2 – N1 – B1 – F1 47.6(1) 
B1 – N1 – C1 – C2 179.5(1) C1 – N1 – B1 – F3 -12.4(1) 
N1 – N2 – C4 – C3 -0.1(2) N2 – N1 – B1 – F3 167.7(1) 
C2 – C3 – C4 – N2 -0.5(2) C4 – C3 – C2 – C1 0.6(2) 
C1 – N1 – B1 – F2 107.9(1) N1 – C1 – C2 – C3 -0.1(2) 
 
Table 48. Details for X-ray data collection and structure refinement for compound 153a. 
 
 
153a 
Empirical formula C10H8N2 
Formula mass 156.18 
T[K] 143(2) 
Crystal size [mm] 0.40 × 0.30 × 0.20 
Crystal description colorless block 
Crystal system monoclinic 
Space group P21/c 
a [Ǻ] 18.4159(8) 
b [Ǻ] 5.8109(2) 
c [Ǻ] 7.3249(3) 
α [°] 90.0 
β [°] 100.034(4) 
γ [°] 90.0 
V [Ǻ3] 771.87(5) 
Z 4 
ρcalcd. [g cm-3] 1.344 
μ [mm-1] 0.082 
F(000) 328 
Θ range [°] 3.37 – 25.24 
Index ranges -26 ≤ h ≤ 26 
 -8 ≤ k ≤ 8 
 -10 ≤ l ≤ 10 
Reflns. collected 14786 
Reflns. obsd. 1886 
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Reflns. unique 2363 
(Rint = 0.0401) 
R1, wR2 (2σ data) 0.0451, 0.1134 
R1, wR2 (all data) 0.0598, 0.1259 
GOOF on F2 1.044 
Peak/hole [e Ǻ-3] 0.355 / -0.222 
 
 
Figure 15. Molecular structure of compound 153a in the crystal. DIAMONDe) representation; 
thermal ellipsoids are drawn at 50 % probability level. 
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Table 49. Selected bond lengths (Å) of compound 153a. 
C4 – N1 1.341(1) C8 – C7 1.391(2) 
C4 – C3 1.403(1) C6 – C7 1.389(2) 
C4 – C5 1.483(1) C9 – C10 1.388(2) 
C5 – C6 1.397(2) C2 – C3 1.369(2) 
C5 – C10 1.402(1) C2 – C1 1.390(2) 
N1 – N2 1.346(1) C8 – C9 1.390(2) 
N2 – C1 1.332(2)   
 
Table 50. Selected bond angles (°) of compound 153a. 
N1 – C4 – C3 122.1(1) C6 – C7 – C8 120.2(1) 
N1 – C4 – C5 115.6(1) N2 – C1 – C2 123.4(1) 
C3 – C4 – C5 122.3(1) C2 – C3 – C4 118.0(1) 
C6 – C5 – C10 119.0(1) C10 – C9 – C8 120.5(1) 
C6 – C5 – C4 120.4(1) C9 – C10 – C5 120.2(1) 
C10 – C5 – C4 120.5(1) C1 – N2 – N1 119.5(1) 
C4 – N1 – N2 119.7(1) C3 – C2 – C1 117.3(1) 
C9 – C8 – C7 119.6(1) C7 – C6 – C5 120.5(1) 
 
Table 51. Selected torsion angles (°) of compound 153a. 
N1 – C4 – C5 – C6 -151.0(1) C9 – C8 – C7 – C6 0.7(2) 
C3 – C4 – C5 – C6 29.0(2) N1 – N2 – C1 – C2 0.0(2) 
N1 – C4 – C5 – C10 28.6(1) C3 – C2 – C1 – N2 0.2(2) 
C3 – C4 – C5 – C10 -151.4(1) C1 – C2 – C3 – C4 -0.1(2) 
C3 – C4 – N1 – N2 0.3(2) N1 – C4 – C3 – C2 -0.2(2) 
C5 – C4 – N1 – N2 -179.7(1) C5 – C4 – C3 – C2 179.8(1) 
C4 – N1 – N2 – C1 -0.2(2) C7 – C8 – C9 – C10 -0.5(2) 
C10 – C5 – C6 – C7 -0.9(2) C8 – C9 – C10 – C5 -0.5(2) 
C4 – C5 – C6 – C7 178.7(1) C6 – C5 – C10 – C9 1.2(2) 
C5 – C6 – C7 – C8 0.0(2) C4 – C5 – C10 – C9 -178.4(1) 
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Table 52. Details for X-ray data collection and structure refinement for compound 155c. 
 
 
155c 
Empirical formula C11H10N2S 
Formula mass 202.27 
T[K] 143(2) 
Crystal size [mm] 0.35 × 0.15 × 0.10 
Crystal description colorless block 
Crystal system monoclinic 
Space group P21/c 
a [Ǻ] 22.6579(7) 
b [Ǻ] 5.7173(2) 
c [Ǻ] 7.4545(2) 
α [°] 90.0 
β [°] 93.893(3) 
γ [°] 90.0 
V [Ǻ3] 963.44(5) 
Z 4 
ρcalcd. [g cm-3] 1.394 
μ [mm-1] 0.292 
F(000) 424 
Θ range [°] 3.61 – 25.24 
Index ranges -32 ≤ h ≤ 32 
 -8 ≤ k ≤ 8 
 -10 ≤ l ≤ 10 
Reflns. collected 9508 
Reflns. obsd. 2442 
Reflns. unique 2939 
(Rint = 0.0270) 
R1, wR2 (2σ data) 0.0386, 0.0933 
R1, wR2 (all data) 0.0494, 0.0998 
GOOF on F2 1.048 
Peak/hole [e Ǻ-3] 0.408 / -0.210 
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Figure 16. Molecular structure of compound 155c in the crystal, DIAMONDe) representation; 
thermal ellipsoids are drawn at 50 % probability level. 
 
Table 53. Selected bond lengths (Å) of compound 155c. 
S1 – C2 1.754(1) C8 – C9 1.390(2) 
S1 – C1 1.801(1) C3 – C4 1.365(2) 
N2 – C5 1.336(2) C6 – C5 1.482(2) 
N2 – N1 1.353(1) C4 – C5 1.407(2) 
C2 – N1 1.333(2) C11 – C6 1.402(2) 
C2 – C3 1.405(2) C7 – C8 1.389(2) 
C10 – C11 1.391(2) C7 – C6 1.400(2) 
C10 – C9 1.394(2)   
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Table 54. Selected bond angles (°) of compound 155c. 
C2 – S1 – C1 102.3(1) C7 – C6 – C11 118.7(1) 
C5 – N2 – N1 120.4(1) C7 – C6 – C5 120.8(1) 
N1 – C2 – C3 123.1(1) C11 – C6 – C5 120.5(1) 
N1 – C2 – S1 118.7(1) C3 – C4 – C5 118.3(1) 
C3 – C2 – S1 118.3(1) C8 – C9 – C10 119.6(1) 
C11 – C10 – C9 120.2(1) N2 – C5 – C4 121.8(1) 
C2 – N1 – N2 119.1(1) N2 – C5 – C6 116.0(1) 
C10 – C11 – C6 120.5(1) C4 – C5 – C6 122.2(1) 
C8 – C7 – C6 120.6(1) C4 – C3 – C2 117.4(1) 
C7 – C8 – C9 120.3(1)   
 
Table 55. Selected torsion angles (°) of compound 155c. 
C1 – S1 – C2 – N1 4.1(1) C10 – C11 – C6 – C5 -178.2(1) 
C1 – S1 – C2 – C3 -176.7(1) C2 – C3 – C4 – C5 -0.4(2) 
C3 – C2 – N1 – N2 1.4(2) C7 – C8 – C9 – C10 0.6(2) 
S1 – C2 – N1 – N2 -179.4(1) C11 – C10 – C9 – C8 -0.8(2) 
C5 – N2 – N1 – C2 -0.4(2) N1 – N2 – C5 – C4 -1.0(2) 
C9 – C10 – C11 – C6 0.3(2) N1 – N2 – C5 – C6 178.7(1) 
C6 – C7 – C8 – C9 0.1(2) C3 – C4 – C5 – N2 1.4(2) 
N1 – C2 – C3 – C4 -1.0(2) C3 – C4 – C5 – C6 -178.2(1) 
S1 – C2 – C3 – C4 179.8(1) C7 – C6 – C5 – N2 -152.8(1) 
C8 – C7 – C6 – C11 -0.6(2) C11 – C6 – C5 – N2 25.7(2) 
C8 – C7 – C6 – C5 177.9(1) C7 – C6 – C5 – C4 26.9(2) 
C10 – C11 – C6 – C7 0.4(2) C11 – C6 – C5 – C4 -154.7(1) 
 
  
C. EXPERIMENTAL PART    355 
 
Table 56. Details for X-ray data collection and structure refinement for compound 156c. 
 
 
156c 
Empirical formula C10H6ClIN2 
Formula mass 316.52 
T[K] 143(2) 
Crystal size [mm] 0.40 × 0.15 × 0.02 
Crystal description colorless platelet 
Crystal system triclinic 
Space group P1 
a [Ǻ] 4.5667(3) 
b [Ǻ] 4.5669(3) 
c [Ǻ] 12.2111(6) 
α [°] 95.502(5) 
β [°] 95.480(4) 
γ [°] 95.919(5) 
V [Ǻ3] 250.71(3) 
Z 1 
ρcalcd. [g cm-3] 2.096 
μ [mm-1] 3.417 
F(000) 150 
Θ range [°] 4.51 – 25.24 
Index ranges -6 ≤ h ≤ 6 
 -6 ≤ k ≤ 6 
 -17 ≤ l ≤ 17 
Reflns. collected 4651 
Reflns. obsd. 3033 
Reflns. unique 3033  
(Rint = 0.0275) 
R1, wR2 (2σ data) 0.0273, 0.0479 
R1, wR2 (all data) 0.0273, 0.0479 
GOOF on F2 0.985 
Peak/hole [e Ǻ-3] 0.665 / -0.692 
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Figure 17. Molecular structure of compound 156c in the crystal. The phenyl ring of the 4-
chlorophenyl substituent is disordered over two positions with respect to a rotation around the 
C3-C5 bond. Only one of the two positions is represented for reasons of clarity. DIAMONDe) 
representation; thermal ellipsoids are drawn at 50 % probability level. 
 
Table 57. Selected bond lengths (Å) of compound 156c. 
N2 – C1 1.319(7) C8A – C7A 1.409(11) 
N2 – N1 1.343(8) C7A – C6A 1.389(14) 
C1 – C2 1.396(7) C10A – C9A 1.384(16) 
I1 – C2 2.090(5) C4 – C5A 1.489(9) 
Cl1 – C8A 1.732(7) C5A – C6A 1.378(11) 
C3 – C2 1.356(7) C5A – C10A 1.405(13) 
C3 – C4 1.408(8) C8A – C9A 1.347(13) 
N1 – C4 1.327(7)   
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Table 58. Selected bond angles (°) of compound 156c. 
C1 – N2 – N1 120.0(5) C9A – C8A – Cl1 119.7(7) 
N2 – C1 – C2 122.5(5) C7A – C8A – Cl1 118.9(6) 
C2 – C3 – C4 116.5(5) C6A – C7A – C8A 118.0(9) 
C4 – N1 – N2 119.3(5) C5A – C6A – C7A 121.3(9) 
N1 – C4 – C3 123.1(6) C9A – C10A – C5A 120.4(12)
N1 – C4 – C5A 115.9(6) C8A – C9A – C10A 119.8(11)
C3 – C4 – C5A 121.0(6) C6A – C5A – C10A 118.5(8) 
C3 – C2 – C1 118.5(5) C6A – C5A – C4 121.3(7) 
C3 – C2 – I1 121.4(3) C10A – C5A – C4 120.2(8) 
C1 – C2 – I1 120.1(4) C9A – C8A – C7A 121.3(8) 
 
Table 59. Selected torsion angles (°) of compound 156c. 
N1 – N2 – C1 – C2 0.3(8) N1 – C4 – C5A – C10A -20.7(12) 
C1 – N2 – N1 – C4 -0.6(9) C3 – C4 – C5A – C10A 157.5(7) 
N2 – N1 – C4 – C3 1.0(11) C9A – C8A – C7A – C6A 7.4(14) 
N2 – N1 – C4 – C5A 179.2(6) Cl1 – C8A – C7A – C6A -177.0(7) 
C2 – C3 – C4 – N1 -1.0(10) C10A – C5A – C6A – C7A 4.8(15) 
C2 – C3 – C4 – C5A -179.2(6) C4 – C5A – C6A – C7A -175.5(9) 
C4 – C3 – C2 – C1 0.6(8) C8A – C7A – C6A – C5A -5.9(15) 
C4 – C3 – C2 – I1 -179.6(4) C6A – C5A – C10A – C9A -5.1(15) 
N2 – C1 – C2 – C3 -0.3(8) C4 – C5A – C10A – C9A 175.3(11) 
N2 – C1 – C2 – I1 180.0(4) C7A – C8A – C9A – C10A -7.8(16) 
N1 – C4 – C5A – C6A 159.6(8) Cl1 – C8A – C9A – C10A 176.6(9) 
C3 – C4 – C5A – C6A -22.1(12) C5A – C10A – C9A – C8A 6.6(17) 
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